Biological and Clinical Significance of Circulating Tumor Cells in Breast Cancer by Fina, Emanuela
Open Research Online
The Open University’s repository of research publications
and other research outputs
Biological and Clinical Significance of Circulating
Tumor Cells in Breast Cancer
Thesis
How to cite:
Fina, Emanuela (2017). Biological and Clinical Significance of Circulating Tumor Cells in Breast Cancer. PhD
thesis The Open University.
For guidance on citations see FAQs.
c© 2016 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
  
 
 
The Open University (Milton Keynes, UK) - Faculty of Science  
PhD Research Degree Programme in Life and Biomolecular Sciences 
 
Affiliated Research Centre: 
Fondazione IRCCS Istituto Nazionale dei Tumori – Milan 
______________________________________________________________ 
 
BIOLOGICAL AND CLINICAL SIGNIFICANCE  
OF CIRCULATING TUMOR CELLS  
IN BREAST CANCER 
 
PhD candidate: EMANUELA FINA (Personal Identifier C4842278) 
 
Director of Studies: Dr MARIA GRAZIA DAIDONE 
Internal Supervisor: Dr VERA CAPPELLETTI 
External Supervisor: Dr ROBERT B. CLARKE 
Examiners: Dr CHRISTOPH A. KLEIN   
Dr ANGELA GRECO 
Chair: Dr LUCA ROZ 
 
Academic Session 2012-2016 
Date of submission: October 31, 2016 
ii 
 
ABSTRACT 
Circulating tumor cells (CTCs) represent a unique source of information that might help 
clarifying numerous aspects of metastasis biology and finding new clinically relevant biomarkers. 
On the hypothesis that CTCs possess a distinct profile compared to solid primary and secondary 
lesions, the transcriptome of experimentally-derived CTCs was compared with those of the 
primary tumor (PT) and metastases at lymph-nodes (LNs) and lung, in order to identify 
CTC-specific signatures involved in hematogenous dissemination and which might represent 
possible prognostic biomarkers. 
PTs, CTCs, LNs and lungs were collected from the breast cancer (BC) MDA-MB-231 
xenograft model and characterized in two independent experiments using a microarray platform. 
CTCs were distinguishable from solid lesions by a set of 474 significantly differentially expressed 
genes. Among genes up-regulated in CTCs, the trefoil factor 3 secreted peptide (TFF3) was 
selected to evaluate its role in CTC biology. TFF3 down-modulation or knock-out (KO) 
significantly impaired MDA-MB-231 cell migratory and invasive properties, but not their 
proliferation rate or vascular-mimicry ability, in in vitro assays. Xenograft experiments with 
MDA-MB-231 TFF3KO clones did not allow drawing conclusions on the involvement of TFF3 in 
dissemination and metastasis as the interpretation of results was hampered by the biological 
heterogeneity observed among clones. Interestingly, the expression status of TFF3 and some 
other CTC/metastasis-specific genes assessed in CTCs isolated from peripheral blood of BC 
patients, but not CTC status alone defined using standard markers, allowed identifying a group 
at higher risk of relapse or progression. Indeed, patients with TFF3+ CTCs had a significantly 
shorter progression-free survival compared to those with TFF3- CTCs. On the contrary, TFF3 
expression level assessed in publicly available primary BC datasets did not correlate with tumor 
relapse. 
The study of biologically relevant CTC-specific genes may allow deciphering the molecular 
mechanisms which orchestrate dissemination and real-time monitoring tumor evolution. 
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1.1. BREAST CANCER 
1.1.1. The mammary gland development 
The mammary gland is structurally a modified and highly specialized sweat gland, 
which distinguishes mammals from all other animals, and whose function is the production 
and secretion of milk during lactation. Differently from other glandular organs, the female 
mammary gland exhibits great plasticity during the lifetime and it reaches full development 
only during postnatal life. Its development can be subdivided into three major stages: 
embryonic, pubertal and reproductive (Figure 1.1.1). At present, our knowledge of normal 
mammary morphogenesis and molecular mechanisms which regulate its development and 
functions derives primarily from studies performed in mice (Moore et al., 2013; Macias and 
Hinck, 2012; Cowin and Wysolmerski, 2010). Interaction between the ectodermal epithelium 
and the mesenchymal cells of the underlying mesoderm is fundamental for tissue 
architecture, remodeling and functions, and each step of this process undergoes a tiny 
regulation by selective expression of transcription factors, integration and coordination of 
signals by endocrine and paracrine molecules and activation of differentiation and 
proliferation pathways, featuring morphogenetic variation during puberty, pregnancy, 
lactation, and regression. 
During female puberty, the ductal system is stimulated to elongate and further ramify 
into primary and secondary ducts. At this stage, epithelial ductal cells invade the stroma, a 
process called branching morphogenesis (Sakakura, 1987) and stratify at their leading edges 
to form the terminal ductal lobular units - terminal end buds (TEBs) in mice (Cardiff and 
Wellings, 1999). Ducts consist of an inner layer of luminal epithelial cells surrounded by a 
layer of myoepithelial cells, which is discontinuous in the small ducts (Figure 1.1.2). With 
rounds of menstrual cycle the pre-existing ducts continue to branch, as observed by Stute 
and colleagues in macaques (Stute et al., 2004), making the mammary gland more and more 
complex. 
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During pregnancy, the mammary gland undergoes massive tissue remodeling 
(reviewed in Oakes et al., 2006). The first transformation consists of a tremendous increase 
in secondary and tertiary ductal branches, providing ductal buds for the second phase, the 
alveolar morphogenesis (Figure 1.1.2). Rapid and global proliferation of epithelial cells 
occurs within the ductal branches and developing alveoli (hollow cavities), in order to enlarge 
the epithelial surface area for milk production (Richert et al., 2000). From mid-pregnancy the 
gland moves to the secretory phase, where developing alveoli cleave and alveolar cells form 
a sphere-like milk-secreting single layer (Richert et al., 2000).  
 
 
Figure 1.1.1. Schematic representation of the different stages of mammary gland development. 
At embryonic stage, the mammary placodes differentiates into mammary buds that penetrate the 
surrounding mesenchyme, elongating and bifurcating in ducts. At puberty the rudimentary ductal tree 
branches in secondary and tertiary structures. Pregnancy is characterized by alveolar cell expansion, 
and maturation to milk-secreting acini/alveoli occurs during lactation. Upon weaning, the mammary 
gland involves to its original adult state. Oakes et al., 2014 
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Each individual alveolus is surrounded by a discontinuous basket-like architecture of 
myoepithelial cells, and joins to neighbor alveoli to form groups known as lobules. Each 
lobule is connected with a lactiferous duct and will mature to milk-secreting acini or alveoli 
during lactation (Oakes et al., 2006). With the cessation of lactation, programmed cell death 
and extracellular matrix (ECM) remodeling occur, and the mammary gland returns to the 
virginal phenotype (Macias and Hinck, 2012).  
 
 
 
Figure 1.1.2. Cellular bases of mammary gland development. (A) The mammary anlage is present 
at birth and remains quiescent until puberty. (B) Epithelial ductal cells expand into the mammary fat 
pad, led by the terminal end buds, comprising an outer layer of epithelial cap cells surrounded by 
multi-layered epithelial body cells in rodents. (C) The ducts of the adult virgin are characterized by an 
outer layer of myoepithelial cells and an inner layer of luminal epithelial cells. (D) Pregnancy is 
accompanied by alveolar cell expansion and alveoli morphogenesis. (E) After lactation cell death and 
extracellular matrix remodel the gland to a simple ductal architecture. Inman et al., 2015 
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The adult mammary gland is composed of multiple cell types, including epithelial, 
adipose, immune, lymphatic and vascular cells and fibroblasts, which interact to maintain the 
architecture and function of the organ also during specific stages of its development 
(reviewed in Inman et al., 2015). Since many molecular pathways observed in breast cancer 
(BC) mimic those regulating mammary cell fate and remodeling in normal breast, studies on 
mammary gland development are of interest also to cancer biologists and, as epithelial cells 
are those showing the most dramatic changes during pregnancy and lactation and mammary 
tumors predominantly arise from the epithelial compartment, recent research efforts have 
focused on elucidating the hierarchy of epithelial cell differentiation.  
 
 
1.1.2. Models of mammary cell hierarchy 
The observation that the mammary gland is a dynamic organ suggested that a 
renewable stem or progenitor cell population exists. As such, elucidating normal epithelial 
differentiation hierarchy is helpful to understand BC heterogeneity and identify the potential 
cell of origin.  
The remarkable regenerative ability of specific cells to reconstitute a mammary gland 
was first demonstrated by Deome and colleagues (Deome et al., 1959) by transplanting 
small epithelial fragments of normal or hyperplastic mouse mammary epithelium into 
de-epithelialized mammary fat pads (m.f.p.). Years later, it was shown that the entire 
functional mammary gland can be derived from a single cell (Kordon and Smith, 1998; 
Shackleton et al., 2006), thus supporting the hypothesis that the mammary epithelium 
contains a stem cell population. Since Deome’s demonstration, many studies have focused 
on identifying and isolating the mammary stem cell (MaSC) population and defining the 
differentiation potential of different mammary epithelial cell types (reviewed in Oakes et al., 
2014, and in Inman et al., 2015). 
 For half a century, transplantation assay has represented the most common method to 
identify cells with the ability to reconstitute the glandular epithelium. Significant progress 
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occurred when mammary tissue dissociation was coupled to fluorescent activated cell sorting 
(FACS) methods, by which populations with a specific cell surface immunophenotype were 
injected in the cleared m.f.p. of mice at limiting dilutions to evaluate their ability to form 
mammary gland-reconstituting units. Moreover, DNA labeling assay was used to identify 
slow cycling adult stem cells, although the retention of DNA labels might be explained also 
by asymmetrical segregation of DNA strands (Smith, 2005). FACS analysis allowed the 
identification and prospective isolation of adult MaSCs based on their CD24+CD29hi/CD49fhi 
cell surface marker profile (Shackleton et al. 2006; Stingl et al., 2006). Years later, retention 
of DNA labeling in addition to the expression of Lin-CD29highCD49fhighCD24+ profile allowed 
identifying a population with 5-fold higher gland-reconstituting capacity compared to 
non-labelled/non-label-retaining cells (dos Santos et al., 2013). Further molecular analysis of 
Lin-CD29highCD49fhighCD24+ DNA-label-retaining cells revealed that the expression of CD1d 
(glycoprotein typical of antigen presenting cells) or the lipoprotein receptor-related proteins 
Lrp5 and Lrp6, as also one of its G-protein coupled receptor downstream effectors Lgr5, 
improved the selection of cells with regenerating properties compared to the parental 
population (dos Santos et al., 2013).  
Lineage tracing techniques, where a single cell is marked in such a way that the mark 
is transmitted to the cell’s progeny, allowed monitoring the number of founder cells, their 
location and their differentiation status (reviewed in Kretzschmar and Watt, 2012). This 
approach, with the advent of genetic recombination and the use of multicolor reports, allows 
not only better defining the regenerative potential of the traced cell, but also dissecting the 
mammary epithelial cell (MEC) hierarchy. During the murine mammary gland development 
the invasion of the m.f.p. by primitive branching structure is accompanied by a concomitant 
expansion in the MaSC population, also called fetal MaSCs (fMaSCs) by Spike and 
colleagues (Spike et al., 2012). fMaSCs can be enriched selecting for CD24highCD49fhigh cells 
and may presumably overlap with the bipotent MaSC population defined as keratins 
K14+/K18+ observed in lineage tracing studies (Van Keymeulen et al., 2011; Rios et al., 
2014). Indeed, such single-color lineage tracing studies concluded that mammary 
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development during puberty predominantly occurs through unipotent mammary epithelial 
progenitors, a luminal and a basal progenitor founder cell (Van Keymeulen et al., 2011; 
van Amerongen et al., 2012). By contrast, conflicting results emerged from another study by 
Rios and colleagues (Rios et al., 2014), who demonstrated that the pubertal gland contains 
several different stem and progenitor cell populations, including bipotent MaSCs, able to 
generate both the luminal and myoepithelial cells of the duct. Nevertheless, in addition to this 
bipotent stem cell population, Elf5+ luminal cells labeled before puberty gave rise to luminal 
and alveolar cells alone, as also observed for K14+/K18+ luminal cells in Van Keymeulen’s 
study. 
In a post-pubertal mammary gland, lineage tracing of Elf5+ luminal cells revealed the 
presence of patches of luminal cells derived from the same progenitor and gradually 
regressing from week 8 to 20, but when using lineage tracing of K5+ basal cells, both luminal 
and myoepithelial cells were observed, including some doublets, for long time period (Rios 
et al., 2014).  
Lineage tracing experiments in pregnant mice using K5+, K14+ or Lgr5+ suggested 
that alveolar cells derive from bipotent progenitor cells passing through the luminal progenitor 
state first (Rios et al., 2014). Nevertheless, studies based on lineage tracing of Axin2, which 
is expressed exclusively in basal cells, suggested that alveolar cells arise from a bipotent 
MaSC instead of a luminal progenitor (van Amerongen et al., 2012). The fate of alveolar cells 
during mammary gland involution remains unclear. Elf5-labeled luminal progenitors die and 
are replaced with a new pool of progenitors (Rios et al., 2014), whereas K8- or K18-labeled 
luminal progenitors persist through multiple cycles of pregnancy (Van Keymeulen et al., 
2011). 
The molecular mechanisms behind the differentiation of mammary progenitors and/or 
their progeny into luminal, myoepithelial and alveolar cells are not well understood, but 
recent transcriptome profiling studies coupled with mouse knock-out models have provided 
new insights. Crucial driver of luminal progenitor cell differentiation is the transcription factor 
Gata-3 (Asselin-Labat et al., 2007), whereas potential mediators of the basal phenotype are 
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p63 (Yalcin-Ozuysal et al., 2010) and MRTF-A (Sun et al., 2006) transcription factors. A 
cross-talk between the two compartments mediated by Nrg1 (neuregulin 1), which is 
expressed in myoepithelial cells in a p63-dependent manner, was observed (Forster et al., 
2014). Nrg1 binds luminal cells via Erbb4 receptor and induces the expression of the Stat5a 
targets Elf5 and cyclin D1, necessary for luminal and luminal progenitor cell function (Forster 
et al., 2014). 
The mammary gland is thought to house multiple populations of stem cells that fulfill 
the requirement of self-renewal and differentiation into mature cell lineages. At present, 
according to the most widely accepted hypothetical model of the mammary epithelial 
hierarchy (Visvader and Stingl, 2014; Figure 1.1.3), a multipotent fetal MaSC gives rise to a 
heterogeneous stem cell compartment, comprising long-term and short-term repopulating 
cells, from which luminal and basal precursors originate.  
 
Figure 1.1.3. Hypothetical model of the mammary epithelial hierarchy. A multipotent fetal MaSC 
has been identified. In the adult mammary gland, the stem cell compartment is heterogeneous and 
appears to comprise long-term and short-term repopulating cells (LT-RCs and ST-RCs, respectively), 
both of which are multipotent. These in turn give rise to committed progenitor cells for the 
myoepithelial and luminal (ductal and alveolar) epithelial lineages, but the precise number of 
progenitor cells is yet to be determined. Luminal progenitors are restricted to either a ductal or alveolar 
cell fate. The ductal progenitor possibly comprises both hormone receptor (HR)-positive and 
HR-negative cells, while the early and late alveolar-restricted progenitors are likely to be HR-negative. 
There may be a common luminal progenitor for these sublineages. The prospective isolation of cellular 
subsets from mouse and human mammary tissue provides support for the depicted hierarchical 
organization. In addition, two types of unipotent cells (lum-SC and myo-SC) may exist; current lineage 
tracing data is also consistent with long-lived progenitors performing these functions in vivo. Visvader 
and Stingl, 2014 
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One of the most controversial issues arising from in situ lineage tracing studies is 
related to the identity and the role of stem cells in the adult mammary gland homeostasis 
(Figure 1.1.4). One model suggests that the luminal and basal compartments are maintained 
by lineage-restricted, unipotent stem cells (Van Keymeulen et al., 2011; van Amerongen et 
al., 2012); the other proposes that the adult mammary epithelium is maintained by bipotent 
stem cells (Rios et al., 2014). To address the issue of lineage identity and developmental 
plasticity, Granit and colleagues have recently proposed an alternative to the traditional MEC 
hierarchy. They suggest a multidimensional classification of MECs along several distinct 
axes, including stem cell versus differentiated, basal versus luminal and mesenchymal 
versus epithelial identity. Such multidimensional model allows description of intermediate and 
mixed differentiation states and can be applied to both normal mammary gland and BC. 
Cancer cells possessing a high degree of stemness would display increased capacity to shift 
between positions on such a multidimensional scale, and to acquire intermediate phenotypes 
on its different axes (Granit et al., 2014). 
 
 
Figure 1.1.4. Contrasting models of mammary stem cell hierarchy across breast development 
stages. (A) During puberty mammary stem cells are present in the terminal end bud. They are able to 
self-renew and differentiate into mature cell lineages. (B) Other evidence from the adult virgin mouse 
gland suggests that bipotent stem cells can give rise both to luminal and myoepithelial cells. (C) By 
contrast, other lines of evidence suggest that unipotent progenitor cells contribute to ductal 
maintenance in the adult gland, thus myoepithelial progenitors are thought to differentiate directly into 
myoepithelial cells. (D) Finally, during pregnancy, alveolar progenitor cells in the luminal compartment 
give rise to the secretory alveolar cells. Inman et al., 2015 
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1.1.3. Epidemiology of breast cancer 
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of 
cancer death in females worldwide, accounting for 23% (1.38 million) of the total new cancer 
cases and 14% (458,400) of the total cancer deaths, according to GLOBOCAN 2008 
estimates (Ferlay et al., 2010; Jemal et al., 2011). About 50% of BC cases and 60% of 
related deaths are estimated to occur in economically developing countries, as a result of 
population aging and growth, as well as an adoption of cancer-associated lifestyle choices 
including smoking, physical activity and food habits (Jemal et al., 2011). Incidence rates are 
high in Western and Northern Europe, Australia/New Zeland and North America, while 
intermediate and low incidence can be observed in South America, the Caribbean and 
Northern Africa, and in sub-Saharan Africa and Asia, respectively (Jemal et al., 2011). Such 
international variation in incidence rates is largely due to differences in reproductive and 
hormonal factors (Jemal et al., 2010), as in alcohol consumption (Key et al., 2006). During 
the 1990s both incidence rates strikingly increased in many Western countries, in 
concomitance with the introduction of screening by mammography (Jemal et al., 2011). In 
contrast, mortality has been declined in North America and several European countries over 
the past 25 years, largely as a result of early detection and improved treatment (Jemal et al., 
2011). 
At present, many factors increasing the risk of developing disease have been clarified, 
while others are still under investigation, and efforts to identify strategies for preventing BC 
have been made. 
One of the most documented risk factors for BC is age (Singletary, 2003). The 
incidence is extremely low before age 30, after which increases linearly until the age of 80. 
As also reported for many types of cancers, a strong link exists between aging and the 
accumulation of damages at molecular level, as a result of less effective cellular repair 
mechanisms, which may explain why cancer is typically a disease of advanced age 
(DePinho, 2000). 
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The association between BC risk and reproductive factors has been widely 
investigated, and it still represents a matter of study since it strongly supports a hormonal 
role also in BC etiology (reviewed in Key et al., 2001). Early menarche and late menopause 
increase risk of developing BC. Early age at first term birth is related to lifetime incidence 
reduction and women who had at least one full-term pregnancy benefit from around 25% 
reduction, compared with nulliparous women. Childbearing seems to have a dual effect as 
risk increases in the period immediately after birth, but it gradually diminishes with time and, 
in the longer term, it is protective. Furthermore, protection increases with the number of 
full-term pregnancies. In addition to nulliparity, the absence or short-lifetime duration of 
breastfeeding, which is typical of developed countries, substantially contributes to the high 
incidence of BC. Also studies in less developed countries, where the total duration of 
breastfeeding can be very long, have reported a protective effect. Such observations might 
be explained by the occurrence of cell differentiation during lactation and subsequent lower 
susceptibility of epithelial stem cells to carcinogenesis. 
Use of exogenous hormones was also linked to the risk of developing BC as a 
meta-analysis of 51 epidemiologic studies by the Collaborative Group on Hormonal Factors 
in Breast Cancer (1997) demonstrated a 26% increase in the risk of BC over a 5-year period. 
Importantly, the risk reduces after use of hormonal replacement therapy is stopped and 
disappears after about 5 years. Researchers have also been looking to the use of oral 
contraceptives for many years, but results of these studies are still controversial.  
At the present time there is growing interest in the possible health threat posed by 
endocrine-disrupting chemicals (EDCs), which are substances in our environment, food, and 
consumer products that interfere with hormone biosynthesis, metabolism, or action, resulting 
in a deviation from normal homeostatic control or reproduction. Indeed, some of them are 
chemicals with structural similarities to estrogens, and there is evidence that endocrine 
disruptors have effects on male and female reproduction, breast development and cancer 
(reviewed in Diamanti-Kandarakis et al., 2009). 
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Importantly, family history of the disease represents a key risk factor, indicating that 
genetic determinants also contribute to the incidence of BC. Indeed, 10% to 30% of BC 
cases can be attributed to hereditary factors (reviewed in Apostolou and Fostira, 2013). The 
two most important BC susceptibility genes are BRCA1 and BRCA2 tumor suppressors, 
identified by linkage analysis and positional cloning in the 1990s as key regulators of DNA 
repair, transcription, and cell cycle in response to DNA damage (Miki et al., 1994; Wooster et 
al., 1995; Ralhan et al., 2007). Germline mutations in the BRCA1 gene have been associated 
with the triple-negative (TN) BC subtype, accounting for 60% to 80% of BCs from BRCA1 
mutation carriers (Atchley et al., 2008). 
Over the past several years, our knowledge of specific genetic defects that may 
contribute to familial BC has significantly increased thanks to genome-wide-association 
studies, and beside BRCA1/2, other genes showing variable penetrance are now associated 
with BC genetic risk, e.g. TP53, PTEN, STK11/LKB1, CDH1, CHECK2, PALB2, ATM, BRIP1, 
RAD51C, XRCC2, NBS1, RAD50, MRE11, BARD1, ABRAXAS, RAD51D, MAP3K1, FGFR2, 
LSP1, TNRC19 and H19 (reviewed in Mavaddat et al., 2010; Apostolou and Fostira, 2013).  
Recent advances in DNA sequencing have led to the development of BC susceptibility 
gene panels for germline genetic testing. Risk assessment models and criteria for cancer 
genetics referral as well as guidelines for screening, surveillance protocols and prophylactic 
options were reported by the American Cancer Society and amended by the National 
Comprehensive Cancer Network (reviewed in Stuckey et al., 2016; www.ncnn.org). A major 
limitation of genetic testing is represented by the number of inconclusive results due to 
variants of unknown significance, as missense and splice-site mutations or silent variants or 
mutations in the exonic splice enhancers, thus further efforts should be made to better 
understand their contribution to the pathogenesis of BC. The potentials of next-generation 
sequencing (NGS) technologies may accelerate the process towards the discovery of new 
susceptibility genes and their defects, providing the route to more precise genetic counseling 
and new targeted therapies.   
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1.1.4. On the molecular origin of breast cancer 
Several lines of evidence indicate that tumorigenesis is a multistep process in which all 
tumor cells derive from a single ancestral cell that acquired genetic and epigenetic changes 
providing strong clone-specific selective advantages (Nowell, 1976; Greaves and Maley, 
2012). Such a process is the result of many factors, including inherited mutations or 
polymorphism of cancer susceptibility genes, environmental agents that influence the 
acquisition of somatic genetic changes, and several other systemic and local factors, such as 
hormones and inflammation (Ponder et al., 2001; Polyak, 2001; Coussens and Werb, 2002).  
According to the so-called model of Darwinian somatic evolution of cancer (Nowell, 
1976; Fearon and Vogelstein, 1990), it was assumed that cancer proceeds as a linear 
succession of clonal expansions of cells with progressively increased fitness, triggered by the 
acquisition of advantageous driver mutations. In line with this model, colorectal cancer has 
for more than two decades served as the paradigm for the multi-step concept of cancer 
initiation and progression, theorized by Fearon and Vogelstein (1990). 
A major challenge to BC researchers has been and continues to be the ability to 
distinguish genetic alterations that are critical to tumor initiation from those that are 
epiphenomena of genetic instability, which is a hallmark of tumor progression (Hanahan and 
Weinberg, 2011). Sporadic BC, which constitutes more than 90% of all BCs, is a complex 
and heterogeneous disease at both the clinical and molecular levels. Understanding this 
heterogeneity is crucial for the development of effective therapies and adequate 
management of patients.  
The genomic diversity present in cancer cells ranges from single nucleotide changes to 
large-scale cytogenetic alterations and is caused by increased genomic instability (Lengauer 
et al., 1998). Two main classes of genomic instability exist, each one giving rise to nucleotide 
mutations or complex chromosomal rearrangements (chromosomal instability, CIN). There 
are many mechanisms at the basis of CIN, including multipolar spindles, improper 
chromosome condensation or cohesion, defects in mitotic spindle assembly/dynamics, 
defective mitotic checkpoint and telomere attrition, replication stress, and improper 
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kinetochore-microtubules attachments (Gordon et al., 2012; Thompson et al., 2010). 
Telomere dysfunction drives chromosome fusion and breakage-fusion-bridge (BFB) cycles, 
resulting in complex, unbalanced chromosome rearrangements (Artandi and DePinho, 2000), 
a phenomenon also called “telomere crisis” observed by in situ analysis during the transition 
from mammary ductal hyperplasia to ductal carcinoma in situ (DCIS) (Chin et al., 2004).  
One of the main products of CIN is aneuploidy, a condition associated with the gain or 
loss of whole chromosomes or parts, thereof, leading to genomic imbalances (Geigl et al., 
2008; Gordon et al., 2012). In BC, DNA aneuploidy is detectable in up to a third of patients 
with atypical hyperplasia of mammary epithelium (Carpenter et al., 1987), and it is present in 
the majority of patients with invasive BC carcinoma (Aasmundstad and Haugen, 1990). CIN 
has been suggested to provide phenotypic variation and increase tumor heterogeneity, 
therefore fuelling the ability of cancer cells to progress and adapt to chemotherapy (Roschke 
and Rozenblum, 2013; McGranahan et al., 2012). However, the relationship between CIN 
and drug resistance is far from simple. Indeed, by stratifying tumors using a CIN expression 
signature, Swanton and colleagues found that BCs with the lowest or the highest CIN 
signatures were associated with improved prognosis compared to those with intermediate 
scores (Birkbak et al., 2011). 
Studies based on fluorescence in situ hybridization (FISH) and conventional 
comparative genomic hybridization (CGH) analysis (Gray et al., 1994; Courjal and Theillet, 
1997) describe recurrent DNA amplifications (with presumptive oncogene driver) at 8p12 
(FGFR1), 8q24 (MYC), 11q13 (CCND1), and 17q12 (ERBB2). Another type of genetic 
abnormality frequently observed in breast tumors is the loss of heterozygosity (LOH) on 
chromosomes and chromosome arms 1, 3p, 6q, 7q, 8p, 11, 13q, 16q, 17, 18q, and 22q 
(Bièche and Lidereau, 1995). 
Along with the development of array-based CGH protocols and whole-genome 
sequencing (WGS), several studies defined the fine structure of BC genomes, providing a 
high resolution catalogue of recurrent alterations in correlation with the molecular 
classification based on transcriptome analysis (Cancer Genome Atlas Network, 2012; 
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Nik-Zainal et al., 2016). Beside to genes previously described as implicated in BC (PIK3CA, 
PTEN, AKT1, TP53, GATA3, CDH1, RB1, MLL3, MAP3K1, ERBB2, MYC and CDKN1B), 
such studies allowed the identification of a number of novel mutated genes (TBX3, RUNX1, 
CBFB, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1, CCND3, MED23, FOXP1, MLLT4, 
XBP1 and ZFP36L1), harboring somatic mutations supposed to be implicated in BC 
oncogenesis, defined as driver mutations (Stratton et al., 2009). 
A clear picture of the molecular pathogenesis of BC has not been drawn yet, due to the 
intrinsic heterogeneity of this neoplasm. Since increasing genetic instability is a hallmark of 
tumor progression, Kornelia Polyak sustains and even provided evidence that understanding 
at the molecular level the pathophysiology of lesions in early stage cancers, such as DCIS, 
could be useful to identify critical events in the development of BC and could lead to the 
development of novel therapies that decrease the incidence of potentially lethal invasive 
cancers (Polyak, 2001). 
 
 
1.1.5. Genes and signaling pathways involved in breast cancer initiation and 
progression 
Cancer development is a gradual and complex process resulting from the disruption of 
molecular pathways involved in a series of biological processes (Hanahan and Weinberg, 
2011).  
In breast cancer, the functional implication of the human epidermal growth factor 
receptor 2 (HER2/neu or ERBB2) aberrant expression was first demonstrated two decades 
ago (Slamon et al., 1987) and numerous data now support its transforming potential. The 
rodent neu oncogene, so called because discovered in a rodent neuroblastoma cell line, was 
demonstrated to be the same ortholog of the human ERBB2 (Coussens et al., 1985). The 
transforming function in the neu oncogene is conferred by a point mutation within the 
transmembrane domain, resulting in a V664E mutated protein named neuT that promotes 
receptor dimerization and enhances tyrosine kinase activity (Bargmann et al., 1986; Weiner 
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et al., 1989). Numerous mouse transgenic models have also confirmed the role of this 
oncogene in tumorigenesis since the activated neu oncogene (neuT) expressed in mice 
mammary tissue (MMTV-neuT mice) induces adenocarcinomas (Muller et al., 1988; 
Bouchard et al., 1989).  
The relevance of the experimental data to human disease is also supported by a 
substantial body of clinical data. Overexpression of the HER2 protein, either through gene 
amplification or through transcriptional deregulation, is seen in approximately 25-30% of 
breast and ovarian cancers, and it confers worse biological behavior (Slamon et al., 1989; 
Burstein, 2005). Breast cancers can have up to 25–50 copies of the HER2 gene, and up to 
40–100-fold increase in HER2 protein resulting in 2 million receptors expressed at the tumor 
cell surface (Kallioniemi et al., 1992). Nevertheless, recent genome-sequencing works 
allowed identification of HER2 somatic mutations in BCs lacking HER2 gene amplification, 
some of which were demonstrated to be activating mutations, suggesting that they likely 
drive tumorigenesis (Bose et al., 2013). 
ERBB2 proto-oncogene encodes for a 185 kDa transmembrane glycoprotein belonging 
to the family of four human epidermal growth factor receptors, designated HER1 to HER4, 
respectively. A ligand for HER2 has not been identified and it is hypothesized that the main 
function of HER2 is to co-operate in signal transduction by forming heterodimers with other 
members of the HER family (Graus-Porta et al., 1997; Figure 1.1.5). Several mechanisms of 
HER2-mediated tumorigenesis have been proposed (reviewed in Moasser, 2007), and in the 
most widely accepted mechanistic model HER2 induces transformation through increased 
kinase activity (reviewed in Harari and Yarden, 2000).  
Numerous studies have shown an intriguing interrelationship between HER2 and 
estrogen receptor (ER), and to a lesser extent, progesterone receptor (PgR) expression in 
BC. With exceptions, there is a strong, highly significant inverse relationship between ER 
status and either HER2 or HER1 overexpression (Battaglia et al., 1988; Cappelletti et al., 
1988) and numerous studies also indicate that a mutually repressive feedback signaling loop 
exists between HER2 and ER expression (reviewed in Harari and Yarden, 2000). 
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Nevertheless, even estrogen, working via the non-genomic activity of the 
membrane-associated ER, has been shown to activate HER2 signaling (Shou et al., 2004). 
 
 
Figure 1.1.5. ERBB2 heterodimerization and signaling pathway. Signaling downstream of HER 
family activation is dependent on heterodimerization of the HER family member triggered by ligand 
binding to the extracellular ligand-binding domain (with the exception of HER2, which has no identified 
ligand and is always in an open conformation that allows dimerization). Phosphorylation of the HER 
kinase domains (with the exception of HER3, which does not have a kinase domain) initiates a 
downstream cascade resulting in VEGF transcription and other physiological responses required for 
carcinogenesis. Abbreviations: AR, amphiregulin; BTC, betacellulin; EPG, epigen; EPR, epiregulin; 
HB-EFG, heparin-binding EGF-like ligand; NRG, neuregulin. Arteaga et al., 2011 
 
The connection between a woman’s hormonal status and her risk of developing BC has 
been suspected since 1713, when Bernardino Ramazzini noted that nulliparous were more 
likely to develop BC than women who had borne children. In 1896 George Beatson provided 
evidence for the first time for the dependence of BC on ovarian function. He observed the 
regression of both advanced cancer (Beatson, 1896) and metastatic disease (Boyd, 1900) in 
premenopausal women following oophorectomy.  
Estrogen effects are exerted through two types of specific nuclear receptor, estrogen 
receptor alpha (ERα, ESR1, chromosome 6) and beta (ERβ, ESR2, chromosome 14), which 
act in a ligand-dependent manner. The binding of estrogen in the hormone-binding domain 
(HBD), induces a trans-conformational change of the whole molecule allowing unmasking of 
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the activating function 1 (AF-1) in domain A/B, with subsequent dimerization, translocation to 
the nucleus and binding to estrogen-responsive element (ERE, reviewed in Sommer and 
Fuqua, 2001). 
Beside the classical model, estradiol (E2) modulates transcription via a non-canonical 
activation pathway, according to which ligand binding leads to the interaction of ER with 
other transcription factors as AP-1, Sp1 or NF-κB. A number of genes, including those 
encoding for trefoil factor 1/pS2, cathepsin D, cyclin D1, gene regulated by estrogen in breast 
cancer 1 (GREB1), c-Myc and progesterone receptor, are positively regulated by ERα, as 
also confirmed for the majority of them by chromatin immunoprecipitation studies (reviewed 
in Welboren et al., 2007).  
Another mechanism, originally called “non-genomic” (Morley et al., 1992), has been 
implicated in the ER activity, since a rapid activation of several signaling pathways 
(PLC/PKC, Ras/Raf/MAPK, PI3K/Akt and cAMP/PKA) was observed to occur upon estradiol 
binding. The plasma membrane-associated ER is responsible for non-genomic pathway and 
co-operates with ER’s nuclear activity (Björnström and Sjöberg, 2005; Figure 1.1.6).  
Regulation of ER activity is also mediated in a ligand-independent manner (reviewed in 
Marino et al., 2006) by a series of signaling pathways downstream of growth receptors, such 
as EGFR, IGFR and ERBB2, which induce activation of the receptor via phosphorylation of 
some serine (for example S118, Kato et al., 1995) and tyrosine residues in the AF-1 and 
AF-2 domains. In addition, mutations in the ERα gene ESR1, such as the first described 
Tyr 537 Asn (Zhang et al., 1997) at the HBD level, and others more recently identified 
(Robinson et al., 2013), have been shown to elicit changes in receptor activation by 
conferring constitutive activity.  
Ample clinical and experimental data demonstrates the major role played by ER in BC 
development and progression, so that pharmacological targeting of the receptor has become 
an important treatment strategy, also for chemoprevention. Antiestrogens (AEs) are used 
successfully in order to inhibit ER-mediated activation of gene transcription although, 
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unfortunately, clinical resistance develops eventually (reviewed in Clarke et al., 2003, and in 
Viedma-Rodríguez et al., 2014).  
 
 
 
Figure 1.1.6. Estrogen receptor signaling pathway. ER response to estradiol and its metabolites is 
exerted by transcription of genes prevalently related to cell proliferation, and by a non-genomic 
pathway which involves a cytosolic or membrane-located form of ER. Its activity is also mediated in a 
ligand-independent manner, via the activation of tyrosine kinase receptor pathways. Abbreviations: 
ER, estrogen receptor; EGFR, epidermal growth factor receptor; IGF-1R, insulin growth factor 
receptor 1; E2, 17-β-estradiol. Yager and Davidson, 2006 
 
 
During the last decade much attention has been focused on targeting the receptor 
tyrosine-kinases (RTKs) signaling pathway, which is aberrantly activated in BC with 
overwhelming frequency (Alvarez et al., 2010). RTKs, such as EGFR, IGFR, FGFR and 
VEGR, can activate downstream Ras/Raf/MAPK, JAK/Stat, PI3K/AKT/mTOR, JNK, and 
PLCγ signalling pathways, which regulate a plethora of cellular functions such as growth, 
survival, proliferation, metabolism, apoptosis, adhesion and motility (Figure 1.1.7).  
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Figure 1.1.7. Deregulated signaling pathways in breast cancer. Eroles et al., 2012 
 
 
IGFR has been reported to be involved in BC progression. Fifteen percent of BCs 
contain genomic alterations in the IGF pathway, documented by NGS (Cancer Genome Atlas 
Network, 2012), which consist mainly of amplification and are generally rare, with only IGF1R 
and IRS2 showing amplification in >5% of cases, whereas when considering mRNA levels 
45.3% of BCs show a molecular alteration in at least one IGF family member. IGF pathway is 
regulated in many critical points, from ligand availability to negative feedback mechanisms 
exerted by mTOR (Wan et al., 2007), and IGF1R/PI3K/AKT/mTOR pathway has been largely 
looked into the past decade as a target to treat BC (Tabernero et al., 2008).  
Amplification of FGFR genes, including FGFR1 and FGFR2, was initially documented 
in human BC samples in the early 1990s (Adnane et al., 1991). A surge of studies within the 
last 5-10 years has both confirmed these initial observations and expanded significantly upon 
the mechanisms through which the FGF/FGFR axis contributes to BC (Hynes and Dey, 
2010). 
Apoptosis plays a key part in the development of the normal breast and its deregulation 
overrides many of the normal checkpoint pathways and leads to the expansion of neoplastic 
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cells. Recent data suggest that a subset of triple-negative/basal-like breast cancer cells is 
sensitive to TRAIL as a single agent (Rahman et al., 2009). In addition, many studies have 
demonstrated that resistance to TRAIL-mediated apoptosis in BC cells can be overcome by 
combinations of TRAIL with chemotherapy, radiation, and various targeted agents. Moreover, 
cyclin D1 has been reported to be overexpressed in more than 50% of human BC. Its 
expression causes mammary cancer in transgenic mice, altered CCND1 expression 
contributes to the loss of normal cell cycle control during tumorigenesis and recent studies 
have demonstrated that cyclin D1 conducts additional specific functions to regulate gene 
expression at chromatin level, promotes cellular migration and inhibits mitochondrial 
metabolism (reviewed in Velasco-Velázquez et al., 2011).  
One feature of BRCA-mutated cancers is the defective function of one of the major 
DNA damage repair pathways, the homologous recombination (HR) pathway. The 
observation that BRCA-mutated BCs show impairment in HR pathways and that some 
sporadic triple-negative BCs (TNBCs) display a phenotype resembling BRCA1-mutated 
cancers without harboring a BRCA1 mutation (Turner et al., 2004) led to the application of 
PARP inhibition, as enzyme involved in DNA-damage repair, for TNBC treatment (reviewed 
in Livraghi and Garber, 2015). 
Finally, recent discovery and revaluation of the portion of human genome non-coding 
for proteins opened a new window in cancer studies. More interestingly, it has been noticed 
that also alterations of non-coding genes, including micro-RNAs and long non-coding RNAs 
(lncRNAs), are related to BC pathogenesis. Altered micro-RNA expression has been 
observed in BC, and a large body of evidence proved a contribute for some of these gene 
expression modulators, such as miR-21, miR-155, miR-10b, miR-34a, miR-125a,b, and the 
miR-200 family, also to the development of cancerous phenotypes (reviewed in 
van Schooneveld et al., 2015). Accumulating evidence also highlights the potential role of 
lncRNAs as biomarkers and therapeutic targets in solid tumors. Recently, compelling results 
in preclinical transgenic models proved that targeting MALAT1 could represent a safe and 
effective treatment for BC (Arun et al., 2016). Moreover, the first profiling study on 658 cases 
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of infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project allowed 
identification of lncRNAs that are likely to play important role as regulators of BC initiation 
and progression, probably affecting gene expression by chromatin remodeling and histone 
modification (Su X. et al., 2014). 
 
 
1.1.6. Histological pathogenesis of breast cancer  
The current model of human BC progression proposes a linear multistep process which 
initiates as flat epithelial atypia (FEA) - characterized by replacement of the native epithelial 
cells of the terminal duct and lobular units (TDLUs) by one and up to five cell layers of mildly 
atypical cuboidal to columnar cell population with apical snouts - progresses to atypical 
ductal hyperplasia (ADH) – when the ducts are only partially or largely populated by the 
atypical cells, i.e. cells with morphological and differentiation alterations -, evolves into low to 
high grade ductal carcinoma in situ (DCIS) - presence of mildly to highly atypical cells with 
low to high-grade, pleomorphic nuclei with irregular contour -, and culminates in the 
potentially lethal stage of invasive ductal carcinoma (IDC), in a sort of evolutionary continuum 
(Oyama et al., 1999; Page and Rogers, 1992).  
The ductal and lobular histological subtypes constitute the majority of all BCs 
worldwide, with the ductal subtype accounting for 50-80% of all diagnosed cases (Ellis, 2003; 
Lakhani et al., 2012). Epidemiologic and morphologic observations led to the formulation of 
several linear models of BC initiation, transformation and progression (reviewed in 
Bombonati and Sgroi, 2011; Figure 1.1.8). For the ductal subtype, two models have been 
proposed. The first “ductal” model recognizes FEA, ADH and DCIS as the non-obligate 
precursors of invasive and metastatic ductal carcinoma. The second “ductal” model, 
supported by epidemiological studies, proposed usual epithelial ductal hyperplasia (UDH) - 
characterized by proliferation of a heterogeneous cell population with irregularly shaped and 
sized secondary lumens - as an intermediate stage of progression between FEA and DCIS. 
Immunohistochemical and recent molecular biological evidence strongly suggests that UDH 
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is not a precursor to ADH and that this second model of progression is likely to be invalid. 
For the lobular subtype, the progression scheme recognizes atypical lobular hyperplasia 
(ALH) and lobular carcinoma in situ (LCIS) as the non-obligate precursor lesions to invasive 
lobular carcinomas (reviewed in Bombonati and Sgroi, 2011). 
Additional support for these models is provided by several genome and transcriptome 
analyses. CGH studies demonstrated frequent loss of 16q in low-grade DCIS and 13q loss 
and amplification of 17q12 and 11q13 in high-grade DCIS. LOH-based studies identified loss 
of 16q as a hot spot in ADH and a recurrent chromosomal aberration in FEA, and revealed 
that this alteration is most frequently shared with low-grade rather than high-grade DCIS. 
Notably, this common pattern of genomic alterations is not observed in UDH, lesion that 
displays rare and randomly distributed chromosomal alterations that make it more similar to 
the histopathologically normal breast than ADH. Until recently, identification of the precursor 
lesion of high grade DCIS remained elusive (reviewed in Bombonati and Sgroi, 2011).  
Together, these studies provide evidence that: 1) DCIS, like IDC, consists of two 
distinct genetic pathways correlating with tumor grade, and that DCIS is direct precursor to 
IDC, 2) ADH is a precursor to low-grade DCIS, 3) FEA is genetically related to ADH and is 
likely a precursor to ADH, 4) at the genomic level UDH is most similar to normal breast 
epithelium and is not a precursor to ADH. In addition, immunohistochemistry (IHC) and 
comparative genomic hybridization (CGH) studies suggest that 5) microglandular adenosis 
may represent a precursor lesion to a subset of high grade DCIS lesions (reviewed in 
Bombonati and Sgroi, 2011). 
Comparative gene expression studies support the concept that low-grade and 
high-grade DCIS likely arise from two distinct evolutionary pathways and that ADH is the 
precursor of low-grade DCIS, since ADH and low-grade DCIS share a near identical gene 
expression profile enriched in genes associated with the ER-positive phenotype, whereas 
high-grade DCIS possesses uniquely different profile enriched in genes associated with 
mitotic-activity and cell-cycle progression (Ma et al., 2003). In addition, the study 
demonstrated that globally no consistent major transcriptional changes occurred between the 
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preinvasive and invasive stages and that the transition from preinvasive disease to invasive 
disease was mainly associated with quantitative, rather than qualitative, differences. This 
indicates that BC progression may be more intricate than predicted by the traditional model 
based on activation of oncogenes and inactivation of tumor suppressor genes, and that this 
process may be reliant upon quantitative and temporal gene expression shifts. 
 
 
Figure 1.1.8. Models of breast cancer progression. (A) One of the “ductal” models recognizes FEA, 
ADH and DCIS as the non-obligate precursors of invasive and metastatic ductal carcinoma. (B) 
Another “ductal” model proposes usual epithelial ductal hyperplasia (UDH) as an intermediate stage of 
progression between FEA and DCIS. (C) Progression model for the lobular subtype, according to 
which atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are the non-obligate 
precursor lesions to invasive lobular carcinoma. Bombonati and Sgroi, 2011 
 
 
Differently from DCIS, few studies have focused on the genomic alterations associated with 
LCIS. These studies demonstrated common loss of chromosome 16q in ALH, LCIS and ILC 
supporting an evolutionary link among the three lesions (Mastracci et al., 2006; Morandi 
et al., 2006). 
Recent advances in comprehensive, high-throughput genome, transcriptome and 
epigenome analyses has provided a more complete understanding of the complex genetic 
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and biological inter-relationships of the different stages of human BC evolution. Human BC 
appears to progress along two distinct molecular genetic pathways that strongly associate 
with tumor grade. Moreover, the cancer stem cell (CSC) model and the role of the tumor 
microenvironment as not simple bystander of the cancerogenesis process contribute to the 
complexity of BC. Despite these significant advances, we have only begun to understand the 
pathogenesis of BC and it is anticipated that our knowledge in this field will receive novel 
insights with the advent of additional novel technologies.  
 
 
1.1.7. Breast cancer heterogeneity and biomarkers 
The classification of invasive BC currently involves the assessment of histological 
criteria encompassing both morphology-based and IHC analyses. Traditional pathological 
parameters such as histological type, tumor size, histological grade and axillary lymph-node 
(LN) involvement have been shown to correlate with clinical outcome and provide the basis 
for prognostic evaluation (Elston et al., 1999). IHC markers such as the expression of 
hormone receptors ER and PgR and the overexpression and/or amplification of HER2 
provide additional therapeutic predictive value and are of key importance in guiding treatment 
selection (Harris et al., 2007). 
Hormone receptor-positive breast cancers account for around 75–80% of all cases and 
standardized IHC assays for the routine testing of ER and PgR are used to guide the 
selection of patients for hormonal-based therapies. HER2 represents the only additional 
predictive marker currently in routine use. Approximately 10–15% of breast cancers have 
HER2 overexpression and/or amplification with around half of these co-expressing hormone 
receptors (Konecny et al., 2003). These patients are selected for anti-HER2 based therapies, 
including the humanized monoclonal HER2 antibody, trastuzumab, which targets the 
extracellular domain of the HER2 receptor. The remaining 10–15% of BCs are defined by 
hormone receptor and HER2 negativity (i.e., TNBCs), which represent a key clinical entity 
given their lack of therapeutic options (Dawson et al., 2009).  
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While the current classification of human breast tumors has been fundamental for 
prognostic and predictive evaluation, there remain a number of important limitations. First, 
considerable variation in response to therapy and clinical outcome still exists, even for 
tumors with apparent similarities in clinical and pathological characteristics. Second, this 
classification continues to provide limited insight into the complex underlying biology and the 
molecular pathways driving the disease in different subtypes.  
Expression analysis using microarray-based technology has provided researchers with 
an opportunity to begin moving towards comprehensive molecular profiling of breast cancer. 
These efforts have resulted in the identification of clinically relevant molecular subtypes, and 
have provided early insights into the molecular heterogeneity of the disease (Perou et al., 
2000; Sorlie et al., 2003; Hu et al., 2006). Five distinct intrinsic subtypes have been identified 
based solely on gene expression: luminal A, luminal B, HER2 overexpressing, basal-like and 
normal breast tissue-like. Differences in gene expression patterns reflect basic alterations in 
the cell biology of the tumors and importantly are associated with significant variation in 
clinical outcome (Sorlie et al., 2003). The prognosis of patients with ER-positive disease is 
largely determined by the expression of genes related to proliferation (Hu et al., 2006). More 
recently, the intrinsic classification has been refined in a PAM50 assay based on the 
expression of 50 genes designed to classify single samples into each of the five intrinsic 
subtypes (Parker et al., 2009; Nielsen et al., 2010).  
Following the initial identification of the intrinsic molecular subtypes, gene expression 
studies have evolved and further sub-classification of BCs into new molecular entities have 
been proposed. For example, a detailed analysis of genes differentially expressed in 
ER-negative tumors has demonstrated that basal breast cancers are a heterogeneous group 
with at least four main subtypes (Teschendorff et al., 2007). Furthermore, this analysis 
revealed an immune response gene expression module, which identifies a good prognosis 
subtype in ER-negative disease. Other recent studies have also identified a new breast 
cancer intrinsic subtype known as Claudin-low or mesenchymal-like (Prat et al., 2010). This 
subtype is characteristically negative for ER, PgR and HER2 and carries an intermediate 
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prognosis between basal and luminal subtypes. Importantly, Claudin-low/mesenchymal 
tumors appear to be enriched with cells showing distinct biological properties associated with 
mammary stem cells and tumor initiating potential (Hennessy et al., 2009; Lim et al, 2009; 
Lehmann et al., 2011). 
Distinct patterns of genomic rearrangements in BC have been characterized and 
changes in gene expression patterns were shown to be influenced by the genomic 
architecture (Chin et al., 2006; Ding et al., 2010). The emergence of NGS technologies has 
now allowed the characterization of the mutational landscape of the disease. These analyses 
have identified novel cancer genes found to be recurrently mutated in BC and have 
demonstrated the extent of heterogeneity across BC genomes (Shah et al., 2009; Shah et 
al., 2012; Nik-Zainal et al., 2016). Through the integrated analysis of both genomic and gene 
expression data across large numbers of BCs, Curtis and colleagues have recently 
extensively characterized 2000 breast tumors as part of METABRIC (Molecular Taxonomy of 
Breast Cancer International Consortium), revealing the existence of 10 novel molecular 
subgroups (Curtis et al., 2012), called integrative clusters (IntClust 1–10), each associated 
with distinct copy number somatic aberrations (CNAs) and gene expression changes. These 
clusters clearly demonstrated the heterogeneity present within tumors classified according to 
ER, PgR and HER2 expression, and they divided all of the previously identified intrinsic 
subtypes into separate groups (Figure 1.1.9). Furthermore, the 10 groups were associated 
with distinct clinical features and outcomes (Curtis et al., 2012). 
In parallel with the identification of the intrinsic subtypes, gene expression profiling 
(GEP) has also been used by several groups to identify distinct prognostic signatures 
(van de Vijver et al., 2002; van’t Veer et al., 2002; Paik et al., 2004). Two of these signatures, 
MammaPrint, a microarray-based assay of 70-gene breast cancer signature developed in 
Amsterdam, and OncotypeDX, a polymerase chain reaction (PCR)-based assay of a panel of 
21 genes, have been approved for clinical use and are now being tested in randomized 
clinical trials (Cardoso et al., 2008; Sparano and Paik, 2008).  
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Figure 1.1.9. Relationship between the 10 integrative clusters and ER, HER2 and PgR 
expression. Dawson et al., 2013 
 
 
MammaPrint is a Food and Drug Administration (FDA)-cleared microarray-based test 
that uses expression levels of the 70 genes to assess distant recurrence risk in early-stage 
BC. The primary analysis of the MINDACT trial to prospectively test the 70-gene signature 
was conducted on patients deemed clinically high risk but genomically low risk who were 
randomized not to receive chemotherapy. The 5-year distant metastasis–free survival 
(DMFS) for this group was 94.7%, thus confirming the value of genomic profiling for patients 
with early BC with 0 to 3 positive LNs (Piccart et al., 2016). Moreover, the prospective 
RASTER study proved that MammaPrint Low Risk patients can safely forgo chemotherapy 
(Drukker et al., 2013), which is further subject of the prospective randomized MINDACT trial. 
The 21-gene expression assay was proven to predict recurrence in tamoxifen-treated 
node-negative BC patients (Paik et al., 2004) and benefit from adjuvant chemotherapy in 
estrogen-receptor–positive disease (Paik et al., 2006), and its usefulness was furthermore 
validated in the prospective TAILORx study (Sparano et al., 2015). However, a recent report 
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showed that intratumor heterogeneity may affect the detection of genes included in various 
GEP signatures (Oncotype Dx, MammaPrint, PAM50, EndoPredict, and Breast Cancer 
Index), and therefore the ability of the test to predict prognostic risk (Gyanchandani et al., 
2016). 
Monitoring tumor-specific alterations in cell-free DNA (or circulating tumor DNA) is now 
under investigation as tumor ‘liquid biopsy’. Circulating tumor DNA (ctDNA) may be used to 
characterize tumor heterogeneity and metastasis-specific mutations providing on tumor 
adaptation during therapy and helping clinical decision-making when a shift toward 
alternative and personalized therapies is needed. Recent studies provided a proof of concept 
of the potential utility of ctDNA monitoring, demonstrating that tracking specific mutations in 
blood allows early measurement of response to treatment in metastatic BC (Dawson et al., 
2013) and early prediction of relapse in early BC (Garcia-Murillas et al., 2015). 
 
 
1.1.8. Breast cancer diagnosis and treatment 
(Senkus et al., Primary BC:ESMO clinical practice guidelines, Ann Oncol 2015; 
www.cancer.gov; AIOM guidelines www.aiom.it) 
 
The diagnosis of BC is based on clinical examination in combination with imaging, and 
it is confirmed by pathological assessment. Other assessments are complete personal and 
family medical history. Clinical examination includes bimanual palpation of the breasts and 
locoregional LNs and assessment for distant metastases (bones, liver and lungs; a 
neurological examination is only required when symptoms are present). Imaging includes 
bilateral mammography and ultrasound of the breast and regional LNs.  
At present, bilateral mammography is considered the most effective screening test and 
many European countries have established national or regional population-based 
mammography screening programmes to detect BCs at a pre-clinical stage. Indeed, 
screening every 2 years has shown the greatest mortality reduction benefit in the 50- to 
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70-year age group, while the evidence for effectiveness of mammography screening in 
women aged 40-49 years is limited. In women with familial BC, with or without proven BRCA 
mutations, annual screening with magnetic resonance imaging (MRI) of the breast, in 
combination with mammography is recommended, but it should be considered also in cases 
of breast implants, lobular cancers, suspicion of multifocality/multicentricity (particularly in 
lobular BC) or large discrepancies between conventional imaging and clinical examination.  
Apart from physical examination and imaging, it is mandatory to perform pre-treatment 
pathological examination of the primary tumor histology and cytology of the axillary nodes, if 
involvement is suspected. Indeed, BC cells are most likely to spread first to LNs located in 
the axilla, even if in cancers near the breastbone they tend to spread first to LNs inside the 
chest before they can be detected in the axilla. Lymph node involvement occurs at different 
extent. Isolated tumor cells are defined as small clusters of cells not greater than 0.2 mm, or 
nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single 
histologic LN cross section. Micrometastatic nodal involvement is defined as a cluster of cells 
>0.2 mm but no greater than 2.0 mm. Macrometastatic involvement of the axillary nodes 
(classically designated as "node-positive") is defined by any tumor cell cluster >2.0 mm. The 
presence of macrometastases within the axillary nodes is a well-established and 
independent prognostic factor, with a worse prognosis associated with greater nodal 
involvement. Occult micrometastases refer to nodal metastases that are not seen on initial 
histological examination but are detected subsequently by IHC or PCR.  
Pathological diagnosis provides information useful for tumor staging, histological 
classification, grading and IHC evaluation of ER status (using a standardized assessment 
methodology, e.g. Allred or H-score), PgR status and HER2 expression, as also of Ki67 
labeling index. HER2 gene amplification status may be determined directly on all invasive 
tumors using in situ hybridization (fluorescent, chromogenic or silver), in addition to IHC or 
only for tumors with an ambiguous (2+) IHC score. The guidelines for HER2 testing have 
recently been updated by the ASCO–College of American Pathologists group. A change has 
been introduced in the definition of HER2 positivity by IHC (tumor are defined 3+ when more 
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than 10% of the cells, instead of 30%, show a complete membrane staining), and by in situ 
hybridization (positive if the number of HER2 gene copies is ≥6 or the ratio 
HER2/chromosome 17 is ≥2, instead of 2.2). The definition of equivocal cases is broader; if a 
case is defined as equivocal after two tests it is eligible for trastuzumab, and should be 
discussed in multidisciplinary tumor boards (Wolff et al., 2013).  
As asymptomatic distant metastases are very rare, assessment of metastatic disease 
is based on physical examination. Additional investigations such as chest computed 
tomography (CT), abdominal ultrasound or CT scan and bone scan are considered for 
patients with clinically positive axillary nodes, large tumors (e.g. ≥5 cm), aggressive biology 
or clinical signs, symptoms or laboratory values suggesting the presence of metastases. 
Dual imaging methods combining functional and anatomical information such as the 
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET)/CT may be useful 
when conventional methods are inconclusive. 
Patients with BC have different treatment options: surgery, radiation therapy, 
chemotherapy, hormone therapy and targeted therapy. The choice of treatment strategy is 
based on biology (pathology including biomarkers, gene expression) and tumor 
extent/location (size and location of primary tumor, number of lesions, number and extent of 
lymph node involvement), as well as on the age and menopausal status. 
Local treatment includes surgery and radiation therapy (RT). The major change in the 
surgical treatment of primary BC has been a shift from radical mastectomy towards breast 
conservation, which started more than 30 years ago (Veronesi et al.,1977, Veronesi et al., 
1981; Veronesi et al., 2002).  
Regional lymph node status remains one of the strongest predictors of long-term 
prognosis in primary BC. Historically, removal of tumor positive lymph nodes (called axillary 
lymph node dissection) was done to help disease staging and prevent regional recurrence, 
i.e. cell migration to nearby lymph nodes that give rise to a new tumor. Since removing 
multiple lymph nodes at the same time has been associated with adverse effects, as 
lymphedema, sentinel lymph node biopsy (SLNB) procedure has been introduced in order to 
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identify, thanks to injection of a tracer, and remove only lymph nodes involved in cancer 
spread (Veronesi et al., 1997).  
Whole breast RT is recommended after breast-conserving surgery (BCS) to reduce the 
risk of recurrence (including locoregional and distant). Radiation after mastectomy is 
recommended for high-risk patients, including those with involved axillary nodes and/or T3-T4 
tumors. Locoregional RT encompassing the chest wall and all regional lymph nodes is 
indicated when cancer has spread in the lymph nodes or at distant sites, such as the bones 
or brain. 
Diverse systemic treatments for BC are available, and their choice is essentially 
tailored on the phenotypic subtypes, determined by ER/PgR, HER2 and Ki67 assessment, or 
on the molecularly-based intrinsic subtype.  
For tumors with ER-positive and/or PgR-positive cancer cells, whose growth is affected 
by the level of circulating hormones, endocrine therapy (ET) represents the treatment of 
choice. It is based on the administration of hormones analogues that modulate the function 
(tamoxifen, toremifene) or cause degradation (fulvestrant) of their receptors. Aromatase 
inhibitors (AIs), as letrozole, anastrozole and exemestane, are drugs that interfere with 
estrogen production in post-menopausal women, where a small amount of estrogen is still 
made by aromatase enzyme present in the fat tissue. In pre-menopausal women also 
luteinizing hormone-releasing hormone (LHRH) analogs are used to induce temporary 
ovarian ablation. 
Patients with HER2-positive BC are eligible for targeted therapy with a recombinant 
humanized monoclonal antibody directed against the extracellular subdomain IV of HER2 
(trastuzumab). The effect of trastuzumab on tumor proliferation is mediated by several 
mechanisms of actions (Hudis, 2007), such as internalization and degradation of HER2, 
inhibition of MAPK and PI3K-Akt downstream signaling pathways, antigen-dependent cellular 
cytotoxicity mediated by natural killer cells, and inhibition of tumor angiogenesis. Clinical 
studies have shown that the combination of trastuzumab with standard chemotherapy 
produces far better response rates than chemotherapy alone (Slamon et al., 2001; Vogel et 
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al., 2002). Thus, the combinations that include trastuzumab have been considered as the 
standard of care for HER2-overexpressing BC patients (Hudis, 2007).  
In addition to trastuzumab, other anti-HER2 biological therapies have been approved 
(reviewed in Baselga and Swain, 2009). Pertuzumab is a monoclonal antibody which binds to 
HER2 subdomain II and acts by inhibiting HER2 heterodimerization with HER1, HER3 and 
HER4. A recent clinical trial (CLEOPATRA) showed that first-line therapy with pertuzumab, 
trastuzumab, and docetaxel significantly improved overall survival among patients with 
HER2-positive metastatic BC, as compared with placebo, trastuzumab, and docetaxel as 
control groups (Swain et al., 2015).  
Nevertheless, therapy resistance may occur and since women with advanced or 
metastatic HER2-positive BC have limited therapeutic options once their disease has 
progressed on trastuzumab-based standard initial chemotherapy regimens, novel anti-HER2 
therapies have been explored. A new drug is represented by a small molecule (lapatinib), 
acting as a dual receptor tyrosine kinase inhibitor of both ErbB1 and ErbB2. In addition, 
lapatinib combined with capecitabine has demonstrated superior efficacy over capecitabine 
alone in this group of patients compared to the monotherapy arm (Geyer et al., 2006), and 
now it is indicated in combination with capecitabine for the treatment of patients with 
advanced or metastatic BC whose tumors overexpress HER2 and who have received prior 
therapy including an anthracycline, a taxane, and trastuzumab.  
Also surgery and systemic therapies can be combined according to the stage of the 
disease. In just the past decade, there has been a rapid evolution in BC treatment protocols. 
With the primary objective to improve surgical outcomes in patients for whom a primary 
surgical approach is technically not feasible and in patients with operable BC who desire 
breast conservation, but for whom either a mastectomy is required or a partial mastectomy 
would result in a poor cosmetic outcome, neoadjuvant, or perioperative, therapy, i.e. the 
systemic treatment of BC prior to definitive surgical therapy, (Kaufmann et al., 2006; Gralow 
et al., 2008), has been introduced into clinical practice. Neoadjuvant treatment has been 
compared with standard, postoperative adjuvant chemotherapy, with the dual goals of 
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improving survival and facilitating local therapies. Unfortunately, neoadjuvant chemotherapy 
does not seem to improve overall survival, as demonstrated in the National Surgical Adjuvant 
Breast and Bowel Project B18 trial, among others (reviewed in Schott and Hayes, 2012). 
Aside from the potential clinical benefits that are achieved by downstaging, neoadjuvant 
therapy allows direct and early observation of the response to treatment, which in theory 
could lead to modifications of the treatment plan in the event of poor response. However, 
clinical and radiographic monitoring during neoadjuvant chemotherapy to predict pathologic 
complete response (pCR) is notoriously inaccurate and there is little agreement regarding the 
precise definition of pCR. On the basis of the limited clinical advantages of neoadjuvant 
chemotherapy, postoperative adjuvant systemic therapy is considered the standard of care 
(Schott and Hayes, 2012). Nevertheless, excluding these clinical objectives, neoadjuvant 
therapy gives researchers the opportunity to obtain tumor specimens (both fresh and 
formalin-fixed) and blood samples prior to and during the preoperative treatment in order to 
identify tumor- or patient-specific biomarkers (Daidone et al., 2011). 
Although most patients present with localized breast cancer and may be cured with 
local therapy, distant recurrence may occur and is the primary cause of death from the 
disease. The widespread use of adjuvant therapies, including both systemic therapies and 
RT given after the primary treatment, proved to be effective in reducing the risk of distant and 
local recurrence, and has contributed to reduced BC mortality rates (reviewed in Anampa 
et al., 2015). In 1976, Bonadonna and colleagues published the results of their landmark trial 
of adjuvant chemotherapy for breast cancer (Bonadonna et al., 1976), showing that 12 
months of postoperative chemotherapy consisting of cyclophosphamide, methotrexate, and 
fluorouracil (CMF) decreased the risk of recurrence of BC in women with positive axillary 
lymph nodes. Since then, adjuvant cytotoxic chemotherapy regimens have evolved from 
single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or 
taxanes and treatments are recommended to start within 2-6 weeks after surgery. 
Subsequent trials also showed benefit in lower risk post-menopausal women (Albain et al., 
2009) and women with axillary node-negative disease (Mansour et al., 1989; Fisher et al., 
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1997). Despite the most recent publication of the Early Breast Cancer Trialists’ Collaborative 
Group overview states that the relative benefit of chemotherapy is similar in all the subgroups 
independent of age, stage, histopathological grade and ER status (Peto et al., 2012), there is 
large consensus with the 2013 and 2015 St. Gallen guidelines, which recommend, for 
luminal cases with unclear chemotherapy indications, that the decision on systemic adjuvant 
therapies should be based on the surrogate intrinsic phenotype (Figure 1.1.10), that is 
determined by ER/PgR, HER2 and Ki67 assessment, with the help of genomic tests when 
available (Coates et al., 2015). Generally, i) all patients with detectable ER expression, 
defined as ≥1% of invasive cancer cells, should be offered ET, ii) for luminal HER2-negative 
cancers, chemotherapy should not be used concomitantly with ET, iii) while Luminal B 
HER2-positive tumors should be treated with chemotherapy, ET and trastuzumab; iv) 
HER2-positive (non-luminal) cancers should be treated with chemotherapy plus trastuzumab, 
and v) triple-negative tumors benefit from adjuvant chemotherapy only, consisting of four to 
eight cycles of anthracycline- and/or taxane-based regimen, and available alternatives to 
treat these patients are still scarce. 
Patients presenting with metastatic disease at first diagnosis represent only the 7% of 
the population. In the vast majority of cases stage IV BC is diagnosed in patients previously 
treated with neoadjuvant therapy. About 30% of node-negative and 70% of node-positive 
patients will eventually undergo disease relapse, within shorter time for patients with TN and 
HER2-positive BC, and with a higher risk of bone metastases in patients with 
hormone-sensitive tumors, or recurrence at central nervous system in women with 
HER2-positive and triple-negative tumors. The aim of treatment for secondary (metastatic) 
BC is to control the growth or spread of cancer, to relieve symptoms and improve or maintain 
the quality of life. Also in this case biological features of disease are important in treatment 
choice, aside with clinical parameters to distinguish an indolent from an aggressive 
metastatic disease. In the presence of osteolytic lesions, bisphosphonates are used to 
reduce the risk of fractures and studies are ongoing to evaluate if they improve the benefit of 
adjuvant chemotherapies. Overall, treatment options for patients with recurrent or metastatic 
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disease are limited and remain a major therapeutic challenge (Santa-Maria and Gradishar, 
2015). 
New therapies have been developed in recent years, and some of them were also 
approved. In 2007, the U.S. FDA approved ixabepilone – which stabilize microtubules - for 
the treatment of aggressive metastatic or locally advanced breast cancer no longer 
responding to currently available chemotherapies. Ixabepilone, in combination with 
capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally 
advanced breast cancer in patients after failure of an anthracycline and a taxane.  
The mesylate salt Eribulin (fully synthetic macrocyclic analogue of halichondrin B which 
acts on microtubules) was also approved by the FDA in 2010 to treat patients with metastatic 
BC who have received at least two prior chemotherapy regimens for late-stage disease, 
including both anthracycline- and taxane-based chemotherapies.  
Everolimus (mTOR inhibitor) is approved for post-menopausal women with advanced 
hormone receptor-positive, HER2-negative BC. It is used along with the aromatase inhibitor 
exemestane (Aromasin) for women progressing under letrozole or anastrozole treatments. 
PARP inhibitors are most likely to be helpful against cancers caused by BRCA 
mutations. These drugs have shown some promise in early clinical trials treating some types 
of breast and other cancers. Further studies are being done to determine when these drugs 
might be most helpful. Mitoxantrone is a type II topoisomerase inhibitor; also used in 
metastatic BC. 
In 2015 an oral inhibitor of CDK4/6 (palbociclib) received FDA approval for the 
treatment of ER-positive HER2-negative advanced or metastatic BC in combination with 
fulvestrant in women with disease progression following endocrine therapy (Turner et al., 
2015).  
Based on the success of immunotherapeutic agents in the treatment of melanoma, and 
more recently in lung cancer, it is expected that immunotherapeutic strategies will be proven 
efficacious for the treatment of patients with many other solid tumor types.  
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Figure 1.1.10. Schematic treatment strategy in operable breast cancer. (Neo)adjuvant systemic 
treatment choice is tailored on biomarker expression and intrinsic phenotype. ER, estrogen receptor; 
HER2, human epidermal growth factor 2 receptor; ChT, chemotherapy; ET, endocrine therapy; T, 
trastuzumab. Senkus et al., 2015 
 
 
 
In BC, the relevance of the host immune response to the tumor has long been debated. 
The prognostic significance of tumor-infiltrating lymphocytes (TILs) in early BC has been 
reported in numerous studies (reviewed in Ocaña et al., 2015). A robust body of literature 
now suggests that BC, particularly the more aggressive subtypes of HER2-positive and 
TNBC, does elicit host antitumor immune responses, and that the robustness of the 
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response correlates with prognosis (Adams S. et al., 2014; Ali et al., 2014; Loi et al., 2014). 
Therefore, there is great interest in exploring the potential role of immunotherapy in treating 
patients with BC. In addition to monoclonal antibodies and some vaccines strategies, large 
interest has been recently shown for immune checkpoint inhibitors. Data were recently 
reported from two trials of antibodies (pembrolizumab and atezolizumab) targeting the T-cell 
inhibitory molecule PD-1 or its ligand, programmed cell death receptor 1 ligand (PD-L1), two 
negative regulators of immune checkpoint (Muenst  et al., 2013; Nanda et al., 2016), showing 
promising results in terms of safety and treatment response. 
 
 
1.1.9. Breast cancer-initiating cells 
The term “stem cells” was used for the first time by Edmund Beecher Wilson in 1896 
(Wilson, 1896) and was associated for about a century to normal embryonic and adult tissue 
hierarchy and development. Only in most recent years, the use of the term “stemness” has 
been applied also to cancer biology, although the multilineage differentiation potential is 
ascribable to normal stem cells only, while cancer stem cells (CSCs) are not known to 
differentiate into more cell types, except into cells forming the bulk of the tumor. However, in 
this context, CSCs can be located at the helm of tumor hierarchy and possess traits of 
self-renewal, i.e. the ability to divide asymmetrically yielding daughter cells that inherited the 
parental cell’s characteristics, thus remaining CSCs, as well as daughter cells that 
differentiate into the neoplastic cells forming the remaining part of the tumor.  
The phenotypes of CSCs are complex and strictly dependent on the type of tumor. For 
this reason, participants in The Year 2011 Working Conference on CSCs have outlined 
guidelines on how to provide a conceptual classification of these cells depending on the 
biological system in which they are being studied (Valent et al., 2012). Operational definition 
of CSCs comprises three main features: 1) they express a specific set of surface markers 
that allow their identification and isolation, 2) they are able to grow in non-adherence 
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conditions, and 3) they can rebuild the tumor of origin when injected in immunocompromised 
mice even at limiting dilution (Dalerba et al., 2007). 
Hypotheses regarding the origin of CSCs include 1) malignant transformation of 
pre-existing normal stem cells, 2) mature cancer cell dedifferentiation with EMT and 
3) induced pluripotent cancer cells (reviewed in Islam et al., 2015). This implies that rather 
than a stable entity at the top of a hierarchical model, CSCs are in a dynamic status as they 
can continually dedifferentiate from progenitors or differentiated cancer cells (Wicha et al., 
2006; Visvader and Lindeman, 2008; Ni and Huang, 2013).  
The presence of stem-like cells in human BC was first demonstrated in 2003 (Al-Hajj et 
al., 2003). They can be propagated in serum-free and non-adherence culture conditions as 
mammospheres and exhibit a CD44+CD24low/- immunophenotype (Al-Hajj et al., 2003; Dontu 
et al., 2003; Ponti et al., 2005). Also CD133 has been reported as surface marker to identify 
breast cancer-initiating cells (BCICs) (Wright et al., 2008), even if not extensively employed 
in BC. All of these subpopulations, obtained from pleural effusion or breast cancer cell lines 
(BCCLs), proved to be endowed with tumor-initiating ability when injected at low numbers 
(100-1,000 cells) in  the mammary fat pad of immunocompromised mice (Al-Hajj et al., 2003; 
Ponti et al., 2005). 
In addition to certain surface markers, the enzymatic activity of ALDH1 (AldefluorTM 
assay) also proved to identify a fraction of BCICs with higher tumorigenic ability compared to 
the remaining subpopulation (Ginestier et al., 2007). ALDH1+ cells show only partial overlap 
with the CD44+CD24low/- population, displaying varying fractions (0.7-19%) among the 
different tumors (Angeloni et al., 2015).  
The capability of efflux of the Hoechst 33342 or rhodamine-123 dyes represents 
another feature of stem-like cells and is used to identify the so called “side-population”, 
i.e. cells overexpressing the ATP-binding cassette transporters and with high tumorigenic 
ability. These cells account for a limited fraction of mammary epithelial cells and can be 
isolated also from clinical tumors and human BC cell lines (BCCLs; Patrawala et al., 2005).  
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Compared to normal breast epithelium, CD44+CD24low/- BC cells showed a signature 
accounting for 186 differentially expressed genes, called invasiveness gene signature (IGS), 
with prognostic significance (Liu et al., 2007). It appears to be overexpressed in basal-like 
BC, likely ER , although its prognostic role is more evident within ER-positive BCs. Gene 
expression profile analysis including 76 of the 186 IGS genes and performed on BC 
specimens from a series of 110 postmenopausal patients treated with radical or conservative 
surgery plus radiotherapy and under adjuvant monotherapy with tamoxifen (Coradini et al., 
2008) was able to discriminate cases with worst prognosis, whose tumor gene expression 
pattern showed a direct association to IGS, from disease-free cases, whose transcriptional 
profile was inversely associated to the IGS signature (Santilli et al., 2011). Moreover, the 
fraction of ALDH1+ BC cells correlates with basal-like and HER2-positive subtypes 
(Resetkova et al., 2010), and is predictive of clinical outcome in different BC clinical settings 
(Ginestier et al., 2007; Charafe-Jauffret et al., 2010). 
Finally, another approach to enrich tumor cells with the BCIC subpopulation is the 
long-term treatment with chemotherapeutic agents, which takes advantage of the intrinsic 
chemoresistance of these cells (Calcagno et al., 2010; Li H.Z. et al., 2008). 
Several signaling pathways essential for BCIC survival, self-renewal and tumorigenic 
properties are partially shared with those of normal mammary development, including Notch, 
Wnt and Hedgehog (Stylianou et al., 2006; Lamb et al., 2013; Fan et al., 2013). Beside 
canonic stemness pathways, the deregulation of PI3K/Akt/mTOR and JAK/STAT3 has been 
found to be implicated in BCIC maintenance and drug resistance (Zhou et al., 2007). 
Interplay between HER2 activation and Notch pathway has been recently postulated for 
HER2 overexpressing BC cells (Magnifico et al., 2009). Moreover, cytokines as IL-8 exert a 
stimulatory effect on BCICs via autocrine loop (Singh et al., 2013), and reciprocal interactions 
with mesenchymal stem cells via paracrine signaling involving CXCL7 and IL-6 has been 
demonstrated to create a suitable niche that preserve and fuel BCIC stemness capability (Liu 
et al., 2011).  
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Low proliferation rate and the expression of multi-drug resistance proteins represent 
two features of BCICs that have been linked to their intrinsic resistance to conventional 
anticancer therapies. CSCs may enter a quiescence status that protects them from 
antineoplastic agents that target dividing cells. Indeed, increased number of  CD44+CD24low/- 
cells was observed in the residual tumor following primary systemic therapy in BC patients 
(Li X. et al., 2008; Lee et al., 2011), but also after radiotherapy (Philips et al., 2006; Lagadec 
et al., 2010), suggesting a possible mechanism for BCIC selective growth and consequently 
relapse. Inducing de-differentiation in BCICs might render them more sensitive to standard 
therapies, taking advantage of their high level of plasticity that allow shifting from a quiescent 
to a more proliferative state (Liu et al., 2013), and some promising strategies, as the use of 
all-trans-retinoic acid and HDAC inhibitors, have been already proposed (reviewed in 
Angeloni et al., 2015). 
More recently, among the huge number of models and mechanisms which have been 
proposed to explain resistance to antiestrogens (AEs) in BC, also tumor cells with stem-like 
properties were suggested as possible cause of tumor relapse after hormone therapies. 
BCIC models derived from the MCF7 cell line and propagated as mammospheres proved to 
have intrinsic resistance to AEs (Ao et al., 2011), also showing a down-regulation of 
ER-related genes even in basal conditions (Callari et al., 2016). In addition, short term 
exposure to AEs selectively enriches for BCICs via JAG1-NOTCH4 axis both in vitro and in 
patient-derived xenografts (Simões et al., 2015). 
The first evidence for a link between CSCs and epithelial-to-mesenchymal transition 
(EMT) was reported in a seminal work showing that induction of EMT in immortalized human 
mammary epithelial cells was sufficient to induce the expression of stem cell markers; 
consistently, this was accompanied by increases in the formation of mammospheres, 
colonies in a soft agar assay and tumorigenicity in immunodeficient mice (Mani et al., 2008). 
More recently in normal breast tissue overexpression of the transcription factors Slug and 
Sox9 were enough to push luminal lineage cells into a more stem-like state, while only Sox9 
was required in basal cells that already expressed the EMT associated transcription factor 
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Slug (Guo et al., 2012). Recently it was shown that CD44+CD24low/- and ALDH1+ populations 
of BCSCs are plastic and have the capacity to transit between EMT and mesenchymal-to-
epithelial (MET) transition states (Liu et al., 2013). The CD44+/CD24− population displayed a 
molecular pattern of EMT, such as low expression of E-Cadherin and high levels of vimentin, 
and tended to be quiescent (EMT-CSCs). The ALDH-positive population, on the other hand, 
had a relatively opposite phenotype with high expression of E-Cadherin and low expression 
of vimentin, and was also much more proliferative, which pointed towards a more epithelial 
signature (MET-CSCs). The transition between these two states was postulated to be critical 
for tumor expansion (reviewed in Brabletz, 2012): while the EMT-CSCs sit at the invasive 
edge and allow the tumor to invade other tissues, the proliferative MET-CSCs likely drive 
tumor cell growth in the tumor inner part. When tumor conditions change or the invasive 
edge becomes the interior of the tumor, the two CSCs can change their status. This 
reversible, metastable epithelial-mesenchymal plasticity of BCICs is closely connected to 
current model of cancer metastasis postulating that EMT drives tumor cell dissemination and 
a consecutive MET drives metastatic colonization. In the case of BC, the CD24−CD44+ 
EMT-like BCSCs mediate tumor invasion toward the basal membrane and neighboring 
tissues and into the blood, where they survive due to their intrinsic quiescence and anoikis 
resistance. After extravasation in the circulation, these mesenchymal-like BCICs form 
micrometastases in distant organs, where metastatic niche or specific microenvironment in 
distal sites induces MET, which drives BCIC self-renewal and generation of 
macrometastases. An exception to this may be the claudin-low BCs which are characterized 
by a mesenchymal phenotype (Prat et al., 2010). These tumors may contain CSCs that 
simultaneously display EMT and MET properties. The existence of CSCs that are 
simultaneously invasive and proliferating might contribute to the very aggressive nature of 
this BC subtype. 
Considering that CSCs may enter a dynamic EMT-MET state and that BCs are 
classifiable in different subtypes, each characterized by cells with more or less marked 
epithelial or mesenchymal phenotype, Wicha and colleagues summarized the features of 
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CSC subsets according to the BC molecular subtypes and proposed a bimodal model 
(Brooks et al., 2015; Figure 1.1.11). TNBCs can be ascribable to the molecular claudin-low or 
basal subtype. While the former is characterized by a high proportion of CD44+/CD24low/- and 
ALDH1-positive CSCs as well as mesenchymal-like bulk tumor cells, the basal subtype, often 
associated with BRCA1 loss of function, contains epithelial bulk cells along with a 
subcomponent of mesenchymal bulk tumor cells and a higher proportion of epithelial 
ALDH1-positive CSCs. The CSCs subsets give rise to bulk tumor cells that are characterized 
by an epithelial morphology and lack of expression of ER or PgR. Also the HER2-positive 
subtype is characterized by a high proportion of ALDH1-positive CSCs that give rise to 
epithelial bulk populations, but in this case they may or may not express ER and PgR 
(Korkaya and Wicha, 2013). Luminal B breast cancers generally display a lower proportion of 
cells expressing CSC markers than either HER2-positive or TNBCs. The bulk cells in these 
tumors are highly epithelial in morphology and a proportion expresses ER and PgR. 
Luminal A tumors display the lowest proportion of cells expressing CSC markers and, 
accordingly, are also those with the best prognosis compared to the other subtypes. This 
model sustains the existence of an entirely distinct level of BC intratumor heterogeneity in 
which each of the above described subpopulations of cancer cells within a tumor contain its 
own fraction of BCICs and a bulk of non-BCICs that share the same genetic and epigenetic 
background (Pattabiraman and Weinberg, 2014). BCIC marker plasticity enables them to 
pass from a more proliferative epithelia-like state to a more quiescent, invasive and 
mesenchymal-like, each capable of generating their respective epithelial or mesenchymal 
bulk cell progeny which interact and reinforce the CSC one (May et al., 2011; Liu et al., 
2013). 
Single-cell sequencing approaches allowed the identification of BC cells exhibiting 
genomic diversity within the same tumor (Torres et al., 2007; Curtis et al., 2012; Wang et al., 
2014). As carcinomas are the result of a succession and accumulation of genetic and 
epigenetic alterations, it seems plausible that CSCs are invariably present within incipient 
tumors at the various stages of progression, thus each of the cell populations formed at 
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intermediate stages of tumor evolution also should contain its own subpopulation of BCICs 
(Pattabiraman and Weinberg, 2014). However, this model is in contrast with the stem cell low 
mitotic rate, which represents one of their main features.  
 
 
Figure 1.1.11. Scheme of a model illustrating CSCs with different phenotype across the 
spectrum of BC molecular subtypes. The different molecular subtypes of BC are characterized  by 
varying proportions of CSCs in complete mesenchymal (MCSCs) or epithelial (ECSCs) state as well 
as CSCs in transient state from epithelial to mesenchymal state and vice versa (BI-CSCs), that give 
rise to the bulk of differentiated epithelial or mesenchymal progeny. Brooks et al., 2015 
 
Despite the diversity of genetic changes driving the different molecular subtypes of BC 
(Cancer Genome Atlas Network, 2012), BCICs within these subtypes proved to have similar 
patterns of gene expression (Liu et al., 2013) and to share similar genomic alterations with 
the bulk of non-BCICs (Klevebring et al., 2014), suggesting that genetic diversity cannot 
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account for BCIC heterogeneity. Consistently with this observation, differentiated mammary 
epithelial cells were described to be able to spontaneously acquire stem cell features and to 
restore the equilibrium of the population of origin (Chaffer et al., 2011; Gupta et al., 2011), 
thus suggesting that, in line with CSC plasticity and in contrast with the hierarchy model, 
BCICs may arise de novo from non-BCICs. 
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1.2. CIRCULATING TUMOR CELLS 
 
1.2.1. Biological properties of circulating tumor cells 
Circulating tumor cells (CTCs) are by definition tumor cells that are detected while in 
transit within the blood stream (Yu et al., 2011). CTCs originate from the primary tumor (PT) 
and represent a subpopulation of tumor cells which acquired traits of invasiveness and 
motility, and which have the ability to intravasate and survive in blood for short or long 
periods in the attempt to re-establish secondary tumors in other sites (Massagué and 
Obenauf, 2016). However, this classical view of the metastatic cascade as an unidirectional 
process has been recently overturned by studies with experimental models, which 
demonstrated that CTCs may re-infiltrate an established tumor, enriching it with aggressive 
cells after a period of dissemination, a process called “tumor self-seeding” (Norton and 
Massagué, 2006; Kim et al., 2009) and which might have important clinical implications in 
terms of loco-regional recurrence (Bidard et al., 2009). 
Metastases generally appear in a late phase of tumorigenesis, when a PT achieves a 
critical mass of cells and acquires an aggressive phenotype, according to the linear model of 
tumor progression, but dissemination can also represents an early independent event, as 
proposed in the parallel progression model (Klein, 2009) and as frequently observed in BC. 
In fact, tumor cells can disseminate systemically at the earliest stage of mammary epithelial 
cell transformation (Hüsemann et al., 2008), even before they become chromosomally 
instable (Schardt et al., 2005), and they can be detected also in the blood of patients with 
node-negative operable BC (Xenidis et al., 2006), or in patients with atypia (FEA) or DCIS 
(Franken et al., 2012). 
Despite the marked proficiency of BC cells in disseminating, not all CTCs are able to 
give rise to overt metastases since their survival in blood is hampered by a number of 
obstacles, as fluid shear stress exerted by blood flow (Mitchell and King, 2013), anoikis (Kim 
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et al., 2012), and the attacks of the immune system (CD47; Mohme et al., 2016). Indeed, 
consistently with the notorious scarce efficiency of the metastatic process (Luzzi et al., 1998), 
CTC half-life was estimated to be short, from 7-9 minutes to 2.4 hours, according to findings 
reported in experimental and clinical studies (Fidler, 1970; Sasportas and Gambhir, 2014; 
Meng et al., 2004b). Therefore, on the basis of these observations, the existence of a subset 
of CTCs with metastasis-initiating properties has been hypothesized.  
The hypothesis that only a subpopulation of CTCs is really capable of reinitiating 
macroscopic tumor growth in a distant tissue has been reviewed and addressed by various 
authors (Oskarsson et al., 2014; Celià-Terrassa and Kang, 2016). The first evidence that 
CTCs isolated from BC patients are able to give rise to metastases in experimental models 
was provided in 2013 (Baccelli et al., 2013). In this study the authors transplanted CTCs 
isolated from metastatic BC patients into the femoral medullary cavity of 
immunocompromised mice and demonstrated that the metastatic potential of the bulk of 
CTCs obtained after depletion of hematopoietic cells was negligible when less than 1,000 
were injected. In contrast, mice receiving higher number of CTCs enriched in a 
subpopulation of cells with EpCAM+CD44+CD47+MET+/- phenotype developed multiple 
lesions at bones, lungs and liver. Subsequent to this study, other subpopulations of 
metastasis-initiating disseminated cells were identified. CTCs can be found in circulation as 
single cells or clusters of cells, in different kinds of neoplasms (Brandt et al., 1996; Molnar et 
al., 2001; Kats-Ugurlu et al., 2009; Hou et al., 2012), including BC (Stott et al., 2010; Yu et 
al., 2013). The seminal work by Aceto and colleagues (Aceto et al., 2014) revealed that CTC 
clusters, despite representing a rare subpopulation of CTCs (about 2%), display 23- to 
50-fold higher metastatic potential compared to the single CTC subset. Interestingly, CTC 
clusters have proven to have oligoclonal origin and to represent the result of cell aggregation 
events, modulated by the junction protein plakoglobin, which take place before and not after 
intravasation. A more recent work corroborated these results in a different experimental 
model and also demonstrated that clusters are composed by two molecularly distinct 
subpopulations whose proportions vary during metastasis, as tumor cells at the leading edge 
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of the invading cluster in the PT and clusters circulating in blood are 20-fold enriched in 
KRT14+ cells compared to the PT and pulmonary macrometastases (Cheung et al., 2016). 
These results seem to be apparently in contrast when considering the size of epithelial 
tumor cells, (20 to 30 µm diameter), and the size of capillary bed (about 8 µm diameter). 
Therefore, the ability of CTC clusters to pass through capillaries was questioned. A recent 
technical paper provided an explanation for such an aspect of tumor dissemination process 
by using CTC clusters isolated from clinical samples, microscale devices, computational 
simulations and experimental animal models (Au et al., 2016). The authors could show that 
over 90% of clusters containing up to 20 cells did successfully traverse 5- to 10-μm diameter 
constrictions because of rapid and reversible reorganization of cells into single-file chain-like 
geometries. This data highlights once more the importance of CTC morphological plasticity, 
which reduces their hydrodynamic resistances while passing through capillaries and, 
importantly, allowes the CTC cluster to re-establish the original rounded morphology and 
maintain its viability and function. 
Plasticity and heterogeneity have been frequently observed in CTCs also at molecular 
level (Figure 1.2.1). Notoriously, carcinoma cells activate a trans-differentiation program, 
called epithelial-to-mesenchymal transition (EMT), which endows cells with migratory and 
invasive properties, induces the acquisition of stem cell traits, prevents apoptosis and 
senescence, and contributes to immunosuppression and drug resistance (Thiery et al., 2009; 
Brabletz, 2012). Basically, key molecular players, such as Twist, Snail, Slug and others, 
activate a transcriptional program which provokes the down-regulation of epithelial genes, as 
EpCAM, claudins, occludins, E-cadherin etc., and the up-regulation of mesenchymal genes, 
as vimentin, fibronectin, N-cadherin, etc. (Sleeman and Thiery, 2011). As a consequence, 
cells undergo crucial changes in their cytoskeleton and lose the expression of adhesion 
molecules, two events that confer the typical spindle-shaped morphology and culminate in 
increased cell motility (Thiery et al., 2009). The shift toward a different phenotype is 
characterized by a sequence of events during which cells can temporarily transit in an 
intermediate state and present both epithelial and mesenchymal features or display a partial 
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EMT-phenotype (Mego et al., 2010; Nieto et al., 2016). Despite technical difficulties in 
describing this transitory process at CTC level, both in animal models and human cancers, 
experiments with a dynamic in vivo model obtained from xenograft of MDA-MB-468 cells 
showed that EMT occurs at the PT level and is responsible for the generation of CTCs 
(Bonnomet et al., 2012). Importantly, longitudinal monitoring of CTCs isolated from BC 
patients during systemic therapy provided evidence for the first time for the co-existence of 
cells with either complete epithelial or transient epithelial-mesenchymal or complete 
mesenchymal CTCs, at different proportion and in the same patient, according to the therapy 
response status (Yu et al., 2013). In particular, the fraction of cells with marked 
mesenchymal features was preponderant during tumor progression compared to stages 
during which patients had reached good response to treatment, consistently with the model 
attributing therapy resistance traits to cells with EMT-phenotype and with the concept of the 
EMT process as a continuum (Mego et al., 2010; Nieto et al., 2016).  
 
 
Figure 1.2.1. The CTC population is heterogeneous. CTCs may shift from an epithelial to a 
mesenchymal phenotype, and can transit in blood as single cells or clusters, either forming homotypic 
interactions with other tumor cells or heterotypic interactions with other kinds of cells. Ignatiadis et al., 
2015 
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If EMT is a requisite for carcinoma cells to become CTCs, the return from a 
mesenchymal to an epithelial phenotype (called mesenchymal-to-epithelial transition, MET) 
seems to be the necessary driving force for CTC homing and efficient colonization. In 
agreement with this view, comparison of central areas of primary colorectal carcinomas and 
matched metastases revealed the presence of similar patterns related to differentiated 
epithelial cells (Brabletz et al., 2001). Two more recent papers elegantly demonstrated that 
down-modulation of Twist1 and Prrx1 EMT transcription factors and subsequent 
re-differentiation (MET) are necessary for distant colonization (Ocaña et al., 2012; Tsai et al., 
2012). However, the role of EMT in dissemination is not completely understood and data on 
the involvement of this process in metastasis are still controversial. Indeed, recent studies 
with a lineage-tracing transgenic BC model showed that inhibiting EMT by overexpressing 
the microRNA miR-200 did not affect lung metastasis development (Fischer et al., 2015).  
Preclinical studies have demonstrated that CTC clusters are not solely formed by tumor 
cells but also include accessory cells, as fibroblasts, leukocytes, endothelial cells, pericytes 
and platelets, which form heterotypic interactions with CTCs. Duda and colleagues 
demonstrated that fibroblasts are shed from the PT with CTCs and confer them increased 
survival and early growth advantage at metastatic site; CTCs, in turn, are likely to activate 
stromal cells to a CAF-state as the majority of fibroblasts carried over by CTCs were αSMA+ 
and FSP1+ (Duda et al., 2010).  
It is widely recognized that tumor-associated macrophages (TAMs) facilitate almost 
every step of the metastatic cascade, including intravasation, dissemination and 
establishment of metastasis at secondary sites (Belgiovine et al., 2016). Multiphoton imaging 
allowed the visualization of perivascular macrophages during tumor cell intravasation 
(Wyckoff et al., 2007). More strikingly, studies with clodronate liposomes and zoledronic acid 
showed that elimination of macrophages significantly influenced CTC numbers and tumor 
metastasis formation (Rodrigues et al., 2011; Zhang et al., 2010). Beside the involvement of 
macrophages in EMT (Su S. et al., 2014), an alternative model considers fusion of 
monocyte-derived cells with tumor cells in blood (macrophage-tumor cell fusions, MTFs) as a 
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possible process to promote colonization (Pawelek and Chakraborty, 2008; Lazova et al., 
2013; Clawson et al., 2015). Interestingly, circulating giant macrophages-like cells were 
found bound to CTCs in patients with different kinds of tumors, including BC (Adams D.L. et 
al., 2014; Mu et al., 2016).  
CTCs are also able to attract a multitude of aggregating platelets (Camerer et al., 2004; 
Nieswandt et al., 1999), which in turn protect tumor cells via TGF-β signaling and stimulate 
the acquisition of aggressive phenotype, facilitating the metastatic process (Gay and 
Felding-Habermann, 2011; Labelle et al., 2011).  
Other allies of CTCs are represented by tumor-associated endothelial cells, which 
protect them from anoikis (Yadav et al., 2015) and increase the number of CTCs and 
spontaneous metastases in experimental models (Stacer et al., 2016). Endosialin-expressing 
pericytes, too, have proven to promote tumor cell intravasation in a cell contact-dependent 
manner, resulting in elevated numbers of CTCs in mouse models (Viski et al., 2016). 
Furthermore, circulating tumor-associated neutrophils (cTANs) contribute to CTC survival by 
suppressing peripheral leukocyte activation (Zhang et al., 2016).  
 
 
1.2.2. CTC detection and clinical applicability of CTC blood-tests 
CTCs offer an opportunity to obtain key information for the development of 
personalized medicine. However, since these cells represent rare events, due to the 
presence of circulating cell populations of hematopoietic origin (few million white blood cells 
and a billion red blood cells per milliliter of blood), and are heterogeneous and subject to 
changes during the various phases of dissemination or in response to therapy, it is clear that 
their value as biomarkers strongly depends on the detection method. Operational definition of 
CTCs is strictly related to the methodological approach as no specific marker exists to 
discriminate them from other cells. No single parameter, such as size, morphology, protein 
expression or chromosomal aberration pattern can be considered sufficient to define a CTC. 
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This implies that pre-enrichment and detection methods should be combined to increase 
specificity, although at the cost of sensitivity. 
CTCs were observed for the first time in 1869 in the blood of a man with metastatic 
cancer by Thomas Ashworth (Ashworth, 1869). He found cells with identical aspects of those 
present in solid malignant lesions and concluded that “One thing is certain, that if they [CTC] 
came from an existing cancer structure, they must have passed through the greater part of 
the circulatory system to have arrived at the internal saphena vein of the sound leg”. Since 
then, many decades have passed until CTCs could be systematically studied in human 
samples.  
In more recent years, driven by technical progress, numerous assays and devices to 
isolate and detect CTCs have been described. The most commonly used approaches for 
CTC analysis were briefly described in Table 1, including positive and negative aspects and 
key methodological papers, with special reference to BC studies.  
Blood samples can be enriched for CTCs by positive selection approaches, generally 
intended as solid-phase capture strategies, as magnetic beads or devices coated with 
antibodies directed against epithelial and tumor surface markers. Among them, the epithelial 
marker EpCAM has been widely exploited to catch CTCs, but this approach may 
underestimate the number and composition of CTCs since it fails to detect tumor cells with 
mesenchymal features, which might provide further and probably more useful information on 
therapy response (Wicha and Hayes, 2011). Therefore, not only technical but also biological 
specificity should be taken into account as the detected cancer cell might represent only a 
fraction of the entire CTC population or might possess variable ability to give rise to 
metastases. Alternatively, CTCs can be isolated taking advantage of their size and 
morphology (Vona et al., 2000), by using devices which allow physical size-based exclusion 
of hematopoietic cells and unbiased CTC isolation with regard to the expression of surface 
markers. Basically, tumor cell diameter is around 20-30 µm, much larger compared to the 
vast majority of hematopoietic cell populations. In this perspective, specific devices have 
been created in order to entrap CTCs, but also other atypical cells, onto microporous 
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membranes (Table 1). Despite this approach appears free from technical limitations, the 
blood flow rate has proven to be crucial for isolation of intact cells, especially for CTC 
clusters (Stott et al., 2010), whose biological and clinical relevance has been demonstrated 
both in experimental and clinical studies.  
Semi-automated high-throughput technologies have been recently introduced, 
determining a revolution in CTC studies (Table 1). The DEPArray™ technology is based on 
the ability of a non-uniform electric field to exert forces on neutral, polarizable particles, 
such as cells, that are suspended in a liquid (Medoro et al., 2003). This electrokinetic 
principle, called dielectrophoresis (DEP), can be used to gently trap and move cells 
within DEP “cages”, allowing image-based isolation of single cells. However, this system 
does not work on whole blood volumes, but on few microliters of sample. Therefore, a 
preliminary enrichment step is required. Another powerful technology is represented by 
the CTC-chip, which is based on the generation of a microfluidic vortex that increases 
the chance of interaction between target cells and antibodies on the surface of a 
herringbone-like device (Nagrath et al., 2007). Differently from the DEPAarrayTM, this 
technology is suitable for isolation of both single CTCs and CTC clusters. 
A second phase necessarily follows the pre-enrichment step as, once isolated, the 
presence of CTCs has to be verified and a multitude of approaches can be applied to 
characterize them. CTCs can be directly counted and characterized by in situ analyses, 
cultured for functional studies or lysed for nucleic acid extraction and molecular analysis 
(Yu et al., 2011). Cytological staining protocols allow direct count and morphological 
analysis of CTCs according to classical cytopathological criteria for identification of 
malignant cells (Hofman et al., 2011). This approach requires that sample analysis should 
be performed by a pathologist, although elements subjected to doubt interpretation, as cells 
having nonhematologic origin but with uncertain malignant or benign feature, can be 
observed (Hofman et al., 2011). 
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Table 1. Methodological approaches for CTC analysis 
Technology Enrichment method Detection method Pros Cons Ref. 
AdnaTest 
CTC capture by 
immunomagnetic beads 
(wash buffer for leukocyte 
contamination reduction). 
Multiplex semi-
quantitative PCR. 
High sensitivity (2 CTCs 
in 5 ml of blood) due to 
the detection method. 
Reliable CTC gene 
profiling feasible by low-
density and high-density 
arrays. 
Enrichment dependent on the 
expression of surface markers 
(EpCAM, MUC1, ERBB2, 
EGFR). 
Direct CTC count not feasible. 
Tewes et al., 
2009; Aktas 
et al., 2009 
CAM assay Depletion of leukocytes or FACS. 
Cell culture on a cell-
adhesion (collagen) 
matrix and detection of 
CTCs with invasiveness 
properties.  
Unbiased enrichment. 
CTC culture. Cell viability. 
CTC analysis at functional 
level. 
Possible modifications of CTC 
molecular features due to 
culture conditions. 
Lu et al., 
2010 
CellSearch® 
system 
CTC capture by 
immunomagnetic beads. 
Immunofluorescence-
based detection by 
KRTs and CD45 
staining. Nucleic acid 
analysis. 
Direct CTC count and 
visualization. Semi-
automated. Approved by 
FDA. 
Enrichment dependent on the 
expression of EpCAM on the 
cell surface. Maximum 4 
fluorescence channels for 
CTC detection. 
Riethdorf et 
al., 2007 
CellSieveTM 
microfilters 
Size-based isolation by 
blood filtration through 
microporous membranes 
(pores diameters 7 µm). 
Direct visualization and 
in situ analyses, CTC 
culture or nucleic acids 
analysis. 
Precision, uniform and 
high porosity microfilters. 
Filter flatness facilitates 
images acquisition. High 
recovery rate. Unbiased 
CTC enrichment. 
Identification of single 
CTCs, CTC clusters and 
other atypical cells. 
No possibility to retrieve intact 
isolated cells. 
Adams D.L. 
et al., 2014 
Microfluidic 
HB-chip  
No pre-enrichment 
required. Highthroughput 
device which generates 
microvortices, increasing 
the number of interactions 
between CTCs and an 
antibody-coated surface. 
Imaging 
(histopathological stains 
and IF). 
Minimal damage of 
sensitive CTC 
populations. Coating with 
different kinds of 
antibodies. Good capture 
efficiency.  
Enrichment dependent on the 
expression of specific 
markers. Manual pick-up of 
isolated cells for further 
analysis. Not commercially 
available. 
Nagrath et 
al., 2007 
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Table 1. (continued) Methodological approaches for CTC analysis  
Technology Enrichment method Detection method Pros Cons Ref. 
EPISPOT 
assay Depletion of leukocytes.  
Cell culture and 
IF-based detection of 
proteins secreted by 
CTCs. 
Unbiased enrichment. 
CTC culture. Assessment 
of CTC viability and 
biological activity 
(secretion of PSA, MUC1, 
FGF2, etc.). 
Possible modifications of CTC 
molecular features due to 
culture conditions.  
Ramirez et 
al., 2014 
DEPArrayTM Leukocyte depletion with other devices. 
Image-based single cell 
sorting by 
dielectrophoresis of 
IF-labeled cells. 
Pure and single cell 
isolation and 
characterization. 
30% cell loss due to the 
technical limits of the 
instrument. Only 4 
immunofluorescence 
channels. Limited number of 
input (≤40,000) cells per chip. 
Peeters et 
al., 2013; 
Fernandez 
et al., 2014 
Ikoniscope® 
Density gradient 
centrifugation or filtration 
and CTC labeling with 
immunofluorescent 
antibodies (KRTs, 
EpCAM). 
FISH analysis by robotic 
fluorescence 
microscope imaging 
system. 
Reliable CTC 
identification by analysis 
of chromosomal 
alterations. 
Tumors with known 
chromosomal rearrangements. 
Probes for specific FISH tests 
required. 
Ntouroupi et 
al., 2008 
ScreenCell® 
Size-based isolation by 
blood filtration through 
microporous membranes 
(pores diameters ~8 µm). 
Direct visualization by in 
situ analyses. CTC 
culture or nucleic acids 
analysis. 
Direct CTC count, 
morphological/cytological 
evaluation and 
immunological analysis 
(ICC and IF). High 
sensitivity (1 CTC in 3 ml 
of blood). Unbiased CTC 
enrichment. Identification 
of single CTCs, CTC 
clusters and other atypical 
cells. 
Micro-coagulation may cause 
blood flow arrest during 
filtration. Fast filtration rate (~1 
ml blood/min) may damage 
CTC clusters.  
Desitter et 
al., 2011; 
Mu et al., 
2016 
OBP-401 
assay 
No pre-enrichment 
required. Infection with 
telomerase-specific 
replication-selective 
adenovirus. 
GFP-positive cells 
visualization. FISH 
analysis. 
High specificity for tumor 
cells due to enhanced 
virus replication compared 
to normal cells. 
Not applicable to 
hTERT-independent 
neoplasms. 
Kim et al., 
2011 
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Protein analysis by immunocytochemistry (ICC) and immunofluorescence (IF) may 
provide further information, but subsets of CTCs can be missed due to their heterogeneity 
and lack of expression of some markers. Moreover, atypical cells called macrophages-like 
cells were found in the blood of cancer patients, identified as giant cells expressing 
monocytic markers, but in some cases either expressing or not the common leukocyte 
antigen CD45 and also resulting positive for epithelial and endothelial protein markers 
(Adams D.L. et al., 2014). Therefore, CTC identification by direct staining for proteins is 
limited by the complexity and variety cell types circulating in blood and lack of univocal 
markers.   
Molecular analysis of CTCs, following positive or negative selection approaches, can 
be performed by in situ techniques, as FISH or mRNA probe hybridization, or after cell lysis 
and nucleic acids extraction. In the first case, direct visualization of target cells might help 
identifying them and provide reliable results, although limited number of assays can be used 
on the same sample. In the second case, extensive molecular analysis can be performed 
using high- or low-density arrays, qPCR, RNA sequencing, digital PCR and whole exome or 
whole genome sequencing. Nevertheless, in this situation the purity of the sample has strong 
implications on the type of markers that can be analyzed at mRNA level. For example, genes 
characterizing mesenchymal and stem-like cells, such as VIM and ALDH1, are also 
expressed by leukocytes. Parallel analyses on healthy donor case series or on 
patients’ blood samples after CTC depletion (for example by incubation with 
mock-functionalized antibodies with the same isotype of those used for CTC capture) are 
necessary to identify reliable positivity threshold values to assign CTC positivity status or 
CTC-marker positivity. Actually, the scenario is more complex than expected as there is 
evidence that marker genes commonly used to detect CTCs in PCR-based tests, as 
squamous-cell carcinoma antigen, epidermal growth factor receptor, mammaglobin, small 
breast epithelial mucin, are expressed in normal, mitogen-stimulated peripheral blood 
mononuclear cells (PBMNC). Thus, considering the inflammatory reactions often 
accompanying cancer development, but also other pathologies as inflammatory bowel 
70 
 
disease, molecular markers were suggested to be validated not against normal peripheral 
blood cells, but against activated lymphoid cells, such as in vitro mitogen-stimulated PBMNC, 
in order to reduce false-positives (Kowalewska et al., 2006). 
The opportunity to characterize single cells completely resets the need for specificity 
tests as the nature of the target cell can be verified exploiting one of the most important 
hallmarks of cancer, which is represented by genetic instability. Basically, DNA ploidy status 
and copy number variation analyses definitively allow target cell rating as real CTC or not. 
Moreover, mutational analysis does not need additional specificity tests beyond those 
required for technical threshold definition, since the investigated genetic alteration should be 
private, i.e. of the tumor, and theoretically not detectable at germline level.  
CTCs hold the key to understand the biology of metastasis and provide a biomarker to 
noninvasively measure the evolution of the tumor during treatment as also disease 
progression. Indeed, differently from cell-free circulating nucleic acids and proteins, CTCs 
are biological entities whose clinical significance as biomarkers can be assessed at different 
levels. First, CTC presence or absence in the sample analyzed can be informative per se on 
disease aggressiveness and response to therapy. In non-metastatic BC detection of at least 
1 CTC in 7.5 mL of blood or positivity for CK-19 assessed by RT-PCR are sufficient to 
identify patients at high risk of relapse (Saloustros et al., 2011; Lucci et al., 2012). 
Interestingly, longitudinal monitoring of CTC status is likely to be much more informative than 
CTC assessment at a single time point (Musella et al., 2015; Fina et al., 2016). Second, the 
number of detected CTCs in a defined volume of blood generally mirrors the tumor burden, 
thus indicating that prognostic cut-off need to be identified to predict the clinical outcome 
(Cristofanilli et al., 2004). Finally, CTC characterization may outperform simple CTC 
enumeration or CTC detection by EpCAM-based methods, as already shown in BC and CRC 
studies (Mostert et al., 2015; Gazzaniga et al., 2011).    
At present, technical constraints limit the applicability of CTC-test in the clinical context 
(Alix-Panabières and Pantel, 2014), except for the FDA-cleared technology called 
CellSearchTM system (Table 1), approved for CTC monitoring in metastatic breast, colorectal 
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and prostate cancers (https://www.cellsearchctc.com/clinical-applications/clinical-relevance). 
Nevertheless, CTC studies represent an opportunity that should not be missed and, even if 
hard to find, CTCs cannot be ignored and deserve further investigations. 
The route toward personalized medicine is long, but certainly standardization studies 
are required to make CTCs a useful biomarker that could support clinical decision-making. 
 
 
1.2.3. Clinical significance of circulating tumor cell count in breast cancer 
CTC-based tests may rely on CTC detection by applying cyto-morphological criteria or 
by the analysis of the expression pattern of specific proteins to distinguish tumor cells from 
other cells transiting in blood. The majority of platforms currently available holds great 
promise to improve CTC detection and monitoring in the clinical context. In the last decade 
the assessment of CTC levels has been widely tested as a new prognostic tool in BC. In 
2004, CTC enumeration using the CellSearch system (Janssen Diagnostics, Raritan, NJ, 
USA) was shown to be significantly associated with progression-free survival (PFS) and 
overall survival (OS) in 177 patients with metastatic breast cancer (Cristofanilli et al., 2004). 
The hazard ratio (HR) for the difference between late and early progression of disease 
reached a plateau at 5 CTCs per 7.5 mL or higher. In the same cohort, changes in CTC 
count after the initiation of a new line of therapy were also shown to correlate with PFS and 
OS (Cristofanilli et al., 2005). Since then, numerous observational studies on the prognostic 
and predictive value of CTC count have been reported (reviewed in Bidard et al., 2016). The 
prognostic value of CTC levels was also observed during treatment, as by combining 
dichotomized CTC count (high or low) at two time-points (baseline and after one cycle of 
treatment), four different PFS profiles were obtained: the worse prognosis was seen in 
patients with high CTC count at both time points, as expected, while patients with a high CTC 
count at baseline but a low CTC count after one cycle of therapy had a much better 
prognosis, almost similar to that of patients with low CTC count at baseline, thus 
demonstrating that CTC count may also represent a dynamic prognostic marker (Hayes et 
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al., 2006). Moreover, CTC count was shown to accurately anticipate the information provided 
by radiological imaging since patients without disease progression according to instrumental 
response and with ≥5 CTCs had a shorter median overall survival than those with lower CTC 
number; on the contrary, patients who presented with radiological progression and <5 CTCs 
had a longer survival than those with elevated CTCs (Budd et al., 2006).  
 In 2014 a pooled analysis of 1944 individual patient data provided level-1 evidence for 
the clinical validity of baseline CTC ≥5 per 7.5 mL of blood as an independent marker of poor 
prognosis in metastatic BC (Bidard et al., 2014). Hazard ratio of survival between high and 
low CTC counts increased together with the threshold used to define high CTC count. 
Finally, in contrast to serum tumor markers, such as CEA and CA15.3, which showed 
inferiority to CTC count, the study demonstrated that by adding CTC count and its change 
during therapy to an optimized clinico-pathological model, the prognostic value of the model 
significantly increased (Bidard et al., 2014).  
However, the value of CTC enumeration for treatment decision making in metastatic 
BC was not validated. It was prospectively tested in the Southwest Oncology Group (SWOG) 
S0500 clinical trial (Smerage et al., 2014), in order to evaluate the benefit of an early change 
in chemotherapy for patients with persistent high CTC level at first follow-up after starting 
first-line chemotherapy. Although CTCs were strongly prognostic, an early switch to an 
alternative chemotherapy did not increase overall survival. These negative results were 
supposed to be related to the study design, since switching from one ineffective therapy to 
another ineffective therapy it is expected not to change the outcome even if this shift is 
anticipated thanks to the information given by the CTC status, and changing treatment based 
on CTC molecular features now seems to be a more promising approach. 
Another issue related to the failure of the first CTC-based clinical trial is represented by 
the criteria used to define the CTC threshold. The 5 CTC threshold was the median CTC 
count that maximized the significance of the log-rank test in the first paper by Cristofanilli 
(Cristofanilli et al., 2004). Further data, obtained in the large European pooled analysis of 
CTC in metastatic BC patients, showed that the survival hazard-ratio increases together with 
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the CTC count, with no clear threshold (Bidard et al., 2014). Furthermore, it is critical to point 
out that the ≥5 CTC/7.5 mL threshold is an overall prognostic factor in metastatic BC of 
global survival, but was never optimized to detect early tumor progression, i.e. resistance to 
chemotherapy with tumor progression within the first 3-4 months; therefore, Bidard and 
colleagues recommend that thresholds for clinical validity should be distinguished, whenever 
needed, from those intended for clinical utility (Bidard et al., 2016). 
At present two main studies are ongoing and results are expected in the following two 
years. The CirCe01 trial (NCT01349842) is based on the early changes of CTC count, but 
patients are enrolled before the start of third line of chemotherapy and followed with the CTC 
test throughout the successive lines of chemotherapy. The efficacy of therapy is determined 
by comparison of CTC level before the first injection of each new line of chemotherapy with 
conventional clinical and radiological evaluation. Instead, the STIC CTC trial (NCT01710605) 
investigates the clinical utility of the prognostic value of baseline CTC count. In this trial, the 
choice of the first line of treatment (hormone therapy or chemotherapy) for relapsing 
hormone-positive BCs is determined either by the clinician or by the baseline CTC count: 
hormone-therapy if <5 CTC/7.5mL (CellSearch technique) or chemotherapy if =5. The main 
medical objective is to demonstrate the non-inferiority of the CTC-based strategy for the 
progression-free survival. 
The authors of the first report on the phase III CirCe01 trial observed that among 
patients with ≥5 CTC/7.5 mL at baseline, a composite criteria (<5 CTC/7.5 mL or relative 
decrease ≥-70% of the baseline CTC count) showed better prognostication for early tumor 
progression (within 4 months) than the proposed <5 CTC/7.5 mL threshold (Helissey et al., 
2015). The role played by this threshold-related issue in the SWOG0500 trial failure is 
potentially critical, as using ≥5 CTC/7.5 mL after 3-5 weeks on treatment as a predictive test 
of early (<6 months) tumor progression, only 60% of patients with a positive test 
(i.e., ≥5 CTC/7.5 ml) have a PFS shorter than 6 months, while 75% of patients with 
<5 CTC/7.5 mL after 3-5 weeks on treatment have a PFS >6 months. The positive and 
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negative predictive values of the 5 CTC/7.5 mL threshold are therefore limited when used as 
a test to predict early tumor progression (Figure 1.2.2).  
 
 
Figure 1.2.2. CTC count thresholds with clinical validity may have limited clinical utility. 
Progression-free survival (PFS) curves of metastatic BC patients with ≥5 CTC/7.5 mL at baseline, 
according the CTC count at weeks 3-5: the red curve displays the PFS of patients who retains a CTC 
count ≥5 CTC/7.5 mL after 3-5 weeks on treatment and the blue curve displays the PFS of patients in 
whom the CTC count decreases <5 CTC/7.5 mL after 3-5 weeks on treatment (curves inspired from 
the European pooled analysis (Bidard et al., 2014)). Adapted from Bidard et al., 2016 
 
 
The use of CTCs as a prognostic and predictive marker was proven to be important 
also for patients with early BC, as preliminary prospective clinical trials suggest that the 
presence of CTCs at the time of primary diagnosis could predict early disease recurrence 
and reduced survival (Franken et al., 2012; Ignatiadis et al., 2008; Lucci et al., 2012; Pierga 
et al., 2008; Rack et al., 2014). Strikingly, in opposition to most of the currently used 
clinic-pathological prognostic factors, CTC detection studies using the CellSearch technique 
showed no association with the response to therapy, measured by the completion of a 
pathological complete response in the neoadjuvant setting. A pooled analysis including 
individual data from 3,173 patients with nonmetastatic (stage I–III) breast cancers confirmed 
that baseline detection of ≥1 CTC per 7.5 mL of blood (using the CellSearch system) is an 
independent predictor of poor disease-free, overall, breast cancer–specific, and distant 
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disease-free survival in both the neoadjuvant and adjuvant setting (Janni et al., 2016). These 
results fostered the initiation of the ongoing Treat CTC trial (NCT01548677), which assesses 
the efficacy of Trastuzumab to treat HER2-negative primary BCs with detectable CTCs. 
According to Treat CTC study design, patients with HER2-negative primary tumor who have 
completed either adjuvant chemotherapy (adjuvant cohort) or neoadjuvant chemotherapy 
and have residual disease in either the breast or the lymph nodes (neoadjuvant cohort) will 
be screened for the presence of CTCs using the CellSearch technology. Then, patients with 
detectable CTCs will be grouped to evaluate the effect of six cycles of therapy with Herceptin 
in CTC detection rate versus an observation untreated arm. The first report was published by 
Ignatiadis and colleagues (Ignatiadis et al., 2016), who described preliminary results 
obtained after screening 350 patients. According to CTC test results, performed in three 
central laboratories, 39 out of 318 (12%) assessable cases had ≥1 CTC/15 mL of blood after 
completing chemotherapy, data which is consistent with CTC detection rates already 
observed in non-metastatic breast cancers when using the CellSearch technology. 
Twenty-six out of 39 CTC+ patients, 20 (76%) with 1 CTC/15 mL of blood and 6 (24%) with 2 
to 14 CTC/15 mL, were then assigned either to the Herceptin treated or untreated group; 
results of correlation analyses with the clinical outcome will be available in the following 
3 years.  
Interestingly, in the first stage of Treat CTC Trial, 1 out of 26 CTC-positive patients had 
1 HER2-positive CTC by CellSearch-based score (Ignatiadis et al., 2016). Discordance in 
HER2 status between the PT and disseminated cells has been reported in many studies, 
although the real clinical efficacy of anti-HER2 therapies, either in HER2-positive or 
HER2-negative CTCs, is still controversial (Houssami et al., 2011; Meng et al., 2004a; 
Pestrin et al., 2012; Janni et al., 2016). A further level of complication is represented by 
recent evidence that HER2-positive and HER2−negative CTCs interconvert spontaneously, 
with cells of one phenotype producing daughters of the opposite within four cell doublings 
(Jordan et al., 2016). Moreover, the authors of these studies showed that although 
HER2-positive and HER2−negative CTCs have comparable tumor initiating potential, 
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differential proliferation favors the HER2-positive state, while oxidative stress or cytotoxic 
chemotherapy enhance transition to the HER2-negative phenotype. 
 
 
1.2.4. Molecular characterization of circulating tumor cells in breast cancer 
CTCs represent a unique opportunity to repeatedly monitor the metastatic process in 
patients and to study the molecular (genomic, transcriptomic and proteomic) processes 
associated with the spread of tumor cells. This opportunity has important implications for the 
development of blood-tests to monitor the expression of biomarkers in CTCs and possibly to 
support clinical decision-making.  
Molecular characterization can be performed on single CTCs or on the CTC bulk. Both 
approaches present advantages and pitfalls. Single-cell analysis requires sophisticated 
technologies to isolate pure single CTCs and to enable sensitive and reliable detection of 
transcripts or genomic alterations. On the contrary, studies on the whole CTC population 
allow easier and faster recover of CTCs but the quality of the clinical sample depends on the 
CTC/background leukocytes ratio and requires the identification of reliable positivity cut-offs; 
moreover, these approaches do not allow exploring the CTC heterogeneity. However, 
independently from the method, CTC characterization was proven to outperform the simple 
CTC count in various studies.  
Mostert and colleagues (Mostert et al., 2015) showed that a 16-gene expression 
signature of CTCs correlates with prognosis, in addition to, but also irrespective of, CTC 
count. In fact, among patients with <5 CTCs, who would be classified as good prognosis 
according to their CTC count by CellSearch, the 16-gene CTC profile was able to distinguish 
a good from an intermediate prognosis group, providing additional information to CTC count. 
However, the results were not validated in a further cohort, suggesting that the CTC isolation 
approach, which was EpCAM-based, and the panel of genes chosen underestimated the 
biological heterogeneity of CTCs.  
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Interestingly, many studies based on single CTC analysis are reporting high 
discrepancy between CTCs and matched primary and secondary lesions, as also among the 
same CTCs. PIK3CA mutation status, for example, was shown to be heterogeneous among 
tumor cells of different origin or within the CTC population, as also to change over time, 
according to disease progression (Pestrin et al., 2015; Deng et al., 2014; Markou et al., 
2014). However, it is unclear whether these high discrepancies are due to either the limited 
sensitivity of single cell characterization techniques, leading to false negative results, or to a 
real intercellular heterogeneity, previously ignored.  
Notwithstanding technical and interpretative difficulties, and the actual need for 
extensive and reproducible studies, CTC characterization deserves attention and effort to 
turn this great opportunity into readily usable tests and new therapeutic protocols. 
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1.3. THE BIOLOGY OF BREAST CANCER METASTASIS 
 
1.3.1. Landmark discoveries and theories on cancer metastasis 
The term “metastasis” was first applied to all maladies that seem to transpose from 
their point of origin to another organ with no specific reference to or knowledge of cancer. 
The first recorded definition of metastasis in the context of cancer diagnosis and treatment 
was made by Jean Claude Recamier in 1829 (Récamier, 1829) and since then metastasis 
was recognized as a multistage process during which malignant cells spread from the 
primary tumor to distant organs (Dorland, 1965; Christofori, 2006; Gupta and Massagué, 
2006; Figure 1.3.1). After initial neoplastic transformation events, the establishment of a 
vascular network and local invasion of the host stroma occur as a consequence of tumor cell 
adherence loss, proteolytic degradation of the surrounding extracellular matrix, acquisition of 
motility properties and passage through thin-walled venules and lymphatic channels, both of 
which offer little resistance to tumor cell invasion; once the cancer cell(s) has detached from 
the primary tumor, it may intravasate into blood or lymphatic system, both routes of 
dissemination leading to venous circulation; survival pathways are activated and interactions 
with the vascular microenvironment are established during tumor cell trafficking through the 
bloodstream, until tumor cells arrest in a capillary bed and extravasate; after homing to 
distant sites, successful colonization depends on interaction with the local microenvironment, 
defense against host immune response and the formation of a pre-metastatic niche by bone 
marrow-derived hematopoietic progenitors that attract tumor cells and support metastatic 
outgrowth; cells at secondary lesions can also re-disseminate to re-seed the site(s) of origin 
or form other metastases (reviewed in Steeg, 2006; Nguyen et al., 2009; Talmadge and 
Fidler, 2010). Each step can be rate limiting (Figure 1.3.1), as a failure or an impairment of 
any of these steps can stop the entire process (Fidler, 1970; Poste and Fidler, 1980).  
In 1889, Stephen Paget proposed that metastasis depends on the cross-talk between 
selected cancer cells, defined as “seeds”, and the microenvironment of host tissues, which 
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Figure 1.3.1. The metastatic cascade. The process of cancer metastasis consists of sequential and 
interlinked events, each representing a potentially rate limiting step, such that the formation of 
clinically relevant metastases depends on the completion of the entire process. Talmadge and Fidler, 
2010 
 
 
represents the “soil” (Paget, 1889), on the basis of a series of observations regarding the 
blood supply and the frequency of metastasis in specific organs, thus contradicting the 
prevailing theory of Virchow, according to which tumor dissemination is determined by 
mechanical factors (Virchow, 1989). Forty years later, in 1928, Ewing challenged the “seed 
and soil” hypothesis (Ewing, 1928). He proposed that mechanical forces and circulatory 
patterns between the primary tumor and the secondary site accounted for organ specificity. 
The seminal studies by Fidler and coworkers (Fidler and Kripke, 1977; Hart and Fidler, 1980) 
conclusively showed that, although tumor cells traffic through the vasculature of all organs, 
metastases selectively develop in congenial organs. The “seed and soil” hypothesis 
represents the basis for current research as it is now widely accepted that the outcome of the 
metastatic process, and consequently of therapeutic protocols, is dependent on both the 
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intrinsic properties of tumor cells and their interaction with host factors (Quail and Joyce, 
2013). 
Studies focused on metastasis biology indicated that in vivo analyses are required to 
describe the biological phenomenon at mechanistic level and that in the absence of animal 
models the probability for misinterpretation is high. On the other hand, clinical studies provide 
high fidelity models of the timing of dissemination and allow defining intra- and inter-lesion 
heterogeneity. For instance, studies based on in vitro and in vivo selection of cells with 
enhanced metastatic capability demonstrated that cell subpopulations with heterogeneous 
metastatic potential exist within the same tumor (reviewed in Fidler, 2003). The biological 
heterogeneity of cells that survive in a foreign microenvironment suggested that the 
metastatic process is selective and that phenotypic diversification occurs during tumor 
growth. The British pathologist Leslie Foulds was the first to interpret the heterogeneity of 
cancer cell populations in a dynamic perspective, describing cancer progression as a 
stepwise acquisition of permanent and irreversible changes (reviewed in Klein, 1998). This 
view of cancer was definitively explicated by Peter Nowell, who attributed tumor evolution to 
acquired genetic variations, suggesting the first explicit Darwinian model of tumor 
progression (Nowell, 1976). According to the linear progression model, tumor cell phenotypic 
heterogeneity represents both the effect of cancer cell genetic instability, characterized by 
multiple rounds of genomic alterations, and of selective pressures exerted from the 
microenvironment, which determines selective growth of cell clones endowed with enhanced 
competitive fitness. Accordingly, metastases appear at the latest stage of tumor progression, 
as a result of the temporal evolution and acquisition of specific molecular traits (Figure 1.3.2). 
However, this model did not explain the first observations that metastasis may initiate long 
before the first symptoms appeared or the primary tumor was diagnosed (reviewed in Klein, 
2009). On the basis of these considerations, a parallel progression model has been 
proposed, which places dissemination among the events that occur at the earliest stages of 
disease by the accumulation of genetic and epigenetic alterations and adaptation to foreign 
microenvironments in the primary tumor in a parallel and independent manner compared to 
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metastases (Klein, 2009). Therefore, marked genetic divergence is expected between 
primary and secondary lesions, including disseminated tumor cells (either circulating in blood 
or hidden in the bone marrow).  
The application of the one or the other model has important implications for clinical 
studies. In the case of parallel progression, the genetic divergence between primary and 
metastatic tumors makes the primary tumor unsuitable for diagnostic purposes and for the 
design of effective therapies. Therefore, the analysis of disseminated tumor cells can provide 
additional and more useful information rather than studying the primary lesions only. 
However, even when considering the stepwise progression model, diagnostic and treatment 
decisions that are based on the analysis of the whole primary tumor and do not take into 
account the intra-tumor heterogeneity may be inaccurate, since a minor subclone might have 
determined the formation of metastases.  
 
 
Figure 1.3.2. The linear and parallel progression models. Two hypothetical models of tumor 
progression during metastasis are stepwise progression, in which metastases are seeded at the latest, 
clinically diagnosable stage of tumor progression, and parallel progression, in which tumor 
dissemination occurs at earlier stages of tumor progression. Marusyk et al., 2012 
 
 
Experimental and clinical data are in favor of the early dissemination and parallel 
progression of breast cancer (Hüsemann et al., 2008; Schardt, 2005), although different 
behavior of tumor cells regarding the timing of dissemination should be expected due to the 
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heterogeneity of the disease and the tendency to colonize organs with different 
characteristics (Klein, 2009).  
 
Figure 1.3.3. The parallel progression model in breast cancer. At early stage, (A) cancer cells 
disseminate from tumors with small volumes and give rise to metastases within 6-15 years according 
to the features of the distant organ. (B) Multiple waves of dissemination may occur before diagnosis, 
under the stimulation of factors secreted by the primary tumor, which can influence the timing and 
aggressiveness of metastases. Klein, 2009 
 
According to the early dissemination and parallel progression model, dissemination 
starts when tumor diameter is 1–4 mm. Metastases in different organs are seeded in parallel 
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and develop within 6 to 12 years, with the exception of brain metastases, which can establish 
later due to organ specific barriers and microenvironment. Late-disseminating tumor cells 
from primary or secondary tumors with larger volumes are possibly less capable of forming 
metastases or contributing to poor outcome as death might occur before they can be 
detectable. Moreover, tumor cells may disseminate in several waves before diagnosis and 
may progress in parallel at different rates in different organs. Behind cancer cell molecular 
traits and behavior, factors secreted by the primary tumor may stimulate colonization and 
account for the relationship of tumor size and probability of metastatic outgrowth 
(Figure 1.3.3). 
 
 
1.3.2. Genetic determinants of breast cancer metastases 
A salient feature of metastasis is the ability of different tumor types to colonize the 
same or different organ. However, it remains unclear to what extent these genes are used by 
different tumor types that show the same pattern of metastasis. 
Breast cancer is a heterogeneous disease and also different metastatic behavior was 
observed according to the molecular subtype. Hormone receptor-positive tumors have a 
tendency to develop bone metastases and they have better survival outcomes compared to 
hormone receptor-negative tumors with a tendency of developing visceral metastasis; 
luminal/HER2-positive and HER2-enriched tumors are associated with a significantly higher 
rate of brain, liver, and lung metastases; basal-like tumors have a higher rate of brain, lung, 
and distant nodal metastases but a significantly lower rate of liver and bone metastases; TN 
non-basal tumors demonstrate a similar pattern but were not associated with fewer liver 
metastases compared to TN non-basal tumors (Kennecke et al., 2010). 
Genetic determinants associated to the different stages of BC metastatic process were 
identified. Numerous studies revealed that TGF-β signaling may have a multifunctional 
nature, as clinical and experimental results showed that it may exert a pro-metastatic or a 
tumor-suppressive role within the same tumor, depending on the cellular context and the 
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stage of disease (Padua and Massagué, 2009; Massagué, 2012; Kang et al., 2005). In 
breast cancer TGF-β was proven to mediate the induction of Angptl4 in cancer cells that are 
going to enter the circulation, with subsequent enhanced retention of these cells in the lungs, 
but not in the bone; in fact, tumor cell-derived Angptl4, in turns, disrupts vascular endothelial 
cell-cell junctions, increases the permeability of lung capillaries, and facilitates the 
trans-endothelial passage of tumor cells (Padua et al., 2008). Metastatic BCs may also 
evade the growth-inhibitory action of TGF-β by defects in genes that play a key role in the 
coordination of TGF-β cytostatic response, as the accumulation of C/EBPbeta inhibitory 
isoform LIP (Gomis et al., 2006).  
Active cross-talk between breast cancer cells and bone has been largely documented, 
and studies in this field allowed defining a vicious cycle which regulates the formation of 
osteolytic breast cancer metastases to bone (Roodman, 2004; Kozlow and Guise, 2005). 
Factors, such as MMPs, chemokine receptor 4 (CXCR4), vascular endothelial growth factor 
(VEGF), and connective tissue growth factor (CTGF), target metastatic tumor cells to bone 
and facilitate survival within the bone microenvironment. Physical factors within the bone 
microenvironment, including hypoxia, acidic pH, and extracellular Ca2+, and bone-derived 
growth factors, such as TGF-β and IGFs, activate tumor expression of osteoblast-stimulatory 
factors, including VEGF, platelet-derived growth factor (PDGF), and endothelin 1. 
Osteoclast-stimulatory factors, including PTHrP, TGF-β, and IL-11, can also be increased. 
These factors stimulate bone cells, which in turn release factors that promote tumor growth in 
bone. The angiogenesis factor fibroblast growth factor-5, the connective tissue-derived 
growth factor, the activator of osteoclast differentiation interleukin-11, the matrix 
metalloproteinase/collagenase MMP1, follistatin, and the metalloproteinase-disintegrin family 
member ADAMTS1 were also listed among genes which drive tumor cells toward bone 
colonization (Kang et al., 2003).  
A gene signature that regulates breast cancer cell tropism to lung was also identified. 
ID1, VCAM1 or IL13Rα2 knock-down was proven to decrease the lung metastatic activity of 
breast cancer cells (Minn et al., 2005). The establishment of distant metastases depends on 
85 
 
the capability of small numbers of cancer cells to regenerate a tumor after entering a target 
tissue. A role for the transcriptional inhibitors of differentiation Id1 and Id3 as selective 
mediators of lung metastatic colonization in the TNBC was also reported (Gupta et al., 2007). 
Moreover, a gain-of-function cDNA screen revealed that Coco, a secreted antagonist of 
TGF-β ligands, induces dormant breast cancer cells to undergo reactivation in the lung by 
blocking lung-derived BMP ligands (Gao et al., 2012). In order to decipher the mechanism 
that regulates tumor cell dormancy and re-awakening, Malladi and co-workers  used another 
approach, based on the isolation of disseminated cancer cells able to survive as latent 
entities, called latency competent cancer (LCC) cells (Malladi et al., 2016). They 
demonstrated that LCC cells show stem-cell-like characteristics and express SOX2 and 
SOX9 transcription factors, which are essential for their survival in host organs under 
immune surveillance and for metastatic outgrowth under permissive conditions. By 
expressing a Sox-dependent stem-like state and actively silencing WNT signaling, LCC cells 
can enter quiescence and evade NK-mediated innate immunity to remain latent for extended 
periods. 
The blood-brain barrier (BBB) exerts a dual role in brain metastasis formation: it forms 
a tight barrier protecting the central nervous system from entering cancer cells, but it is also 
actively involved in protecting metastatic cells during extravasation and proliferation in the 
brain (Wilhelm et al., 2013). Gene expression analysis of cells that preferentially infiltrate the 
brain isolated from patients with advanced breast cancer, coupled with functional analysis, 
identified the cyclooxygenase COX2 (also known as PTGS2), the EGFR-ligand HBEGF, and 
the alpha2,6-sialyltransferase ST6GALNAC5 as mediators of cancer cell passage through 
the blood–brain barrier (Bos et al., 2009). Once passed through the BBB, tumor cells 
necessitate the establishment of interactions with the stroma microenvironment in order to 
fuel their metastatic ability, as reported in a recent paper on the role of protocadherin 7 
(PCDH7) (Chen et al., 2016). PCDH7, which is expressed by breast and lung cancer cells, 
promotes the assembly of carcinoma-astrocyte gap junctions; once engaged with the 
astrocyte gap-junctional network, brain metastatic cancer cells use these channels to transfer 
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the second messenger cGAMP to astrocytes, activating the STING pathway and the 
production of inflammatory cytokines such as interferon-α (IFNα) and tumor necrosis factor 
(TNF); acting as paracrine signals, these factors activate the STAT1 and NF-κB pathways in 
brain metastatic cells, thereby supporting tumor growth and chemoresistance.  
Information on the mechanisms that regulate the late phase of BC metastasis, 
including colonization of distant organs and metastasis outgrowth, represent a large part of 
literature; however, data on the mechanisms regulating the early events of dissemination and 
survival of tumor cells in blood are still scarce. 
 
 
1.3.3. Modeling breast cancer metastases in the mouse 
Studies carried out in recent years have brought impressive advancements in BC 
metastasis research by the use of a large number of experimental models, including 
drosophila, zebrafish, mice, rats and more rarely, rabbits, companion pets and monkeys 
(reviewed in Saxena and Christofori, 2013). Metastasis is a biological process that requires 
the completion of a cascade of events. The main hallmark properties of a metastatic cell are 
its migratory and invasive abilities (Yang and Weinberg, 2008; Friedl and Wolf, 2010). In vitro 
assays, such as scratch wound, Boyden chamber migration, transendothelial migration, and 
Matrigel invasion (Stoker and Perryman, 1985; Boyden, 1962; Reiske et al., 1999; Shaw, 
2005; McClatchey, 1999; Lee et al., 2007), have been employed to investigate on the 
molecular mechanisms that orchestrate these processes. Also experimental systems that 
more reliably represent the tumor microenvironment, as the implantation of tumor cells into 
the chorioallantoic membrane of the chick embryo, allowed the live monitoring of tumor cell 
invasion, as also angiogenesis and interaction between cancer cells and blood vessels 
(Sherman et al., 1998).  
While in vitro model systems are instrumental for the analysis of single functional 
aspects of cancer cells, the information gained on the complexity of the metastatic process is 
limited as it is free from the biological context offered by an entire organism. A major 
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contributor to deciphering of the multistage nature of metastasis comes from transgenic and 
transplantation laboratory mouse models, which have served as important preclinical tools 
for both mechanistic and pharmacological studies (Bos et al., 2010). Cancer models driven 
by the introduction of oncogenic mutations in a tissue-specific manner can faithfully 
recapitulate important aspects of tumor initiation, local progression, and response to therapy 
(Bos et al., 2010). In BC models as those MMTV-driven HER2-transgenic or MMTV-driven 
PyMT-transgenic (which resemble the luminal B molecular subtype, Herschkowitz et al., 
2007), cancer develops with high penetrance in a stepwise manner, enabling the study of 
tumor initiation and of the early steps of metastatic dissemination (Lin et al., 2003; 
Ursini-Siegel et al., 2007). The MMTV-PyMT model shares many aspects of human BC 
progression, and multistage progression from hyperplasia to multifocal mammary 
adenocarcinomas followed by the development of metastatic lesions in lymph nodes and 
lung with high penetrance and short latency (Guy et al., 1992; Maglione et al., 2001). The 
MMTV-Her2/neu mice develop multifocal adenocarcinomas with lung metastases at about 15 
weeks after pregnancy (Muller et al., 1988). In a seminal paper, Hüsemann and colleagues 
found that in MMTV-Her2/neu mice cancer cells leave the primary tumor site and reach bone 
marrow and lung before cancer become morphologically detectable (Hüsemann et al., 2008).  
Another exemplary model is represented by tail vein injection of mammary epithelial 
cells genetically modified for several oncogenes under control of a doxocyclin-inducible 
promoter, which showed that few untransformed epithelial cells may colonize the lung once 
they have entered the bloodstream and are capable of surviving and form colonies at lung 
upon oncogene activation (Podsypanina et al., 2008). However, metastasis in these models 
is often restricted to lymph nodes and lungs.  
Syngeneic and xenograft models in which mouse or human cancer cells are introduced 
into immunocompatible or immunocompromised mice, respectively, provide at present two 
methods of choice to experimentally induce metastatic dissemination and colonization of 
relevant organs.  
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Syngeneic BC cell lines were derived from a single spontaneous tumor arising in 
BALB/cfC3H mouse (Dexter et al., 1978; Miller et al., 1983), and murine BCCLs with different 
metastatic potential were then obtained: the 66cl4 (Miller et al., 1983), 67NR and 168FARN 
(reviewed in Heppner et al., 2000) variants were derived from 66, 67 and 168 lines, 
respectively, and showed low metastatic potential (Aslakson and Miller, 1992), whereas 4T07 
and 4T1 variants were derived from the 410.4 line and, notoriously, metastasize to lung, liver 
and lymph nodes (Dexter et al., 1978; Aslakson and Miller, 1992; Heppner et al., 2000), 
when injected in Balb/c mice. Clone 4T1.2 (and others), showing tropism also to bone, was 
derived from the 4T1 cell line, (Lelekakis et al., 1999; Eckhardt et al., 2005). The various 
sublines of 4T1 have also been used to generate distinct gene expression signatures for 
each stage of tumor progression, and comparison of their profiles has led to the identification 
of the EMT-inducing transcription factor Twist, which was also shown to be important for BC 
metastasis (Yang et al., 2004), as also the BMP inhibitor Coco, able to re-awake 4T07 
dormant cells at lung in Balb/c mice (Gao et al., 2012). Importantly, transplantation of cancer 
cells in mice with identical genetic background bypasses the immunologic host-versus-graft 
rejection and concomitantly allows investigating the contribution of an intact immune system 
and other players of the tumor microenvironment to malignant tumor progression (Khanna 
and Hunter, 2005).  
Metastatic xenograft mouse models have been established also for BC studies, in 
particular with the MDA-MB-231 cell line and its derivatives, providing a suitable system to 
investigate the late steps of the metastatic cascade (Nguyen et al., 2009). In experimental 
metastasis assays, the tumor cells are injected directly into the systemic circulation. The 
development of metastasis in these models is rapid and is largely influenced by the site of 
injection and the inherent tropism of the tumor cells, especially after in vivo selection of 
organ-specific metastatic variants after several rounds of transplantation (Nguyen et al., 
2009; Bos et al., 2010). The various routes include lateral tail vein, intra-portal, intra-splenic, 
intra-carotid, intra-peritoneal and intra-cardiac injections (Khanna and Hunter, 2005). 
Injection into the tail vein is the most commonly used assay and primarily leads to formation 
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of metastatic nodules in the lung (Minn et al., 2005), whereas intra-peritoneal injection 
usually provokes local invasion (Khanna and Hunter, 2005). Intra-portal vein and 
intra-splenic injections usually result in liver metastasis, intra-carotid injection leads to brain 
(Bos et al. 2009), and left ventricle injection favors multiorgan metastases (Harms and 
Welch, 2003; Khanna and Hunter, 2005), including bones (Yin et al., 1999; Kang et al., 
2003).  
In spontaneous metastasis assays, cancer tissue or tumor cells are primarily implanted 
into the organ from which the cancer cells have been originally derived (orthotopic 
transplantation) or into a tissue of high vascularization and convenient anatomical location 
that does not represent the organ of origin (ectopic transplantation), such as the skin or the 
subrenal capsule (Khanna and Hunter, 2005). Ectopic transplantation models mostly fail to 
mimic the appropriate microenvironment of the primary tumor and the corresponding 
metastatic dissemination to the relevant organs. Hence, orthotopic transplantation models 
have been developed that more closely mimic the human situation, including tumor histology, 
vascularity, tumor-stroma interactions, gene expression profiles, metastases development, 
and also chemotherapy responsiveness (Céspedes et al., 2006). With spontaneous models, 
most stages of the metastatic cascade can be observed and investigated (Saxena and 
Christofori, 2013). 
Despite the recognized importance of the previously described models, BC modeling 
remains a challenge due to the intrinsic heterogeneity of this neoplasm. In order to 
successfully identify new therapies, it is fundamental that preclinical models could 
recapitulate the complexity observed in the clinical context (Landis et al., 2013; Whittle et al., 
2015). Improvements in engraftment protocols and utilization of more severely 
immunocompromised mouse models set the stages for advancements in generating 
patient-derived xenograft (PDX) models of BC. Marangoni and colleagues (Marangoni et al., 
2007) achieved a 15% and 24% initial engraftment rate from primary tumors and metastatic 
sites, respectively. These Swiss nude mouse models produced a 12.5% (25/200) stable take 
rate and ten models with lung metastases. In comparing xenograft response to patient 
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response to treatment, a 5/7 concordance was observed, supporting the utility of these 
models for evaluating therapeutics. DeRose and colleagues obtained metastases after 
engraftment of biospecimens of primary tumors, pleural effusates and ascites, with 
frequencies from 38% to 100% in sites corresponding to those diagnosed in patients 
(DeRose et al., 2011). Zhang and colleagues established a large cohort of 35 stable cell lines 
representing 27 patients, with 12 lines (48%) developing metastatic lesions in the lung 
(Zhang et al., 2014). Regardless of the challenges in establishing PDX, these models 
generally retained the pathological characteristics and biomarker status of the original patient 
tumor and were proven to be stable across multiple transplant generations. Several groups 
have documented retention of histopathological characteristics and biomarker status by IHC, 
whereas molecular analysis, although showing shared alterations between primary and 
xenograft tumors, revealed more pronounced mutational status or aggressiveness tumor 
characteristics in PDXs (Zhang et al., 2014), as also observed by Ding and colleagues by 
comparing deep sequencing results of peripheral blood, the primary tumor, a brain 
metastasis and a xenograft derived from the primary basal-like TN breast tumor (Ding et al., 
2010). More recently, the use of CTCs isolated from small cell lung cancer and prostate 
cancer patients has been also adopted as reliable model to study tumor aggressiveness and 
chemosensitivity, and to provide tractable systems for therapy testing (Hodgkinson et al., 
2014; Williams et al., 2015; Alix-Panabières et al., 2016). A major challenge to the 
establishment of PDXs from BCs is the low take rate of luminal tumors compared to TNBC 
(reviewed in Landis et al., 2013). In addition, xenograft models in general do not allow 
studies on the role of the microenvironment and the immune system in metastasis and 
therapy response.  
Overall, all of these models provide complementary tools to study BC metastasis 
biology since no single metastasis model is sufficient to answer all questions. As such, the 
selection or development of suitable models is necessary. 
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1.4. TREFOIL FACTOR 3 
 
1.4.1. Structure and physiopathological functions of trefoil factors 
The trefoil factor (TFF) peptides consist of a family of three highly conserved, 
thermostable and protease-resistant secreted polypeptides (Thim and May, 2005): human 
TFF1 (formerly pS2), TFF2 (formerly spasmolytic polypeptide/SP), TFF3 (previously called 
intestinal trefoil factor/ITF or hP1.B). TFF1 was the first member of the family to be 
discovered via cDNA cloning of an estrogen-responsive gene from a BC cell line 
(Masiakowski et al., 1982); human TFF2 was characterized few years later (Tomasetto et al., 
1990); human TFF3 from rat intestine was the third mammalian TFF-peptide described 
(Suemori et al., 1991) and its human homolog was reported in 1993 (Hauser et al., 1993; 
Podolsky et al., 1993).  
 
 
Figure 1.4.1. Trefoil domain 3D structure. Picture represents the predicted 3D structure of TFF3 
(http://prosite.expasy.org/PS51448); trefoil domain is highlighted in green.  
 
 
The protein family was named for the disulphide bond configuration of the P domain, or 
trefoil domain, which forms a three-leaved structure similar to a trefoil or clover leaf 
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(Figure 1.4.1), and the official nomenclature was assigned upon an agreement at a 
Conférence Philippe Laudat (Wright et al., 1997).  
The trefoil domain was originally defined as a conserved sequence of 38 or 39 amino 
acidic residues, containing 6 cysteine residues forming disulphide bonds in a 1-5, 2-4 and 
3-6 configuration, which are responsible for the remarkable protease resistance of TFF 
peptides. Later, examination of the available three-dimensional structure and comparison of 
the conservation between mammalian TFFs revealed that the conserved P domain extends 
beyond the 38-39 amino acidic residues originally suggested, and protein structure data 
revealed that trefoil domain has a sequence of 42-43 amino-acidic residues. The analysis of 
the tertiary structure also showed that the 3 loops do not lie on a single plane but are stacked 
parallel to each other (reviewed in Thim and May, 2005).   
Genes encoding for TFF peptides are located as a head to tail oriented cluster in a 
55 kb region on the reverse strand of chromosome 21q22.3. The 5’-flanking regions of these 
genes have similar regulatory sequences, suggesting that the three genes are transcribed 
and regulated in a coordinated fashion (reviewed in Regalo et al., 2005). TFF1 gene has 1 
transcript with 3 exons encoding for a 84 amino-acidic residues polypeptide and the mature 
peptide consists of 60 residues containing a single trefoil domain. TFF2 gene has 3 
transcripts, 1 of them encoding for a 129 amino-acidic residues polypeptide, while the mature 
sequence consists of 106 residues containing 2 trefoil domains, encoded by 2 separate 
exons. TFF3 gene has 4 transcripts, 3 of them encoding for a 94, a 125 and a 74 
amino-acidic residues polypeptide, respectively, but the 94-residues peptide, consisting of 59 
amino-acidic residues and containing a single trefoil domain, seems to be the most 
represented and supported variant, according to Transcript Support Level and APPRIS 
computational methods (www.ensembl.org). Residues from 1-24, 1-23 and 1-21, respectively 
for TFF1, TFF2 and TFF3, encodes for signal peptide (www.uniprot.org).  
Both TFF1 and TFF3 form homodimers via disulphide bond with a seventh cysteine 
residue and can form disulphide bonds with other proteins (Westley et al., 2005; Chadwick 
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et al., 1997, May et al., 2003). TFF2 has two extra-trefoil domain cysteine residues that form 
an intramolecular disulphide bond (Thim, 1989).  
According to overall microarray, RNAseq and SAGE gene expression profile (GEP) 
data (www.genecards.org), TFF1 shows high expression in the stomach and colon and 
moderate expression in the prostate, small intestine, pancreas, thyroid, salivary gland and 
breast; TFF2 shows high expression in the stomach and moderate expression in the thyroid, 
placenta, salivary gland and pancreas. Overall, both peptides are expressed at low level in 
other visceral organs, in the nervous system, muscle and hematopoietic cells. TFF3 is 
expressed at higher level in the small intestine, colon, thyroid and pancreas compared to the 
mammary gland, ovary, uterus, prostate, liver, kidney, bladder, testis, salivary gland, 
adipocytes and bone marrow, where moderate signals were observed, whereas it can be 
detected at low levels in the nervous system and muscle. No peptide expression was found 
in white blood cells and serum, whereas TFFs are all detectable in urine and pancreatic juice 
(www.genecards.org). TFF3 expression body map is reported in Figure 1.4.2. 
TFF peptides have a pivotal role in maintaining the surface integrity of a number of 
mucin-producing epithelia, with TFF1 and TFF2 principally expressed in gastric mucosa and 
TFF3 manly secreted by goblet cells of intestine and lung (reviewed in Taupin and Podolsky 
2003). They can be co-secreted with mucins into the lumen to form a gel-like mucus layer 
and their association with mucins exerts a protective effect on the mucosa, serving as a 
barrier from mechanical stress, noxious agents and pathogens (Hoffmann 2009; Kjellev 
2009). Consistently, TFF3 binding on epithelial cell surface is regulated by mucins, TFF2 has 
been shown to catalyze the formation of stable mucin complexes and TFF1 interacts with 
MUC5AC through binding to the von Willebrand C cysteine-rich domains VWFC1 and 
VWFC2. However, TFF peptides can also act at intracellular level, where they are believed to 
contribute to protein folding. Indeed, the lack of TFF1 leads to the accumulation of misfolded 
proteins in the endoplasmic reticulum.  
TFF peptides are rapidly up-regulated and secreted in response to gastrointestinal 
injuries and act as motogens in autocrine and paracrine fashion to facilitate cell migration into 
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the lesion, thus forming a protective barrier in a process known as restitution (Poulsom et al., 
1996). In addition, they are potent inhibitors of apoptosis and prevent anoikis during the cell 
migration process (Taupin et al., 2000; Figure 1.4.3).  
 
 
Figure 1.4.2. TFF3 expression body map. Map reports expression scores based on data from GTEx, 
BioGPS, Illumina Human BodyMap, and SAGE (www.genecards.org). 
 
 
Aberrant expression of TFF-peptides was widely observed during various chronic 
inflammatory diseases of epithelial tissues, as for example in ileal Crohn's disease, in colon 
mucosa of patients with ulcerative colitis and in gallbladder during acute cholecystis 
(reviewed in Poulsom and Wright, 1993). Moreover, all TFF peptides are typically secreted 
by a specific gland-like structure termed the ulcer-associated cell line (UACL) (Poulsom and 
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Wright, 1993). This mucin-secreting glandular structure appears during a variety of chronic 
inflammatory conditions and contains a clearly defined proliferative zone which develops 
from stem cells, most commonly in the small intestine, and is thought to represent a natural 
repair system which is activated after mucosal damage, particularly in Crohn's disease and 
duodenal ulcer disease.  
 
 
Figure 1.4.3. Established and putative functions of trefoil proteins. Established functions are 
indicated by solid arrows, whereas putative functions are denoted by dashed arrows. Mucous-cell (for 
example, goblet cell) secretion of trefoil factors (TFFs; red circles) or mucins (green circles) is 
concomitant. Secreted TFF acts on adjacent mucosal cell populations (for example, enterocytes) 
either at extracellular or intracellular level. Cell migration is the result of integrated disruption of 
cell-cell and cell–substratum adhesion and prevention of anoikis. TFF response elements in TFF gene 
promoters allow increases in TFF expression through auto-induction (red circles) and cross induction 
of other TFFs (blue and yellow circles), in addition to mucin expression and possibly tumor 
suppression. Taupin and Podolsky, 2003 
 
 
1.4.2. Role of trefoil factors in cancer 
In addition to the protective and restorative effects of TFFs in the gastrointestinal tract, 
recent evidence has indicated that members of this family also possess pivotal role in the 
development and progression of human cancers. Aberrant expression of TFFs has been 
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reported for a variety of solid tumors, including breast, prostate, colon, lung and gastric 
cancers (reviewed in Perry et al., 2008).  
In the current literature a role as tumor suppressor genes and potential tumor 
progression factors is reported for TFF peptides. The reason for this apparent contradiction 
might be a consequence of the complex relationships between the inflammatory environment 
frequently observed in the digestive tract during neoplastic transformation (included 
generation of reactive oxygen species, associated genotoxic damage, cellular stress and 
mitogenic signals) and oncogenic activation of key genes involved in cellular transformation 
and tumor progression (Emami et al., 2004).  
In support of a tumor suppressor role, both TFF1 and TFF3 reduce the growth of the 
human colon cancer cell lines LoVo and SW837 in vitro and in vivo (Calnan et al., 1999; 
Uchino et al., 2000). More recently it was demonstrated that deficiency in TFF1 increases 
tumorigenicity of human breast cancer cells and mammary tumor development in 
TFF1-knock-out mice (Buache et al., 2011).  
However, as also summarized in Table 2, TFF peptides were proven to promote cell 
migration and resistance to anoikis and antiapoptotic role was also observed after serum 
starvation in in vitro assays. They also act as motogens both in normal and malignant states 
and promote invasiveness and angiogenesis (references are listed in Table 2). Moreover, 
TFF3 enhances cell proliferation and survival and reduces sensitivity to ionizing radiations in 
prostate carcinoma cells (Perera et al., 2015). Further functional in vitro studies revealed that 
forced expression of TFF3 increased cell proliferation and survival, enhanced 
anchorage-independent growth, promoted migration and invasion (Kannan et al., 2010; 
Pandey et al., 2014) and stimulated endothelial cells adhesion, transmigration through and 
endothelial barrier and de novo angiogenesis (Pandey et al., 2014; Lau et al., 2015). 
Moreover, forced expression of TFF3 in MCF7 cells stimulated the formation of metastatic 
nodules at lung when injected in mice, and consistently, siRNA-mediated depletion or 
neutralization of secreted TFF3 by antibodies reduced invasive potential, promoted 
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apoptosis, decreased cell growth in vitro and arrested tumor growth in xenograft models 
(Kannan et al., 2010; Pandey et al., 2014). 
Regarding the oncogenic role of TFF3, no evidence exists for the TFF3–mediated 
acquisition of tumor initiation ability in animal models. 
TFF3 expression has also been explored in clinical samples and tested as potential 
biomarker to predict BC outcome. Immunohystochemistry analysis revealed variable 
expression of TFF3 in breast tissues. Ahmed et al. described (Figure 1.4.4) strong TFF3 
immunoreaction in most of the normal breast tissue from premenopausal and 
perimenopausal women. As in normal tissues, TFF3 was expressed by epithelial - and not 
myoepithelial - cells of benign breast lesions, and it was especially concentrated in the 
lumen, where cells appeared with large secretory granules, suggesting active release of 
TFF3 in the lumen. It was detected in 89% of in situ and in 83% of invasive carcinomas, 
although TFF3 was concentrated at the luminal edge in well-differentiated tumor cells, 
whereas in poorly differentiated tissues it preferentially accumulated in the stroma. In 
invasive malignant lesions the immunoreaction was cytoplasmic with a tendency toward 
perinuclear condensation in some cells, and cells with strong TFF3 expression were 
scattered diffusely throughout the stroma, whereas in tumors with weaker expression they 
had a tendency to cluster or aggregate together within the stroma. Within these clusters, 
malignant cells with higher TFF3 expression were concentrated on the edges of the cell 
aggregates and in some cases had polarized TFF3 immunoreaction that was more intense 
toward the stromal edge of the tumor cell. The authors of this work also observed that TFF3 
expression was high in well-differentiated tumors and was significantly associated with low 
histological grade and with ER and PgR expression, which is in line with the induction of 
TFF3 mRNA by estrogen in BC cells. Paradoxically, notwithstanding association of TFF3 
with features of good prognosis, its expression was also associated with muscle, neural and 
lymphovascular invasion, and it was an independent predictive marker of lymph node 
involvement (Ahmed et al., 2012). Consistently with an angiogenic function (Lau et al., 2015), 
TFF3 expression correlated strongly with microvessel density evaluated with CD31 and 
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CD34 (Ahmed et al., 2012). In an independent study on two cohorts of BC patients, TFF3 
expression was also positively associated with larger tumor size and reduced relapse-free 
and overall survival (Pandey et al., 2014). 
The association between TFFs and ER is not completely clear. TFF3 - and also TFF1, 
but not TFF2 - mRNA was detected in breast tumors and estrogen-responsive BCCLs and it 
was also observed to be induced in an estrogen-dependent and progesterone-independent 
manner (May and Westley, 1997). Furthermore, TFF3 was among the top genes whose 
expression correlated strongly with that of ER in large cohorts of BC patients (Gruvberger et 
al., 2001). Consistently, forced expression of TFF3 additively increased ER transcriptional 
activity in the presence of estradiol, promoted estrogen-independent growth and induced 
resistance to tamoxifen and fulvestrant (Kannan et al., 2010). However, GEP analysis of 
ER-negative/PgR-negative tumors allowed identifying TFF3 among a panel of markers 
characterizing a distinct subset of tumors, showing paradoxical expression of direct ER target 
genes, as also genes responsive to estrogen or typically expressed in ER-positive BCs 
(Doane et al., 2006). Interestingly, TFF1 and TFF3 were also differentially expressed 
between BC patients who experienced relapse to bone versus those who experienced 
relapse in other parts of the body (Smid et al., 2006), and TFF3 was also detected in tumor 
cells isolated from the cerebrospinal fluid of metastatic BC patients with leptomeningeal 
carcinomatosis (Magbanua et al., 2013).  
In an attempt to move from the analysis of solid tumor lesions toward the possibility to 
develop a blood test for detection circulating biomarkers, Bosma et al. identified a series of 
genes abundantly expressed in BC tissues but absent in normal peripheral blood cells and 
bone marrow, including TFF3  and TFF1  (Bosma et al., 2002). Few years later Smirnov and 
colleagues analyzed the GEP of at least 100 tumor cells isolated from the blood of one 
metastatic breast, one metastatic colorectal and one metastatic prostate cancer patient and 
they found that both TFF1 and TFF3 were among genes distinguishing between patients and 
healthy donors (Smirnov et al., 2005).     
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Figure 1.4.4. Expression of TFF3 in normal and diseased human breast. TFF3 protein expression 
was analyzed in different benign and diseased tissues by Ahmed and co-workers. Arrows indicate 
malignant epithelial cells with TFF3 expression absent (M and N; white), weakly positive (M–O; pale 
gray), moderately positive (M–O; intense gray), and strongly positive (M–O; black). Examples of cells 
in which TFF3 expression is polarized either away from the lumen (pink arrows) or away from the 
stroma (blue arrows) are indicated. Multinucleated cells in a carcinoma with prominent cytologic atypia 
(W), and mitotic cells in a carcinoma with mild cytologic atypia (X) and in a ductal carcinoma of no 
specific type (M) are indicated (red arrows). Ahmed et al., 2012 
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More recently, a multi-marker panel including both TFF1 and TFF3 was developed to 
identify circulating tumor cells (CTCs) in the blood of metastatic BC patients, revealing that 
TFF3 was 10 to 15-fold more expressed in the peripheral blood mononuclear cell fraction  
isolated from patients compared to healthy controls (Lasa et al., 2013). Interestingly, dynamic 
changes of CTCs in the epithelial and mesenchymal composition were recently studied in BC 
patients, showing that tumor cells with epithelial features, which were highly representative of 
the CTC population in ER-positive/PgR-positive cases and persistent in patients with initial 
response to therapy, overexpressed TFF1 and TFF3 compared to tumor cells with 
mesenchymal or intermediate features (Yu et al., 2013).  
CK+/CD45- CTCs isolated from metastatic BC patients were also characterized by 
high-resolution copy number profiling: unsupervised clustering of probe level copy number 
data allowed identification of two CTC-genomic signatures consisting of recurrent copy 
number gain, either including dormancy-related or tumor aggressiveness-related genes 
(Kanwar et al., 2015). The two signatures were almost mutually exclusive, except for two 
copy number aberration regions including among others also TFF3 gene, thus suggesting 
that genes located in these regions harbored aberrations early in the hierarchy of cancer cell 
clones in order to provide CTCs with a survival advantage in the bloodstream and thus a 
higher metastatic potential (Kanwar et al., 2015). 
The role of TFF peptides in cancer is still controversial and probably it cannot be 
generalized. TFFs function in tumor progression should be investigated according to the type 
and stage of disease, and the expression of a specific member of the TFFs family is worth 
being explored both at mRNA and protein level and in different tissues. 
 
 
1.4.3. Molecular regulators and signaling pathways linked to trefoil factors 
Several observations indicate that TFF expression is modulated by many different 
factors. Among them, cis-regulatory elements were identified. Goblet-cell-specific 
transcription is partly conferred through a nine-base-pair goblet-cell response element 
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(GCRE) that is present in the proximal TFF3 promoter region (Ogata et al., 1998). Adjacent 
positive and negative regulatory elements also contribute to this selective expression (Iwakiri 
and Podolsky, 2001). Another element, designated the goblet-cell silencer inhibitor (GCSI), is 
located 2,216 base pairs upstream of the transcriptional start site and interacts with a 
GCSI-binding protein (GCSI-BP); interaction of this GCSI-BP with the GCSI seems to 
underlie the induction of TFF3 expression that is seen after stimulation of undifferentiated 
cells of the colon cancer cell line HT-29 (Iwakiri and Podolsky, 2001).  
A plethora of transcription factors (TFs) and environmental and chemical agents were 
also proven to activate the TFF promoter genes (reviewed in Emami et al., 2004). Regarding 
trans-regulatory elements, analysis of human and mouse TFF genes has identified 
consensus sequences for binding of promiscuous transcription factors. The consensus 
HNF3/Forkhead-binding motif lies within 100 base pairs of the transcriptional start sites of all 
three human and mouse TFFs, and HNF3 was shown to bind the TFF1 promoter and 
strongly activate TFF1 transcription in reporter-gene assays. Consensus binding sites for 
zinc-finger transcription factors have also been characterized in TFF promoters, and GATA6, 
in particular, was shown to activate reporter-gene expression driven by TFF1 and TFF2 
promoter sequences. Also USF, a member of the basic-helix-loop-helix leucin zipper family 
of transcription factors, was proved to bind TFF promoters in cell lines and to regulate the 
activation of endogenous TFF2. Moreover, promoter analysis of the human TFF1 gene 
showed the presence of an estrogen-response element as also enhancer sites responsive to 
EGF, tissue plasminogen activator and the c-ras and c-jun oncogene products, whereas 
TFF3 expression is induced in an ER-dependent but PgR-independent manner. 
Signaling pathways triggered by TFF peptides are still poorly known, also because 
putative TFF receptors or recognition sites have not been clearly identified yet. TFFs are 
fundamental players of a physiological process called epithelial cell restitution, thus they act 
as motogens, promoting cell migration, as pro-angiogenic factors, and prevent 
anchorage-dependent cell death. Multiple signaling pathways appear to be linked to the 
biological actions of TFF peptides, including PI3K/AKT pathway, the Rho-ROCK cascade, 
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COX-2/TXA2-R/Gaq signaling, PLC/PKC, MAP kinases and EGFR signaling. TFF-related 
signaling pathways were summarized in Table 2 and a model of molecular cascades 
triggered by the TFF peptides is reported in Figure 1.4.5. 
 
 
Figure 1.4.5. Proposed model for TFF signal transduction pathways in neoplastic progression 
and tumor cell invasion. TFF effects are transmitted by unknown adaptor (A?) proteins. TFFs can 
act through the EGF receptor, which activates several downstream effector pathways such as 
PI3K/PKB Akt, RAS/Raf/MEK/ERK and MAP kinases MEEK1/JNK. TFF signaling affects apoptosis, 
cell survival and cell cycle progression through regulation of transcription factors such as NF-κB, STAT 
and STAT3. TFF signaling involves iNOS (inducible nitric oxide synthase)-stimulated activation of 
COX1 an COX2, whose prostaglandin products are able to activate PG-R/TXA2-R pathway. Their 
action is transmitted by heterotrimeric G-protein subunits and activates various cascades such as 
Rho/RO and PLC, leading to cell migration and invasion, and Src activation that activates NF-κB and 
PKB/Akt regulated BAD phosphorylation, thus promoting cell survival. TFF1 reduces the activity of 
caspase-3, -8 and -9, and inhibits apoptosis. TFF1 also delays cell cycle progression by inducing 
cyclin-dependent kinase inhibitors INK and CIP. TFF peptides activate several signaling pathways 
leading to cell migration, survival, angiogenesis and, when overexpressed, to cell transformation. 
Emami et al., 2004  
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Table 2. TFF-related signaling pathways involved in cancer 
TFF factor 
Biological process 
Reference(s) 
SURVIVAL/APOPTOSIS/ANOIKIS MIGRATION/INVASION ANGIOGENESIS 
TFF1 
 Growth inhibition in colon 
cancer via MAPK/ERK 
phosphorylation and increased 
levels of p16INK4 and 
p21CIP1/Waf1 (1) 
 
 Cellular invasion dependent on 
EGFR tyrosine kinase activity in 
kidney and colonic cancer (4) 
 Cellular invasion abolished by 
inhibition of STAT3 signaling in 
colonic cells (5) 
 Cellular invasion by induction of 
COX-1 and COX-2 in colonic cells 
(8) 
 Angiogenesis induction in a 
COX-2 and EGFR-dependent 
manner in chick chorioallantoic 
membrane assay and also via 
KDR/flk-1 in human umbilical 
vein endothelial cells (3) 
 Angiogenesis by induction of 
COX-1 and COX-2 in colonic 
cells (8) 
(1) Calnan et al., 
1999; (3) Rodrigues 
et al., 2003b; (4) 
Rodrigues et al., 
2003a; (5) Rivat et 
al., 2005; (8) 
Rodrigues et al., 
2001 
TFF2  
 Cellular invasion dependent on 
EGFR tyrosine kinase activity in 
kidney and colonic cancer (4) 
 Motogenic effect via PKC, ERK1/2 
and Src in bronchial epithelial 
cells(12) 
 
(4) Rodrigues et al.,  
2003a; (12) Graness 
et al., 2002 
TFF3 
 Growth inhibition in colon 
cancer via MAPK/ERK 
phosphorylation (2) 
 Resistance to apoptosis via 
PI3K and EGFR in colon 
cancer (6) 
 Resistance to anoikis  via 
NF-κB in intestinal epithelial 
cells (7) 
 Cellular invasion independent on 
EGFR tyrosine kinase activity in 
kidney and colonic cancer (4) 
 Cellular invasion by induction of 
PGE2, PGI2 and TXA-2 in colonic 
cells (8) 
 Cell migration via Tyr 
phosphorylation of β-catenin, 
activation of EGFR, and modulation 
of E-cadherin and APC expression 
in colon cancer (9) 
 Disruption of cell-substratum contact 
via FAK phosphorylation in colon 
cancer (10) 
 Angiogenesis by induction of 
PGE2, PGI2 and TXA-2 in 
colonic cells (8) 
 De novo angiogenesis via 
IL-8/CXCR2 and partially via 
STAT3 in breast cancer cells 
(11) 
(2) Uchino et al., 
2000; (4) Rodrigues 
et al., 2003a; 
(6) Taupin et al., 
2000; (7) Chen et al., 
2000; (8) Rodrigues 
et al., 2001; (9) Liu et 
al., 1997; (10) Taupin 
and Podolsky, 2003; 
(11) Lau et al., 2015 
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Thus far, all attempts have failed to identify specific TFF receptors and currently no 
definitive functional membrane-bound receptors exist. Chemokine receptors were proposed 
to be possible candidates (reviewed in Hoffmann, 2009). However, recombinant dimeric 
TFF3 has been reported to bind the glycoprotein DMBT1GP340, belonging to the scavenger 
receptor cysteine-rich (SRCR) superfamily of membrane-bound or secreted proteins, in a 
Ca2+-dependent manner (Madsen et al., 2013). Interestingly, TFF3 has also been reported to 
act as a lectin (Reeves et al., 2008), suggesting that it could bind to a plethora of 
transmembrane glycoproteins. 
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 2. PROJECT’S AIM AND 
OBJECTIVES 
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2.1. BACKGROUND AND RATIONALE 
 
The identification of mechanisms involved in the progression from the primary tumor 
(PT) to metastasis remains a challenge in clinical oncology. At present, research in this field 
has been based on the hypothesis that a metastatic phenotype is already traceable in the 
PT. However, favorable and unfavorable prognostic signatures may coexist in different 
regions of the same tumor, due to spatial heterogeneity, and tumor may adapt and change 
its molecular features in response to treatment. Thus, to overcome the tumor heterogeneity 
issue, increasing attention has been paid to circulating tumor cells (CTCs) as they represent 
an easily accessible source of tumor samples to trace cancer clonal evolution and an early 
sign of the metastatic process.  
CTC studies are particularly useful in breast cancer (BC), known to be heterogeneous, 
since composed by subsets with distinct features, and able to disseminate at the earliest 
stages of disease (Hüsemann et al., 2008). Considering the high disseminating potential of 
BC cells, much attention has been paid to the study of preclinical animal models to shed light 
on the complexity of BC metastasis biology. Recent studies, in particular, allowed the 
identification of potential biomarkers, gene signatures and functional mediators for the 
survival, activation and expansion of metastasis from CTCs in mouse models of many type of 
tumors (reviewed in Kang and Pantel, 2013), suggesting that mouse models effectively 
recapitulate the complexity of clinical situations.  
Although preclinical research helped deciphering different steps of the metastatic 
cascade, the clinical validity for many of the identified molecular markers has not been 
validated yet (reviewed in Bidard et al., 2013), thus suggesting that a refinement of the 
experimental approaches used for the identification of novel biomarkers is still needed. In the 
past, the characterization of MDA-MB-231-derived variants showing specific organotropism 
to lung (Minn et al., 2005), bone (Kang et al., 2003) and brain (Bos et al., 2009), allowed 
identifying new genetic determinants of the metastatic process able to predict distant 
metastasis-free survival in BC case series. However, while undoubtedly able to generate 
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clinically valid information, such BC metastasis experimental models are not suitable for 
studies on CTC biology as they were obtained by injecting cells directly in the bloodstream.  
In the last decade, taking advantage of the improvements in technology for the isolation 
and molecular analysis of rare cells, efforts were also made to characterize CTCs in animal 
models. Recent studies provided an experimental demonstration that MDA-MB-231-derived 
CTCs are more aggressive compared to the parental cell line (Ameri et al., 2010), and that 
EMT-related changes in cell phenotype are associated with an enhanced ability to 
intravasate and generate CTCs in MDA-MB-468 xenograft models (Bonnomet et al., 2012). 
Moreover, CTCs isolated from BC patients were proven to contain a subset of cells showing 
metastasis-initiating properties when injected in immunocompromised mice (Baccelli et al., 
2013). 
 
 
2.2. HYPOTHESES 
Given the unquestionable role of CTCs in tumor progression, we firstly hypothesized 
that, as tumor cells undergo dynamic changes during hematogenous dissemination, 1) CTCs 
have a distinct molecular profile compared to solid lesions. Consequently, 2) CTC-specific 
genes might represent new genetic determinants of the hematogenous phase of metastasis 
and 3) clinically relevant biomarkers which might help identifying patients at high risk of 
relapse or progression. Finally, assuming that CTCs are molecularly different from the 
primary and secondary lesions, it is possible that 4) the expression pattern of CTC-specific 
genes assessed in the ‘liquid biopsy’ by real-time monitoring of CTC gene profile has 
superior prognostic power compared to the molecular profile assessed in the PT. 
 
 
2.3. AIMS 
The aims of this project focused on BC are 1) to provide further knowledge on the 
molecular mechanisms which regulate cell systemic dissemination, survival in foreign 
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environments (either when present in ‘liquid phase’ or when colonizing distant organs) and 
outgrowth at regional/distant sites, by investigating the role of CTC-specific genes in the 
metastatic cascade, and 2) to identify new prognostic biomarker, by assessing the 
expression of CTC-specific genes in CTC case series. 
 
 
2.4. TASKS AND EXPERIMENTAL PLAN 
 
Task #1. Modeling of BC metastases with BC cell lines. 
The dissemination and metastatic potential of four BC cell lines (BT-474, MDA-MB-453, 
MDA-MB-468, MDA-MB-231) was assessed by evaluating CTC load and formation of 
metastases in different organs, in two independend experiments. The two experiments 
allowed 1) the identification of an approximate time-point for animal sacrifice, specific for 
each model, according to the maximum tumor load ethically acceptable and a moderate 
suffering level per animal, 2) the evaluation of CTC load and the assessment of 
morphological heterogeneity within the CTC population, and 3) the identification of organs 
with metastatic involvement, on the basis of information already reported in literature, a 
macroscopic evaluation of explanted organs at sacrifice, and systematic IHC analysis to 
assess the frequency and extent of metastases.  
 
Task #2. Molecular characterization of BC xenograft models. 
A) CTC-model with the highest CTC load and metastatic potential was characterized by 
transcriptome analysis of PTs, CTCs, lymph-nodes (LNs) and pulmonary metastases by 
microarray platform, in two independent experiments.  
B) The hypothesis that CTCs have a different molecular profile compared to solid 
lesions was verified by bioinformatic tools. 
 
109 
 
Task #3. Identification of candidate genes for basic studies and clinical validation 
studies. 
A) For functional validation studies, genes significantly up-regulated in CTCs compared 
to the PT and not differentially expressed between CTCs and the parental cells were listed 
and a panel of candidate genes was selected. 
B) For clinical studies, 22 genes of interest were selected. The panel includes i) genes 
significantly up-regulated in CTCs compared to the solid lesions in the two gene expression 
profile experiments, ii) genes already proven to be involved in stemness and metastasis in 
the literature and iii) a classical predictive marker in BC.  
 
Task #4. Assessment of the biological role of candidate genes by in vitro and in vivo 
assays.  
Loss-of-function experiments were performed by gene knock-down and knock-out 
approaches and the involvement of one candidate gene in proliferation, migration, invasion, 
vascular-mimicry, dissemination in blood and metastasis formation at lungs and LNs was 
assessed by in vitro assays and in vivo experiments. 
 
Task #5. Comparison of the clinical impact of CTC monitoring by two different 
methodological approaches. 
Blood samples were collected from BC patients with non-metastatic disease, under 
neoadjuvant therapy, and patients in treatment for metastatic disease. CTCs were analyzed 
using a positive selection-based (AdnaTest) and a size-based (ScreenCell®) isolation 
approach before starting therapy and at different time points during treatment. Data were 
correlated with the clinico-pathological characteristics and follow-up data.  
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Task #6. Assessment of the clinical relevance of CTC-specific genes in BC CTC case 
series and gene expression datasets of primary BCs. 
A) The expression of the 22 genes selected after the molecular characterization of 
experimental models was assessed in CTCs isolated by AdnaTest and correlated with the 
clinico-pathological characteristics and follow-up data. 
B) The prognostic relevance of CTC/metastasis-specific genes was also assessed in 
publicly available datasets.  
 
The project flowchart is illustrated in Figure 2. 
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Figure 2. Project flowchart. (left upper panel) Breast cancer cells (Results Section, Chapter 1) from commercially available cell lines were injected at 
orthotopic level (i.e., in the mammary fat pad) in immunocompromised female mice. Animals were sacrificed at specific time points according to the 
experimental model in order to collect fresh blood samples for CTC isolation, fresh bone marrow samples for DTC isolation, primary tumor nodules and organs 
involved by secondary lesions (e.g. lymph-nodes and lung). Microarray analysis (Results Section, Chapter 2) was performed to compare the transcriptome of 
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(Figure 2. continued) CTCs with those obtained from DTCs, OCT-embedded frozen sections of primary tumors and metastases, and the parental cell line. 
Genes significantly up-regulated or down-regulated in CTCs compared to solid lesions were classified as CTC-specific. (right middle panel) The biological 
significance of a candidate CTC-specific gene (Results Section, Chapter 3) was assessed by functional validation assays performed in vitro (e.g. proliferation, 
migration, invasion, etc.) and in vivo (CTC dissemination and metastasis formation, evaluated by cytological or IHC analysis, respectively) using genetically 
modifies cell lines. (left lower panel) In parallel to basic studies, longitudinal monitoring of CTC status and levels (Results Section, Chapter 4) in breast 
cancer case series was carried out using either a positive selection-based method, followed by PCR analysis, or a size-based isolation method, followed by 
cytological analysis. The clinical significance of a panel of CTC-specific genes (Results Section, Chapter 5) was assessed by correlation analysis between 
each gene expression status, assessed by quantitative PCR, and patients’ clinico-pathological features and follow-up data. 
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3. MATERIALS AND METHODS 
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3.1. In vitro studies 
 
3.1.1. Cell lines 
Breast cancer MCF7, BT-474, MDA-MB-453 and MDA-MB-468 cell lines were cultured 
in Dulbecco’s Modified Eagles’s Medium (DMEM)/F-12 medium (Lonza, Switzerland) 
supplemented with 10% South America Fetal Bovine Serum (FBS, Lonza). MDA-MB-231 
breast cancer cell line was cultured in DMEM/F-12 medium supplemented with 5% FBS. All 
cell lines were grown in a controlled chamber at 37°C in a 95% humidified 5% pCO2 
atmosphere. They were purchased from the American Type Culture Collection organization 
and verified for identity via STR profile analysis using the StemElite™ ID System kit 
(Promega, Madison, WI, USA). STR profiles yielded a 100% match (all 8 of the 8 loci) in all 
cases. All experiments were performed using cells from the second to the seventh in vitro 
passage from thawing, showing at least 95% viability by Trypan blue exclusion test.  
 
3.1.2. Cell transfection and transient gene silencing with siRNA molecules 
MDA-MB-231 cells were transfected with the TransIT-X2® Dynamic Delivery System 
(Mirus Bio LLC, Madison, WI, USA) according to the standard protocol provided by the 
manufacturer. Transfectant reagent toxicity was preliminarily assessed by proliferation assay 
in a 3-days time-course experiment before performing loss-of-function experiments (growth 
rate was comparable in transfected and non transfected cells). Delivery efficiency was 
assessed by transfecting cells with the BLOCK-iT™ Fluorescent Oligo labeled with Cy3 
(Thermo Fisher Scientific, Waltham, MA, USA). 
Transient TFF3 silencing was performed using three unique TFF3 (ID 7033) 
Trilencer-27mer Human siRNA molecules (Origene, Rockville, MD, USA) at concentration of 
25 nmol/L. Cells were seeded in 96-well plates to reach 70% confluence (about 2.0 x 104 
cells per well). Transfection was performed 24 hours after seeding in a time-course 
experiment. The Trilencer-27mer Universal Scrambled Negative Control siRNA Duplex 
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(Origene) was used as control. One out of three tested siRNA molecules was able to reduce 
TFF3 expression at mRNA (by real-time qPCR) and secreted protein (by ELISA assay) level.  
 
3.1.3. Lentivirus-mediated long term stable gene knock-down 
MDA-MB-231 cells were seeded in 6-well plates to reach 70% confluence (about 
6.5 x 105 cells/well). Infection was performed 24 hours after seeding using the TFF3 - Human 
shRNA lentiviral particles, delivering 4 unique 29mer target-specific shRNA and a scramble 
control by a pGFP-C-shLenti vector (Origene), at a multiplicity of infection (MOI) 5 and 10. 
Infection efficiency was monitored by cell observation on a Nikon Eclipse TE2000-S 
fluorescence microscope. After 48 hours medium was changed and cells were put under 
constant selection with 0.5 µg/mL Puromycin (Sigma-Aldrich, Saint Louis, Missouri, USA) for 
10 days. Selected cells were then amplified under standard culture conditions and 72-hours 
conditioned media were collected to assess protein knock-down (ELISA assay). Two out of 
the four tested shRNAs were able to produce ~80% TFF3 knock-down compared to control 
cells. 
 
3.1.4. Gene knock-out by CRISPR-Cas9 system   
CRISPR/Cas9-mediated TFF3 knock-out experiments were performed according to the 
protocol published by Ran and colleagues (Ran et al., 2013). Guide sequences were 
designed using the on-line available CRISPR-design tool (http://crispr.mit.edu/). Two 
sequences designed on Exon 1 and one sequence designed on Exon 2 were chosen 
(Table 3.1), according to the quality score and mismatches predicted by the algorithm. Guide 
RNA oligos were cloned in pSpCas9(BB)-2A-Puro (PX459) vectors (Addgene, Cambridge, 
MA, USA; Figure 3), according to Ran and colleagues’ protocol.  
MDA-MB-231 cells were seeded in 35 mm culture dishes to reach 80% confluence 
(about 5.0 x 105 cells/well). Cell were transfected 24 hours after seeding with 3 μg of each 
plasmid or a mixture of two plasmids, at equimolar ratio, to a final amount of 4 μg, using 3 μL 
of TransIT-X2® Dynamic Delivery System (Mirus) per microgram of DNA. Empty vector was 
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used as negative control. Cell transfection efficiency was monitored in independent samples, 
consisting of cells transfected with a pSpCas9(BB)-2A-GFP (PX458) plasmid (Addgene), by 
cell observation on a Nikon fluorescence microscope. After 48 hours medium was changed 
and cells were put under constant selection using 0.5 µg/mL Puromycin for 10 days. 
Selected cells were harvested and cell suspensions were prepared in order to seed 
0.6 cells/well. About 2 weeks after seeding, wells were screened to search for proliferating 
clones, and cell supernatants conditioned for 72 hours were collected from 90 putative 
TFF3KO clones which had reached a 70% confluence.  
 
Table 3.1. Guide sequences for CRISPR/Cas9-mediated TFF3 
knock-out 
exon g# guide sequence score on-target locus 
Ex1 #2 CTGGCAGCCATGACCACCGT (GGG) 79 
chr21:                
-43735432 
 
Ex1 #5 CCCCAGCATGCAGAGCGCTC (TGG) 73 chr21:                -43735451 
Ex2 #1 CCCAAGGAGTGCAACAACCG (GGG) 92 chr21: +43733656 
 
 
Genomic DNA was extracted by semi-automated approach (QIACube, Qiagen) using 
the DNeasy Blood & Tissue Kit (Qiagen, Düsseldorf, Germany). DNA concentration was 
measured by Nanodrop and DNA integrity was assessed by the E-Gel® EX Agarose 
Gels 1% (Invitrogen™, Thermo Fisher Scientific) using the E-Gel® iBase™ Power System 
for running and the E-Gel® Safe Imager™ Real-Time Transilluminator for sample migration 
viewing.  
PCR primers were designed to amplify the desired genomic regions in Exon 1 (forward 
5’-GACCTCTCCCCTTTGGGAGA-3’, reverse 5’-TGCAGAATCCCCCCTTATCC-3’) and 
Exon 2 (forward 5’-CAGCAGTGGTTGAACTCGGC-3’, reverse 
5’-GGTCCTTGTGCCTCCATCTC-3’) using the OligoCalc tool 
(http://biotools.nubic.northwestern.edu/OligoCalc.html). Optimal thermal profile was set after 
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testing different annealing temperatures using the Veriti™ Thermal Cycler (Applied 
Biosystems, Thermo Fisher Scientific). 
 
Figure 3. Map of CRISPR/Cas9 vector. Vector backbone PX459, total size 9200 bp. 
https://www.addgene.org/62988/  
 
 
The thermal profiles used to amplify the desired genomic regions were: 5 min hold at 
95°C, 35 cycles of amplification including a 30 sec denaturation step at 95°C, a 1 min 
annealing step at 60.4°C or 61.4°C for Exon 1 and Exon 2, respectively, and a 30 sec 
elongation step at 72°C, and 10 min hold step at 72°C. Fifty nanograms of genomic DNA 
were amplified using the AmpliTaq Gold® DNA polymerase at a 0.05 U/µL concentration with 
2.5 mM MgCl2 (Thermo Fisher Scientific), 0.2 mM concentrated primers and 0.5 mM dNTP 
mix (InvitrogenTM). PCR products were separated and collected using the E-Gel® 
SizeSelect™ Agarose Gels, 2% (Invitrogen™).  
Sanger sequencing was performed at Eurofins (Germany) in two distinct runs in order 
to sequence both DNA strands using either the forward or the reverse specific primer. 
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Sequencing output data were analyzed by comparison with a reference sequence 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Possible protein sequences were predicted by the 
Translate tool (http://web.expasy.org/translate/).  
When overlapping sequences were obtained, on the hypothesis that 
CRISPR/Cas9-mediated genome alteration occurred in heterozygosis, PCR products were 
cloned in plasmids using the TOPO® TA cloning® Kit for Sequencing (InvitrogenTM, Thermo 
Fisher Scientific) and chemically competent E. coli bacteria were transformed. A number of 6 
colonies were randomly selected in order to obtain cells expressing one of the two alleles, 
and for plasmid DNA sequencing was performed. Clones showing gene knock-out in both 
alleles were included in subsequent studies.  
Five out of five clones obtained after transfection with negative control vector showed 
100% homology with the reference genomic sequence. Fifteen out of 19 clones called as 
TFF3-negatìve by ELISA test showed clear gene knock-out at both alleles, by partial gene 
deletion or single nucleotide insertion/deletion events which caused a frame-shift in the 
nucleotide sequence, with consequent introduction of a stop codon or change in the 
predicted aminoacidic sequence. Five validated TFF3WT and 8 validated TFF3KO clones were 
used for functional assays. 
 
3.1.5. Proliferation assay 
MDA-MB-231 cell proliferation rate was assessed using the CellTiter 96® AQueous 
One Solution Cell Proliferation Assay (MTS, Promega). For transient silencing experiments, 
MDA-MB-231 cells were seeded in 24-well plates to reach 70% confluence (about 1.3 x 105 
cells/well), and transfected for 48 hours. Cells were then seeded in 96-well plates to reach 
20% confluence (about 6.5 x 103 cells/well) and MTS assay was performed 12, 24, 48 and 
72 hours after seeding. Briefly, 20 µL reagent were added to 100 µL culture medium per well 
and cells were incubated at 37°C in a culture chamber for 2 hours. Cells were lysed by 
adding 20 µL SDS 10% to stop the reaction, and optical density (O.D.) was immediately 
measured at a 490 nm absorbance wavelength by the iMark™ Microplate Absorbance 
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Reader spectrophotometer (Biorad, Hecules, CA, USA). Output O.D. values were obtained 
by the Microplate Manager 6 software, and corrected for signals emitted by blank (medium 
without cells). For experiments with MDA-MB-231 cells with TFF3 stable knock-down, and 
with TFF3WT and TFF3KO clones, cells were directly seeded in 96-well plate and MTS assay 
was performed as described before. 
 
3.1.6. Migration assay 
MDA-MB-231 migration ability was assessed using a Boyden chamber assay. For 
transient TFF3 silencing experiments, cells were seeded in 24-well plates to reach 
70% confluence, and transfected with the TFF3 siRNA molecule for 24 hours. Medium was 
removed and replaced by serum-free medium for cell starvation. After 24 hours 6.0 x 104 
cells were seeded in serum-free medium on 6.5-mm diameter Transwell® membrane cell 
culture inserts with 8.0-μm pore diameter (Corning®, New York, USA) and migration was 
stimulated by using complete growth medium as an attractant in the bottom well. Cells on the 
top of the membrane were removed 24-36 hours after seeding, using a cotton-tipped 
applicator. Cells were washed in Dulbecco's Phosphate-Buffered Saline (DPBS, Lonza), 
fixed in ethanol absolute for 20 minutes at -20°C and stained with 0.4% sulforhodamine B 
(SRB, Sigma-Aldrich) for 30 minutes at room temperature (RT). Migration areas were 
acquired on a Nikon microscope and densitometric analysis was performed using the ImageJ 
software version 1.51g (https://imagej.nih.gov/ij/). 
For experiments with MDA-MB-231 cells with TFF3 stable knock-down, and with 
TFF3WT and TFF3KO clones, cells underwent starvation for 24 hours and seeded for migration 
assay as described before. Migrating GFP-expressing cells (stable TFF3 knock-down) were 
directly visualized and images were acquired on a Nikon fluorescence microscope, whereas 
TFF3WT and TFF3KO clones were stained with SRB as described before. 
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3.1.7. Invasion assay 
MDA-MB-231 invasion ability was assessed using a Boyden chamber assay. 
MDA-MB-231 cells with TFF3 stable knock-down, and TFF3WT and TFF3KO clones were 
seeded in 24-well plates to reach 70% confluence for 24 hours. Medium was removed and 
replaced by serum-free medium for cell starvation. After 24 hours 6.0 x 104 cells were 
seeded in serum-free medium on 6.5 mm diameter Transwell® membrane cell culture inserts 
with 8.0-μm pore diameter membranes (Corning) coated with BD MatrigelTM Basement 
Membrane Matrix Growth Factor Reduced (BD Biosciences, San Jose, CA, USA) at a 
200 μg/mL concentration, and invasion was stimulated by using complete growth medium as 
an attractant in the bottom well. Matrigel and cells on the top of the membrane were removed 
24-36 hours after seeding, using a cotton-tipped applicator.  
Invading GFP-expressing cells (stable TFF3 knock-down) were visualized and images 
were acquired on a Nikon fluorescence microscope; densitometric analysis was performed 
using the ImageJ software. 
For experiments with TFF3WT and TFF3KO clones, invading cells were stained using the 
SRB protocol. 
 
3.1.8. Vascular-mimicry assay 
Vascular-mimicry ability was assessed using MDA-MB-231 cells with stable TFF3 
knock-down. Cells suspensions at 4.0 x 105 cells/ml density were prepared in serum-free 
medium and 2.0 x 104 cells were seeded onto pure Corning® Matrigel® Basement 
Membrane Matrix (Corning) coated 96-well plates (35 μL per well). Cells were monitored for 
6-12 hours to assess loop formation, and images were acquired on a Nikon TE 2000-S 
fluorescence inverted microscope.   
 
3.1.9. Cell spiking-capture experiments 
Spiking experiments were performed by manual pipetting of defined numbers of cells, 
showing at least 99% viability by Trypan blue exclusion assay, into 5 mL whole blood 
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samples withdrawn from healthy donors. Blood samples were processed within 1 hour from 
spiking, using the AdnaTest EMT-1/Stem CellSelect or EMT-2/Stem CellSelect kits 
(AdnaGen, Langenhagen, Germany). Tumor cell detection was performed using the 
AdnaTest EMT-1/Stem CellDetect kit (AdnaGen), according to the manufacturer’s 
instructions. Primer mix (forward and reverse) and experimental protocol for MET 
amplification were kindly provided by AdnaGen. Briefly, 4.0 μL of cDNA were amplified using 
the HotStarTaqMaster Mix (Qiagen, Düsseldorf, Germany) in a final volume of 25.0 μL, using 
the following PCR thermal profile: hold step at 95°C for 15 min, 35 cycles of denaturation, 
annealing and amplification at 94°C for 60 seconds, 58°C for 2 minutes and 72°C for 30 
seconds, respectively, and hold step at 72°C for 5 minutes.  
 
 
3.2. Animal studies 
 
3.2.1. Mouse models  
Animal experiments were performed according to Italian law (D.L. 116/92 and following 
additions), which enforces the 2010/63/EU Directive; the study was approved by the Ethical 
Committee for Animal Experimentation at Fondazione IRCCS Istituto Nazionale dei Tumori, 
Milan (INT). All efforts were deployed to minimize animal suffering, following the most 
recently published version of recommended guidelines (Workman et al., 2010). 
Six- to 8-week-old female NOD.CB17-Prkdcscid/J (NOD scid) and 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from Charles River 
(Wilmington, MA, USA) and The Jackson Laboratory (Sacramento, CA, USA), respectively. 
Animals were bred in individually ventilated cages, 3 to 5 animals per cage. 
Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (5 mg/kg) cocktail before tumor cell orthotopic injection and sacrifice. Animals were 
sacrificed by cervical dislocation at the desired experimental time point or immediately when 
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they started to show signs of moderate level of suffering (e.g. decrease in activity, hunched 
appearance, ruffled hair coat, respiratory distress). 
 
3.2.2. Tumor cell injection  
Cell lines were tested for Mycoplasma contamination by the MycoAlert® mycoplasma 
detection kit on the GloMax® 20/20 luminometer before performing injection in mice. Tumor 
implant was performed in 9-10 week-old anesthetized mice by injection with a 30G needle 
syringe in the mammary fat pad (m.f.p.). Intravenous injection was performed using 106 or 
2 x 106 cells, resuspended in 400 µL DPBS. 
The experimental scheme of each xenograft model is reported in Table 3.2. ECM Gel 
Matrigel was purchased from Sigma-Aldrich. Mice injected with BT-474 cells were treated 
with estrogens by subcutaneous implantation of 0.72 mg 90-day release 17-β-estradiol 
pellets, performed using a trocar, 24 hours before tumor implant.  
 
Table 3.2. Experimental conditions for CTC modeling with BC cell lines 
Cell line Mouse model 
Number of cells 
per injection 
Cell suspension 
composition and 
volume 
Injection 
sites 
Hormone 
supplemen 
tation 
BT-474 NSG 5.0 x 106 
1:1 DPBS:Matrigel, 
80 µL 
4th left 
mammary 
gland 
yes 
MDA-MB-453 NSG 107 1:1 DPBS:Matrigel, 90 µL 
4th left 
mammary 
gland 
no 
MDA-MB-468 NSG 5.0 x 106 1:1 DPBS:Matrigel, 80 µL 
2nd right and 
4th left 
mammary 
glands 
no 
MDA-MB-231 NOD scid 5.0 x 10
6 1:1 DPBS:Matrigel, 80 µL 
2nd right and 
4th left 
mammary 
glands 
no 
 
For the time-course experiments with MDA-MB-231 cells, 4 groups of 6 animals each 
were injected with cells according to the standard scheme (Table 3.2). Animals were 
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randomized before sacrifice at the defined time points (day 35, 50, 65 and 80) according to 
the tumor growth rate and the cage where they had been bred. 
Pools of MDA-MB-231 TFF3KO or TFF3WT clones were prepared after mixing equal 
amounts of cells to reach 5.0 x 106 cell suspensions. Injection was performed according to 
the standard scheme for MDA-MB-231 reported in Table 3.2. 
Tumor growth was monitored every week using a caliper and tumor weight (TW) was 
estimated by the TW (g) = (D x d2)/2 formula, where D and d represent the longest and the 
shortest diameter, respectively, of the tumor.   
 
3.2.3. Collection of tissues and organs 
Blood samples were collected in EDTA (1.8 mg/mL) tubes by cardiac puncture in 
anesthetized mice by using a 1 mL 26G needle syringe. Mice were immediately sacrificed 
and primary tumor nodules and organs (lung, axillary or inguinal lymph-nodes, ovaries, liver, 
kidneys, brain) were collected and fixed in 10% neutral buffered formalin (Bio-Optica, Milan, 
Italy) for 18 to 24 hours. Samples were then embedded in paraffin (FFPE).  
For gene expression profile experiments with MDA-MB-231 xenografts, tumors, lungs, 
and axillary or inguinal lymph-nodes were OCT-embedded and snap-frozen in liquid nitrogen. 
Samples were stored at -80°C until processing.  
 
3.2.4. Circulating tumor cell isolation 
For gene expression analyses, CTCs were isolated using the AdnaTest EMT-2/Stem 
CellSelect kit and the ScreenCell® Molecular biology kit. For AdnaTest, blood samples were 
incubated for 25 minutes with 50 µL of immunomagnetic beads and captured cells were 
isolated using a magnet (AdnaMag magnetic separator), according to the manufacturer’s 
instructions. Residual blood was filtered by the ScreenCell® Molecular Biology kit, according 
to the manufacturer’s instructions. Cell lysates were obtained by both samples using the 
AdnaGen proprietary lysis buffer and samples were stored at -20°C for no more than 14 days 
until processing. 
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For in situ analyses, CTCs were isolated using the ScreenCell® Cyto kit (ScreenCell, 
Sarcelles, France), according to the manufacturer instructions. The isolation supports (IS) 
were stained with Hematoxylin Solution S (Merck, Darmstadt, Germany) for 1 minute and 
Shandon Eosin Y Aqueous Solution (Thermo Fisher Scientific Inc., Waltham, MA, USA) for 
30 seconds, or with pure May-Grünwald solution for 2.5 minutes, followed by a 2.5-minute 
incubation step with May-Grünwald solution diluted 1:2 with distilled water pH 7, and Giemsa 
solution (Merck) 1:10 diluted in distilled water pH 7, for 10 minutes. 
Cells disseminated in the bone marrow were obtained by flushing of femurs with DPBS 
and they were isolated using the AdnaTest and ScreenCell approaches for nucleic acids 
analysis, as described above. 
 
3.2.5. Tumor cell detection and quantification  
For CTC quantification, mRNA was isolated from cell lysates using the AdnaTest 
EMT-2/Stem CellDetect kit and resuspended in 10 µL nuclease-free water. Half RNA volume 
was stored at -80°C for microarray gene expression profile analyses, while the remaining 
was retrotranscribed using the High-Capacity cDNA Reverse Transcription Kit with RNase 
Inhibitor (Applied BiosystemsTM, Thermo Fisher Scientific) in a 10 µL reaction volume. Two 
out of 10 μL cDNA were amplified for indirect quantification, which was performed using a 
standard curve constructed by correlating different numbers of MDA-MB-231 cells (2-5-10-
20-40-100-200-1,000-5,000-10,000-50,000-100,000), directly spiked in the lysis buffer by 
manual pipetting or after serial dilution from cell suspensions (when ≥200 cells), to Ct values 
obtained by qPCR using a TaqMan assay specific for human ACTB. 
Total RNA from MDA-MB-231 cell pellets or from two 10-µm thick frozen sections of 
tumors, lungs and lymph-nodes OCT-embedded samples was extracted by the Agencourt® 
RNAdvance™ Tissue Kit (Beckman Coulter, Breas, CA, USA), according to the 
manufacturer’s instructions, and quantified at Nanodrop. RNA quality was assessed by the 
Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA). RIN values 
ranged from 9.5 to 9.9 for cultured cells and from 6.7 to 9.3 for frozen sections. Convenient 
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RNA volumes were retrotranscribed using the High-Capacity cDNA Reverse Transcription Kit 
with RNase Inhibitor in 20 µL reaction volume, and tumor cells were quantified by qPCR as 
described above. 
 
 
3.3. Clinical studies  
 
3.3.1. Study design and case series 
Patients with histologically confirmed breast cancer and no evidence of metastatic 
disease (M0) who were receiving anthracycline/taxane-based neoadjuvant therapy and 
trastuzumab if HER2-positive, and breast cancer patients with metastatic disease (M+) who 
were going to start a new line of systemic treatment (mostly endocrine treatment) were 
recruited at the Department of Medical Oncology at INT. Fifty-nine M0 and 56 M+ patients 
were enrolled from February 2011 to September 2016.  
For each patient, samples were collected at baseline (before starting treatment) and 
during treatment at established times: 3 and 6 months after initiation of neoadjuvant 
treatment and around 4 weeks after mastectomy in M0 cases; at the beginning of a new line 
of treatment and at 3 months from treatment start or at progression in M+ cases. 
Thirty female healthy subjects donated blood samples for technical fesibility 
experiments and to define CTC positivity cut-off values.  
This study was submitted and approved by the Institutional Review Board and the 
Ethics Committee at INT. All patients and healthy subjects signed and informed consent for 
withdrawing blood samples dedicated to this research. 
 
3.3.2. Blood sampling 
Samples of peripheral venous whole blood were drawn from BC patients and healthy 
donors using a 26 G needle and collected in K3EDTA or K2EDTA BD Vacutainer tubes, if 
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processed with the AdnaTest (AdnaGen, AG, Langenhagen, Germany) or ScreenCell® Cyto 
(ScreenCell, Sarcelles, France) kits, respectively. The first blood tube was discarded to 
minimize the risk of contamination with skin epithelial cells. Samples were stored in the dark 
at 4°C and processed within 1 hour from withdrawal according to the manufacturer’s 
instructions.  
 
3.3.3. CTC enrichment and detection by AdnaTest kits 
CTC enrichment with the AdnaTest EMT-1/Stem CellSelect and EMT-2/Stem 
CellSelect kits was performed in parallel on two 5-mL blood samples from the same patient 
according to the manufacturer’s instructions.  
For CTC detection, the expression levels of EPCAM, MUC1, ERBB2, PIK3CA, AKT2, 
TWIST1 and ALDH1A transcripts were evaluated by semi-quantitative multiplex PCR 
according to the manufacturer’s instructions and using the suggested thresholds for positivity 
(0.15 ng/μL for EPCAM, MUC1, ERBB2 and ALDH1, and 0.25 ng/μL for PIK3CA, AKT2 and 
TWIST1). According to the results obtained in a series of 5 healthy donors, samples with 
ACTB expression <0.70 ng/μL were excluded from the analysis, whereas those passing the 
quality control where considered as positive when positive for at least 1 of the above 
mentioned markers. 
 
3.3.4. CTC isolation and detection by ScreenCell® Cyto kits 
All blood samples were processed within 1 hour after collection using the 
ScreenCell® Cyto kit (ScreenCell, Paris, France) according to the manufacturer’s 
instructions. Briefly, blood was diluted in 4 mL of red blood cell lysis and fixation buffer and 
incubated for 8 minutes at room temperature. Three filtrations of 3-mL blood samples each 
were separately performed for each patient; IS were rinsed with DPBS, collected from the 
device, air-dried and immediately stained at room temperature for 1 minute with Hematoxylin 
Solution S (Merck, Darmstadt, Germany) and then for 30 seconds with Shandon Eosin Y 
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Aqueous Solution (Thermo Fisher Scientific Inc., Waltham, MA, USA). IS were stored at 
-20°C until cytological evaluation.  
All samples were analyzed by the same pathologist without knowledge of the clinical 
data. Major criteria for CTC identification were a high nucleus-to-cytoplasm ratio (≥0.75) and 
large nuclear size (≥20 μm), whereas minor criteria included irregular nuclear contours and 
nuclear hyperchromatism. The cytomorphological analysis and CTC count were based on 
the previously reported criteria of malignancy (Hofman et al., 2011). Circulating tumor 
microemboli (CTMs) were defined as clusters of at least 2 CTCs, often mixed with platelets 
and various leukocytes, showing criteria of malignancy like those described for single CTCs. 
The nucleus-to-cytoplasm ratios in single CTCs are similar to those in CTC aggregates (Cho 
et al., 2012). Results were expressed as numbers of CTCs and CTMs for single membranes. 
For each patient, total CTC or CTM numbers derived from 3 membranes 
(corresponding to 9 mL of blood) were added together to better meet the criteria for accurate 
detection of rare events following the Poisson probability distribution (Allan and Keeney, 
2010). Membranes showing poor quality of cytology, estimated on the basis of poor 
preservation of the leukocytes, were excluded from the analysis. Samples were rated as 
CTC or CTM positive if at least 1 CTC or CTM was detected in the 3 membranes. 
 
 
3.4. Gene expression studies 
 
3.4.1. RNA extraction, quantification and quality control testing 
Total RNA was isolated from cell pellets and OCT-embedded frozen sections using the 
Agencourt® RNAdvanceTM Cell v2 or the Agencourt® RNAdvance™ Tissue Kit (Beckman 
Coulter) according to the manufacturer’s instructions. The procedure is based on Solid 
Phase Reversible Immobilization paramagnetic bead technology, which ensures efficient 
removal of genomic DNA and other contaminants. RNA quantification and integrity control 
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were performed by Nanodrop and the Agilent RNA 6000 Nano Kit (Agilent Technologies) by 
the Bioanalyzer, respectively. RIN values were higher than 9.5 for cell lines and ranged from 
roughly 6.5 to 9 for frozen animal tissues. 
Messenger RNA was isolated using the AdnaTest EMT-1/Stem CellDetect kit, 
containing (dT)25-coated Dynabeads® for the isolation of pure polyadenylated RNA.  
Isolated RNA was eluted in convenient volumes of nuclease-free water (Ambion, 
Thermo Fisher Scientific) and stored at -80°C until processing.  
 
3.4.2. cDNA synthesis and quantitative real-time PCR 
cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription 
Kit with RNase Inhibitor (Applied BiosystemsTM, Thermo Fisher Scientific) in a GeneAmp® 
PCR System 9700 thermal cycler, using a modified thermal profile (10 minutes at 25°C, 
60 minutes at 42°C, 5 minutes at 85°C). Reverse transcription products were stored at -20°C 
until processing.  
Amplification of specific genes was performed by real-time qPCR using the single 
TaqMan assays listed below:  
target assay ID 
Human ACTB Hs03023943_g1 
Human ELF3 Hs00963882_g1 
Human GAPDH Hs00266705_g1 
Human NR4A1 Hs00374230_m1 
Human TFF1 Hs00907239_m1 
Human TFF2 Hs00193719_m1 
Human TFF3 Hs00902278_m1 
Murine GAPDH Mm99999915_g1 
 
 
Ten nanograms of cDNA were amplified in technical triplicates using the TaqMan® 
Universal PCR Master Mix, according to the standard protocol. PCR reactions were run in 
MicroAmp Fast Optical 96-Well Reaction Plates by the QuantStudio™ 12K Flex Real-Time 
PCR System, according to the standard thermal profile. The threshold cycle (Ct) for each 
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gene was automatically set by the 7900 SDS v2.4 dedicated software. Analysis of relative 
gene expression was performed applying the 2-ΔΔCT method. GAPDH was used as 
endogenous control gene for qPCR analysis to assess TFF3 silencing upon siRNA delivery. 
 
3.4.3. Low-density array gene expression profiling  
Gene expression profiling of CTCs from clinical samples was performed using custom 
384-Well Microfluidic Card TaqMan® Gene Expression Assays for the analysis of 23 genes 
and an endogenous control in technical duplicate. Target specific pre-amplification was 
performed using a Custom TaqMan® PreAmp Pool of 24 TaqMan assays, according to the 
manufacturer’s instructions.  
Table 3.3. Low-density array gene expression 
assays and relative positivity cut-off Cq values 
target gene assay ID cut-off 
NR4A1 Hs00374226_m1  29.90 
HDAC10 Hs00368899_m1  27.17 
CRIP1 Hs00832816_g1 24.09 
TPPP Hs00389316_m1  40.00 
GAS2L1 Hs00977983_g1  29.38 
FIS1 Hs00211420_m1  27.21 
FCF1 Hs01056861_gH  40.00 
STRN4 Hs01026676_m1  29.13 
TAF6 Hs00425763_m1  29.18 
TFF1 Hs00907239_m1  40.00 
TFF2 Hs00193719_m1  40.00 
TFF3 Hs00902278_m1  40.00 
ELF3 Hs00963881_m1  40.00 
ESR1 Hs00174860_m1  31.00 
ADPRHL1 Hs00293405_m1  40.00 
KLC2 Hs03988192_m1  28.53 
PTPRC Hs04189704_m1  - 
GIGYF1 Hs01119153_g1  29.01 
YAP1 Hs00902712_g1  40.00 
OPN (SPP1) Hs00959010_m1  40.00 
PTPN11 Hs01590331_gH  29.50 
SPARC Hs00234160_m1  31.51 
SOX2 Hs01053049_s1  40.00 
GAPDH Hs02758991_g1 - 
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PCR were run in technical duplicate by the 7900HT Fast Real-Time PCR System. Data 
were analyzed using the Relative Quantification analysis module RQ Manager version 2.3. 
The relative threshold method (Crt) was used to set the threshold cycle, as it was proven to 
be more robust than the Ct baseline threshold method when analyzing multiple gene 
expression data from low-density arrays. Indeed, the Crt method accounts for low reaction 
volumes and associated differences in fluorescence levels. Two quality control parameters 
were set before performing Crt analysis: the AMP score (rejection threshold <1.0) and the 
Calculated confidence in the Cq value (rejection threshold <0.8), both related to the 
performance of the amplification, scored according to an ideal sigmoidal amplification curve. 
Mean equivalent Cq values obtained after Crt were used for subsequent gene 
expression analyses. Positivity threshold for each target gene was set according to the mean 
equivalent Cq obtained from 5-mL blood samples of 6 female healthy donors, processed by 
the AdnaTest EMT-2/Stem CellSelect kit. A gene was considered as expressed in a CTC 
sample if the Cq value was lower than the lowest Cq observed among control individuals. 
Overall mean±SD Cq values for GAPDH and PTPRC in patients’ samples were 33.94±5.63 
and 34.22±3.64, respectively. Samples showing Cq(GAPDH) = 40 and Cq(PTPRC) = 40 were 
excluded from the analysis. Target genes and relative TaqMan assays and positivity cut-off 
Cq values are listed in Table 3.3. 
For bioinformatic analyses, data were normalized on the geometric mean of Cq values 
of GAPDH and PTPRC control genes. 
 
 3.4.4. Microarray gene expression profiling  
RNA samples from the MDA-MB-231 xenograft model, each corresponding to 5,000 
tumor cells according to the indirect quantification approach, and the parental cells (50 ng 
total RNA) were profiled using the Illumina Human Whole-Genome DASL HT Assay 
(Illumina, Inc., San Diego, CA, USA), according to the manufacturer's instructions RNA is 
converted to cDNA using biotinylated oligo(dT) and random nonamer primers. The 
biotinylated cDNA is then annealed to the DASL Assay Pool (DAP) probe groups. Probe 
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groups contain oligonucleotides specifically designed to interrogate each target sequence in 
the transcripts. These probes span about 50 bases, making it possible to profile partially 
degraded RNA.  
Universal human reference RNA from Stratagene (San Diego, CA, USA) and Mouse 
Universal Reference from Clontech (Mountain View, CA, USA) were used as positive and 
species-specificity controls, respectively (50 ng each). The BeadChips were imaged on the 
BeadArray Reader. Illumina BeadScan software was used for image acquisition.  
 
 
3.5. Protein analyses 
 
3.5.1. Measurement of secreted proteins 
Conditioned medium was centrifuged at 1,000 RCF for 5 minutes at 4°C to remove 
floating cells and debris, and stored at -80°C in sub-aliquots. Secreted TFF3 concentration 
was measured by the Human TFF3 Quantikine® ELISA Kit (R&D systems, Minneapolis, MN, 
USA), according to the manufacturer’s instructions. The assay was verified by the 
manufacturer for not interfering with TFF1, TFF2 and other available related molecules. TFF3 
concentrations (pg/mL) were calculated using a standard curve. 
 
3.5.2. Immunohistochemical staining 
Four-micron thick FFPE sections from tumor nodules, lungs, lymph-nodes, ovaries, liver, 
brain and kidneys collected from experimental models were stained using a monoclonal 
antibody against human COX IV (clone 3E11, isotype IgG, produced in rabbit) purchased 
from Cell Signaling Technology (Danvers, MA, USA). Antigen retrieval was performed at 
95°C for 30 minutes in Sodium Citrate Buffer (10 mM Sodium Citrate, 0.05% Tween 20, 
pH 6.0). Endogenous biotin blocking was performed for liver sections only, using the Dako 
Cytomation Biotin Blocking System (Dako, Troy, MI, USA). Samples were incubated with the 
primary antibody at a 1:1,000 dilution at 4°C overnight.  
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Four-micron thick frozen sections from tumor nodules, lung and lymph-nodes were 
fixed in 10% neutral buffered formalin (Bio-Optica) for 10 minutes at RT and incubated with 
the antibody for 1 hour at RT.  
Antibody visualization was obtained using the EnVision®+ System- HRP Labelled 
Polymer (Dako). Nuclei were counterstained with Mayer hematoxylin (Bio-Optica).  
 
 
3.6. Bioinformatic analyses  
Raw data from microarray analysis were pre-processed using the R/Bioconductor 
package “lumi” that provides statistical methods for analysis of Illumina microarray data. As 
first step of pre-processing data were log(base2)-transformed, as the distribution of intensity 
values in the linear scale is skewed towards the background intensity. Log transformation 
makes the data distributions closer to a Normal distribution and makes the variance 
independent of the mean. After log-transformation data were normalized using the robust 
spline normalization method (Du et al., 2008). Probes not associated to HUGO gene symbols 
were filtered out. Multiple probes mapping to the same gene were collapsed selecting the 
probe with the highest inter-quartile range across samples.  
Differential expression analysis was performed using the “limma” package 
(Smyth, 2004) that combines linear models with moderated t-statistic to identify differentially 
expressed genes across experimental conditions. The moderated t-statistics has the same 
interpretation as an ordinary t-statistic except that the standard errors are moderated across 
genes, i.e., queezed towards a common value, using a simple Bayesian model. P-values 
obtained from limma were adjusted for multiple-testing using the Benjamini-Hochberg false 
discovery rate (FDR) to reduce the number of false positives. Genes showing an absolute 
fold change ≥ 2 and an FDR <0.05 were considered significantly differentially expressed. 
Principal variance component analysis (PVCA), used to assign the percentage of 
variability to known biological and technical factors present in gene expression data, was 
performed using the “pvca” package. This approach combines the strengths of principal 
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component analysis to reduce data dimension and variance component analysis to fit a 
mixed linear model using factors of interest as random effects to estimate and partition the 
total variability. This method allows determining which sources of biological and technical 
variability are more prominent in a microarray dataset. 
Unsupervised hierarchical clustering was performed using average linkage and 
1 - Pearson’s correlation as distance measure. Clustering techniques allow to group samples 
in a given dataset according to the similarity in their gene expression profiles. 
Gene Ontology (GO) analysis was carried out using the “topGO” package on the lists of 
genes found significantly differentially expressed in both experiments in order to assess the 
over-representation of genes belonging to specific biological processes. To summarize the 
results of GO analysis the overlap coefficient between each pair of significant GO terms was 
calculated as a measure of similarity, and terms with an overlap coefficient ≥0.5 were 
visualized as a network using Cytoscape version 3.2.1 and manually annotated. 
Gene expression datasets of lymph node-negative primary breast tumors were 
retrieved from NCBI GEO repository with accession numbers GSE2034, GSE2990, 
GSE5327, GSE7390 and GSE11121. All downloaded datasets were generated on the 
Affymetrix GeneChip® Human Genome U133A array and raw CEL files were pre-processed 
using the frozen RMA (fRMA) algorithm that enables the analysis of Affymetrix data at the 
single sample level (McCall et al., 2010). 
 
3.7. Statistical analyses 
Data were analyzed using conventional descriptive statistics. Contingency tables were 
analyzed by two-tailed Fisher’s exact test, two-tailed χ2 test with Yates’correction and by χ2 
test, when appropriate, and the quantitative measure of the agreement between categorical 
variables was evaluated by Cohen’s kappa statistics, κ. Differences among ordinal variables 
were assessed by Mann-Whitney’s U or by Student’s t test or by ANOVA (moderated 
t-statistics).  
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The Kaplan-Meier method was used for estimation of time-to-event outcomes such as 
progression-free survival (PFS), as a function of overall CTC positivity or CTC-specific gene 
status (negative or positive), or distant metastasis-free survival (DMFS), as a function of 
CTC-specific gene expression level (low, intermediate or high), in CTC case series collected 
at INT and in publicly available BC datasets. Cox proportional hazards regression was used 
to investigate the prognostic role of CTC molecular profile, and of the other 
clinico-pathological or CTC status-related factors on PFS, with relative hazard ratios (HR) 
and 95% confidence intervals (CI), whereas log-rank test was used to investigate the 
prognostic role of CTC-specific genes in publicly available BC datasets and of the CTC 
status assessed by AdnaTest in CTC case series collected at INT. 
All tests for comparison of experimental groups in basic studies were performed using 
the GraphPad Prism or R software. All tests for clinical correlation analyses were performed 
using the SAS software, version 9.2. All tests were two-sided and P ≤0.05 was adopted as 
the significance threshold. 
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4. RESULTS 
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4.1. Modeling dissemination and metastasis formation with breast 
cancer cell lines 
 
4.1.1. Detection of CTCs and metastases in xenograft mouse models 
Direct visualization of disseminated tumor cells is fundamental to measure the 
metastatic burden and to analyze morphological parameters related to tumor cell 
heterogeneity, both in blood and solid tissues. For these reasons, CTCs and metastases in 
BC experimental models obtained by orthotopic xenograft of commercially available cell lines 
were detected using cytological and immunohistochemical approaches.  
To this aim, CTC enrichment, detection and quantification were performed using a 
size-based isolation method, which physically excludes the majority of hematopoietic cells by 
exploiting the larger diameter of tumor cells, coupled to a cytological analysis by a referral 
pathologist. This approach also facilitates the identification of different subpopulations of 
CTCs, either presenting as single cells or clusters or circulating tumor microemboli (CTM), 
whose representative images were reported in Figure 4.1.1. Generally, CTCs are 
characterized by i) a larger nucleus (generally 13 to 15 μm in diameter) compared to 
leukocytes, which appear hardly larger (about 7-8 μm in diameter) than membrane pores 
(6.5±0.33 μm), ii) a high nucleus-to-cytoplasm ratio (>0.5), iii) a dense basophilic and 
irregularly outlined nucleus and iv) a pale-bluish ring of cytoplasm, forming a thin rim 
encircling the nucleus. CTC clusters are defined as groups of two or more CTCs, sometimes 
mixed with platelets (i.e., CTM). 
Given the weak metastatic ability of some BC cell lines, direct inspection of biological 
samples to find single disseminated cells or small foci was performed by IHC analysis using 
a commercially available antibody against human COX IV, suggested by the manufacturer as 
non-crossreactive against Mus musculus species’ antigens. The species-specificity of 
anti-COX IV antibody was assessed on a series of 4 FFPE sections from different organs of 
3 non-tumor-bearing NOD scid mice. Despite low-intensity scattered signals were observed 
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at nervous tissue level, sections from lung, liver, lymph-node and kidney did not display 
reactivity after IHC procedure (Figure 4.1.2), thus indicating that the antibody is highly 
specific and that the approach is adequate to assess the presence and extent of metastatic 
foci without turning to the pathologist for consultation.  
 
Figure 4.1.1 Single CTCs and CTC cluster from experimental breast cancer models. Images 
(600X total magnification, oil immersion) of cytological samples (May-Grünwald-Giemsa staining) 
obtained by ScreenCell® Cyto kits represent (A) 1 CTC from MDA-MB-453, and (B) 1 cluster of CTCs 
mixed with some platelets, and 2 single and separated CTCs (below the cluster), from MDA-MB-231 
xenograft mouse models. 
 
 
4.1.2. Hematogenous dissemination and metastatic potential of BC cell lines 
BT-474, MDA-MB-453, MDA-MB-468 and MDA-MB-231 cells, belonging to the 
HER2-positive ER-positive, HER2-positive ER-negative, basal A and basal B molecular 
subtypes respectively, were injected in the m.f.p. of immunocompromised mice and 
monitored for tumor growth (Figure 4.1.3), CTC release (Figure 4.1.4 and Table 4.1.1) and 
invasion of lymph-nodes and distant organs (Table 4.1.2) in two independent experiments 
(hereafter referred to as “Exp1” and “Exp2”).  
Consistently with the fast tumor growth rate, MDA-MB-231 xenograft animals were 
sacrificed around day 80 after injection, whereas animals injected with BT-474, MDA-MB-453 
and MDA-MB-468 cell lines, whose tumor growth rate was lower than MDA-MB-231 cells, 
were sacrificed at later time points (after 100 days) (Figure 4.1.3).  
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Figure 4.1.2. Detection of tumor cells by human COX IV IHC analysis. Images (100X total 
magnification) of COX IV stained FFPE sections from (A) a primary tumor nodule obtained from 
MDA-MB-231 xenograft model, and from (B) lungs, (C) liver, (D) brain and (E) kidneys collected from 
a non-tumor-bearing immunocompromised mouse. 
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Figure 4.1.3. Tumor growth rate of BC cell lines in immunocompromised mice. Tumor growth 
curves represent the mean±SD mass of a single nodule for (A) BT-474 and (B) MDA-MB-453, and the 
mean±SD of the sum of the masses of two nodules for (C) MDA-MB-468 and (D) MDA-MB-231 
models. 
 
Overall, in both experiments, the number of single CTCs and CTM per milliliter of blood 
at sacrifice was higher in the MDA-MB-231 compared to the other CTC-models, in keeping 
with the aggressiveness and high proliferation rate of these cells, although high variability in 
CTC load was observed for both single CTC or CTM subpopulations (Figure 4.1.4, Panels A 
and B, and Table 4.1.1). Moreover, CTM frequency in CTC-positive samples was 
approximately 3-fold lower in less aggressive BC models compared to MDA-MB-231 (7 out of 
24 vs. 6 out of 7 CTM-positive out of the total number of assessable cases, respectively). 
Interestingly, CTCs with different morphology within the same sample could be observed in 
all models, thus suggesting the existence of different subsets within the single CTC and CTC  
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Figure 4.1.4. CTC and CTM load in BC xenograft models. Box plots represent the distribution of (A) 
CTCs and (B) CTM density, and images (400X total magnification) represent CTCs and CTM from 
cytological blood samples of (C) BT-474, (D) MDA-MB-453, (E) MDA-MB-468 and (F) MDA-MB-231 
xenograft models. Red circle and arrows indicate single CTCs and CTC clusters/CTM, respectively. 
 
cluster subpopulations (Figure 4.1.4, Panels C-F): image in Panel C shows a group of 4 
CTCs from the BT-474 model forming a cluster intermingled with some platelets; the 6 single 
CTCs from the MDA-MB-453 model (Panel D) were different in size; a cluster of 4 CTCs and 
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surrounding platelets from the MDA-MB-468 model is depicted in Panel E, showing that 
heterogeneity in size can be observed also within tumor cells forming a CTM; the degree of 
pleomorphism is particularly clear in the MDA-MB-231 model (Panel F), where 11 single 
CTCs are represented, each with a more or less irregularly outlined nucleus of various size 
and shape, in addition to the heterogeneity in the whole cell morphology. 
The metastatic potential of BC cell lines (Table 4.1.2 and Figure 4.1.5) was preliminary 
assessed by macroscopic inspection and IHC analysis on a series of non-adjacent FFPE 
sections (series of 4 consecutive stained and 8 consecutive unstained sections) obtained 
from different organs in Exp1. This preliminary experiment allowed identifying organs with 
high frequency of metastases, as lung, lymph-nodes and ovaries, and those without 
metastatic involvement, as liver, brain and spleen. In the second experiment, systematic IHC 
analysis was focused on a series of 24 or 48 non-adjacent FFPE sections (series of 8 
consecutive stained and 8 consecutive unstained sections) from lung, lymph-nodes and 
ovary samples. The presence of metastatic foci at lung was observed in roughly all of the 
examined FFPE sections and in the majority of animals per experimental model. Ovarian 
metastases were detectable in MDA-MB-468 and MDA-MB-453, but not BT-474 models, 
whereas LNs were not detectable at macroscopic level in BT-474 and MDA-MB-453. On the 
contrary, lymph-nodal involvement was already visible macroscopically and at high frequency 
during sacrifice and organs explant in MDA-MB-468 and MDA-MB-231, as also confirmed by 
IHC analysis. Consistently with CTC load, all COX IV-positive lung sections from weakly 
aggressive models showed the presence of metastatic foci with smaller extent (single 
scattered cells or small foci of 3-30 cells) compared to MDA-MB-231 xenografts.  
Taken together, these experiments provided information for the first time on the CTC 
load and the existence of subtypes of CTCs in different BC cell lines. Considering the limited 
CTC load in BT-474, MDA-MB-453 and MDA-MB-468 models, the molecular characterization 
of CTCs for this work of thesis (reported in “4.2. Molecular characterization of circulating 
tumor cells and solid tumor lesions in the MDA-MB-231 model”) was focused on the 
MDA-MB-231 model only. 
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Table 4.1.1. CTC load in BC xenograft models  
CTC-model 
CTC load CTM load 
Exp1 Exp2 Exp1 + Exp2 Exp1 Exp2 Exp1 + Exp2 
N* 
median(IQR) 
or range 
CTC/mL 
N* 
median(IQR) 
or range 
CTC/mL 
overall 
mean±SD  
CTC/mL 
N* 
median(IQR) 
or range 
CTM/mL 
N* 
median(IQR) 
or range 
CTM/mL 
overall 
mean±SD 
CTM/mL 
BT-474 2 0-2 7 1(1-2) 1.56±1.24 2 0-2 6 0 0.50±0.93 
MDA-MB-453 3 0-111 5 6(3-16) 117.50±278.31 1 0 5 0(0-1) 0.33±0.52  
MDA-MB-468 3 2-5 7 2(1-6) 3.50±2.64 3 0-4 7 0(0-1) 0.80±1.40 
MDA-MB-231 5 7(1-333) 3 1-417 267.00±478.86 4 1-853 3 0-10 124.43±321.29 
* number of animals assessable for CTC and/or CTM count according to the quality of the cytological sample 
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Table 4.1.2. Metastasis sites and frequencies in breast cancer xenograft models 
CTC-model 
Exp1 Exp2 
N 
Lymph-node Lungs Ovary 1 Ovary 2 
N 
Lymph-node Lungs Ovary 1 Ovary 2 
+ve 
cases 
Positi
vity 
frequ
ency 
(%)* 
+ve 
cases  
Positiv
ity 
freque
ncy 
(%)* 
+ve 
cases 
Positiv
ity 
freque
ncy 
(%)* 
+ve 
cases  
Positiv
ity 
freque
ncy 
(%)* 
+ve 
cases 
Positi
vity 
frequ
ency 
(%)* 
+ve 
cases 
Positiv
ity 
freque
ncy 
(%)* 
+ve 
cases 
Positiv
ity 
freque
ncy 
(%)* 
+ve 
cases 
Positiv
ity 
freque
ncy 
(%)* 
BT-474 6 -§ - 6/6 25-100 0/5 - 0/5 - 7 -
§ - 7/7 100 0/7 - 0/7 - 
MDA-MB-453 3 -§ - 2/3 80-100 0/3 - 0/3 - 6 -
§ - 6/6 75-100 6/6 
75-
100 5/5
‡ 43-100 
MDA-MB-468 6 2/2 36-100 6/6 8-100 1/4 21 1/4 21 7 7/7  100 7/7 100 2/7 
23-
100 1/7 90 
MDA-MB-231 4 4/4 100 4/4 100 -§ - -§ - 5 5  100 5/5 100 - - - - 
* range of positivity frequencies (number of metastasis +ve sections: from 10 to 30 sections in Exp1, and from 24 to 48 sections in Exp2) 
§  not available or not detectable at macroscopic level 
‡ 1 out of 2 ovaries was not assessable 
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Figure 4.1.5. Metastatic burden of breast cancer cell lines after orthotopic injection in mice. 
Images represent COX IV stained metastatic cells in a FFPE section of lung samples from (A) BT-474, 
(B) MDA-MB-453, (C) MDA-MB-468 (400X total magnification, oil immersion) and (D) MDA-MB-231 
(200X total magnification) xenograft models.   
 
 
4.1.3. Longitudinal analysis of CTC load and metastatic burden in the 
MDA-MB-231 xenograft model 
The dynamics of dissemination in the MDA-MB-231 model was investigated by a 
time-course experiment, where CTC load and metastatic burden were measured at different 
time points after tumor cell injection. This experiment was designed with the final aim to 
isolate early and late CTCs, i.e. released before and after the completion of the metastatic 
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cascade, and to compare their molecular profile, on the hypothesis that temporal 
heterogeneity could be modeled according to the phase of dissemination, an early dormant 
followed by an active and proliferating one.  
Overall, primary tumor weight (Figure 4.1.6, Panel A), CTC load (Figure 4.1.6, Panel B) 
and CTM load (Figure 4.1.6, Panel C) showed a step-wise increase at each experimental 
time point, although the experimental variability for each biological feature was lower in the 
early phases (day 35 and day 50) compared to the late phases (day 65 and day 80) of the 
time-course. Following a similar trend, the frequency of metastasis-positive cases assessed 
in lymph-node (axillary, inguinal, subclavean or peritoneal) and lung samples increased 
during time, showing the highest positivity frequency during the last two time points, although 
metastases at lymph-nodes, differently than lungs, were detectable since the earliest phase 
of tumor progression in the majority of assessable cases (Figure 4.1.6, Panel D). At day 35 
CTCs were found in 1 out of 5 assessable cases (2 CTCs, Figure 4.1.6, Panel B), 
consistently with the detection of few metastatic cells at lung in the same animal 
(Figure 4.1.6, Panel D). At day 50 concordance between CTC-positive and matched 
metastases-positive lung samples was low as 1 out of 3 CTC-positive cases only had 
metastases. On the contrary, 5 out of 6 cases at day 65 and 5 out of 5 cases at day 80 had 
both CTCs and pulmonary metastases.  
Longitudinal analysis of dissemination in the MDA-MB-231 CTC-model allowed the 
identification of a temporal window, from day 35 to day 50 after tumor implant, during which 
CTCs but not metastases at lung can be found, although complete inspection of lung 
samples is required to confirm this result. However, at the same time, the outcome of the 
experiment revealed that a complete molecular characterization of the CTC-model during 
each step of the tumor progression is not feasible with available techniques due to the limited 
number of CTCs isolated in the early phases, and that a higher number of animals should be 
sacrificed to obtain representative CTC samples. For these reasons, the molecular 
characterization of the CTC-model, reported in the following chapter, was performed at the 
endpoint (around day 80) of the experiment. 
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Figure 4.1.6. Longitudinal analysis of dissemination in the MDA-MB-231 xenograft model. 
Box/dot plots represent the distribution of (A) the total tumor mass (from two nodules), and (B) CTCs 
and (C) CTM at different experimental time points. Scheme (D) represents the frequency of CTC/CTM 
or LN or lung metastasis positive samples for each animal, according to the experimental time point. 
 
On the hypothesis that CTCs isolated during the late phase of metastasis could derive 
from both the PT and metastases at lung, MDA-MB-231 cells were also intravenously 
injected in 5 animals and their presence in blood was monitored during time. Blood samples 
collected at sacrifice 1 hour after injection from one animal injected with 1 million and one 
animal injected with 2 million cells contained 1 and 7 CTCs per milliliter, respectively, thus 
indicating that the vast majority of cells had reached peripheral districts. The remaining 
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three animals, two injected with 1 million and one injected with 2 million cells, were sacrificed 
after 90 days and were all CTC-positive and lung metastasis-positive. CTM numbers were 
detected in all cases and ranged from 1 to 31 per milliliter, while CTCs (about 280) were 
found in one animal only, injected with 1 million cells. Lymph-nodes, ovaries and spleen were 
all negative for metastases by macroscopic examination and IHC of 4 FFPE consecutive 
sections.  
These results show that our model does not completely recapitulate the tumor 
progression steps observed in the clinical setting as MDA-MB-231 cells, once in the 
bloodstream, colonize the lungs rapidly. Moreover, their behavior might have implications for 
molecular profiling studies since lung metastases represent another source of CTCs in 
addition to the primary site.  
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4.2. Molecular characterization of circulating tumor cells and solid 
tumor lesions in the MDA-MB-231 model 
 
4.2.1. Reliable PCR-based quantification and gene expression microarray-
based analysis of tumor cells in biological samples derived from xenograft 
models are feasible  
A series of preliminary tests was run before performing gene expression profile (GEP) 
experiments with the MDA-MB-231 xenograft model in order to address technical issues 
related to the sensitivity and specificity of the assays applied for detection, quantification and 
characterization of tumor cells in biological samples from xenograft mouse models. 
The first limiting step when selecting samples for GEP of CTC-models is the availability 
of a sufficiently representative biological sample and numbers of tumor cells superior to the 
technical detection limit of the platform applied for molecular analysis. In order to detect 
CTCs, which notoriously are rare events, and to confidently discriminate between 
CTC-positive and CTC-negative samples by nucleic acid analysis, tumor cell isolation was 
performed using immunomagnetic beads coupled to a size-based method (AdnaTest and 
ScreenCell® Molecular Biology kits). CTC detection was performed using a qPCR-based 
approach, taking advantage of the species-specificity of commercially available TaqMan 
gene expression assays. Searching for assays which theoretically should not detect murine 
transcripts and designed for a gene expressed at equal levels in tumor cells, a particular 
TaqMan assay for human ACTB constitutive gene was selected and its species-specificity 
verified in a qPCR test with universal murine RNA reference (UMR). Gene encoding for 
murine β-actin was never detected, either when amplifying 10 or 50 ng of cDNA (data not 
shown). 
As second phase, the feasibility of the whole approach for CTC detection was 
assessed using cDNA of blood samples from three MDA-MB-231 xenograft models 
processed using a 3-step approach, consisting of incubation with immunomagnetic beads 
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provided with 1) AdnaTest EMT-1 Select kit, as first step, and with 2) from AdnaTest EMT-2 
Select kit, as second step, followed 3) isolation size-based with the ScreenCell® Molecular 
Biology kit as third step. A total of 8 samples were obtained (1 case processed with 
AdnaTest EMT-2 and ScreenCell only). Samples were considered as positive for the 
presence of tumor cells when Ct values were lower than 40 after 40 cycles of amplification. 
Quality control test for negative samples was performed using a TaqMan assay specific for 
murine Gapdh, previously verified to be specific and not able to detect human transcripts in a 
qPCR test with universal human RNA reference (UHR), in order to exclude possible technical 
failures during the tumor cell isolation procedure, especially for CTC samples. Overall, 
irrespective of the approach used for CTC isolation, Ct values for human ACTB ranged from 
16.78 to 39.35 (median 27.04) in 7 samples, whereas 1 out of 8 samples only did not reach 
the technical threshold value. The CTC-negative sample was submitted to quality control test 
using a TaqMan assay for murine endogenous control gene: Ct value for murine Gapdh was 
22.71, thus indicating that the result was not due to a technical failure and confirming the 
negative CTC status. Therefore, the validity of the method for MDA-MB-231 CTC isolation 
(i.e., by a positive selection step followed by a size-based isolation step) and detection (i.e., 
by qPCR) was in this manner verified. 
Considering its high specificity, the molecular approach designed for CTC detection 
was supposed to be applicable to the estimation of the number of tumor cells not only 
contained in blood samples but also embedded in other tissues and organs, as tumor 
nodules and metastasis positive organs collected from mice at their sacrifice. This kind of 
test, other than representing an alternative approach for tumor cell quantification per se 
(beside direct visualization of tumor cells by image-based techniques), is fundamental to 
reach similar experimental conditions during transcripts amplification and hybridization in 
GEP experiments with high-density oligonucleotide arrays, as it allows input of equal human 
RNA quantities on the microarray platform, information that cannot be obtained from mixed 
murine and human RNA samples by using direct RNA quantification methods. In order to 
indirectly calculate the number of tumor cells a standard curve was generated using different 
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amounts of MDA-MB-231 cells (2-5-10-20-40-100-200-1,000-5,000-10,000-50,000-100,000) 
and correlating them to Ct values obtained by qPCR for human ACTB (Figure 4.2.1). 
Observed and expected Ct values showed high correlation (Pearson’s correlation r = 0.9960), 
indicating that the approach allows reliable quantification of the total number of tumor cells in 
samples containing both human and murine RNA, thanks to the good performance of the 
assay and to homogenous expression of ACTB in MDA-MB-231 cells. 
Enrichment methods that are able to completely exclude hematopoietic or other 
non-tumor cells do not exist nowadays. Nonetheless, CTCs can be detected in whole blood 
samples even when present at low densities. Moreover, the sensitivity and the specificity of 
the methodological approach used for CTC analysis should be preliminarily evaluated, in 
order to ensure adequate sampling and reliable characterization. In our laboratory, spiking 
experiments demonstrated that the WG DASL HT assay (Illumina) has high sensitivity, since 
it allows obtaining reliable GEP from a minimum of 25 tumor cells spiked in a 5-mL sample of 
whole blood of healthy donor and captured with the AdnaTest EMT-1 Select kit (Fina et al., 
2015a), which consists of immunomagnetic beads for enrichment of CTCs and a wash buffer 
that reduces by 10-fold contamination from non-target cells. 
 
 
Figure 4.2.1. Method for estimation of the number of tumor cells in samples from MDA-MB-231 
xenograft models by relative quantification of human ACTB. Standard curve was constructed by 
interpolating different numbers of MDA-MB-231 cells with corresponding Ct values obtained by qPCR 
for hACTB. Mean±SD Ct values of three independent experiments are reported as a function of cell 
number. 
 
151 
 
Although the approach developed for CTC analysis in human samples can be applied  
also in the experimental setting, it should be considered that there is no possibility to 
minimize the contamination of stromal cells in samples of solid tumor lesions obtained from 
xenograft models, unless microdissection or tumor cell disaggregation from fresh or FFPE 
samples are used. In such a case, however, the assessment of the species-specificity of 
molecular probes can represent the solution. Therefore, a specificity test was performed to 
assess if probes of the DASL assay, designed for human transcriptome, also recognize 
transcripts of murine origin. To this aim, considering that the amount of murine mRNA in 
samples from xenograft models might be variable according to the site and extension of solid 
lesion (PT or micro- and macro-metastases) and that contaminating murine mRNA could 
affect the reliability of the GEP at different extent, a test was designed in an attempt to mimic 
the expected composition of the biological sample. To this aim, pure universal RNA 
reference from human (UHR) or murine (UMR) tissues and mixtures of them at 1:3, 1:1 and 
3:1 proportions to a maximum of 50 ng of total RNA were processed with the DASL assay. 
All samples containing UHR had roughly 70% detection rate, independently from the 
contribution of UHR, whereas pure UMR samples had low detection rates (10 and 30%) and 
signal intensities 3-fold lower than those obtained from the other samples (Figure 4.2.2, 
Panel A). Consistently, reciprocal correlation analysis showed that pure UMR and samples 
containing UHR form two distinct clusters of highly correlated samples (Figure 4.2.2, 
Panel B), thus confirming that the GEP obtained from xenograft samples cannot be affected 
by the presence of murine mRNA.  
This test revealed that the DASL assay is sufficiently specific for human transcriptome 
to ensure reliable molecular characterization of CTCs and solid lesions from xenograft 
models. Nevertheless, considering a detection rate of 10% and 30% in the two pure UMR 
samples even if at low intensities, qPCR tests with specific TaqMan assays might be 
required to validate the expression of some genes. 
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Figure 4.2.2. Specificity of the WG DASL HT assay platform for molecular analysis of human 
samples. (A) Scatter plot represents mean signal intensities and detection rates. (B) Heat map 
represents pair-wise correlations between gene expression profiles for duplicate samples (“a” and “b”) 
containing different proportions of UHR (“H”) and UMR (“M”) (numbers indicate the percentage). 
 
 
4.2.2. Circulating tumor cells have a distinct transcriptome profile compared to 
solid primary and secondary lesions 
On the hypothesis that comparing the molecular profile of CTCs with those of the PT 
and metastases at lungs (LUNG) and lymph-nodes (LN) could allow obtaining new 
information on the pathways required for cell dissemination and defining a set of biomarkers 
with clinical relevance in breast cancer, the MDA-MB-231 xenograft model was extensively 
characterized using the WG DASL HT assay after two independent experiments (hereafter 
referred to as “GEP1” and “GEP2”), performed in 2013 and 2015. The GEP of CTC was 
compared with those obtained from LN sections and sections from peripheral and central 
sites (in the attempt to obtain sufficiently representative samples and do not disregard 
possible differences due to heterogeneity) of PT and LUNG. In addition, the analysis was 
extended to the characterization of the parental MDA-MB-231 cells, collected after standard 
in vitro culture conditions, as such information was considered instrumental to select 
candidate genes for preliminary functional studies by in vitro assays.  
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Ten animals per experiment were injected with MDA-MB-231 cells and CTCs were 
indirectly quantified by qPCR on the basis of the standard curve previously created for this 
study model (results are reported in Table 4.2.1). Biological samples for GEP analysis were 
selected from three mice according to the total number of yielded CTCs, in order to profile 
the highest number of tumor cells available. Subsequently, matched samples of PT, LN and 
lungs were processed 1) for preliminary assessment of tumor cell presence by IHC analysis 
on OCT-frozen sections and 2) for indirect quantification of tumor cells in consecutive 
sections of each positive sample. Considering the maximum amount of detected CTCs, 
volumes of RNA solution corresponding to 5,000 tumor cells according to qPCR analysis for 
human ACTB were calculated for each sample and used as RNA input. On the average, 
50 ng of total RNA were used as input, since this amount yields high gene detection and 
reliable profiling analysis with the DASL assay (Fina et al., 2015a).  
Table 4.2.1. CTC load estimated by indirect quantification  
GEP1 experiment  GEP2 experiment* 
Animal ID CTC total number 
DTC total 
number  Animal ID 
CTC total 
number 
63X 0 NA  147X 9,137 
65X 3 0  148X 25 
66X 30 0  149X 268 
67X 0 NA  150X 821 
68X 21,811 NA  151X 565 
69X 36,092 17,884  152X 15,057 
70X 34,431 54  154X 172 
76X 1,714 NA  155X 62,200 
77X 48 NA  156X 513 
78X 172 262  157X 5,442 
* DTC isolation not performed 
NA: not available 
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Preliminary assessment of signal intensities obtained after raw data acquisition 
(Figure 4.2.3) confirmed that low cross-reactivity of the assay with murine RNA occurred in 
both experiments, since in UMR control samples median signal intensities approximated the 
lower limit of detection (corresponding to 4), and the number of detected genes was 
negligible compared to those obtained in experimental samples.  
 
Figure 4.2.3. Raw signal intensities and detection rates for gene expression profiles of 
MDA-MB-231 CTC-model. Box plots (left) represent the distribution of raw signals and bar charts 
(right) display the number of detected genes for each sample in (A) GEP1 and (B) GEP2 experiments. 
“CTC”, circulating tumor cells; “DTC”, tumor cells disseminated to bone marrow; “PT”, primary tumor; 
“LN”, lymph nodal metastases; “LUNG”, pulmonary metastases; “a”, axillary; “i”, inguinal; “(c)”, 
controlateral to PT; “(h)”, homolateral to PT; “(d)”, distal; “(p)”, proximal. 
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The analysis of reciprocal correlations among all samples (excluding UMR) revealed 
that one sample in GEP1 (corresponding to a peripheral section of inguinal PT obtained from 
animal 70X), and three samples in GEP2 (one corresponding to a peripheral section of 
axillary PT obtained from animal 152X, and the other two corresponding to a section of an 
axillary LN contralateral to the tumor and to a peripheral section of lungs of the same animal, 
ID 147X), were scarcely correlated with the other samples (Figure 4.2.4). Since distributions 
of raw intensities in the aforementioned samples were overall lower (Figure 4.2.3), technical  
 
 
Figure 4.2.4. Reciprocal correlations between GEP raw data of samples derived from the 
MDA-MB-231 CTC-model. Heat maps represent pair-wise correlations of raw gene expression data 
from (A) GEP1 and (B) GEP2 experiments. “CTC”, circulating tumor cells; “DTC”, tumor cells 
disseminated to bone marrow; “PT”, primary tumor; “LN”, lymph nodal metastases; “LUNG”, 
pulmonary metastases; “a”, axillary; “i”, inguinal; “(c)”, controlateral to PT; “(h)”, homolateral to PT; 
“(d)”, distal; “(p)”, proximal. 
 
 
failure or suboptimal performance of the assay was considered a more plausible cause of 
their deviance rather than biological variability or heterogeneity among different sites of the 
PT. Importantly, within the main cluster, three sub-clusters were identifiable in both 
experiments, as represented in the heat map in Figure 4.2.4: 1) one including samples 
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obtained from captured cells (i.e., CTC and DTC), 2) one corresponding to cultured cells (i.e., 
MDA-MB-231 parental cell line), and 3) one including all the remaining samples from solid 
lesions, excluded those displaying low intensities. On the basis of these considerations, 
deviating samples were excluded. Therefore, 22 and 20 samples respectively from GEP1 
and GEP2 were included in subsequent analyses.  
Signal intensities of samples which passed the above described quality control test 
were again analyzed after data normalization. Analysis of distribution of normalized (RSN) 
data revealed homogeneous signal intensities among samples in both experiments 
(Figure 4.2.5), again confirming the technical validity of the indirect quantification procedure 
to ensure comparable RNA inputs. 
 
Figure 4.2.5. Normalized signal intensities of MDA-MB-231 CTC-model profiled samples. Box 
plots represent distribution of RSN intensities in (A) GEP1 and (B) GEP2 experiments. “CTC”, 
circulating tumor cells; “DTC”, tumor cells disseminated to bone marrow; “PT”, primary tumor; “LN”, 
lymph nodal metastases; “LUNG”, pulmonary metastases; “a”, axillary; “i”, inguinal; “(c)”, controlateral 
to PT; “(h)”, homolateral to PT; “(d)”, distal; “(p)”, proximal. 
 
 
Again, three clusters emerged from the correlation analysis of normalized data, 
including disseminated tumor cells, solid tumor lesions or the parental cell line (Figure 4.2.6). 
Importantly, all the sections obtained from solid lesions were highly correlated and no clear 
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sub-clusters could be identified either according to the sample class (PT, LUNG or LN) or the 
site of the lesion (peripheral or central, as assessed for PT and LUNG samples), thus 
indicating that tumor lesions share similar expression patterns which are distinct from those 
peculiar of disseminated cells, and even suggesting that after hematogenous dissemination, 
tumor cells colonizing distant organs tend to recapitulate the molecular features of the PT. 
In order to identify genes that allow distinguishing CTCs from the other lesions and 
from the parental cell line, unsupervised hierarchical clustering was performed using the 
most variable genes, i.e. those with IQR intensities >95th percentile (corresponding to 
209 genes in both experiments). Also in this case, samples segregated in three clusters, 
 
Figure 4.2.6. Reciprocal correlations between GEP RSN data of samples derived from the 
MDA-MB-231 CTC-model. Heat maps represent pair-wise correlations using RSN expression data 
from (A) GEP1 and (B) GEP2 experiments. CTC”, circulating tumor cells; “DTC”, tumor cells 
disseminated to bone marrow; “PT”, primary tumor; “LN”, lymph nodal metastases; “LUNG”, 
pulmonary metastases; “a”, axillary; “i”, inguinal; “(c)”, controlateral to PT; “(h)”, homolateral to PT; 
“(d)”, distal; “(p)”, proximal. 
 
 
consisting of MDA-MB-231 cells, CTC samples or solid lesions, thus providing meaningful 
evidence that MDA-MB-231 cells, the tumor lesions they gave rise after orthotopic xenograft 
and the derived CTCs, despite the common origin, have distinct transcriptome profiles 
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(Figure 4.2.7). Considering the overall data, it was observed that MDA-MB-231 cells share 
about 50% of their highly expressed genes with CTCs, which in turn are characterized by a 
large portion (roughly 70% in GEP1, and ranging from 50 to 20%, according to the CTC 
sample, in GEP2) of genes with higher expression level compared to the parental cell line. 
Moreover, genes highly expressed in CTCs and those highly expressed in solid tumor 
lesions displayed slight overlap only, suggesting that molecular traits unique to CTCs exist. 
On the contrary, samples obtained from tissue sections shared the vast majority of genes 
and did not cluster according to the sample class (PT, LN and LUNG).  
 
 
Figure 4.2.7. Hierarchical clustering analysis of GEPs of samples derived from the MDA-MB-231 
CTC-model. Heat map representing the expression pattern of the most variable genes (IQR intensities 
>95th percentile) in (A) GEP1 and (B) GEP2 experiments.  
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To exclude the possibility that the biological variability among animals more than the 
variability among classes of samples could have confounded the interpretation of results, 
principal variant component analysis was performed considering the most plausible sources 
of experimental variability. The results of this explanatory analysis (Figure 4.2.8) confirmed 
that the major contribution to the different behavior of the three groups of samples was 
 
 
Figure 4.2.8. Sources of variability in GEP experiments with the MDA-MB-231 CTC-model. Bar 
charts represent the contribution of each investigated technical and biological factor to the global 
experimental variability in (A) GEP1 and (B) GEP2 experiments.  
 
 
actually imputable to the tissue source (i.e., disseminated cells, parental cells and solid 
lesions), accounting for 23% variability in GEP1 and for 34% in GEP2, rather than the 
inter-animal variability (7% and 17%) or the sample class (i.e., CTC, PT, LUNG, LN and 
MDA-MB-231; 13% and 9%, respectively for GEP1 and GEP2). In addition, inter-assay 
variability was negligible (1% and 2%), similarly to data already reported in Fina et al., 2015a. 
These results indicate that the different transcriptome profile observed in CTCs compared to 
the other sample types reflects their distinct biological features rather than the result of an 
experimental artifact. 
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Correlations between log(base2) fold changes considering all detected genes in GEP1 
and GEP2 experiments were acceptable as r = 0.66, 0.52, 0.56 and 0.75 (Pearson’s 
correlation coefficient) were obtained respectively for CTC vs. PT or LN or LUNG or 
MDA-MB-231 pair-wise class comparisons. Of note, genes up-regulated and down-regulated 
in CTCs compared to all solid lesions and common to both experiments were 192 and 282, 
respectively.  
 
Figure 4.2.9. Correlation analysis between GEP1 and GEP2 experiments with MDA-MB-231 
CTC-models.  Scatter plots represent correlations among log(base2) fold changes considering all 
detected genes (indicated as dots) in GEP1 and GEP2 experiments, after (A) CTC vs. PT, (B) CTC 
vs. LN, (C) CTC vs. LUNG and (D) CTC vs. MDA-MB-231 class comparisons. Genes significantly 
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(Figure 4.2.9. continued) up-regulated or down-regulated (FC threshold = │2│ and FDR <0.05) in 
both experiments are represented by red and green dots, respectively, and genes with discordant 
trend are represented by pink or blue dots if up-regulated in GEP1 and down-regulated in GEP2 or 
down-regulated in GEP1 and up-regulated in GEP2, respectively. 
 
 
4.2.3. Genes peculiar to circulating tumor cells are mainly related to 
embryogenesis, development and chromatin remodeling 
Extensive molecular characterization of the MDA-MB-231 CTC-model by comparing 
GEPs from PT, LUNG, LN, CTC and the parental cell line, offered the opportunity to better 
understand the molecular bases behind hematogenous dissemination and metastasis and 
generate hypotheses on the biological processes and pathways which might regulate the 
different phases of tumor progression, from tumor growth, to the early steps of dissemination, 
via lymphatic and hematogenous system, to colonization and secondary tumor establishment 
in distant organs.  
Preliminary biological interpretation of GEP data was supported by GO analysis in all 
possible class comparisons, including CTC vs. solid lesions. A summary of GO terms mainly 
represented according to their frequency and significance is reported in Table 4.2.2. Genes 
significantly differentially expressed (FC threshold = │2│ and FDR <0.05) in CTC compared 
to all solid lesions in GEP1 and GEP2 were 474 (192 up-regulated).  
Genes up-regulated in CTCs compared to all solid lesions were enriched in GO terms 
related to embryogenesis, stem cell proliferation, development and morphogenesis of various 
tissues and organs, especially neural, renal and vascular system, suggesting pronounced 
plasticity in this CTC-model. Moreover, also GO terms related to response to physical, 
chemical and biological external stimuli, including response to pathogens, were highly 
represented (Figure 4.2.10, Panel A). Interestingly, GO terms related to metabolism were 
represented among genes up-regulated in CTCs, with special reference to mitochondrial 
metabolism in CTC vs. LUNG class comparison, besides to general biosynthesis processes. 
Genes down-regulated in CTC compared to solid lesions were enriched in GO terms 
mainly related to chromatin remodeling and regulation of transcription, consistently with the 
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considerable transcriptional reprogramming observed in previous analyses, and in terms 
related to tissue development/morphogenesis and regulation of cell adhesion and motility 
(Figure 4.2.10, Panel B).  
Table 4.2.2. Gene Ontology (GO) term enrichment after pair wise class comparison 
using common differentially expressed (DE) genes in GEP1 and GEP2 experiments 
classes GO terms for up-regulated genes GO terms for down-regulated genes 
CTC vs. PT 
Response to external stimuli/factors, 
cellular defense from pathogens, 
biosynthetic/metabolic processes, 
development/morphogenesis/differentia
tion 
Chromatin/transcription regulation, 
development/morphogenesis/differentia
tion 
CTC vs. LN 
Development/morphogenesis/differenti
ation regulation of cell 
adhesion/migration, response to 
external stimuli/factors 
Chromatin/transcription regulation, 
Development/morphogenesis/differenti
ation 
CTC vs. 
LUNG 
Mitochondrial metabolism, biosynthetic 
processes, development/differentiation, 
chromatin/transcription regulation 
Chromatin/transcription regulation, 
development/differentiation 
CTC vs. 
MDA-MB-231 
Development/morphogenesis/differenti
ation metabolism, angiogenesis, 
biosynthetic processes, cell 
motility/migration 
Development/morphogenesis/differenti
ation chromatin/transcription regulation, 
cell adhesion/motility 
CTC vs. 
solid lesions 
Development/morphogenesis/differenti
ation response to external 
stimuli/factors, cellular defense from 
pathogens, protein/ions localization, 
metabolism 
Chromatin/transcription regulation, 
development/morphogenesis/differentia
tion cell adhesion/motility, cellular 
defense, metabolism 
PT vs. LN No significantly DE genes No significantly DE genes 
LUNG vs. PT Development/morphogenesis/differentiation cell adhesion/motility 
Metabolism, response to external 
stimuli/factors, 
development/morphogenesis/differentia
tion 
PT vs. 
MDA-MB-231 
Vasculature development, cell 
migration, regulation of secretion, 
protein modification 
Cell migration/motility regulation, 
development/morphogenesis/differentia
tion 
LN vs. LUNG 
Glycolysis, biosynthetic/metabolic 
processes, 
development/morphogenesis/differentia
tion 
Development/morphogenesis/differenti
ation 
LN vs. 
MDA-MB-231 
Cell adhesion/migration, angiogenesis, 
development/morphogenesis/differentia
tion ions transport, response to external 
stimuli/factors 
Development/morphogenesis/differenti
ation migration, cell signaling 
LUNG vs. 
MDA-MB-231 
Development/morphogenesis/differenti
ation, immune system activation 
Cell adhesion/migration, metabolism, 
development/morphogenesis/differentia
tion 
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Genes up-regulated in PT or LN vs. MDA-MB-231 were enriched in GO terms mainly 
related to vessel formation, crucial step of tumor progression, whereas those up-regulated in 
LUNG vs. MDA-MB-231 were again related to development and activation of defense 
mechanisms, processes required for adaptation to a new microenvironment (Table 4.2.2).  
A list of genes of interest, some of them related to cell metabolism, 
epithelial-to-mesenchymal transition (EMT), transcriptional reprogramming and development, 
interaction with the tumor microenvironment or the acquisition of stemness/metastatic 
properties, including the expression trend in CTCs compared to solid lesions using merged 
data from GEP1 and GEP2, is reported in Table 4.2.3. 
 
Table 4.2.3. Expression trend of genes of interest in 
CTC vs. solid lesions 
gene FC Padj biological process 
HK2 -1.96 2.38E-08 
metabolism PDK1 -1.77 7.62E-06 
ACSS1 2.79 6.56E-07 
SNAI1 -1.00 0.97 
EMT 
SNAI2 -1.15 0.18 
VIM 1.05 0.23 
CDH1 -1.03 0.61 
CDH2 -1.06 0.16 
EPCAM 1.19 0.07 
PRRX1 -3.10 2.41E-08 
SPP1 1.03 0.81 
microenvironment/metastasis SPARC -1.57 0.06 
PTPN11 -1.63 9.62E-07 
stemness/metastasis SOX2 -1.08 0.75 
YAP1 -1.60 2.34E-06 
HDAC10 3.13 2.30E-11 development 
ELF3 4.18 6.66E-07 CTC cluster 
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Figure 4.2.10. GO enrichment analysis of genes exclusively differentially expressed in CTCs 
from MDA-MB-231 CTC-model. Network representation of Gene Ontology (GO) terms enriched in 
the lists of genes found significantly down-regulated (green) or up-regulated (red, Figure 4.2.10 
continued) in the comparison between CTC and solid lesions in both GEP1 and GEP2. Nodes 
represent significantly enriched GO terms. Their size is proportional to the number of genes annotated 
in the term and their color to their significance (darker color, smaller p-value). Nodes that share 
common genes are connected by an edge, with thickness proportional to the overlap coefficient (OC) 
between the two terms, calculated as |A∩B|/min(|A|, |B|). Only terms with an OC ≥0.5 are shown. 
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(Figure 4.2.10. continued)  
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4.3. Role of TFF3 in dissemination and metastasis 
 
4.3.1. Selection of candidate genes for functional validation studies with the 
MDA-MB-231 CTC-model  
Metastasis is a complex biological process which successfully performs once tumor 
cells have acquired the ability to disseminate, survive in blood circulation, colonize distant 
organs and adapt to foreign microenvironments. GEP analyses of the CTC-model obtained 
from MDA-MB-231 cells orthotopic xenograft in immunocompromised mice revealed that 
CTCs have a unique transcriptional profile compared to PT, lymph-nodal metastases and 
lung metastases. In order to evaluate the biological contribute of genes differentially 
expressed in CTCs in the dissemination process, hypotheses were generated and criteria 
were defined to select candidate genes for functional validation in vitro and in vivo studies 
(the results of the analysis reported below refer to GEP1, the first experiment performed in 
2013).  
Focusing on the hematogenous dissemination phase, genes differentially expressed in 
CTC compared to the PT were firstly considered. Genes down-regulated (log2FC ≤-1.5) or 
up-regulated (log2FC ≥1.5) in CTC compared to PT were 308 (106 with Padj <0.0001) and 
291 (81 with Padj <0.0001), respectively. In order to preliminarily evaluate the involvement of 
candidate genes in biological processes related to metastasis using appropriate in vitro 
assays, and to provide the scientific rational that should justify the sacrifice of animals, a list 
of genes was selected also taking into account the relative expression level compared to the 
MDA-MB-231 parental cell line.  
If considering the passage of the parental cell line 1) from an in vitro culture state 2) to 
different growth conditions after injection in mice, i.e. the PT take and growth, 3) to the 
hematogenous dissemination as three temporally distinct but biologically linked events, six 
lists of genes can be generated according to all possible categories coming out from multiple 
MDA231 vs. PT vs. CTC comparisons: 
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 “up/up”: if log2FC ≥1.5 in both paired class comparisons MDA-MB-231 vs. PT and PT 
vs. CTC 
 “up/down”: if log2FC ≥1.5 in MDA-MB-231 vs. PT and log2FC ≤-1.5 in PT vs. CTC  
 “down/up”: if log2FC ≤-1.5 in MDA-MB-231 vs. PT and log2FC ≥1.5 in PT vs. CTC  
 “down/down”: if log2FC ≤-1.5 in both paired class comparisons  
 “notDE/up”: if log2FCє]-1.5;1.5[  in MDA-MB-231 vs. PT and log2FC ≥1.5 in PT vs. CTC  
 “notDE/down" if log2FCє]-1.5;1.5[ in MDA-MB-231 vs. PT and log2FC ≤-1.5 in PT vs. 
CTC. 
Genes significantly differentially expressed (Padj  <0.0001) between PT and CTC were 
then identified for all the aforementioned categories on the hypothesis that such genes could 
be involved in pathways that regulate the dissemination process. The results of this analysis 
are reported in Table 4.3.1. 
 
Table 4.3.1. Number of genes differentially expressed according to 
multiple comparison categories among MDA-MB-231, PT and CTC 
classes 
Categories of multiple 
MDA-MB-231 vs. PT and PT 
vs. CTC class comparisons 
N° of genes (FC 
N° of significantly 
(Padj.<0.0001) DE 
genes in PT vs. CTC 
up/up 6 0 
up/down 51 11 
down/up 50 7 
down/down 11 4 
notDE/up 252 99 
notDE/down 229 66 
TOTAL 599 187 
 
 
For experimental reasons, i.e. to facilitate loss-of-function experiments, genes 
significantly differentially expressed between PT and CTC were analyzed according to the 
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relative expression in MDA-MB-231 vs. CTC class comparison categories. Therefore, after 
excluding genes not differentially expressed between MDA-MB-231 and PT (overall 165 if 
considering those expressed at comparable levels between CTC and both MDA-MB-231 or 
PT), subsequent analyses were focused on three biologically relevant categories, 
aforementioned as “up/up”, “down/up” and “down/down”. 
Taken together, the results of these analyses (Table 4.3.2) revealed that: 
 16 genes were not significantly differentially expressed between MDA-MB-231 and 
CTC;  
 2 genes that underwent down-regulation in PT compared to MDA-MB-231 and were 
significantly up-regulated in CTC compared to PT were still significantly up-regulated in 
MDA-MB-231 compared to CTC (thus their expression levels fluctuated during tumor 
growth but remained substantially lower in CTC compared to the parental cell line),  
 4 genes up-regulated during tumor growth compared to MDA-MB-231 and up-regulated 
during dissemination compared to PT were still significantly up-regulated in CTC 
compared to MDA-MB-231 (thus their expression levels were substantially higher in 
CTC compared to the parental cell line). 
On the hypothesis that the PT represents a biological filter where, during tumor growth, 
few cells committed to dissemination undergo positive selection and that genes up-regulated 
in CTC vs. PT could be involved in intravasation and survival in blood, the attention was 
focused on genes expressed in MDA-MB-231 which underwent significant down-modulation 
after injection in mice and were re-activated in disseminated cells (listed under the “up/down” 
category and marked in grey in Table 4.3.2).  
Before performing gene modulation experiments, the expression level of TFF1, TFF2, 
TFF3, ELF3 and NR4A1 was evaluated by real-time PCR in MDA-MB-231 cells. TFF2, TFF3 
and ELF3 were expressed at high level (Ct ϵ [29.9-24.0]), whereas TFF1 and NR4A1, were 
expressed at intermediate level (Ct ϵ [32.9-30.0]) (Figure 4.3.1, Panel A).  
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Table 4.3.2. List of genes obtained after multiple comparison analysis 
(MDA-MB-231 vs. PT and PT vs. CTC) and classified according to the 
expression level between CTC and MDA-MB-231   
up/down down/up down/down notDE/up notDE/down 
TFF2 LST-3TM12 NCF1 C13ORF23 NR4A3 
TFF1 SNCAIP CRIP2 AOX1 LY6D 
NR4A1 NAV3 C1QB RN7SK MIR196A2 
ELF3 SNORD55 UBE2NL SNORA45 PTGS1 
FLJ45445 SNORA51  INO80D CRYGB 
MMP28 SNORA47  KIAA1632 BCAS1 
TFF3 SNORD95  AGPAT5 CDH8 
ACSS1   ZNF407 OR1L4 
INHBB   JARID2 H19 
SPINK4   SNORA53 SYN1 
IRX5   KIAA2018 CITED1 
   SNORA25 CDH29 
   SACS C6ORF27 
   CTNNB1 RRAD 
   CRYBG3 ADAMTS14 
   C2ORF86 CD14 
   ZNF460 MAMDC2 
   … …             
            genes not differentially expressed (DE) in MDA-MB-231 vs. CTC 
           genes up-regulated in MDA-MB-231 vs. CTC  
            genes down-regulated in MDA-MB-231 vs. CTC 
            genes up- or down-regulated in CTC compared to both PT and MDA-MB-231 
 
 
 
Considering that forced expression of TFF1 was already proven to increase cell 
migration and invasion in MDA-MB-231 cells and other BC cell lines (Buache et al., 2011), 
and that NR4A1 was expressed at low level and was proven to be involved in metastasis in 
MDA-MB-231 xenograft models (Zhou et al., 2014), gene silencing experiments were 
performed to down-modulate the expression of TFF2, TFF3 and ELF3.  
As the silencing of ELF3 and TFF2 genes failed when using different commercially 
available siRNA molecules (data not shown), functional validation experiments were 
performed to evaluate the role of TFF3 in proliferation, migration, invasion, vascular mimicry, 
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dissemination and metastasis. The distribution of signal intensities of TFF3 in GEP1 and 
GEP2 experiments are reported in Figure 4.3.1 Panel B. The overall TFF3 expression trend 
was confirmed by moderated t-statistics (ANOVA Padj <0.0001). 
 
 
Figure 4.3.1. Expression of candidate genes in MDA-MB-231. Color code (A) represents the 
expression levels of TFF1, TFF2, TFF3, ELF3 and NR4A1 genes in MDA-MB-231 cells, ranked 
according to Ct values obtained by qPCR analysis. Box plot (B) represents the expression levels of 
TFF3 in CTC, MDA-MB-231, LUNG, LN and PT samples using data from GEP1 and GEP2. 
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4.3.2. TFF3 transient gene silencing impairs MDA-MB-231 migration but not 
proliferation 
Polymer-mediated siRNA delivery and TFF3 silencing efficiency were firstly assessed 
in order to estimate the number of cells on the whole population able to take the siRNA 
molecule and the protein knock-down efficiency during time. The transfection efficiency after 
48 hours was ~75% (Figure 4.3.2, Panel A) and a stepwise decrease in TFF3 gene 
expression and in TFF3 peptide secretion in the conditioned medium was observed in a 
time-course experiment (Figure 4.3.2, Panels B and C). The best knock-down efficiency was 
reached 6 days after transfection (12% relative optical density, O.D., vs. cells transfected 
with a negative control siRNA). 
Preliminary in vitro assays were performed in order to understand if TFF3, identified as 
a CTC-related gene in the MDA-MB-231 CTC-model, is involved in cell proliferation or if it 
exerts specific role in biological processes peculiar to the metastatic process. The 
involvement of TFF3 in MDA-MB-231 proliferation and migration was assessed by MTS and 
Boyden chamber migration assays, respectively. TFF3 transient knock-down did not affect 
cell proliferation in a time-course experiment (Figure 4.3.2, Panel D), but significantly 
impaired cell migration ability as an 84%±7% mean±SD reduction was obtained in silenced 
vs. control cells (P = 0.0031, two-tailed Student’s t test; Figure 4.3.2, Panel E). 
These preliminary results provided the scientific rationale to assess the metastatic 
potential of TFF3 knock-out MDA-MB-231 cells in mouse models. 
 
 
4.3.3. MDA-MB-231 cell heterogeneity influences the outcome of in vivo 
validation studies after CRISPR/Cas9-mediated TFF3 knock-out 
MDA-MB-231 cells were transfected with vectors containing a guide RNA for TFF3 
gene deletion mediated by the CRISPR/Cas9 system. Cells were seeded in order to obtain 
single clones, and after two weeks in culture 1,018 out of 4,233 screened wells contained 
proliferating cells. Despite the low plasmid transfection efficiency (about 1.3%, Figure 4.3.3,  
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Figure 4.3.2. siRNA-mediated TFF3 silencing effect on MDA-MB-231 cell proliferation rate and 
migration ability. Pictures (A) acquired by DAPI (blue) and TRITC (red) filters (200X total 
magnification) represent MDA-MB-231 cells transfected for 48 hours with a Cy3-labeled oligo; nuclei 
were stained with Hoechst 33342. Relative TFF3 levels measured by (B) qPCR and (C) ELISA assay 
in MDA-MB-231 cells transfected with a TFF3 siRNA vs. cells transfected with a negative control 
siRNA. Bar charts represent the mean±SD relative gene expression or relative optical density (O.D.) 
obtained from three biological replicates, at different time points. Proliferation rate (D) measured by 
MTS assay. Bar chart represents the mean±SD relative O.D. (normalized to O.D. measured 12 hours 
after seeding) of three independent experiments performed in triplicate, measured at different time 
points. Migration ability (E) assessed by Boyden chamber assay. Bar chart represents the mean±SD 
migration area (pixels per unit) from three independent experiments performed in sestuplicate. Images 
below the graph represent migration areas obtained after 36 hours (40X total magnification). 
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Panel A), the CRISPR/Cas9 system allowed obtaining complete TFF3 deletion in 84% of 
cases as TFF3 concentrations in conditioned media were a) undetectable in 76/90 clones, 
b) 88.54%±19.22% mean±SD relative expression vs. control parental cells in 9/90 clones, 
c) on average 34% vs. control parental cells in 2/90 clones, d) under the mean minimum 
detectable dose indicated by the manufacturer of the ELISA assay (6.43 pg/mL) in 3/90 
clones (Figure 4.3.3, Panel B). Validation of gene knock-out by Sanger sequencing was 
performed in 5 wild-type (transfected with control vector) and 8 knock-out clones; the results 
of the nucleotide sequence alignment of the three TFF3KO clones injected in animals for 
in vivo functional experiments were reported in Figure 4.3.3, Panels C-E, for instance. 
The proliferation rate of 13 clones was assessed by MTS assay. High variability among 
clones emerged as a stepwise increase in relative proliferation was observed in two wild-type 
(#02 and #04) and 6 knock-out clones (#25, #27, #29, #70, #76 and #91), similarly to the 
parental cell, whereas a steady state was observed after two days in the 3 out of 5 (#01, #03 
and #05) and 2 out of 8 (#22 and #27) remaining wild-type and knock-out clones, 
respectively (Figure 4.3.4, Panel A). 
In parallel, migration assays were performed in order to verify the biological behavior 
observed in previous gene silencing experiments and select cell clones that better reproduce 
the behavior of the parental cells. Heterogeneity among clones was observed also in these 
experiments, as the calculated migration area ranged from roughly 800 to 460,000 pixels per 
unit, irrespective of the experimental group (Figure 4.3.4, Panel B). Consistently with the 
slower proliferation rate, wild-type clones derived from single MDA-MB-231 cells transfected 
with control vector showed significantly weaker migrating potential compared to the parental 
cells, as migrating areas ranged from 7% to 73% of control (p-values 0.0005, 0.2179, 0.0409, 
0.0001 and  <0.0001, two-tailed Student’s t test, respectively for #01, #02, #03, #04 and 
#05). Unexpectedly, knock-out clone #72 showed a 2-fold higher migrating potential 
compared to the parental cells (P = 0.0188, two-tailed Student’s t test), and clone #91 did not 
differ from the wild-type clone #01 (70,000 pixels per unit). However, all of the other 
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knock-out clones confirmed the impairment in cell motility observed in gene silencing 
experiments.  
 
Figure 4.3.3. Results of TFF3 knock-out experiments with the CRISPR/Cas9 system. Composite 
picture (A) acquired by DAPI (blue) and FITC (green) filters (200X total magnification) represents 
MDA-MB-231 cells transfected with a pSpCas9(BB)-2A-GFP control plasmid for 48 hours. Nuclei were 
stained with Hoechst 33342; yellow arrows indicate GFP-expressing cells. Dot plot (B) represents the 
concentration of TFF3 assessed by ELISA test: green, pink, blue and black dots represent cell clones 
with high, medium, under the minimum detectable dose and undetectable TFF3 expression compared 
to non transfected control cells (“ctrl”). Output of BLAST program (C-E) represents the results of 
nucleotide alignment with the reference gene sequence for clones (C) #22, (D) #25 and (E) #70 
(sequencing of 2 different PCR bands).  
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Figure 4.3.4. Proliferation and migration of MDA-MB-231 cell clones after CRISPR/Cas9-
mediated TFF3 knock-out. Proliferation rate (A) of untreated MDA-MB-231 cells, five TFF3WT and 
eight TFF3KO clones, measured by MTS assay. Bar chart represents the mean±SD relative O.D. 
(normalized to O.D. measured 12 hours after seeding) of three experimental replicates, measured at 
different time points. Migration ability (B) assessed by Boyden chamber assay 36 hours after seeding. 
Bar chart represents the mean±SD migration area (pixels per unit) of six experimental replicates. 
 
 
Considering that MDA-MB-231 cells are genetically unstable and that the prolonged 
clone selection protocol and the amplification steps entailed 7 to 9 in vitro passages, all 13 
clones underwent authentication test. Wild-type #04 and #05 clones did not pass quality 
control by STR profiling as they did not match for 1 out of 8 analyzed loci. Therefore, they 
176 
 
were excluded from the following experiments. All knock-out clones passed the 
authentication test. Among knock-out clones, #27, #29 and #76 were excluded as they 
displayed a proliferating rate less similar to those of wild-type clones, in addition to #72 and 
#91, which displayed unusual increased migrating potential. Therefore, #22, #25 and #70 
were chosen for in vivo dissemination and metastasis formation experiments, in comparison 
with the group of selected wild-type clones (#01, #02 and #03). In the matter of question, 
migrating ability was still significantly lower compared to wild-type clones (P <0.05, two-tailed 
Student’s t test), except when comparing wild-type #03 with knock-out #22 and #25 clones 
(P = 0.06, two-tailed Student’s t test).  
Cells were injected according to the same experimental conditions used for 
MDA-MB-231. Differently from the parental cells and despite results obtained by MTS 
proliferation assay, all clones displayed longer latency time before tumor take and a lower 
growth rate after injection in animals. Animals injected with TFF3WT and TFF3KO clones which 
showed comparable growth rate (i.e., #03 and #22, respectively, Figure 4.3.4, Panel A) were 
sacrificed 100 days after tumor cells implant, when they had reached about 1 g of total tumor 
mass. Growth rate of wild-type and knock-out cells in mice was not significantly different. 
CTCs and CTM were quantified by direct analysis on cytological samples and the presence 
of metastases at lung and LNs was assessed by IHC analysis on 20 consecutive sections 
per organ. CTCs were not detectable in the blood of the three animals injected with the 
knock-out clone #22, whereas 9 CTC/mL in 1 out of 3 samples were observed in the blood 
sample of mice injected with the wild-type clone #03 (Figure 4.3.5, Panel B). As expected, in 
consideration of the results obtained in in vitro assays, discordant data on metastasis 
formation were obtained as wild-type clones failed to form metastases in a similar extent 
compared to mice injected with parental cells, and developed instead just single scattered 
metastatic cells or small cell clusters (5-10 cells per cluster). On the contrary, knock-out 
clones, although the extent of metastases was lower than those observed in mice injected 
with the parental cells, showed larger tumor clusters (from 2 to 200 cells per cluster) 
compared to the wild-type clone in all cases. 
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A similar behavior was observed also in LN FFPE sections, which were 
metastasis-positive in knock-out but not in wild-type cases. 
 
  
 
Figure 4.3.5. Tumor growth rate and CTC load of MDA-MB-231 TFF3WT and TFF3KO clones. Line 
graph represents the mean±SD of the sum of the masses of two nodules from three NOD scid mice 
injected with (A) MDA-MB-231 parental cells, the TFF3WT #03 and the TFF3KO #22 MDA-MB-231-
derived clones, and dot plot (B) represents the distribution of CTCs isolated at animal sacrifice. Line 
graph (C) represents the mean±SD of the sum of the masses of two nodules from three NOD scid 
mice injected with a pool of the three TFF3 wild-type (#01, #02 and #03; “PWT”) and the three 
knock-out (#22, #25 and #70; “PKO”) clones. 
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In an attempt to restore the complexity of the MDA-MB-231 cell population, mice were 
injected with a pool of the three wild-type or knock-out clones. In this case, despite a faster 
growth rate in the wild-type compared to the knock-out experimental group, both pools of 
cells were not able to form tumor nodules with a mass higher than 0.5 g after 80 days from 
injection (Figure 4.3.5, Panel C). 
Selection of single cell clones from the MDA-MB-231 cells did not allow drawing 
conclusions on the biological role of TFF3 due to the high heterogeneity and to the 
discordant results in terms of CTC release and pulmonary metastases formation.  
 
 
4.3.4. TFF3 is involved in MDA-MB-231 migration and invasion, but not 
proliferation and vascular mimicry: confirmation experiments after stable 
knock-down 
MDA-MB-231 cell heterogeneity influenced the outcome of in vivo validation studies 
after CRISPR/Cas9-mediated TFF3 knock-out. In order to overcome this problem, an 
experiment was performed to obtain TFF3 stable knock-down cells by lentivirus-mediated 
delivering. At first, infection efficiency was assessed and estimated to be ~95% (Figure 4.3.6, 
Panel A). Two out of the three shRNA vectors caused ~80% stable knock-down of the 
secreted peptide compared to cells infected with lentivirus delivering a control shRNA vector 
(Figure 4.3.6, Panel B).  
Proliferation and migration assays were repeated for confirmation. The proliferation 
rate was comparable in both control and TFF3 knock-down cells, although slight but not 
significantly lower than MDA-MB-231 parental cells (Figure 4.3.5, Panel C). Migrating ability 
was prevalently impaired after stable knock-down (99% and 90% reduction, P = 0.0068 and 
P = 0.0109, two-tailed Student’s t test, in sh_#1 and sh_#2, respectively, compared to control 
cells; Figure 4.3.6, Panel D), thus confirming the results obtained with the two different gene 
silencing and knock-out systems.  
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Figure 4.3.6. Proliferation, migration, invasion and vascular mimicry of MDA-MB-231 cells after 
TFF3 stable knock-down. Composite picture (A) acquired by DAPI (blue) and FITC (green) filters 
(200X total magnification) represents MDA-MB-231 cells infected for 48 hours with lentiviral particles 
delivering pGFP-C-shLenti control vector; nuclei were stained with Hoechst 33342. Bar chart (B) 
represents the relative expression (optical density) of secreted TFF3 measured in media conditioned 
by MDA-MB-231 cells infected with lentiviral particles delivering 4 different shTFF3 vs. cells 
transfected with a control vector. Proliferation rate (C) of untreated MDA-MB-231 cells, and cells 
infected with lentiviral particles delivering two shTFF3 (“sh_#1” and “sh_#2”) or negative control 
(“sh_negctrl”) vectors, measured by MTS assay. Bar chart represents the mean±SD relative O.D. 
(normalized to O.D. measured 12 hours after seeding) of three independent experiments performed in 
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(Figure 4.3.6. continued) triplicate, measured at different time points. Migration (D) and invasion (E) 
ability assessed by Boyden chamber assay. Bar chart represents the mean±SD migration or Matrigel 
invasion area (pixels per unit) of four and five experimental replicates, respectively. Images below the 
chart (40X total magnification, acquired by FITC filter) represent cells migrating across the nude or 
Matrigel-coated Transwell barrier 24 hours after seeding. Vascular-mimicry ability (F) assessed by 
Matrigel-based tube formation assay. Bar chart represents the mean±SD number of loops from three 
experimental replicates. Images below the chart (40X total magnification, acquired by FITC filter) 
represent cells forming vessel-like networks. 
 
 
Invasion assay was also performed to corroborate the role of TFF3 in key steps of the 
metastatic cascade. Beyond migration, TFF3 was proven to be involved also in Matrigel 
invasion ability as the area invaded by TFF3 knock-down cells was significantly smaller 
compared to control (6% and 0.3% of control, P = 0.0014 and P = 0.0010, two-tailed 
Student’s t test, respectively in sh_#1 and sh_#2 cells; Figure 4.3.6, Panel E).  
Finally, TFF3 knock-down failed to impair the ability of tumor cells of non-vascular 
origin like MDA-MB-231 to acquire vascular cell characteristics and form cell-lined channels 
(i.e., vascular mimicry), as the number of loops in knock-down was comparable to those in 
control cells (Figure 4.3.6, Panel F). 
This experimental setting will provide the advantage of performing validation studies on 
a cell population highly representative of the whole parental cell line. To this aim, in vivo 
experiments are running using TFF3 knock-down cells in order to draw conclusions on the 
role of TFF3 in dissemination and metastasis formation in the MDA-MB-231 CTC model. 
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4.4. CTC longitudinal analysis in breast cancer case series: a 
comparison of two methods 
 
4.4.1. Technical and clinical implications of CTC monitoring by AdnaTest 
Longitudinal analysis of CTCs in specific clinical settings may provide information on 
response to therapy in real-time and may allow identification of biomarkers, either intended 
as CTC status or CTC count or CTC-specific molecular markers, to stratify patients at high 
risk of relapse or progression. Since different kinds of messages can be obtained according 
to the method used to interrogate CTCs, in the present study CTC monitoring was carried out 
using either a positive-selection based method, the AdnaTest EMT-1/Stem and EMT-2/Stem 
CellSelect and Detect kits, and a size-based one, the ScreenCell® Cyto kit, followed by 
multiplex RT-PCR and cytological analysis, respectively. The study was performed on 
independent blood samples from two series of patients under neoadjuvant therapy and two 
series of patients under treatment for metastatic disease. Part of the results presented here 
was published in Fina et al., 2015b. 
Preliminary spiking experiments were performed using the luminal MCF7 and basal 
MDA-MB-231 BC cell lines, which express EpCAM and MUC1 on the cell surface at high and 
negligible level, respectively, in order to test the technical and biological sensitivity of 
AdnaTest. The AdnaTest EMT-1/Stem CellSelect kit (hereafter referred to as “EMT1”), which 
consists of immunomagnetic beads for isolation of EpCAM- and MUC1-positive cells, 
detected at least 5 MCF7 cells spiked in 5 mL of blood from a healthy donor, but failed to 
detect MDA-MB-231 cells (Figure 4.4, Panel A). After implementation of the panel of surface 
markers for CTC enrichment with additional antibodies against ERBB2 and EGFR 
(information kindly provided by the manufacturer of AdnaTest EMT-2/Stem CellSelect kit, 
hereafter referred to as “EMT2”), the approach proved to be adequate for the isolation of 
both epithelial- and mesenchymal-like cells, as it allowed also the isolation of at least 5 
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MDA-MB-231 cells, detectable by RT-PCR for the mesenchymal marker cMET, in a further 
EMT2 vs. EMT1 comparison test (Figure 4.4, Panel B). 
Two 5 mL-blood samples withdrawn from a series of 5 female healthy donors were 
analyzed using in parallel both AdnaTest kits, in order to verify the specificity of the method 
and to define a cut-off value for ACTB, in this case ≥0.70 ng/μL, as quality control of the 
entire methodological approach (Table 4.4.1). 
 
 
Figure 4.4.1. Biological sensitivity of AdnaTest EMT1 and EMT2 kits. Gel-like images of capillary 
electrophoresis represent optical view of signal intensities of (A) EPCAM, MUC1 and ERBB2 PCR 
products from MCF7 and MDA-MB-231 cells spiked in the blood of healthy donors and captured by 
the EMT1 kits, and (B) MET PCR product from MDA-MB-231 cell spiked in the blood of healthy donors 
and captured by the EMT1 or the EMT2 kit. 
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CTC monitoring (started in 2012) in two BC cases series including patients undergoing 
neoadjuvant therapy or treatment for metastatic disease, was performed with EMT1 and in 
parallel, once commercially available (in 2014), with EMT2 kits. CTC positivity was assessed 
in 21 blood samples (3 before starting neoadjuvant treatment, 8 during treatment, 8 before 
surgery and 2 after surgery) withdrawn from 13 BC patients clinically diagnosed as 
non-metastatic (M0), and in 9 samples (2 before starting first-line systemic treatment, 4 
during therapy, 2 at progression and 1 before starting second-line systemic therapy) 
withdrawn from 6 women with metastatic disease (M+). 
 
Table 4.4.1. Analysis of blood samples by AdnaTest in healthy donors 
EMT kit 
and donor 
ID 
Breast PCR EMT PCR Stem PCR 
EPCAM MUC1 ERBB2 ACTB PIK3CA AKT2 TWIST1 ACTB ALDH1 
EMT1 d3 0.00 0.00 0.00 1.82 0.00 0.04 0.00 0.90 0.00 
EMT2 d3 0.00 0.00 0.00 2.98 0.03 0.03 0.00 1.58 0.00 
EMT1 d4 0.00 0.00 0.03 3.48 0.06 0.08 0.01 1.58 0.00 
EMT2 d4 0.05 0.00 0.00 3.34 0.09 0.08 0.00 1.61 0.00 
EMT1 d5 0.00 0.00 0.00 1.54 0.01 0.03 0.00 0.71 0.00 
EMT2 d5 0.00 0.00 0.02 2.58 0.00 0.06 0.00 0.81 0.00 
EMT1 d6 0.00 0.00 0.00 3.23 0.13 0.07 0.00 1.33 0.00 
EMT2 d6 0.00 0.00 0.00 3.93 0.18 0.07 0.00 1.45 0.00 
EMT1 d7 0.00 0.00 0.00 1.95 0.00 0.02 0.01 0.88 0.00 
EMT2 d7 0.00 0.00 0.00 1.77 0.00 0.00 0.00 0.77 0.00 
Marker concentrations are expressed as ng/μL 
 
 
As expected on the basis of spiking experiments using cell lines with marked epithelial 
or mesenchymal-like phenotype, EMT2 was able to detect CTCs in a higher number of 
samples compared to EMT1, 14/30 (47%) vs. 4/30 (13%), respectively, when considering the 
overall case series, thus providing further evidence for the existence of different CTC 
subpopulations in the same patient. Consistently, the overall agreement between EMT1 and 
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EMT2 on CTC status was poor (Cohen’s κ = 0.159; 95%CI (-0.159-0.417)). Only 60% of 
samples were concordantly rated for CTC status and the discordant samples were enriched 
in EMT1-/EMT2+ cases (11 EMT1-/EMT2+ versus 1 EMT1+/EMT2-). Similar results were 
observed also after stratification by clinical setting: a 4-fold and a 3-fold increase in CTC 
detection rates were obtained in M0 and M+ cases, respectively, when using EMT2 
compared to EMT1 kit. Therefore, improvement in CTC detection mainly impacts the 
outcome of studies with patients at early stage of disease and to a lesser extent those 
involving metastatic patients. 
Since the improvement in CTC positivity rate does not solely depend on the efficacy of 
the enrichment method, but also relies on the specificity and representativeness of the 
markers used for CTC detection at transcript level, the effect on CTC positivity when using 
different panels of genes was also assessed. CTC positivity was defined including genes 
related to the activation of the epithelial-to-mesenchymal transition process (EMT), as 
TWIST1,  PIK3CA and AKT2, and the stemness-related gene ALDH1A, beside to the 
classical epithelial- and breast tumor-associated markers EPCAM, MUC1 and ERBB2 
(Table 4.4.2). Overall, independently from the kit used for CTC enrichment, CTC detection 
rates increased when including the panel of EMT- and stemness-related genes. Interestingly, 
the expression of epithelial/breast-tumor markers was sufficient to detect CTCs in the 
majority of patients with advanced stage of disease, since only slight changes could be 
observed when the other two panels of genes were included. On the contrary, in M0 cases 
the implementation of the EMT-gene panel determined a switch from a negative to a positive 
CTC status (when CTC enrichment was performed with EMT1) and a 6-fold increase in 
positivity rates (when the enrichment was performed with EMT2), compared to positivity rates 
assigned according to the expression of the classical epithelial/breast tumor markers only. 
Higher increase in CTC positivity was still observed in M0 cases when including also 
ALDH1A, thus obtaining a 2-fold and 1.3-fold increase for EMT1 and EMT2 capture kits, 
respectively, with an overall 8-fold increase compared to CTC status assessed by using 
epithelial/breast-tumor genes only (EMT2 kit).  
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On the basis of these results, heterogeneity in CTC population was hypothesized when 
considering different stages of disease. In order to evaluate which kind of genes could better 
represent the CTC phenotype in the two clinical settings, the contribution to CTC positivity 
was calculated for each of the 6 genes, at baseline and during therapy, considering all the 
cases who entered the study and assessable for CTC status by the EMT1 kit. In M0 cases 
CTC positivity rates were 5/17 (29.4%) and 2/30 (6.7%) at baseline (T0) and during therapy 
(any time point, Tx), respectively, whereas in M+ cases CTC positivity rates were 14/29 
(48.3%) at T0 and 6/24 (25.0%) at Tx. Considering all of the samples, the two markers which 
mainly contributed to CTC positivity were AKT2 and ALDH1A, either in M0 (4/7 CTC-positive 
samples, 57.1%) and M+ cases (9/20, 45.0%), followed by MUC1 and ERBB2 (1/7, 14.3%) in 
M0 cases and by EPCAM and PIK3CA in M+ cases (6/20, 30.0%), which were never 
detected in M0 cases, either processed with the EMT1 or EMT2 kit. Positivity rates for MUC1 
and ERBB2 in M+ cases were 5/20 (25.0%) and 4/20 (20.0%), respectively. TWIST1 was 
never detected in the overall case series, including samples processed with the EMT2 kit.  
 
Table 4.4.2. CTC positivity rates by EMT1 and EMT2 AdnaTest  kits according to the 
expression of different panels of genes 
Clinical 
stage N 
Epithelial/tumor-
associated genes 
Epithelial/tumor-
associated + EMT-
related genes 
Epithelial/tumor-
associated + EMT-
related + stemness-
related genes 
EMT1+ 
(%) 
EMT2+ 
(%) 
EMT1+ 
(%) 
EMT2+ 
(%) 
EMT1+ 
(%) 
EMT2+ 
(%) 
M0 21 0 1 (5) 1 (5) 6 (29) 2 (10) 8 (38) 
M+ 9 1 (11) 5 (56) 2 (22) 6 (67) 2 (22) 6 (67) 
total 30 1 (3) 6 (20) 3 (10) 11 (37) 4 (13) 14 (47) 
 
 
CTC status assessed at baseline was not associated with the clinico-pathological 
features of the two case series (Table 4.4.3), except for HER2 status and subtype in M0 
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cases only, a trend toward a significantly higher CTC positivity rate was observed in 
HER2-positive compared to HER2-negative cases (75% vs. 15.4%, P = 0.0525, two-tailed 
Fisher’s exact test) and also, consistently, in the HER2-positive subtype compared to the 
luminal and TN ones (100% vs 15.4 and 50%, P = 0.0806, χ2 test for trend).  
Regarding the correlation between CTC status and clinical outcome, in the neoadjuvant 
setting, 20 and 19 out of the 22 enrolled cases were assessable for relapse-free survival and 
pCR, respectively. Median(range) follow-up time was 4(1-5) years and relapse events were 6 
(median(range) time to relapse: 2(1-4) years). CTC status at T0 was not able to predict 
relapse-free survival in 16 assessable cases (75% vs. 57% probability for CTC-positive vs. 
CTC-negative cases, respectively, P = 0.5235, log-rank test). According to pathological 
response criteria, 2 out of 19 cases (11%) reached pCR. An association with CTC status, 
showing a marginal trend toward significance (P = 0.0952, two-tailed Fisher’s exact test), 
could be observed in the 15 assessable cases as, 10 out of 13 cases not achieving pCR 
were CTC-negative, although 2/2 cases with pCR were CTC-positive, thus indicating that this 
result is not really informative as the number of cases is low. 
In the metastatic setting, follow-up and RECIST response data were available in 25 out of 32 
enrolled cases (not the same cases for the two clinical outcomes). Median(range) follow-up 
time was 11(2-58) months and progression events were 20 (median(range) time to 
progression: 10(0-39) months). Twenty-three cases were assessable for CTC status by 
EMT1, 18 cases experienced disease progression. CTC status assessed by AdnaTest at 
baseline was not able to discriminate patients at high risk of progression (9% vs. 20% PFS 
probability for CTC-positive vs. CTC-negative cases, respectively, P = 0.8837, log-rank test). 
Twenty-two cases were assessable for CTC status and response to therapy by instrumental 
analysis. According to RECIST response criteria, 1 case had CR and was CTC-negative, 8 
out of 15 cases who had PR were CTC-positive, 1 case with SD was CTC-negative and 3 out 
of 5 cases with PD were CTC-positive. CTC status assessed at T0 was not significantly 
associated with response to therapy assessed by instrumental analysis in 22 assessable 
cases, either when considering CR+PR vs. SD+PD or CR+PR+SD vs. PD groups. 
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Table 4.4.3. Patients’ baseline characteristics and CTC status by AdnaTest EMT1 kit 
variable 
Neoadjuvant setting Metastatic setting 
N (%) 
N 
assessabl
e 
CTC+ 
(%) P N (%) 
N 
assessabl
e 
CTC+ 
(%) P 
All patients 22 17 5 (29.4) - 32 29 14 (48.3) - 
Age (years) 22 17   32 29   
<50 8 (36.4) 6 2 (33.3) 
1.0a 
5 (15.6) 5 4 (80.0) 
.1686a 
≥50 14 (63.6) 11 3 (27.3) 
27 
(84.4) 24 10 (41.7) 
ER and PgR status 22 17   32 29   
Positive for either 17 (77.3) 13 2 (15.4) .0525a 
28 
(87.5) 26 12 (46.2) .5977a 
Negative for both 5 (22.7) 4 3 (75.0) 4 (12.5) 3 2 (66.7) 
HER2/neu status 22 17   32 29   
positive 6 (27.3) 4 3 (75.0) 
.0525a 
5 (15.6) 5 3 (60.0) 
.6513a 
negative 16 (72.3) 13 2 (15.4) 
27 
(84.4) 24 11 (45.8) 
Subtype 22 17   32 29   
Luminal 16 (72.7) 13 2 (15.4) 
.0806b 
25 
(78.1) 23 10 (43.5) 
.2303b HER2+ 4 (18.2) 2 2 (100) 5 (15.6) 5 3 (60.0) 
Triple-negative 2 (9.1) 2 1 (50.0) 2 (6.3) 1 1 (100) 
Histotype 18 14   32 29   
Ductal 15 (83.3) 12 3 (25.0) 
.2259b 
21 
(65.6) 19 11 (57.9) 
.5080b 
Lobular 2 (11.1) 1 1 (100) 8 (25.0) 7 2 (28.6) 
Ductal+Lobular 1 (5.6) 1 0 1 (3.1) 1 0 
Papillary 0 - - 1 (3.1) 1 0 
Inflammatory 0 - - 1 (3.1) 1 1 (100) 
Tumor grade 16 12   27 25   
G1 0 - - 
.2206a 
1 (3.7) 1 0 
.8874b G2 8 (50.0) 6 1 (16.7) 
14 
(51.9) 13 7 (53.8) 
G3 8 (50.0) 6 3 (50.0) 12 (44.4) 11 5 (45.5) 
Ki67 (%) 19 14   20 17   
<10% 1 (5.3) 1 1 (100) 
.1638a 
5 (25.0) 5 3 (60.0) 
.2801a 
≥10% 18 (94.7) 13 4 (30.8) 
15 
(75.0) 12 3 (25.0) 
a two tailed Fisher’s exact test 
b χ2 test for trend 
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CTC status assessed at T0 was neither able to predict progression in the overall case 
series (i.e., including M0 and M+ cases), as PFS probabilities were 9% and 16% respectively 
for CTC-positive and CTC-negative cases (P = 0.6412, log-rank test).  
CTC status during therapy was assessable for about 50% cases in both cohorts. Low 
numbers do not allow drawing conclusion from longitudinal analysis. 
AdnaTest seems to be a valuable method to isolate and detect CTCs. Nevertheless, 
correlation analyses in these two observational studies revealed that the approach does not 
provide clinically relevant information.  
 
4.4.2. Technical and clinical implications of CTC monitoring by ScreenCell 
CTC monitoring with ScreenCell® Cyto kit was carried out on two BC case series, 
which were distinct from those analyzed by AdnaTest. The study started in 2014 and 
involved 37 patients under neoadjuvant therapy and 24 patients starting a first-line systemic 
therapy (1 out of 24 starting second-line therapy) for metastatic disease. CTC analysis was 
performed on 9 mL of blood collected at baseline (T0) and after about 3 months of systemic 
therapy (T1). Blood was also collected from 4 healthy donors who were all negative for the 
presence of atypical or suspicious cells. 
Differently from the outcome of AdnaTest CTC studies, the size-based isolation 
approach allowed direct visualization of CTC subpopulation, i.e. single CTCs and CTC 
clusters, hereafter referred to as circulating tumor microemboli (CTM). In a preliminary study 
on 14 M0 and 18 M+ BC patients, CTCs were detectable at higher rate compared to 
AdnaTest, as 72% positivity rate at T0 and 95% at T1 were obtained in the overall case 
series. Surprisingly, no significant differences were observed in terms of CTC detection 
frequency when categorizing patients by clinical stage or grouping samples according to the 
treatment time point (Table 4.4.4), and similarly median CTC counts did not differ between 
M0 and M+ patients (8.5 vs. 9 at T0, 15 vs. 10 at T1, and 11 vs. 9 overall). However, overall 
CTM positivity rate was significantly higher in patients with early stage disease compared to 
metastatic women, and the difference remained significant even when considering samples 
189 
 
collected at T0 (79% vs. 28%, P = 0.0113, two-tailed Fisher’s exact test) or at T1 
(77% vs. 25%, P = 0.017, Fisher’s exact test), data consistent with the higher CTM load 
(3 vs. 0, P = 0.0056 at baseline; 2 vs. 0, P = 0.0278 during treatment; and 2 vs. 0, P = 0.001 
overall; two-tailed Mann-Whitney’s U test). This data was confirmed on the overall case 
series including all patients enrolled from June 2014 to July 2016: at baseline CTM positivity 
rates were 25/37 (68%) vs. 6/24 (25%) cases (P = 0.0028, two-tailed χ2 test with Yates’ 
correction), and median(range) values were 2(0-20) and 0 (0-20) (P = 0.0078, two-tailed 
Mann-Whitney’s U test), in M0 and M+ cases, respectively.  
 
Table 4.4.4. CTC and CTM positivity rate by ScreenCell 
Clinical 
stage 
At baseline (T0) During therapy (T1) At any time 
N CTC (%) 
CTM 
(%) N 
CTC 
(%) 
CTM 
(%) N 
CTC 
(%) 
CTM 
(%) 
M0 14 11 (78) 11 (79) 13 12 (92) 10 (77) 27 23 (85) 21 (78) 
M+ 18 13 (72) 5 (28) 12 11 (92) 3 (25) 30 24 (80) 8 (27) 
overall 32 24 (75) 16 (50) 25 23 (92) 13 (52) 57 47 (82) 29 (62) 
 
 
In the neoadjuvant setting CTC status, either assessed as detection frequency using a 
positivity cut-off ≥3 CTC/9 mL, or as mean or median value, did not differ when correlated 
with the clinico-pathological characteristics of the case series (Table 4.4.5). The same trend 
was also observed for CTM, which were analyzed using a positivity cut-off ≥3 CTC/9 mL 
(Table 4.4.6), although they showed significant association with some clinico-pathological 
categories. Actually, CTM were significantly more frequent in the blood of patients having T1 
or T2 compared to those with T3 or T4 tumor stage (65% vs. 24%, P = 0.0202, two-tailed 
Fisher’s exact test), as well as in patients with HER2-negative compared to HER2-positive 
tumor (58% vs. 18%, respectively, P = 0.0365, two-tailed Fisher’s exact test). Moreover, the 
190 
 
proportion of CTM when considering the overall CTC population (i.e., CTC+CTM) was higher 
in M0 compared to M+ cases (38% vs. 11%). 
 
Table 4.4.5. CTC status at baseline by ScreenCell according to patients’ characteristics 
in the neoadjuvant setting 
variable N (%) CTC+ (%)* Pa Mean±SD CTC/9 mL 
Median 
(range) 
CTC/9 mL 
Pb 
All patients 37 25 (68) - 6.65±8.19 3 (0-24) - 
Age (years) 
≤50 17 (46) 10 (59) 
.4821 
4.53±5.2 3 (0-17) 
.1389 
>50 20 (54) 15 (75) 8.5±8.8 6.5 (0-35) 
Tumor size 
T1/T2 20(54) 12 (60) .3193 
6.35±6.52 3 (0-24) 
.9124 
T3/T4 17(46) 13 (76.5) 7.0±8.82 5 (0-35) 
Lymph-nodal status 
N0 9 (24) 8 (89) .2204 
10.89±11.50 7 (0-35) 
.1416 
N1/N2 28 (76) 17 (61) 5.28±5.38 3 (0-17) 
Histotype 
Ductal 22 (59) 13 (59) 
.2863 
7.04±8.88 3 (0-35) 
.7490 
others 15 (41) 12 (80) 6.54±5.53 5 (0-17) 
Tumor grade 
G1/G2 11 (30) 8 (73) 
.7026 
6.73±9.72 5 (0-35) 
1 
G3 21 (57) 13 (62) 6.33±6.76 3 (0-24) 
missing 5 (13) 4 (80) - 5.5±5.29 5 (0-24) - 
ER and PgR status 
Positive for either 18 (49) 11 (61) 
.4951 
6.22±8.61 3 (0-35) 
.3681 
Negative for both 19 (51) 14 (74) 7.06±6.61 5 (0-24) 
HER2 status 
positive 11 (30) 7 (64) 
1 
5.00±6.92 3 (0-17) 
.4473 
negative 26 (70) 18 (69) 7.35±8.22 5 (0-35) 
* cut-off 3 CTCs/9 mL 
a two-tailed Fisher’s exact test 
b two-tailed Mann-Withney’s U test 
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Table 4.4.6. CTM status at baseline by ScreenCell according to patients’ 
characteristics in the neoadjuvant setting 
variable N (%) CTM+ (%) P Mean±SD CTM/9 mL 
Median 
(range) 
CTM/9 mL 
Pc 
All patients 37 17 (46) - 3.70±4.69 2 (0-20) - 
Age (years) 
≤50 17 (46) 8 (47) 
.9003a 
3.12±3.20 2 (0-10) 
.9124 
>50 20 (54) 9 (45) 4.20±5.70 1.5 (0-20) 
Tumor size 
T1/T2 20 (54) 13 (65) 
.0202b 
4.35±4.63 4 (0-20) 
.1645 
T3/T4 17(46) 4 (24) 2.94±4.79 1 (0-15) 
Lymph-nodal status 
N0 9 (24) 2 (22) 
.1371b 
2.33±4.47 0 (0-12) 
.9681 
N1/N2 28 (76) 15 (54) 4.14±4.75 3 (0-20) 
Histotype 
Ductal 22 (59) 9 (41) 
.6828a 
3.55±5.11 1 (0-20) 
.4839 
others 15 (41) 8 (53) 3.93±4.15 3 (0-15) 
Tumor grade 
G1/G2 11 (30) 5 (45) 
1b 
4.0±5.42 1 (0-15) 
1 
G3 21 (57) 9 (43) 3.40±4.66 1 (0-20) 
missing 5 (13) 3 (60) - 4.40±3.78 5 (0-10) - 
ER and PgR status 
Positive for either 18 (49) 10 (56) 
.4170a 
4.72±5.77 3 (0-20) 
.4009 
Negative for both 19 (51) 7 (37) 2.74±3.25 1 (0-10) 
HER2 status 
positive 11 (30) 2 (18) 
.0365b 
1.45±2.61 0 (0-8) 
.0324 
negative 26 (70) 15 (58) 4.70±5.10 3.5 (0-20) 
* cut-off 3 CTCs/9 mL 
a two tailed χ2 test with Yates’ correction 
b two-tailed Fisher’s exact test 
c two-tailed Mann-Withney’s U test 
 
 
Correlation analysis between CTC or CTM status and the response to therapy 
assessed by histological analysis were performed. Eight out of 36 assessable cases reached 
pathologic complete response (pCR). A trend toward CTC and CTM increase, either in terms 
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of detection frequency or number, was observed when categorizing patients according to the 
extent of residual tumor after neoadjuvant therapy (Table 4.4.7). At T0 CTC positivity rates 
were 50%, 69% and 80%, respectively in cases classified as complete responders (CR), 
partial responders (PR) or with stable disease (SD), whereas values at T1 showed only slight 
differences among the three categories (around 90% when considering the overall case 
series). In a similar manner, CTM frequency at T0 increased from ~40% in cases with CR or 
PR to 60% in cases with SD, whereas no differences were observed during therapy. When 
grouping patients with PR or SD in a unique category (non-responders), at baseline higher 
CTC detection rate was observed in non-responders compared to patients with pCR 
(71% vs. 50%, n.s.), whereas opposite trend was obtained at T1. On the contrary, CTM 
frequencies were comparable at T0 in responders and non-responders (46% vs. 54%, 
respectively) but, similarly to CTCs, at T1 CTM were more frequently detected in 
non-responders (65% vs. 35%, respectively, n.s.). At T1 all categories showed an increase in 
CTC load compared to baseline levels. In particular, statistically significant increase in 
median CTCs was reached in CR (4.7-fold, P = 0.044, two-tailed Mann-Whitney’s U test) and 
PR (2.3-fold, P = 0.035, two-tailed Mann-Whitney’s U test) groups.  
In the M+ setting statistical analyses were focused on the correlation between the CTC 
(Table 4.4.8) or CTM (Table 4.4.9) status, assessed at T0 and T1, and the therapy response 
evaluated by imaging after about 3 months from the start of treatment. Data were available 
for 21 out of 24 cases at T0 and 18 out of 19 matched samples collected at T1. None patient 
reached CR, 11 showed PR and 10 were classified as non-responders, 7/10 classified as SD 
and 3/10 experiencing progression (PD). Overall, CTC and CTM status assessed at T0 and 
T1, either in terms of detection frequency or number, was not informative on therapy 
response evaluated by instrumental analysis. 
Representative images of CTCs and CTM from BC patients are reported in Figure 
4.4.2. 
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Table 4.4.7. CTC and CTM status at baseline and during therapy in M0 cases according to pathologic response 
 At baseline During therapy 
pathologic 
response N 
CTC+ 
(%) 
CTC 
mean±SD 
median 
(range) 
CTM+ 
(%) 
CTM 
mean±SD 
median 
(range) 
N CTC+ (%) 
CTC 
mean±SD 
median 
(range) 
CTM+ (%) 
CTM 
mean±SD 
median 
(range) 
CR 8 4 (50) 4.56±5.13 3 (0-13) 
3 
(37.5) 
2.78±2.99 
3 (0-8) 7 7 (100) 
24.57±33.61 
14 (1-97) 3 (43) 
14.71±36.31 
0 (0-97) 
PR 23 16 (69) 
5.78±6.14 
3 (0-24) 
10 
(43) 
3.87±5.33 
1 (0-20) 19 17 (89) 
17.79±24.40 
7 (0-87) 6 (32) 
5.0±10.21 
1 (0-44) 
SD 5 4 (80) 
 
14.4±12.82 
12 (0-35) 
 
3 (60) 
 
4.6±4.56 
4 (0-12) 5 
 
4 (80) 
 
15.80±14.15 
18 (0-35) 
 
2 (40) 
 
1.6±2.30 
0 (0-5) 
       
cut-off  ≥3 CTCs/9 mL 
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Table 4.4.8.  CTC status at baseline and during therapy in M+ cases according to instrumental response 
timing N 
overall 
Response to therapy by imaging 
Partial response Stable disease Progressive disease 
CTC+ 
(%) 
CTC 
mean±SD 
CTC+ 
(%) 
CTC  
mean±SD 
CTC+ 
(%) 
CTC  
mean±SD 
CTC+ 
(%) 
CTC  
mean±SD 
T0 24 17/24 (71) 11.26±12.47 8/11 (73) 13.37±14.38 6/7 (86) 5.86±3.08 2/3 (67) 17.67±11.93 
T1 19 12/19 (63) 6.57±5.28 5/10 (50) 6.7±5.87 5/5 (100) 5.2±1.30 2/3 (67) 8.67±9.02 
cut-off ≥5 CTCs/9 mL 
Table 4.4.9. CTM status at baseline and during therapy in M+ cases according to instrumental response 
timing N 
overall 
Response to therapy by imaging 
Partial response Stable disease Progressive disease 
CTM+ 
(%) 
CTM 
mean±SD 
CTM+ 
(%) 
CTM 
mean±SD 
CTM+ 
(%) 
CTM 
mean±SD 
CTM+ 
(%) 
CTM 
mean±SD 
T0 24 6/24 (25) 2.17±5.31 3/11 (27) 3.27±7.13 2/7 (29) 1.71±4.11 1/3 (33) 0.67±1.15 
T1 19 7/19 (37) 2.16±5.63 6/10 (60) 4.0±7.44 0/15 (0) 0 1/3 (33) 0.33±0.58 
cut-off ≥1 CTM/9 mL 
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Figure 4.4.2. Single CTCs and CTM in M0 and M+ breast cancer patients. Images (400X total 
magnification, hematoxylin and eosin staining) depict a single CTC in a cytological blood sample from 
patients (A) under neoadjuvant therapy for M0 BC or (B) with M+ BC before starting first-line therapy, 
and a CTM mixed with platelets in a cytological blood sample from patients with (C) M0 or (D) M+ BC 
before starting therapy. 
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4.5. Clinical significance of CTC/metastasis-specific genes in breast 
cancer  
 
4.5.1. Selection criteria of genes from experimental metastatic models for 
CTC-clinical studies 
Metastatic experimental models may represent a powerful source of information to 
better understand the biology of the metastatic process and to find new metastasis-related 
and prognostic/predictive biomarkers. Genes identified in experimental models as 
CTC-specific, in particular, deserve gene expression analysis not only in PT but also in CTC 
samples of neoplastic patients, in addition to the conventional evaluation of the CTC status 
(i.e., based on the expression of epithelial/tumor-associated genes in CTC-enriched blood 
samples) or as an alternative to the direct CTC count. To this aim, the association between 
such genes identified in the MDA-MB-231 CTC-model and the clinico-pathological features of 
BC case series were investigated. 
Twelve out of 192 genes up-regulated in CTCs compared to solid lesions in GEP1 and 
GEP2 were selected for clinical studies, according to their biological role, with special 
reference to the metastatic process, as reported in literature (Table 4.5.1). Moreover, some 
of the genes up-regulated in CTC vs. PT in GEP1 experiment and selected for functional 
validation studies were also included (Table 4.5.1). Down-regulated genes were excluded 
from the panel of candidate genes for clinical studies since they were supposed to be less 
frequently detectable and less informative compared to CTC-specific up-regulated genes.  
Further genes known to be involved in lung colonization, stemness and resistance to 
therapy, and in some cases also proved to have clinical significance in BCs, were added to 
the panel of candidate genes for CTC monitoring studies, in an attempt to investigate 
whether they can provide clinically useful information also when detected in the ‘liquid biopsy’ 
(Table 4.5.1).  
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Finally, agreement or discrepancy in ER expression between the PT and CTCs were 
also assessed. 
 
Table 4.5.1. Panel of 22 genes for clinical studies 
 
 
CTC-specific 
 
Up-regulated  
in CTC vs. PT  
 
 
Metastasis and/or 
stemness-related 
 
Classical predictive 
marker 
 
    
ADPRHL1 ELF3 OPN (SPP1) ESR1 
CRIP1 TFF1 PTPN11  
FCF1 TFF2 SOX2  
FIS1 TFF3 SPARC  
GAS2L1  YAP1  
GIGYF1    
HDAC10    
KLC2    
NR4A1    
STRN4    
TAF6    
TPPP 
   
 
 
  
4.5.2. CTC/metastasis-specific genes from experimental models are detectable 
in CTCs from clinical samples  
Data from a GEP experiment with the DASL assay were preliminarily analyzed in order 
to explore the detection rate of the 22 selected genes in blood samples from 13 M+ patients 
(GEP of 7/13 cases reported in Fina et al., 2015), collected before starting primary systemic 
therapy, and from 2 female healthy donors, processed with the EMT1 kit.  
Overall, the majority of the 21/22 genes assessable by the DASL assay (TFF2 was not 
detectable) was detectable in patients at higher frequency compared to healthy donors 
(mean detection rate 52% vs. 31%, respectively) and, if considering genes detected in both 
groups, their signal intensities were overall higher in patients compared to healthy donors 
(Figure 4.5.1).  
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Gene expression analysis was then performed on residual cDNA samples using a 
low-density array. Samples which did not pass the quality control criteria were excluded and 
 
Figure 4.5.1. Detection rate of CTC/metastasis-specific genes in CTCs from BC patients. Heat 
map (A) represents the signal intensity (Row Z-score) and the detection status (detected if detection 
p-value <0.01) for the 22-gene panel and two control genes (GAPDH and PTPRC) in a positive control 
sample (UHR) and blood samples from 13 BC patients and 2 healthy donors processed with the EMT1 
AdnaTest kit and profiled by the WG HT DASL assay. Bar chart (B) represents the detection rate 
(percentage) of each gene on a low-density array in blood samples of 49 BC patients processed with 
the EMT1 AdnaTest kit before starting therapy. 
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positivity for each of the 22 genes was assigned according to the threshold values previously 
set on a case series of 6 female healthy donors (Figure 4.5.2). The lowest mean equivalent 
Cq value for each gene was adopted as positivity cut-off in the analysis of patients’ samples. 
 
Figure 4.5.2. Expression level of CTC/metastasis-specific genes in healthy donors. Dot 
plot represents the mean equivalent Cq of 22 CTC/metastasis-specific genes and the two control 
genes GAPDH and PTPRC in a series of blood samples from 6 female healthy donors processed by 
EMT2 AdnaTest kit. 
 
 
Comparative analysis (Figure 4.5.3) was performed on 11 pairs of CTC samples 
processed in parallel with EMT1 and EMT2 kits, (5 belonging to the M0 setting and 6 to the 
M+ setting, 6 out of 11 collected at baseline). Detection rate was also evaluated on 49 cases 
(20 of the M0 and 29 of the M+ setting), analyzed for CTC status by EMT1 kit before starting 
primary systemic therapy (T0). Molecular profile analysis of CTCs collected after the first 
cycle of therapy (T1) was performed on 30 cases. TFF2 was never detected. Concordance in 
detection frequencies between samples processed by EMT1 and matched samples 
processed by EMT2 was poor in the majority of cases, except for TFF3 and TFF1 (Cohen’s 
ĸ = 0.744, 95%CI (0.3-1.0)), FCF1 and SPARC (Cohen’s ĸ = 0.633, 95%CI (0.2-1.0)), all 
showing good agreement, and NR4A1 (Cohen’s ĸ = 0.421, 95%CI (-0.034-0.877)), showing a 
moderate agreement. The majority of detected genes was more frequently expressed in 
samples processed by the EMT2 kit, whereas EMT1 outperformed EMT2 only for ADPRHL1 
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gene. SPARC, TPPP, TAF6, STRN4, HDAC10 and FCF1 showed the same positivity rate 
both in EMT1 and EMT2 samples. 
Genes with the highest detection rate in the whole case series of CTCs collected at T0 
and processed by EMT1 were ELF3 (21/49, 43%), STRN4 (20/49, 41%), HDAC10 (19/49, 
39%) and TFF3 (18/49, 37%).  
 
Figure 4.5.3. Detection rate of CTC/metastasis-specific genes in matched CTC samples isolated 
by AdnaTest EMT1 and EMT2 kits. Bar chart reports the percentage frequency of detection of each 
of the 22 genes in matched blood samples processed by AdnaTest EMT1 and EMT2 kits and isolated 
from 11 BC patients at different time points. 
 
 
Interestingly, concordance between CTC positivity assessed by AdnaTest (AT) and the 
22-gene panel (GP) was poor (Cohen’s ĸ = 0.117, 95%CI (-0.046-0.280)), as 21 out of 26 
AT-negative samples were rated as CTC-positive according to the detection thresholds of the 
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GP (Table 4.5.2). Overall, GP outperformed AdnaTest as roughly 2-fold higher CTC positivity 
rate was obtained if compared with CTC status assessment by using EPCAM, MUC1, 
ERBB2, PIK3CA, TWIST1 and ALDH1 only (86% vs. 41% for GP and AT, respectively).  
 
Table 4.5.2. Concordance between AdnaTest and the 22-gene panel 
N AT+/GP+ (%) AT-/GP- (%) AT+/GP- (%) AT-/GP+ (%) 
44 17 (38.6) 5 (11.4) 1 (2.3) 21 (47.7) 
 
 
 
4.5.3. CTC/metastasis-specific genes detected in CTCs predict disease 
progression  
The expression rate of the 21 detectable genes was evaluated as a function of clinical 
setting (20 M0 vs. 29 M+ cases) and BC subtype (38 luminal vs. 8 HER2-positive vs. 3 TN). 
The positivity frequency for each gene was calculated on the number of positive samples. In 
this case CTC positivity was re-assigned considering positive those samples with at least 
one positive AT or GP marker. On the basis of these criteria, overall positive cases at T0 
were 15/20 M0 and 25/29 M+, while positive cases according to the subtype were 32/38 
luminal, 5/8 HER2-positive and 3/3 TN. As reported in Figure 4.5.4, some differences in 
detection rates according to the clinical setting could be observed, as 11 genes were more 
frequently detected in M0 cases and the remaining were more frequently detected in M+ 
cases. In particular, the most marked differences between M0 and M+ were observed for 
TFF1 (0 vs. 39%, P = 0.0063, two-tailed Fisher’s exact test) and TFF3 (13% vs. 64%, 
P = 0.0028, two-tailed Fisher’s exact test).  
No statistically significant differences could be identified among BC subtypes, except 
for GIGYF1 (P = 0.0097, χ2 test for trend), which was detectable in 3% only of luminal cases 
and in 38% and 33% of HER2-positive and TN cases, respectively. 
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Figure 4.5.4. Positivity frequency of the 22-gene panel according to the clinical setting and BC 
subtypes. Bar chart reports the detection rate of each CTC/metastasis-specific gene expressed as  
percentage of the number of cases with positive gene status on the number of cases positive for at 
least one of the markers assessed by AdnaTest or the 22-gene panel, according to the (A) clinical 
setting and (B) the BC subtype. 
 
 
The expression status of each gene was correlated with progression-free survival 
probability. Follow-up data were available in 41 out of 49 cases, with 25 unfavorable events. 
As reported in Table 4.5.3, the analysis revealed that the status (negative or positive) of 
TFF3, TFF1, YAP1 and SOX2 genes was able to significantly discriminate between cases at 
higher risk of relapse or progression. ELF3 was proven to be informative since cases with 
ELF3 positive status had 2.1 higher risk to undergo disease progression (20% PFS 
probability compared to 46% in ELF3 negative cases), and there was a trend in favor of a 
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statistical significance (P = 0.0650, Cox proportional-hazards regression model). 
Kaplan-Meier plot for TFF3, TFF1, ELF3, SOX2 and YAP1 are represented in Figure 4.5.5.  
The clinical significance of the expression level of such genes in primary BCs was 
evaluated in publicly available datasets of untreated and node negative BC patients in 
correlation with distant metastases-free survival. Interestingly, ELF3, when expressed at high 
level, and TFF1 and YAP1, when expressed at low level, predicted poor clinical outcome, 
whereas the expression levels of TFF3 and SOX2 were not informative when assessed at 
the PT level (Figure 4.5.6; statistical significance was assessed by log-rank test). 
Bivariate analysis was carried out in order to evaluate whether each CTC-specific 
clinically informative gene maintained its predictive role even in the presence of information 
provided by the other covariates (including stage of disease, CTC status assessed by 
AdnaTest, and the expression of the other investigated genes), using “M0”, “negative CTC 
status” and “negative gene status” as reference categories (Tables 4.5.4-8; statistical 
significance was assessed by Cox proportional-hazards regression model). The outcome of 
such an analysis, although providing interesting hints, should be considered with caution, 
due to the limited number of cases within subsets.  
The prognostic significance was maintained independently from AdnaTest outcome for 
all of the investigated genes, with minimal variations of the unadjusted hazard ratio (HR) 
observed in the univariate analysis (Table 4.5.3), except for ELF3, which showed only a 
trend toward significance. However, all genes failed to predict progression-free survival 
(PFS) when adjusted for the clinical setting; only TFF1 expression was suggestive, although 
not significantly, of disease progression. 
The bivariate analysis carried out to investigate whether each of the 5 genes 
maintained its prognostic relevance even in the presence of information provided by the 
other genes showed that ELF3 and SOX2 failed to independently predict disease 
progression. YAP1 maintained an independent predictive role in the presence of information 
provided by ELF3. Conversely, TFF1 and TFF3 were significantly predictive of 
progression-free survival when adjusted for the other investigated genes, but a significant 
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interaction (P = 0.026, Cox proportional-hazards regression model) was present between 
them and affected their predictive ability. In fact, TFF3 failed to significantly influence PFS 
probability in the presence of TFF1, which conversely maintained its prognostic role only 
within tumors with TFF3-negative CTCs.  
Clustering analysis according to the normalized expression of the 22-gene panel in 
blood samples collected before starting and during therapy, allowed identifying some clusters 
of genes which showed high expression in different groups of patients (Figure 4.5.7). At T0 
(Figure 4.5.7, Panel A), gene cluster “G1” included 9 genes (HDAC10, FIS1, STRN4, CRIP1, 
TAF6, KLC2, FCF1, GIGYF1 and PTPN11) which showed high expression in 5 cases, 3 M0 
(1 lost at follow-up and 2 without evidence of disease) and 2 M+ patients who experienced 
progression. Interestingly, gene cluster “G2” included 5 genes (NR4A1, ELF3, SPARC, 
GAS2L1 and TFF3) which showed high expression in a group of 6 relapsed patients, 5 M+ 
and 1 M0. Finally, gene cluster “G3” included the remaining 7 genes (ADPRHL1, SPP1, 
ESR1, TFF1, SOX2, YAP1 and TPPP) which were highly expressed in 13 patients, 7 
relapsed out of 8 M+ and 3 relapsed out of 5 M0 (follow-up data were available for 10 cases 
only). At T1, one cluster including 10 genes (GIGYF1, ADPRHL1, ELF3, TFF3, TFF1, SPP1, 
ESR1, TPPP, YAP1 and SOX2) was clearly identifiable; such genes were highly expressed 
in 6 M+ (5 relapsed) and 6 M0 (3 relapsed, 1 lost at follow-up) patients (Figure 4.5.7, 
Panel B). 
 
 
4.5.4. CTCs detected in ER-positive BCs are prevalently ER-negative  
Concordance in ER status between CTC and PT was assessable in 40 cases. High 
discrepancy was observed (29/40 cases, 72.5%) as only 4 cases had concordant ER positive 
status at PT and CTC level, whereas 7 cases showed negative ER status for both tumor 
sites. All of the other patients had ER-positive BCs but did not express ESR1 at CTC level. 
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Figure 4.5.5. Progression-free survival probability according to the status of CTC/metastasis-
specific genes detected in CTCs from BC patients. Survival analysis by Cox regression model and 
Kaplan-Meier plots of progression-free survival according to the status (negative or positive) of 
(A) TFF3, (B) TFF1, (C) ELF3, (D) SOX2 and (E) YAP1 CTC/metastasis-specific genes, assessed in 
CTC samples of 41 BC cases before starting therapy. 
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Figure 4.5.6. Distant metastasis-free survival probability according to the expression data of 
CTC/metastasis-specific genes in primary BCs. Kaplan-Meier plots of distant metastasis-free 
survival probability according to the expression level of (A) TFF3, (B) TFF1, (C) ELF3, (D) SOX2 and 
(E) YAP1 CTC/metastasis-specific genes, assessed in publicly available datasets from untreated and 
LN negative primary BCs.  
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Table 4.5.3. Progression-free survival probability according to the positivity by 
AdnaTest and by the 22-gene panel  
 
Genes 
 
Negative 
 
 
Positive 
 
   
N 
 
PFS 
probability 
(%) 
 
N 
 
PFS 
probability 
(%) 
 
HR 95% CI P** 
        
CTC status 
by AdnaTest 
20 42 16 25 1.0 0.6-1.6 .8608 
        
ADPRHL1 30 34 6 33 1.6 0.5-4.6 .4054 
CRIP1 30 31 6 50 0.6 0.2-2.1 .4724 
ELF3 19 46 17 20 2.1 1.0-4.7 .0650 
FCF1 27 35 9 33 1.3 0.6-3.0 .4701 
FIS1 32 39 9 33 1.1 0.4-2.7 .9256 
GAS2L1 33 34 3 33 1.2 0.3-5.2 .7814 
GIGYF1 31 30 5 60 0.5 0.1-2.0 .3144 
HDAC10 22 33 14 36 1.0 0.4-2.2 .9405 
KLC2 32 38 9 33 1.1 0.5-2.8 .7948 
NR4A1 30 38 6 17 1.6 0.6-4.4 .3234 
STRN4 21 34 15 33 1.3 0.6-2.9 .5240 
TAF6 28 37 13 38 1.0 0.4-2.1 .8206 
TFF1 27 46 9 0 4.5 1.9-10.6 .0007 
TFF3 24 47 12 8 3.6 1.6-8.2 .0022 
TPPP* 35 35 1 0 - - - 
ESR1 33 34 3 33 1.5 0.3-6.4 .5880 
PTPN11 32 32 4 50 0.7 0.2-2.8 .5729 
SOX2 32 39 4 0 3.4 1.1-10.2 .0310 
SPARC 25 37 11 27 1.3 0.6-3.1 .5024 
SPP1* 34 30 2 100 - - - 
YAP1 33 38 3 0 5.6 1.5-21.0 .0100 
* Genes with ≤2 CTC+ cases were not analyzed 
** Cox proportional-hazards regression model 
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Table 4.5.4. Bivariate analysis of 4-year progression-free survival as a function of 
ELF3 status (N = 41) 
variable HR 95% CI P HR for ELF3 status 95% CI P 
Clinical setting 4.3 1.7-11.8 .0029 1.3 0.6-3.0 .5099 
CTC status by 
AdnaTest 0.9 0.5-1.7 .7462 2.1 1.0-4.8 .0626 
TFF1 status 3.8 1.4-10.3 .0078 1.3 0.5-3.3 .5492 
TFF3 status 3.3 1.2-9.3 .0241 1.1 0.4-3.1 .7895 
SOX2 status 2.7 0.9-8.4 .0861 1.9 0.8-4.2 .1349 
YAP1 status 4.1 1.0-16.1 .0475 1.8 0.8-4.1 .1820 
Table 4.5.5.  Bivariate analysis of 4-year progression-free survival as a function of 
TFF1 status (N = 41) 
variable HR 95% CI P HR for TFF1 status 95% CI P 
Clinical setting 3.7 1.3-10.2 .0129 2.3 0.9-5.9 .0745 
CTC status by 
AdnaTest 1.0 0.5-1.7 .8881 4.5 1.9-10.6 .0007 
TFF3 status* 1.9 0.5-7.7 .3934 2.6 0.6-11.4 .2043 
SOX2 status 1.9 0.6-6.3 .2881 3.9 1.6-9.9 .0040 
YAP1 status 2.1 0.5-8.8 .3221 3.8 1.4-1.0 .0072 
*interaction 
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Table 4.5.6.  Bivariate analysis of 4-year progression-free survival as a function of 
TFF3 status (N = 41) 
variable HR 95% CI P HR for TFF3 status 95% CI P 
Clinical setting 3.7 1.3-10.5 .0133 1.9 0.8-4.6 .1707 
CTC status by 
AdnaTest 0.9 0.5-1.7 .8492 3.6 1.6-8.2 .0022 
SOX2 status 2.5 0.8-7.7 .1206 3.3 1.4-7.7 .0059 
YAP1 status 2.7 0.7-10.8 .1657 3.1 1.3-7.5 .0131 
Table 4.5.7.  Bivariate analysis of 4-year progression-free survival as a function of 
SOX2 status (N = 41) 
variable HR 95% CI P HR for SOX2 status 95% CI P 
Clinical setting 4.5 1.7-11.7 .0023 1.8 0.6-5.7 .2920 
CTC status by 
AdnaTest 1.0 0.5-1.7 .8491 3.4 1.1-10.2 .0313 
YAP1 status 4.0 1.0-16.7 .0589 2.4 0.7-8.2 .1564 
Table 4.5.8.  Bivariate analysis of 4-year progression-free survival as a function of 
YAP1 status (N = 41) 
variable HR 95% CI P HR for YAP1 status 95% CI P 
Clinical setting 4.5 1.7-11.7 .0021 3.3 0.9-12.5 .0762 
CTC status by 
AdnaTest 0.9 0.5-1.6 .6608 5.9 1.6-22.2 .0092 
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Figure 4.5.7. Clustering analysis of CTC samples at baseline and during therapy according to 
the expression of 22 genes. Heat maps represent the result of clustering analysis in (A) 49 CTC 
samples collected at baseline and (B) 32 CTC samples collected during treatment, according to the 
normalized expression of 22 genes.  
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5. DISCUSSION 
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Tumor cell dissemination is definitely a hallmark of cancer, but dynamics and molecular 
mechanisms required for the successful completion of the metastatic process are not fully 
understood, and at present metastasis onset represents the main cause of BC-related 
deaths. In an attempt to contribute to the understanding of the metastatic dissemination, this 
dissertation work explored the hypothesis that by comparing the molecular profile of CTCs 
with those of the solid lesions in BC experimental models new metastasis-associated and 
clinically useful biomarkers can be identified.  
Preliminary studies were therefore designed to model BC metastases to provide 
information for the first time on the hematogenous dissemination potential of four BC cell 
lines belonging to different molecular subtypes. Consistently with the growth rate of the PTs, 
mouse xenograft models generated using the HER2-positive BT-474 and MDA-MB-453 and 
the basal A MDA-MB-468 cell lines showed lower CTC load compared to CTCs generated by 
the highly proliferating and metastatic MDA-MB-231 cell line, belonging to the more 
aggressive basal B molecular subtype. Importantly, similarly to what obtained with the 
MDA-MB-231 model, we observed pleomorphism in the CTC population, since we were able 
to detect both single CTCs and CTC clusters, also in the so called low CTC-burden models. 
In fact, CTM were found in all models, although at a higher frequency in the MDA-MB-231 
and, similarly to what happens in the clinical context, at reduced frequency compared to the 
whole CTC population. Beside low CTC and CTM load, systematic examination of FFPE 
sections from different organs confirmed also a weak metastatic potential in models with low-
rate proliferating tumors, in agreement with their low CTC-burden. Assessment of metastasis 
formation by IHC analysis of COX IV using a species-specific antibody not cross-reacting 
with the murine counterpart, allowed a reliable identification of metastases even at single cell 
resolution. In particular, the site of metastases was different among the various models, as 
for instance clusters or foci consisting of few cells were found in the ovaries of MDA-MB-453 
and MDA-MB-468 models only, whereas lymph-nodal involvement was exclusively observed 
in the MDA-MB-468 and MDA-MB-231 models. All cell lines were instead able to give rise to 
pulmonary metastases, although at different extent as single scattered cells or small foci 
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consisting in about 3-30 cells only could be observed in low CTC-burden models compared 
to metastatic nodules in MDA-MB-231. 
In the literature, MDA-MB-231 cell were proven to induce lung metastases when 
injected in the tail vein of nude mice (Fraker et al., 1984), and transplantation experiments in 
the m.f.p. allowed ranking them among the most aggressive BC cell lines (Price et al., 1990; 
Zhang et al., 1991). Since the first reports, studies employing such cell line have started to 
proliferate and even nowadays they represent a large fraction of the literature on BC 
metastasis biology. Experiments using variants of the human MDA-MB-231 breast cancer 
cell line, capable of spontaneous metastatic spread following several rounds of in vivo 
selection (Saxena and Christofori, 2013; Munoz et al., 2006; Francia et al., 2008) were also 
reported. However, despite their popularity, the majority of these experimental models do not 
recapitulate the entire tumor progression process as in many cases metastases formation is 
induced by intra-venous or -arterial injection, thus providing a model for the dissection of the 
late phases of the metastatic cascade, but by-passing an important step of early 
dissemination.  
Moreover, although a reasonable number of BC metastases models is now available, 
relevant models for some of the BC molecular subtypes are still lacking. ER-positive cell lines 
such as MCF7, T47D, and BT-474 are able to form tumors only in the presence of an 
exogenous source of estrogen, whereas, MDA-MB-468 and MDA-MB-453 take rate is not 
dependent on hormones. However, despite the metastatic origin of these cell lines, they have 
limited ability to invade and metastasize (Lacroix and Leclercq, 2004), unless subjected to 
selection of hormone-resistant variants or genetically modified (Clarke, 1996).  
More recently, severely immunocompromised mice, such as NSG and Rag2-/- γc-/- 
models, which exhibit T cell, B cell and NK cell immunodeficiency, were proposed to create 
new metastatic models. This time, MCF7 were able to give rise to metastases at lymph-node, 
lung, spleen and, sporadically, even at renal level when injected in the m.f.p. of NSG mice 
(Iorns et al., 2012). BT-474 cells were instead less metastatic in these mice, generating 
macro-metastases in only a few cases (axillary lymph node in 17% of mice, and spleen in 8% 
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of mice). The latter result is in contrast with our model where, although no macrometastases 
were found, small foci were detected in all animals and in all FFPE sections analyzed. In 
another study, use of bioimaging instruments allowed detecting multi-organ metastases in 
Rag2-/- γc-/- mice injected at orthotopic level with MDA-MB-453 and BT-474 cell lines (Nanni 
et al., 2012). Therefore, a comparison of our results with information reported in literature 
suggests that although all our models enable the study of the entire metastatic process, 
spanning from PT formation and growth to metastatic colonization, not all of the BC 
metastatic sites observed in the clinical setting, as brain and bones, were represented. This 
is mainly the case with bone metastases, which are instead frequently observed in patients. 
First attempts to explore hematogenous dissemination in BC experimental models 
were made only recently. In a technical paper published in 2008 (Eliane et al., 2008), 
different approaches for blood collection were tested to isolate CTCs from tumor-bearing 
mice, finally demonstrating that the cardiac puncture represents the most suitable approach 
to reach high yields without interference from contaminating normal murine epithelial cells. 
The authors also validated a method to enumerate CTC by applying a modified version of an 
in vitro diagnostic system for quantifying CTC in patients, obtaining numbers of CTC ranging 
from ∼100 to 1,000 per milliliter of blood. In line with our results, the reported CTC 
concentration in the blood of MDA-MB-231 xenograft models was highly variable among 
different animals. Concerning CTC variability, despite a wide range of cells detected in this 
model, we have observed correlation between CTC load and tumor burden, whereas 
literature data from experiments with GFP-expressing MDA-MB-231 cells suggested that the 
PT size is not a strong indicator of CTC load (Juratli et al., 2014). Such remarkable variability 
in CTC load in experimental models could also be the result of fluctuations in CTC release, 
as suggested by a paper on a melanoma CTC-model (Juratli et al., 2014). Here the authors 
performed a real-time continuous monitoring of CTCs and could estimate a release of 0 to 54 
CTCs every 5 minutes, also alternated to CTC-free phases. 
Different results were observed in a MDA-MB-468 CTC-model (Bonnomet et al., 2012), 
where CTCs were detectable as early as 8 days after injection and increased 36 days later, 
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after which their levels remained quite constant. Differently from data obtained in the 
MDA-MB-231 CTC-model (Juratli et al., 2014), this peak in CTC level mirrored the increase 
in tumor growth at the same time point, suggesting again that the number of CTCs may 
indeed correlate with tumor size. In line with our results, CTCs numbers were markedly lower 
(ranging from 4 to 27 per blood sample) compared to the MDA-MB-231 model. 
An important issue in CTC studies is represented by the timing of dissemination. We 
performed a time-course experiment to define a temporal window for isolation and 
characterization of early CTCs, where by “early CTC” we define those CTCs in a dormant 
state which have not yet completed the metastatic cascade. Collecting and characterizing 
such CTC fraction is crucial to understand the molecular steps required for early CTC 
survival in a quiescent state, and to unravel the molecular mechanisms behind tumor cell 
re-awakening and metastatic outgrowth. The MDA-MB-231 model, probably due to its 
pronounced aggressiveness, did not allow defining an optimal time point to isolate CTCs 
before they were able to colonize distant organs, since in a time-course experiment CTC 
release and increase during time mirrored the onset, frequency and extent of pulmonary 
metastases in matched FFPE sections. On the contrary, dissemination via lymphatic system 
was observed at the earliest time points (after 35 days from injection), suggesting that 
different molecular mechanisms are required to enter the lymphatic system compared to 
blood vessels. In agreement with this latter observation, also another study with 
MDA-MB-231 model reported that metastatic foci at lymph-nodes can be observed two 
weeks after orthotopic inoculation (Juratli et al., 2014).  
Taken together, the results of our dynamic studies with the MDA-MB-231 model 
indicate that CTCs can be observed in the blood of animals after long period from 
intravenous injection as they can be actively released from pulmonary metastases. At the 
same time, once in the bloodstream, MDA-MB-231 cells, either intravenously injected or 
disseminating from the PT as CTCs, are able to rapidly reach peripheral districts and 
colonize the lung. This behavior might have important implications for CTC profiling studies 
as the CTC population isolated at animal sacrifice should contain tumor cells released by the 
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PT and lung metastases. Nevertheless, the possibility that the two putative CTC populations 
could activate or de-regulate the same pathways irrespective of the site of origin is also 
plausible. It is possible that studies on CTC dormancy require a different experimental model 
displaying specific biological characteristics, such as the one reported by Gao and 
colleagues (Gao et al., 2012). In that work the authors used murine BC cell lines endowed 
with differential metastatic potential, suggesting that time-course experiments with low 
CTC-burden BC cell lines might represent a solution. Indeed, also Bonnomet and colleagues 
found lung metastases at later time point only, despite CTC recovery was possible even few 
days after cell injection in a time-course experiment with the MDA-MB-468 model (Bonnomet 
et al., 2012). Moreover, a higher number of animals should be analyzed per experiment in 
order to overcome the variability in CTC load and recovery, and the support of bioimaging 
instruments would facilitate CTC dissemination and metastasis formation monitoring in 
longitudinal studies (Bonapace et al., 2012; He et al., 2007).  
Further interesting data which emerged from our study is the detection of CTM in all 
our models. Overall, to our knowledge, the presence of CTM in experimental TN and non-TN 
BC models has not been reported yet, except for the LM2-MDA-MB-231 (Aceto et al., 2014) 
and MDA-MB-435 (Glinsky et al., 2003) xenografts, probably as a consequence of the 
technical approach used for CTC isolation. In our preliminary study we were instead able to 
monitor CTCs by size-based isolation supports and direct analysis of cytological samples 
which allowed detecting CTC clusters in different BC models.  
After having carefully explored the limits of the experimental models with low 
CTC/metastases-burden, we decided to focus our molecular and biological analyses on the 
highly aggressive MDA-MB-231 CTC-model. Extensive molecular characterization of tumor 
cells in xenograft models relies on the availability of sufficiently sensitive and specific 
methodological approaches for their isolation, detection and molecular analysis. Since 
biological samples obtained from mouse xenograft models inevitably contain both human 
and murine cells when the method used for tumor cell isolation does not guarantee 100% 
purity, we designed a strategy for specific human cell detection and quantification and we 
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assessed that the microarray platform was sufficiently sensitive (Fina et al., 2015a) and 
specific to obtain reliable GEPs. The main hypothesis we have tested is that the molecular 
profile of CTCs is different from those of the PT and metastases. The results of the first GEP 
experiment, obtained in 2013, revealed for the first time (Fina et al., 2014), that 
experimentally obtained CTCs have a distinctive transcriptome compared to the solid lesions 
they give rise to or from which they originate, and that they do not retain all the molecular 
characteristics of the parental cell line. Importantly, this data was confirmed in an 
independent xenograft experiment and was furthermore corroborated after having excluded 
the possibility of artifacts generated from technical and experimental variability. Such 
analysis suggested that molecular differences observed among sample classes (PT, CTC, 
LN, LUNG and MDA-MB-231) are indeed mainly imputable to the tissue source, either solid 
tissues or blood or in vitro cultured parental cells, and are not simply the results of batch 
effects or individual variability. Differently from systemic disease the molecular profiles of 
transplanted cells, which gave rise to mammary nodules in two different sites, and cells 
disseminated via the lymphatic system or colonizing the lung were widely similar among 
them, thus indicating that after hematogenous or lymphatic dissemination tumor cells that 
establish distant lesions tend to recapitulate the characteristics of the PT. Overall, these 
observations demonstrate that CTCs share few properties with the source from which they 
originate (either the PT or pulmonary metastases, if considering the ability to re-disseminate 
or re-seed), while the acquisition of new molecular traits is needed during dissemination.  
The achievement of such a result is the outcome of the methodological approach we 
have proposed, based on the combination of two CTC-enrichment approaches, a first 
positive selection step with immunomagnetic beads and a second size-based isolation step 
with dedicated filters, in order to avoid selection biases and maximize the CTC capture, 
followed by indirect quantification of tumor cells, either deriving from blood or solid tissues, 
and by gene expression profiling using species-specific molecular assays, paying attention to 
ensure equal inputs of human RNA in mixed murine-human samples. The outcome of 
preliminary quality control tests and feasibility experiments to isolate and characterize tumor 
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cells from blood and other tissues in our experimental models confirmed the robustness of 
each step in the proposed experimental workflow. Finally, large sample size (10 animals per 
experiments) also facilitated the selection of the best candidates for performing GEP 
analyses. Therefore, the usefulness and adequacy of our approach has been also 
demonstrated.  
The extensive molecular characterization of different tumor sites and comparison 
analyses allowed identifying about 500 genes differentially expressed between CTCs and all 
solid lesions, indicating that important transcriptional reprogramming occurred during the 
hematogenous dissemination step or circulation in blood. Genes up- and down-regulated in 
CTCs are supposed to be involved not only in cell migration or intravasation, but also in 
resistance to anoikis, shear stress and attacks from the immune system. Gene Ontology 
analysis of genes exclusively up-regulated in CTCs identified a series of terms related to 
embryogenesis and development, suggesting that CTCs might be able to dedifferentiate, 
thus recapitulating fundamental steps of tissue migration or remodeling, and to acquire 
plasticity features in order to adapt to foreign environments. According to our hypothesis, 
up-regulated genes were also enriched in GO terms related to cell surface receptor signaling 
pathways and response to external stimuli and pathogens, suggesting that CTCs might 
modify their phenotype to react against external cues encountered during their trip. Instead, 
genes exclusively down-regulated in CTCs were mainly related to chromatin remodeling, 
packaging and methylation in particular, and negative regulation of transcription and RNA 
metabolism, which is consistent with the substantial transcriptional reprogramming we 
observed and that is supposed to orchestrate the activation of molecular pathways enabling 
tumor cell dissemination, survival in blood and homing to distant organs.  
CTCs isolated from MDA-MB-231 xenografts were already proven to have peculiar 
behavior compared to the parental cell line in response to different microenvironmental 
conditions (Ameri et al., 2010). Ameri et al. demonstrated altered response to hypoxia, 
assessed as induction of ATF3, ATF4 and its target gene ASNS, after CTC culture under 
hypoxia conditions, and subsequent higher tumorigenicity compared to parental cells. More 
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recently the analysis of transcripts related to several metabolism pathways in CTC, PT and 
lung metastases from a 4T1 mouse model demonstrated an increased activation of oxidative 
phosphorylation pathways and enhanced mitochondrial biogenesis in CTCs compared to the 
other samples, while glucose metabolism was not deregulated (LeBleu et al., 2014). These 
data provided evidence for an opportunistic switch from an aerobic glycolysis to an oxidative 
metabolism in metastatic cells in order to fulfill the increased energetic demand of CTCs; it 
also supports the importance of characterizing CTCs to find molecular traits which distinguish 
them from PT and metastases. Recent data support the role of other enzymes involved in 
cell metabolism, as the acetyl-CoA synthetase 2, which was proven to promote acetate 
utilization and maintain cancer cell growth under metabolic stress in an experimental model 
of prostate cancer (Schug et al., 2015). Consistently, in our model gene encoding the 
mitochondrial fission 1 protein (FIS1) emerged among those significantly up-regulated in 
CTCs compared to solid lesions in both GEP experiments, while genes encoding the 
hesokinase 2 (HK2), the first rate-limiting enzyme of glycolysis, and the pyruvate 
dehydrogenase kinase (PDK1), involved in the regulation of pyruvate conversion to 
acetyl-CoA, were found to be down-regulated in CTCs, whereas acetyl-CoA synthetase 1 
(ACSS1) was classified among genes up-regulated in CTC compared to the PT but not 
differentially expressed between CTC and the parental cell line. More extensive molecular 
analysis of CTCs isolated from mouse melanoma models allowed identifying a CTC-derived 
signature correlated with invasiveness and cellular motility in human melanoma after 
unsupervised clustering, thus providing first evidence that tumor cells committed to 
dissemination undergo an important transcriptional reprogramming (Luo et al., 2014). 
However, in this study the authors were not able to confirm data also in a second 
independent experiment, suggesting that the experimental variability might influence the 
outcome of the experiments and twist the biological interpretation of results.  
Our approach can be applied to basic studies on CTC biology employing commercially 
available cell lines, as also primary cultures or clinical specimens (either solid biopsies or 
CTCs) engrafted in immunocompromised mice. One limit of the MDA-MB-231 model is 
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however the low representativeness of the basal B molecular subtype in the clinical setting 
(Neve et al., 2006). Nevertheless, seminal studies with MDA-MB-231-derived cell lines 
showing tropism toward specific organs unveiled the genetic determinants responsible for 
pulmonary metastases in BC and demonstrated their clinical relevance in predicting distant 
metastasis-free survival (Minn et al., 2005). Understanding metastasis initiation and 
progression is also critical to find genes responsible for the molecular switch from a dormant 
to a proliferating state, which is critical for the development of new drugs able to arrest the 
metastatic cascade at the earliest phases, especially if considering that CTCs can be 
detected even in patients with DCIS or with T1-T2 invasive BCs (Franken et al., 2012). 
Single-cell studies with BC PDX models at early and late phases of metastasis (Lawson et 
al., 2015) reported that tumor cells isolated from low-metastatic burden tissues prevalently 
expressed stem cell, EMT, pro-survival, and dormancy-associated genes, whereas 
metastatic cells from high-burden tissues were similar to PT cells, which were characterized 
by a luminal differentiation phenotype. Our model did not however allow tracing molecular 
changes and CTC plasticity during time as the number of cells detected at early time points 
in a time-course experiment were under the technical detection limit of the DASL assay 
platform. More importantly, once in the bloodstream, they were able to rapidly reach 
pulmonary capillaries and form metastatic foci.  
Data emerged from the molecular characterization of experimentally derived CTCs 
confirmed the importance of plasticity for a tumor cell that is starting the metastatic process. 
One of the most debated aspects in tumor dissemination concerns the activation of an 
epithelial-to-mesenchymal transition process, which besides being linked to the acquisition of 
a stemness-like and drug-resistance phenotype enables tumor cells to migrate, invade and 
enter the bloodstream. In our model no shift toward a different phenotype, either pure 
epithelial or transient or more markedly mesenchymal, was observed in CTC compared to 
the PT when considering the expression of EMT-related genes, such as SLUG, SNAIL, VIM, 
CDH1 and others, probably because MDA-MB-231 have a pronounced mesenchymal 
phenotype. However, similarly to the data published by Ocaña and colleagues (Ocaña et al., 
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2012), CTCs were found to undergo significant down-regulation of the EMT-inducer 
homeobox transcription factor PRRX1, thus indicating that different genes and pathways can 
be activated, alternatively to the commonly assessed EMT-markers. Despite the fact that 
recently published evidence rejected the hypothesis that EMT is needed for pulmonary 
metastases in BC (Fischer et al., 2015), our data suggest that a reversion to an epithelial 
phenotype mediated by the down-regulation of PRRX1 gene might be needed to complete 
the metastatic cascade, and that a subpopulation of MDA-MB-231-derived CTCs 
re-expressing epithelial genes may exist. The concordance between results obtained in our 
laboratory and those published by Ocaña (Ocaña et al., 2012), using two different 
experimental settings, furthermore corroborates data in favor of a metastatic model which 
requires the reversion from a mesenchymal to an epithelial phenotype. In our model, no 
modulation of the EPCAM gene was observed. However, it should be considered that 
EpCAM, although detectable at mRNA level, is expressed at low density on the surface of 
MDA-MB-231 cells, making it undetectable by standard antibodies and, consequently, once 
spiked in blood samples, MDA-MB-231 cells cannot be recovered using EpCAM-based 
approaches. A possible impairment of EMT, following PRRX1 down-modulation, could be 
hypothesized in our CTC-models. This implies that a possible shift toward the acquisition of 
epithelial features could occur during dissemination. If so, we should be able to observe a 
re-expression of EpCAM at functional level in CTCs by in situ protein analysis. However, 
studies with MDA-MB-231 xenografts report discordant data regarding the possibility to 
capture CTCs using EpCAM-based approaches. The AdnaTest approach based on 
EpCAM/MUC1-dependent enrichment failed to detect CTCs in MDA-MB-231 xenografts in a 
spiking experiment, notwithstanding in another study the application of EpCAM-based CTC 
enrichment devices, as the MagSweeper (Ameri et al., 2010), allowed detecting and culturing 
CTCs derived from MDA-MB-231 xenografts. In line with this latter observation, in a 
preliminary test to evaluate the efficacy of our CTC enrichment approaches we could detect 
CTCs in blood samples from MDA-MB-231 xenografts processed with the AdnaTest 
EpCAM/MUC1-based approach.  
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CTCs may be regarded as a sort of “black-box” worth being deciphered in order to find 
new metastasis-associated genes for basic and pharmacological studies. The identification 
of candidate genes, emerging from the molecular analysis of our experimental model, worth 
being investigated in in vitro and in vivo assays, was driven by the hypothesis that genes 
up-regulated in CTCs compared to the PT are important to permit the entrance and survival 
in blood. Systematic analysis of gene lists, obtained according to multiple comparison 
between PT and CTC, taking into account also the expression level in the parental cells in 
order to allow preliminary evaluations in vitro by loss-of-function studies, led us to the 
definition of a panel of candidate genes significantly up-regulated in CTC compared to the PT 
and not significantly differentially expressed between CTC and the parental cells. Among 
them, TFF3 gene, encoding for a secreted peptide of the trefoil factors family, was selected 
to study its role in metastasis. 
We demonstrated that TFF3 is specifically involved in cell motility and invasiveness 
since significant impairment of migration and invasion potential was obtained after transient 
or stable TFF3 knock-down in the MDA-MB-231 cell line, as also in cell clones obtained 
following CRISPR/Cas9-mediated gene knock-out. On the contrary, MDA-MB-231 cell 
proliferation rate remained unvaried, thus indicating that TFF3 can be numbered among 
metastasis-related genes. However, the hypothesis that TFF3 could also drive the 
vascular-mimicry ability, typical of MDA-MB-231 and other triple-negative cells, was not 
confirmed, thus suggesting that while TFF3 is important for motility and invasion, the 
activation of TFF3-independent pathways is required for the formation of tumor cell-lined 
channels. It is also plausible that cells do not have the same role and cooperate in different 
ways to enable tumor initiation and progression. Consistently with this view of cancer as an 
organized, though aberrant tissue consisting of cell populations committed to different 
biological functions, studies with MDA-MB-231 clones selected after TFF3 knock-out by the 
CRISPR/Cas9 system revealed that cells are highly heterogeneous as the proliferation or 
migration potential of a single clone did not mirror the behavior of the entire cell population, 
irrespectively from the TFF3 gene status. Indeed, although results of in vitro assays obtained 
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in experiments with gene knock-down were again confirmed, both TFF3 wild-type and 
knock-out clones showed high variability in proliferation rate, and remarkably the migration 
potential of wild-type clones was significantly reduced compared to the parental cells. 
Moreover, cell clones with unexpected abnormal behavior were observed during migration 
experiments.  
In an attempt to assess the actual role of TFF3 in dissemination and metastasis 
formation, three wild-type and knock-out clones were injected in mice. Two out of 3 clones, 
either wild-type or knock-out, failed to initiate a tumor, and those clones able to take in the 
animal showed a slower growth rate compared to MDA-MB-231 parental cells. Similar results 
were obtained also after injecting pooled cell clones, on the hypothesis that cell cooperation 
could obviate to biological heterogeneity; such an attempt, however, failed, maybe because 
the representativeness of the entire population was too low. Animals injected with the 
wild-type or knock-out clones which were able to give rise to tumor nodules were sacrificed 
at later time points compared to the standard experimental scheme for MDA-MB-231 
xenografts and, in agreement with the results obtained in in vitro assays, their growth rate, 
although similar, was slower compared to the parental cells. Despite the fact that CTCs were 
not detected in the blood of mice injected with the TFF3KO clone, both wild-type and 
knock-out clones were able to metastasize at lung. Moreover, contrarily to what expected on 
the basis of the outcome of in vitro preliminary experiments, the TFF3KO clone exhibited 
increased metastatic potential as pulmonary foci were larger than those originated from the 
TFF3WT cells. 
At present, few data are available on the role of TFF3 in BC. TFF3 - and also TFF1, but 
not TFF2 - mRNA was detected in breast tumors and estrogen-responsive BC cell lines (May 
and Westley, 1997; Poulsom et al., 1997). In a comprehensive transcriptome and proteomic 
profile analysis of normal breast, noninvasive and invasive BC cell lines TFF3 was ranked 
among the genes down-regulated in MDA-MB-231 compared to MCF7 cells (Nagaraja et al., 
2006). In another study TFF3 was found to be up-regulated in BT-474 and MDA-MB-361, but 
not SK-BR-3, HER2-positive BC cell lines compared to the HER2-negative MDA-MB-435 and 
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MDA-MB-468 BC cell lines, which failed to express TFF3 in Northern blot analysis (Wilson et 
al., 2002), as also observed in MDA-MB-231 cells by semi-quantitative PCR (May and 
Westley, 2015). Putative interaction with HER2 was also confirmed in another study showing 
that inhibition of HER2 induces TFF3 down-regulation. Differently from data reported in 
literature, our GEP experiments and biochemical analyses demonstrated that TFF3 secreted 
peptide is detectable at mRNA level by TaqMan-based qPCR and in the conditioned medium 
of MDA-MB-231 using an ELISA test specific for TFF3 and which does not detect TFF1, 
TFF2 and other secreted molecules, suggesting that the low sensitivity or specificity of the 
methods used in previous studies might have caused false negatives. The expression at 
functional level of TFF3 was unexpected if considering its correlation with ER. In fact, in 
agreement with the large part of literature data, the expression of TFF3 was observed to be 
induced in an estrogen-dependent and progesterone-independent manner (May and 
Westley, 1997) and that it is increased in tamoxifen resistant MCF7 cells (Kannan et al., 
2010). Consistently, forced expression of TFF3 in ER-positive cell lines additively increased 
ER transcriptional activity in the presence of estradiol, promoted estrogen-independent 
growth and induced resistance to tamoxifen and fulvestrant (Kannan et al., 2010). In line with 
this evidence, we have found that TFF3 is significantly overexpressed in MCF7-derived 
mammospheres, which were proven to be non-responsive to estradiol and fulvestrant (Callari 
et al., 2016) and to have high tumorigenicity (Ponti et al., 2005), compared to the parental 
cell line. 
In our study, TFF3 was found to be significantly up-regulated in MDA-MB-231-derived 
CTCs compared to the PT, and not significantly differentially expressed compared to the 
parental cell line, despite a trend toward an increased expression in CTCs. This might imply 
that MDA-MB-231 cell growth in the m.f.p. of mice and the establishment of a tumor exerted 
the function of a biological filter, which determined the selection of specific subsets of cells. 
The molecular analysis of disseminated cells allowed identifying genes which are responsible 
for MDA-MB-231 aggressive behavior and that probably could not have been discovered 
using different experimental designs. Therefore, also considering CTC plasticity, it is not 
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surprising that triple-negative cells could exploit molecular pathways generally proven to be 
fundamental in other BC subtypes. 
Further functional in vitro studies revealed that forced expression of TFF3 in 
ER-positive BC cells increased proliferation and survival, enhanced anchorage-independent 
growth, promoted migration and invasion (Kannan et al., 2010, Pandey et al., 2014) and 
stimulated endothelial cells adhesion, transmigration through an endothelial barrier and 
de novo angiogenesis (Pandey et al., 2014; Lau et al., 2015). Similarly, we have 
demonstrated that MDA-MB-231-derived CTCs overexpress TFF3 compared to the PT, and 
that the migration and invasion ability assessed in vitro after gene modulation in the parental 
cells is dependent on the expression of TFF3, which instead is not involved in proliferation or 
vascular-mimicry ability.  
More studies with animal models are however needed to better decipher the role of 
TFF3 in BC, although it was reported in the literature that forced TFF3 expression in MCF7 
cells induces the formation of metastatic foci at lung (Pandey et al., 2014). The outcome of 
our experiments did not allow drawing conclusion on the metastatic ability of MDA-MB-231 
cells after TFF3 knock-out, notwithstanding the hypothesis that clonal heterogeneity and/or 
gene compensation events could have produced biased results is plausible. Tumor 
heterogeneity is a well-known issue in BC, although many of its aspects still need to be 
clarified, and both inter-patient and intra-patient heterogeneity is observed at genomic, 
transcriptional and proteomic level (Polyak, 2011). In the past, seminal studies by Fidler had 
revealed that cell clones with different metastatic potential co-exist within a tumor cell line 
(Fidler, 1978; Fidler and Kripke, 1977; Kripke et al., 1978; Fidler, 2016). More recently two 
distinct populations were observed in MDA-MB-231 in culture, one with low surface levels of 
various chemokine receptors and a second with much higher levels, the latter showing 
increased metastatic ability in in vivo experiments (Norton et al., 2015). Moreover, there is 
growing evidence that cancer cells behave as communities and that the level of variability 
and cooperation among subclones can influence disease progression (Tabassum and 
Polyak, 2015). Recent analysis of clonal subpopulations in MDA-MB-231 and CN34 cell lines 
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revealed inter-cell transcript expression variability, which may enhance the cell fitness under 
changing environmental pressures encountered during cancer progression, including the 
tendency to metastasize (Nguyen et al., 2016). On the basis of these observations and given 
an established heterogeneity in clinical and experimental tumors, we can assume that the 
biological behavior of MDA-MB-231 cells is the result of a cooperation among different 
subsets of cells within the same population, and that the biological effects observed in in vitro 
and in vivo assays following artificial modulation of specific genes may be the consequence 
of an impairment of the cross-talk among different cell clones caused by previous in vitro 
selection procedures. Surprisingly, one of the MDA-MB-231 TFF3KO clones selected in our 
studies, although validated by Sanger sequencing and ELISA test, showed extraordinary 
migration ability compared to the parental cell line. This might suggest that, behind clonal 
heterogeneity, a gene compensation effect could be hypothesized, as demonstrated in 
different experimental models where cells showed the ability to compensate the loss of one 
gene with the aberrant expression of other genes (Rossi et al., 2015). We have to consider 
that the CRISPR/Cas9 system can provoke alterations in many genes beyond the desired 
target, although its function is mediated by sgRNA designed to be specific for the gene of 
interest. In order to overcome this issue, in vivo validation experiments have recently started 
and are now in progress using TFF3 stable knock-down cells.  
The applicability of biologically relevant data obtained from experimental models 
depends on the outcome of validation studies in the clinical context. In order to evaluate the 
clinical significance of the molecular signatures identified in our model, the expression of 
genes classified as CTC-specific was assessed in CTCs isolated from clinical samples and 
correlated with the clinical outcome. However, a plethora of methods to isolate, identify and 
characterize CTC exists, and the message coming from CTC analysis may influence the 
outcome of a clinical study according to the methodological approach. For this reason, CTC 
changes were firstly monitored in two independent BC case series, both including patients at 
different stages of disease, using the AdnaTest positive selection-based or the ScreenCell 
size-based isolation approaches. To our knowledge, this is the first study that compares a 
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positive selection-based with a size-based isolation approach in BC (Fina et al., 2015b).  
CTC enrichment based on standard EpCAM and MUC1 surface markers failed to detect 
CTCs in the vast majority of M0 BC patients (about 70%), whereas roughly 50% CTC 
positivity rate was obtained in M+ cases. Considering that not all CTCs express epithelial 
markers and that subsets of CTCs with transient epithelial-to-mesenchymal or completely 
mesenchymal phenotype can be generated during the dissemination phase or selected as a 
consequence of the adaptation to therapy, part of the case series was in parallel analyzed 
using another AdnaTest kit to capture CTCs, based on additional markers (ERBB2 and 
EGFR) beyond the classical one. The alternative CTC enrichment method showed an 
improved biological sensitivity as it allowed detecting CTCs in a higher number of samples 
compared to EpCAM/MUC1-based capture, especially in patients without clinical evidence of 
metastatic disease. Interestingly, CTC positivity rate was mainly driven by the detection 
frequency of EMT- and stemness-related genes rather than the epithelial/tumor-associated 
ones in M0 cases. In fact, all CTC positive samples in this clinical setting were negative for 
the expression of EPCAM, whereas the higher contribute to CTC positivity rate (more than 
50%) was imputable to the expression of genes encoding ALDH1 and Akt2. Taken together, 
these results are consistent with the hypothesis that CTCs released in the early stage of BC 
progression have a marked mesenchymal/stemness-like phenotype, which might be 
responsible for CTC long-term dormancy and ability to resist to therapy, compared to CTCs 
detectable in patients with metastatic disease. Indeed, although ALDH1A and AKT2 were the 
most represented markers in the overall case series, disseminated cells isolated from 
metastatic patients expressed EPCAM in 30% cases, suggesting that CTCs, differently from 
those released at earlier stages of disease, might have undergone a reversion in the EMT 
process at the end of their trip in order to colonize distant sites. Overall these data indicate 
that subsets of CTCs can be missed when using certain markers for their detection, 
especially in studies including patients with early-stage disease.  
These observations are corroborated by the results obtained in further case series, 
including M0 and M+ patients, analyzed for CTC status and CTC load by a size-based 
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approach. In this case CTC capture is not dependent on the expression of surface markers 
and allows appreciating the CTC heterogeneity. ScreenCell called as positive the vast 
majority of cases (roughly 80%), irrespectively of the stage of disease. This data confirms 
that in BC tumor cells are endowed with high disseminating potential and that hematogenous 
dissemination is a frequent event also at the earliest phases of tumor progression, as already 
observed in previous experimental and clinical studies. Moreover, this approach allowed 
appreciating the typical CTC pleomorphism and the tendency to establish interactions, either 
homotypic or heterotypic, with other cells. Actually, we observed both single CTCs and CTC 
clusters, although at different frequency according to the clinical stage. CTC clusters, known 
to have increased metastatic potential compared to single CTCs according to recent reports, 
were surprisingly observed at higher frequency in non-metastatic patients. Moreover, also 
CTM total load and CTM proportion in relation to the entire CTC population were 
considerably high compared to M+ patients, suggesting that tumor cells preferentially 
disseminated as aggregates rather than single cells in this early stage. However, it should be 
considered that the nature of these clusters should be confirmed in light of the genetic 
instability as a fundamental hallmark of cancer cells as a recent single cell analysis of 
clusters in non metastatic colorectal cancer patients demonstrated that a discrete population 
of these cells is not cancerous but consists of tumor-derived circulating endothelial cells 
(Cima et al., 2016). 
After exploring the CTC detection rate with both methods, data were analyzed in 
relation to the clinico-pathological features of the case series. The solely CTC status by 
AdnaTest, assigned on the basis of the expression of a limited panel of molecular markers, 
was not able to predict progression-free survival. Moreover, CTC status did not provide 
useful information on response to neoadjuvant therapy, probably due to the low pCR 
frequency in this clinical setting and the low number of cases enrolled in our study. However, 
CTCs seems to be associated to the HER2 status as a trend toward a significantly higher 
positivity was obtained in patients with HER2-positive M0 BC. Similarly to the results 
obtained with the AdnaTest positive selection-based approach, also CTC and CTM counts 
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were not associated to standard BC prognostic factors, except for the tumor size and the 
HER2 status. Indeed, CTM were more frequently detected in patients with T1/T2 or with 
HER2-positive primary BCs. This data corroborates the hypothesis that dissemination is an 
event that requires homotypic - and possibly heterotypic - interactions among cells when the 
tumor is at early stage, since stronger tendency to circulate as clusters rather than single 
cells was observed. It is also plausible that CTCs observed in metastatic patients derive from 
the metastatic site and that dissemination from the PT requires the activation of different 
pathways or the interaction with cells exerting a supportive role compared to cells that have 
already completed their trip and are newly released from metastatic sites. Indeed, the vast 
majority of patients did not present with metastatic disease at diagnosis and their tumor had 
been removed by chirurgical resection many years before progression. Neither the CTC nor 
CTM load was informative on response to therapy assessed by instrumental analysis in M+ 
patients, while significant increase in CTC count was observed in M0 patients categorized as 
complete or partial responders according to pathological assessment. 
Overall, we can conclude that the CTC-message might change according to the 
methodological approach used, as different subsets of cells can be missed when using 
standard markers. Moreover, our data revealed that CTC release in early stage BC is more 
frequent than expected. Studies with the CellSearch system in patients with early BC allowed 
obtaining about 20% only of CTC positivity at baseline (Rack et al., 2014; Janni et al., 2016), 
compared to ~30% by AdnaTest and ~80% by ScreenCell in our case series.  
AdnaTest failed to identify patients at high risk of relapse or progression when CTCs, 
isolated by the EpCAM/MUC1-based approach, were evaluated at baseline (cases 
processed with the improved kit were too low to perform correlation analysis). The same 
result was obtained in the DETECT trial for metastatic BC patients, designed to compare the 
prognostic impact of AdnaTest BreastCancer kit and the CellSearch system (Müller et al., 
2012). However, longitudinal analysis of CTC by AdnaTest was proven to have superior 
prognostic value compared to CTC analysis performed at baseline only, as dynamic CTC 
changes assessed at early time points from the start of therapy allowed identifying patients 
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with significantly shorter progression-free survival both in colorectal (Musella et al., 2015) 
and bladder cancer (Fina et al., 2016) case series. In this thesis work, the low number of 
cases and missing blood samples during administration of therapy did not allow drawing 
conclusions on the clinical usefulness of AdnaTest for CTC longitudinal monitoring in 
metastatic BC.   
The biological and clinical significance of CTC clusters in early BC remains to be 
clarified. Permanent presence of CTC clusters at different time points during therapy was 
associated to poor outcome in M+ BC patients (Aceto et al., 2014) and provides additional 
prognostic information beyond CTC enumeration alone (Wang et al., 2016). However, no 
data have been reported on the clinical relevance of CTM in M0 BCs, yet. 
On the basis of the global outcome of our clinical studies, we hypothesized that the 
molecular characterization of CTCs isolated by AdnaTest using additional genes and in situ 
analyses at protein level to evaluate the composition of CTC clusters are needed and might 
help unveiling the real CTC message. To this aim, we assessed the clinical significance of a 
panel of CTC/metastasis-specific genes, including 12 genes exclusively up-regulated in 
CTCs, 4 genes selected for functional validation studies as up-regulated in CTCs compared 
to the PT and not significantly differentially expressed compared to the parental cell line 
(including TFF3), and 5 genes already reported in literature as related to metastasis and/or 
stemness: OPN (Minn et al., 2005), SPARC (Minn et al., 2005), PTPN11 (Aceto et al., 2012), 
SOX2 (Leis et al., 2012; Lee et al., 2016; Basu-Roy et al., 2015), and YAP1 (Cordenonsi et 
al., 2011). From a technical point of view, we obtained encouraging results as our gene panel 
called positive a twofold higher number of cases compared to AdnaTest and detection rates 
were at least 15% for the majority of genes. Moreover, low concordance among genes was 
obtained when comparing samples processed by EMT1 with matched samples processed by 
EMT2 AdnaTest kits, thus confirming that different CTC subsets exist in the same patient. 
Interestingly, TFF1 and TFF3 genes were more frequently expressed in CTCs isolated from 
patients with metastatic disease, suggesting that they might be responsible for tumor 
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aggressiveness or confer metastasis-initiating properties. Instead, HDAC10 and PTPN11 
were found among genes more frequently detected in CTCs isolated from M0 patients.  
In addition to its classical role in regulating transcription, HDAC10 aberrant expression 
was proven to suppress metastases (Song et al., 2013), promote autophagy-mediated cell 
survival and confer drug resistance (Oehme et al., 2013). A number of genes that prevent 
tumor growth at secondary sites, including those encoding KISS1, MKK4, MKK6, 
BHLHLB3/Sharp-1, and Nm23-H1, among others, were identified in dormant disseminated 
tumor cells (Sosa et al., 2011). On the contrary, tyrosine phosphatase SHP2 (PTPN11) was 
proven to promote progression and maintain tumor-initiating properties in breast cancer 
(Aceto et al., 2012). Given that CTCs can be present in the blood of patients who underwent 
mastectomy many years after primary tumor treatment (Meng et al., 2004b), the expression 
of HDAC10 and PTPN11 genes in CTCs released from clinically non metastatic tumor 
supports the view of dormant disseminated cells as quiescent low-proliferating cells, with 
stem cell-like phenotype, and displaying enhanced survival and drug resistance properties 
(Sosa et al., 2014).  
When analyzing detection rates as a function of the molecular subtype, no significant 
trend toward the expression of particular sets of genes was observed, except for GIGYF1 
which was mainly detected in CTCs isolated from TN and HER2-positive BC. This result 
suggests that CTC features might not be influenced by the molecular subtype, and that their 
behavior is mainly driven by the activation and down-regulation of specific pathways involved 
in the dissemination process rather than subtype-specific genes, as also indicated by the 
discordant ESR1 or HER2 status between CTCs and PT (Aktas et al., 2011; Pestrin et al., 
2009), already reported in many studies and confirmed also in our case series.  
Interestingly, notwithstanding the limited and heterogeneous case series, correlation 
analyses with follow-up data revealed that TFF3, TFF1, YAP1, SOX2 and, to a lesser extent, 
ELF3 genes have prognostic role when their expression is assessed at CTC level, as 
patients with CTCs showing positivity for one of these genes had shorter progression-free 
survival compared to patients rated as negative. 
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According to literature data, TFF3 detection in lymph-nodes allowed upstaging of 
sentinel lymph-nodes containing metastastic disease of 10% compared to the routine 
histological analysis (Weigelt et al., 2004). TFF3 expression is also strongly correlated with 
breast cancers with metastases to bone (Smid et al., 2006) and was found among genes 
belonging to a specific genomic region displaying copy number gain at CTC level in patients 
with metastatic BC (Kanwar et al., 2015). However, analysis of a publicly available GEP 
datasets including node negative and untreated patients with primary BC showed that 
assessing TFF3 expression level in the PT does not allow predicting disease outcome, thus 
indicating that the molecular characteristics of CTCs have distinct prognostic value compared 
to those of the PT.  
The identification of BC biomarkers by high-throughput molecular analyses has rapidly 
increased in the latest year, but few studies were able to demonstrate the real clinical validity 
or the clinical utility of such biomarkers, probably because their biological significance is not 
usually investigated and top-down rather than bottom-up approaches are generally preferred. 
CTC-based clinical studies also lack demonstration of the clinical utility of CTC status 
assessment, as probably more attention should be paid to the molecular profile in addition to 
the CTC burden alone in order to exploit the ‘liquid biopsy’ opportunity fully. 
To our knowledge, we have demonstrated for the first time that CTC-specific genes 
identified in experimental models and related to metastasis can represent clinically relevant 
biomarkers when their expression is monitored in the systemic disease rather than at PT 
level, thus confirming the superior prognostic value of biologically meaningful blood-borne 
biomarkers.   
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In the last decades, the view of cancer as systemic disease has changed the way of 
approaching to basic and clinical studies. Differently from cell-free nucleic acids and other 
circulating biomarkers, CTCs can be viewed as biological entities endowed with metastatic 
potential and holding a plethora of information, which are worth being investigated in order to 
broaden our knowledge on metastasis biology and to find new and clinically relevant 
prognostic biomarkers. This thesis demonstrates that extensive and comparative 
characterization of experimentally-derived CTCs and solid lesions allows identifying genes 
associated to the hematogenous phase of dissemination and defining molecular signatures 
to discriminate breast cancer patients at high risk of relapse or progression from those with 
better prognosis by real-time monitoring of such genes in the CTC fraction. Overall, the 
results of this work open up new opportunities for basic and clinical cancer research studies.  
The development of a method to obtain reliable detection, quantification, visualization 
and gene expression profiles of CTCs and tumor cells in solid lesions in xenograft models 
was instrumental to the purpose of this thesis. We provided a useful tool since the 
species-specificity of molecular assays can be largely applied to studies with different model 
systems derived from human specimens, either cell lines or primary cultures or intact pieces 
of tumors or CTCs themselves, injected in laboratory animals. Indeed, the results of our 
approach confirmed that the biological model we have characterized is reproducible as it 
provides largely overlapping biological information in independent experiments. An ambitious 
perspective might be the use of species-specific assays to decipher the role of the tumor 
microenvironment in xenograft models when the stromal component of a tumor specimen 
has been progressively substituted by the murine counterpart, phenomenon which might 
imply a cross-species activity in support of tumor growth and dissemination. 
From a biological point of view, we demonstrated that the CTC-specific gene profile is 
relevant to the CTC behavior if considering that data revealed an important transcriptional 
reprogramming during the dissemination phase. A hypothesis-guided approach led us 
identifying TFF3 as candidate gene for functional studies, and the results of our in vitro 
studies demonstrated that this secreted peptide is important for cell migration and invasion 
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not only in the luminal subtype but also in the TN MDA-MB-231 BC cell line. However, 
technical and biological constraints due to the CRISPR/Cas9 system limited the possibility to 
draw conclusion on the role of TFF3 in dissemination. As also anticipated in few recent 
reports, cell lines are heterogeneous and our work also highlighted the effect of clonal 
selection in functional studies. A valid alternative beside the use of lentivirus-delivered short 
hairpin RNAs might be the delivering of an active Cas9 protein, instead of a plasmid-based 
expression, which reduces the persistence of the endonuclease in the cells, thus limiting 
potential off-target effects, and the analysis of the whole population instead of single 
cell-derived clones. If the role of TFF3 in metastasis will be validated in vivo, further 
experiments should be carried out to decipher the molecular network regulated by TFF3. To 
this aim, the possibility that TFF3 may act not only by autocrine or paracrine signaling in the 
blood microenvironment but also within an intracellular circuit, i.e. independently from its 
secretion, should be also considered if we assume that it may exert a biological role while 
cells are transiting in blood circulation. Moreover, as CTCs are supposed to be 
heterogeneous if considering the marked pleomorphism in the MDA-MB-231 CTC-model, the 
hypothesis of an association between TFF3 expression and the presence of a subset of 
CTCs with an epithelial phenotype, e.g. expressing EpCAM at protein level, should be taken 
into account and would deserve further investigation. Single cell studies and in situ analyses 
will represent a valid choice to explore tumor heterogeneity and to understand the 
composition and the functional role of tumor subpopulations at the different stages of disease 
progression, both in experimental models and, whenever possible, in patients. 
Our work also revealed that CTC clusters represent a common feature in the 
dissemination phase of breast tumors, both in the experimental and the clinical context, 
irrespective of the metastatic potential, since they can be found in low metastatic-burden 
models and in M0 patients. However, considering that CTM may contain cells of different 
origin, e.g. tumor and stromal cells, an approach to decipher the identity of cells at single cell 
resolution by the analysis of genomic instability (i.e., point mutations, copy number 
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alterations, or karyotyping) should be designed as it is fundamental to define the biological 
nature of such clusters of circulating cells unambiguously. 
The clinical significance of experimentally-derived CTC-specific genes in our CTC case 
series shifts the attention to the importance of the panel of markers chosen for CTC detection 
and characterization when using classical techniques rather than ‘omics’ approaches, and 
tell us that depicting the molecular portrait of CTCs rather than counting them or assessing 
the CTC status only using standard markers can help refining the design of translational 
studies. Basically, the scenario offered by the study of CTCs is useful either when the 
investigated biomarkers show or not different expression pattern compared to the traditional 
biopsy, as gene signatures with prognostic value identified by the molecular characterization 
of the primary tumor can be monitored in real-time and repeatedly during patients treatment 
by a minimally-invasive approach in the systemic disease. In our work we also demonstrated 
that experimentally-derived and biologically relevant CTC-specific genes do not provide the 
same information when studied at the PT level, as interrogation of publicly available gene 
expression databases confirmed the prognostic role of one of our genes only. The message 
of these results is that the ‘liquid biopsy’ is not only an opportunity to retrieve information on 
the tumor biology and adaptation by a blood-test, but also to have access to a new set of 
information that only well-designed CTC studies could reveal. On the basis of these 
consideration, it is desirable that the outcome of this study will provide the rationale for the 
application of such an approach, based on the comparison between CTC and solid lesions 
profile, also to the clinical setting, with the possibility to understand if the identified genes 
exert a biological role in tumor progression, adaptation and metastasis and if they represent 
actionable targets. 
From a general point of view, this data will help generating new hypotheses on the 
mechanisms that regulate hematogenous dissemination, and the role of further genes will be 
investigated in future functional studies with animal models and also CTC-cultures derived 
from xenografts, in order to have an illimited biological source to explore signaling pathways 
deregulated in CTCs and to test the efficacy of drugs in preventing transendothelial migration 
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in vitro and dissemination in vivo. The prognostic role of a series of CTC-specific genes and 
their modulation during patients’ treatment should be validated in confirmation studies with 
other larger CTC and healthy donors’ case series, and also extended to the analysis of 
CTC-subsets or single cells, with the final aim to provide a snapshot of tumor evolution and 
to identify new clinically useful CTC-signatures, as also therapeutic strategies based on the 
evolving nature of the disease.  
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Gene Expression Proﬁling of Circulating Tumor Cells
in Breast Cancer
Emanuela Fina,1 Maurizio Callari,1 Carolina Reduzzi,1 Francesca D’Aiuto,1 Gabriella Mariani,2
Daniele Generali,4 Marco A. Pierotti,3 Maria G. Daidone,1* and Vera Cappelletti1
BACKGROUND: Determining the transcriptional profile
of circulating tumor cells (CTCs) may allow the acqui-
sition of clinically relevant information while over-
coming tumor heterogeneity-related biases associated
with use of tissue samples for biomarker assessment.
However, such molecular characterization is challeng-
ing because CTCs are rare and outnumbered by blood
cells.
METHODS: Here, we describe a technical protocol to
measure the expression of 29 000 genes in CTCs
captured from whole blood with magnetic beads
linked with antibodies against epithelial cell adhesion
molecule (EpCAM) and the carcinoma-associated mu-
cin, MUC1, designed to be used for CTC character-
ization in clinical samples. Low numbers of cells (5–
200) from the MCF7 and MDA-MB-468 breast
cancer cell lines were spiked in healthy donor blood
samples and isolated with the AdnaTest EMT-1/Stem
CellSelect kit. Gene expression profiles (GEPs) were
obtained with the WG-DASL HT assay and compared
with GEPs obtained from RNA isolated from cultured
cell lines and unspiked samples.
RESULTS: GEPs from samples containing 25 or more
spiked cells correlated (r 0.95) with cognate 100-ng
RNA input samples, clustered separately from blood
control samples, and allowed MCF7 and MDA-MB-
468 cells to be distinguished. GEPs with comparable
technical quality were also obtained in a preliminary
series of clinical samples.
CONCLUSIONS: Our approach allows technically reliable
GEPs to be obtained from isolatedCTCs for the acquisition
of biologically useful information. It is reproducible and
suitable for application in prospective studies to assess the
clinical utility of CTCGEPs, provided that25CTCs can
be isolated.
© 2014 American Association for Clinical Chemistry
Attempting to guide cancer treatment on the basis of the
features of the primary tumor (PT)5 (1–4)may not repre-
sent an optimal approach owing to frequently reported dis-
cordance between the primary tumor and metastatic sites
(5, 6) and the occurrence of intratumoral clonal heteroge-
neity (7, 8). Moreover, in clinical practice, metastatic le-
sions are seldom biopsied owing to their anatomic inacces-
sibility or the comorbidity associated with the procedure.
Blood-based biomarker monitoring represents a new direc-
tion in the development of a precision medicine approach
tailored to provide information on the specific progression
step of the disease.
Circulating tumor cells (CTCs) are the purported in-
termediates of metastatic dissemination and are likely to
contain cellular clones responsible for disease progression;
CTCs therefore represent a preferred source for the identi-
fication of drug targets. Beyond the clinical validity of CTC
counts in both early and metastatic breast cancer patients
(9–11), CTCs offer the possibility of obtaining informa-
tion on the disease in real time without invasive biopsies; a
biological characterization of such cells is likely to be more
representative of the disease evolution and treatment resis-
tance than the PT (12–14). Unfortunately, molecular char-
acterization of CTCs is seriously hampered by their low
numbers and by the contamination of blood samples with
leukocytes. Primarily for these 2 reasons, most studies have
pursued a candidate gene approach focusing on a limited
number of genes known to give therapeutic information
(15–17), and only few studies have performed an unbiased
characterization of numerous genes by array approaches
(18). Because CTCs are likely to represent a very heteroge-
neous cell population, single-cell profiling has been applied
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to investigate their transcriptional heterogeneity (19–22) as
well as multimarker approaches on the bulk of CTC popu-
lation (23–27).
With the goal of providing a reliable assay allowing
the acquisition of valuable information on CTC features
in the clinical setting, we have adapted a commercially
available method that captures CTCs by use of beads
coated with antibodies against epithelial cell adhesion
molecule (EpCAM) and the carcinoma-associated mu-
cin, MUC1. Extensive gene expression profiling is then
performed on the captured cells with the cDNA-
mediated annealing, selection, extension, and ligation
(DASL) platform, which allows measurement of the ex-
pression of 29000 genes in low-quantity RNA samples
(28 ). The method has been tested with cell line cells
spiked at different numbers into healthy donor blood
(HDB) samples, and has been subsequently validated in
metastatic breast cancer patients entering systemic treat-
ment at the Fondazione Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) Istituto Nazionale Tu-
mori of Milan and at the Breast Unit of Cremona
Hospital.
Materials and Methods
CELL CULTURE AND CELL SPIKING
Breast cancer cell linesMCF7 andMDA-MB-468 (ATCC)
were grown in DMEM/F-12 (Lonza) medium supple-
mentedwith 10% fetal bovine serum (Lonza) in humidified
5%CO2 atmosphere.Cell lineswere authenticated by short
tandem repeats DNA profiling with the StemElite™ ID
System kit (Promega). For spiking experiments, cells were
harvestedwithTrypLE™Select 1X (Invitrogen, Life Tech-
nologies), and single cells from highly diluted cell suspen-
sions were micropipetted under an inverted optical micro-
scope directly into 5 mL of whole HDB in AdnaCollect
EDTA collection tubes (AdnaGen). Samples were pro-
cessed immediately or stored at 4 °C for2 h after spiking.
CLINICAL SAMPLES
Gene expression profile analysis was carried out on CTCs
quantified in parallel by different approaches (CellSearch
and AdnaTest) from blood of 7 patients with advanced
breast cancers entering primary systemic treatment proto-
cols ongoing at the Breast Unit, Istituti Ospitalieri at Cre-
mona (6 cases, CTC counted by CellSearch) and at the
Medical Oncology Department at Istituto Nazionale Tu-
mori, Milan (1 case, CTC evaluated by AdnaTest). Blood
samples for CTC gene expression (5 mL) were collected
before starting a new line of treatment, drawn into BD Va-
cutainer K3EDTA tubes, and processed within 1 h after
collection. Blood samples (7.5 mL) for CTC counts with
the CellSearch® System were collected in parallel into Cell-
Save Preservative sample tubes (Janssen Diagnostic),
whereas an additional 5 mL were collected in parallel for
CTC determination by AdnaTest. Cremona andMilan in-
stitutional reviewboard and ethics committees approved the
study protocol, and all patients provided written informed
consent.
The patients’ clinicopathologic features and CTC
status/counts are summarized in Supplemental Table 1,
which accompanies the online version of this article at
http://www.clinchem.org/content/vol61/issue1.
TUMOR CELL ENRICHMENT, RNA EXTRACTION, AND
SINGLE-GENE EXPRESSION EVALUATION
We isolated tumor cells spiked into blood by the
AdnaTest EMT-1/StemCell Select kit (AdnaGen
AG). Captured cells were incubated with lysis buffer
from the Agencourt RNAdvance Cell v2 kit (Beckman
Coulter) for 30 min at room temperature, and bead-
free lysates were stored at80 °C. We performed total
RNA extraction according to the manufacturer’s in-
structions; RNA was eluted in 5 or 10 L nuclease-free
water (Ambion), depending on the experimental
setting.
For single-gene expression studies, enriched tumor
cells were incubated with the AdnaTest lysis buffer, and
mRNA was isolated with the Dynabeads® mRNA
Direct™ Micro Kit included in the AdnaTest and
reverse-transcribed.We used the cDNA obtained as tem-
plate for evaluation of PTPRC (protein tyrosine phospha-
tase, receptor type, C)6 (the gene coding for CD45) with
the TaqMan assay Hs 00365634_g1 (Applied Biosystems).
WHOLE GENOME EXPRESSION PROFILING ASSAY
We performed the Illumina Human Whole-Genome
DASL HT Assay according to manufacturer’s instruc-
tions. The BeadChips were imaged on the BeadArray
Reader.
A flow chart summarizing the experimental design is
reported in Fig. 1.
DATA PROCESSING AND STATISTICS
Microarray raw data were generated with Illumina Bead-
Studio 3.8 software and processed with the Lumi package
(29 ) of Bioconductor. For each gene, we selected the
probe with the highest interquartile range. Array data
were deposited at Gene Expression Omnibus data repos-
itory (GSE55470).
6 Human genes: PTPRC, protein tyrosine phosphatase, receptor type, C; EPCAM, epithelial cell
adhesion molecule;MUC1,mucin 1, cell surface associated; ERBB2, v-erb-b2 avian erythro-
blastic leukemia viral oncogenehomolog2, (HER2);AKT2, v-aktmurine thymomaviral onco-
gene homolog 2; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha;TWIST1, twist familybHLHtranscription factor1;ALHD1A1,aldehydedehydrogenase1
family, member A1. See Fig. 6 legend for gene symbols and namesmentioned only in that
ﬁgure.
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Unsupervised hierarchical clustering was performed
with the Geneplotter package with Euclidean distance
and average linkage.
Results and Discussion
SUITABILITY OF THE DASL ASSAY TO DETERMINE GENE
EXPRESSION PROFILES OF EPITHELIAL CELLS SPIKED AT LOW
FREQUENCIES IN HDB AND EFFICACY OF AdnaWash BUFFER
To evaluate the reliability of the DASL assay for obtain-
ing gene expression profiles (GEPs) from both low RNA-
input samples and CTCs, experiments were run with low
predefined numbers of breast cancer cells (MCF7 and
MDA-MB-468), spiked into a HDB at final concentra-
tions of 400, 200, and 100 cells/5 mL. For this step, a
single healthy donor was chosen to ensure comparable
samples when investigating the efficiency of leukocyte
removal and the interference by leukocyte-specific genes
in GEPs from spiked cells.
Total RNA from captured cells was split in 2 equal
aliquots and processed in duplicate on 2 distinct chips
of the DASL platform together with total RNA (0.5–
Fig. 1. Flowchart summarizing the experimental design.
The experimental steps carried out on isolated RNA extracted from cell lines and from healthy donor blood samples spiked with different
amounts of cells are reported highlighting for each step the technical and biological issues addressed by the experiment. BC, breast cancer;
HD, healthy donor.
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100 ng) isolated from the same in vitro cultured cells,
in the same amplification/hybridization session. This
experiment was designed to (a) verify the sensitivity of
the assay; (b) test the reliability of GEP obtained with
200, 100, and 50 cells; and (c) assess the interassay
variability (under conditions in which no interference
by capture-associated variability was present). In addi-
tion, blood samples from the same healthy donor, not
containing any spiked cells, were processed similarly
with and without use of the AdnaWash buffer (de-
signed to limit leukocyte contamination in the cap-
tured samples) to test its ability to prevent contamina-
tion by leukocyte-expressed genes.
We generated diagnostic plots (Fig. 2) to judge
the technical reliability of the data computing mean
signal intensities and probe detection rates (Fig. 2A).
As expected, the lowest mean log2 signal intensities
(around 5) and probe detection rates (30%) were ob-
served in healthy controls when captured cells were
treated with AdnaWash buffer before lysate preparation.
These results suggest that after treatment with the wash-
ing buffer, few cells remained attached to the immuno-
magnetic beads. In fact, both the mean signal values and
detection rates increased, respectively, to 6% and 45%
compared with the lower values obtained in untreated
control samples, demonstrating that AdnaWash buffer
effectively reduced leukocyte contamination.
The plots in Fig. 2A indicate that both the spiked sam-
ples and the samples with higher RNA input were charac-
terized by mean log2 intensities between 7 and 7.7 and
probe detection rates 60%. In the case of isolated RNA
samples, only those containing 1 or 0.5 ng of RNA showed
lower detection rates and intensities.
Fig. 2B summarizes the correlations between samples.
Samples from HDB, either untreated or treated with Adna-
Wash, were weakly correlated with the remaining samples,
with a poor correlation between technical duplicates. A sep-
aration on the basis of GEP was obtained between the
MCF7 and MDA-MB-468 blood-spiked cells, supporting
the biological reliability of the GEPs obtained from cells
spiked into HDB and captured with immunomagnetic
beads. Of note, MDA-MB-468 cells spiked into blood and
samples containing their isolated RNA (in the concentra-
tion range 10–100 ng) clustered together. However, low-
input RNA samples (1 or 0.5 ng) deriving fromMDA-MB-
468 cells clustered separately. In fact, when the RNA input
was decreased from 10 to 1 or 0.5 ng, the correlation coef-
ficients with profiles obtained from a 100-ng RNA sample
(anRNA inputwithin the range suggested by the chipman-
ufacturer) dropped from r 0.99 to r 0.89 and r 0.83,
respectively. As reported in online Supplemental Fig. 1A,
the expression levels of a subset of genes spanning low to
intermediate intensities in the high-RNA-input sample
were found to be at background levels in samples with lower
RNA input. About one-third of the genes were present only
in samples with high RNA content, whereas the remainder
were found also in low-RNA-input samples. Importantly,
the 6578 probes exclusively detected in high-RNA-input
samples represent a group of low-expression genes that were
not significantly enriched in any specific biological process
(see online Supplemental Fig. 1B), suggesting that a lower
RNA input affects low-expression genes belonging to any
cellular process, without causing any modification in the
biological interpretation of data. Such a result, therefore,
allows confidence in the GEPs obtained from samples with
lower RNA input, as also suggested by April et al. (28).
The efficacy of AdnaWash in removing the contribu-
tion of leukocyte-derived genes is further shown in Fig. 2C.
Removal of leukocytes is crucial for wide gene expression
analysis, since many genes are expressed by both epithelial
and mesenchymal cells, and consequently leukocyte con-
tamination can bias GEPs of putative CTCs.
The top scatterplot in Fig. 2C correlates GEPs ob-
tained from the same HDB with or without washing
steps with AdnaWash buffer. A substantial number of
genes with a wide expression range in samples not treated
with AdnaWash appeared to be expressed at low levels
after leukocyte removal and, overall, samples not
treated with AdnaWash were characterized by higher
expression levels for many genes. These data suggest
high leukocyte contamination in immunomagnetic
bead– captured samples not submitted to AdnaWash
treatment.
The next 2 scatterplots in Fig. 2C report correlations
betweenGEPs obtained fromahealthy donor sample after a
washing step with AdnaWash without any spiked cells and
samples from the same donor that were spiked with 50
MCF7 or MDA-MB-468 cells. It appears that for the ma-
jority of genes, cell-spiked HDB samples showed higher
gene expression levels, suggesting an efficient removal of
leukocytes without affecting epithelial cells. Furthermore, a
distinct set of genes characterized by a wide range of expres-
sion in samples spiked with cells showed only a low expres-
sion in unspiked HDB samples, suggesting an enrichment
in epithelial-specific genes. The specificity of AdnaWash
buffer in the removal of leukocytes is finally supported by
the last scatterplot in Fig. 2C, which shows that distinguish-
ing cell-type specific genes from genes equally expressed by
MCF7 andMDA-MB-468 cells is possible. On the basis of
all the reported observations, we concluded that the treat-
mentwithAdnaWash buffer represents a useful step to limit
leukocyte contamination that does not affect detection of
epithelial-specific genes.
Finally, reproducibility of the AdnaWash procedure
for the removal of leukocytes was tested by evaluating the
levels of PTPRC gene expression with a quantitative PCR
approach in 7 samples from the same healthy donor
spiked with breast cancer cells. Different numbers of
breast cancer cells (0–50) were spiked into 7 independent
Gene Expression of CTCs
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Fig. 2. Intensities and correlations.
(A), Distribution plot of signal mean intensities in gene expression data derived from isolated MDA-MB-468 RNAs (green squares), from
50–100–200 MDA-MB-468 (red dots) or MCF7 (blue dots) cells spiked into healthy donor blood (HDB) and from cell-free HDB (yellow
triangles), proﬁledwith the IlluminaHumanWhole-GenomeDASLHT. (B), Heatmap reporting the reciprocal correlations (Pearson correlation
coefﬁcient) among GEPs obtained from RNA directly isolated fromMDA-MB-468 cells or from captured cell RNA corresponding to 200, 100,
and50MDA-MB-468orMCF7 cells spiked intoHDB. All GEPswereobtainedby IlluminaHumanWhole-GenomeDASLHT. Before computation
of the correlations, data were separately normalized with the robust spline normalization method. (C), Correlations between samples:
AdnaWash buffer–treated vs –untreated HDB samples; AdnaWash buffer–treated HDB containing 50MCF7-spiked cells vs AdnaWash buffer–
treated HDB; AdnaWash buffer–treated HDB containing 50 MDA-MB-468–spiked cells vs AdnaWash buffer–treated HDB; AdnaWash buffer–
treated HDB containing 50 MDA-MB-468–spiked cells vs AdnaWash buffer–treated HDB containing 50 MCF7-spiked cells. AW, AdnaWash.
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5-mL blood samples obtained from the same healthy do-
nor at a single time point to minimize leukocyte varia-
tion. After the standard washing procedure with the
AdnaWash buffer, captured cells were lysed, and PTPRC
gene expression was assayed by quantitative PCR. The
mean cycle threshold (Ct) value was 36.53 (0.46) with a
CV of 1.26%. The CV value obtained supports the re-
producibility of the leukocyte removal.
BIOLOGICAL RELIABILITY OF GEPs OBTAINED FROM CELLS
SPIKED INTO BLOOD
We assessed the biological reliability of GEPs by comparing
genes shared by captured cells and their corresponding iso-
lated RNA and genes selectively expressed by samples de-
rived from isolated RNA (100 ng) or from captured cells
(200 cells). Results for MDA-MB-468 cells are shown in
Fig. 3A. Reliability of profiles was supported by the high
number of shared genes (90.4%) and by the fact that genes
exclusively expressed by captured cells (5.5%)were enriched
in geneontology terms referring to leukocytes (e.g., immune
response, immune system process, lymphocyte activation),
whereas genes exclusively expressed in isolated RNA sam-
ples did not show a specific type of gene ontology enrich-
ment. A list of gene ontology terms exclusively enriched in
captured cells and in the corresponding isolated RNA is
reported in online Supplemental File 1.
The actual enrichment in specific gene categories in
cells captured from spiked blood samples compared with
control HDB was evaluated considering both types of
controls, either washed or not with AdnaWash buffer
(Fig. 3B). A proportion of genes (41.5%) expressed by all
3 samples was enriched in terms referring to biological
functions common to all types of cells (e.g., RNA pro-
cessing, cellular macromolecule catabolic process, RNA
binding), whereas a smaller set of genes (21.9%) was
shared between samples spiked with cells and the control
samples that were not treated to remove leukocytes. Such
genes that are enriched in cellular biological functions
common to all types of cells likely represent common
genes with lower expression levels, and this could explain
their absence in the AdnaWash-treated samples. The ef-
ficacy of leukocyte removal was supported by the Gene
Ontology of the 430 genes exclusively expressed in con-
trols untreated with AdnaWash that were enriched in
151 gene ontology terms that all referred to leukocytes
and included immune response, inflammation, leuko-
cyte activation, macrophage activation, and lymphocyte
differentiation (see online Supplemental File 2). The
same analysis was repeated for MCF7-spiked cells, and a
similar interpretation could be made (see online Supple-
mental Fig. 2 and Supplemental File 3). Similar results
were also obtained by repeating the analysis with the
replicated samples (data not shown).
SENSITIVITY AND EXPERIMENTAL VARIABILITY OF THE
DEVELOPED CTC GENE PROFILING METHOD
The sensitivity and experimental variability of the entire
CTC capture and profiling assay was tested by spiking
independent triplicates of 50, 25, 10, and 5 MCF7 and
MDA-MB-468 cells into HDB. RNA (100 ng) extracted
from the 2 cell lines was also hybridized in triplicate as a
gold-standard sample, and in the case of the MCF7 cell
line, triplicate spikes with 50 cells were also performed in
parallel in a different donor.
To understand the quality of the data, we carried out
Pearson correlation analysis on all samples. The resulting
correlation plot is shown in Fig. 4. One sample (10 spiked
MDA-MB-468 cells) found to be completely unrelated to
the other sampleswas rated as a technical failure andwas not
taken into consideration in the following analyses (see also
online Supplemental Fig. 3).
The remaining samples segregated into 2 clusters. A
larger cluster (cluster A in Fig. 4) contained all samples
derived from isolated RNA and 69% (18/26) of spiked
cell samples. In both the RNA samples cluster and the
spiked cells cluster, a clear separation betweenMCF7 and
MDA-MB-468 cells was observed. For both MCF7 and
MDA-MB-468 cell lines, 73% and 63.6% of spiked sam-
ples, respectively, correlated as expected.
The specificity of capture of CTCs and the efficacy
of leukocyte removal is also supported by the strong cor-
relation between GEPs derived from 50 MCF7 cells
spiked into different HDB.
A second cluster of less well-correlated samples (clus-
ter B) contained the 3 negative samples (HDB with no
spiked cells) and 8 spiked samples (both with MFC7 and
withMDA-MB-468 cells) with low cell numbers (4 sam-
ples spiked with 5 cells, 3 with 10 cells, and 1 with 25
cells). Although the overall number of spiked cell samples
processed was not high, the data suggest that in samples
containing 50 CTCs reliable GEPs can be obtained,
whereas for samples with 10 or fewer CTCs, the failure
rate exceeds the success rate. In fact, the majority of low-
input samples were more strongly correlated with donors
rather than with other samples containing the same cell
type. Finally, profiling of 25 captured cells appears to be
feasible, although with a success rate of around 80% (5/
6). Considering the low numbers of CTCs usually recov-
ered in clinical samples, we therefore suggest that to en-
sure the successful profiling of CTCs in clinical samples,
a larger volume of blood (10–15 mL) should be used.
In GEPs of CTCs from patients, the main aim is to
detect biologically significant differences among individu-
als. To understandwhether the developedmethodwas suit-
able for this purpose, fold changes in gene expression be-
tween the luminal MCF7 cell line and the triple-negative
MDA-MB-468 cell line were computed. The quality of the
data obtained from spiked cells was assessed by correlating
fold changes obtained from 50, 25, and 10 spiked cells with
Gene Expression of CTCs
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Fig. 3. Gene Ontology.
(A), Eulero-Venn diagrams highlighting the numbers of common and exclusive genes detected in samples derived from 200 spikedMDA-MB-468
cells and 100 ng isolated RNA derived from MDA-MB-468 cells. Gene Ontology analysis results for exclusive genes in each set are reported with
character sizes and color intensities directly proportional to the P values for the gene set enrichment. (B), Eulero-Venn diagrams highlighting the
numbersofcommonandexclusivegenesdetected insamplesderivedfrom200MDA-MB-468cells spikedintoHDB,HDBnot treatedwithAdnaWash
buffer,andHDBtreatedwithAdnaWashbuffer.Geneontologiesanalysis results forexclusivegenesineachsetarereportedwithcharactersizesdirectly
proportional to the gene set enrichment.
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Fig. 4. Heat map reporting the reciprocal correlations (Pearson correlation coefﬁcient) among GEPs obtained from 100 ng RNA
directly isolated fromMCF7 andMDA-MB-468 cells, or fromRNAextracted from50, 25, 10, and5MCF7orMDA-MB-468 cells spiked
in independent triplicates into HDB.
All GEPs were obtained by Illumina Human Whole-Genome DASL HT. Before computation of the correlation values, data were separately
normalized with the robust spline normalization method. On the basis of correlations, samples separated in 2 clusters: cluster A containing
samplesderived from isolatedRNAand sampleswithhigher number of spiked cells, and cluster B containing controls and samples spikedwith
low cell numbers. AW, AdnaWash.
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those obtainedwith gene expressiondata derived fromRNA
(100 ng) directly isolated from cultured cells. Data are re-
ported in Fig. 5. Correlations among log2 fold changes
dropped significantly when the number of spiked cells was
reduced (fold-change correlations by Pearson coefficient:
r 0.66 for 50 cells, r 0.54 for 25 cells, and r 0.26 for
5 cells).
APPLICATION TO CLINICAL SAMPLES
The approachdeveloped for spiked sampleswas applied to 7
clinical samples. A CellSearch-based CTC number estima-
tion was available for 6 samples, whereas in 1 sample CTC
status was evaluated by AdnaTest EMT-1/StemCellDetect
kit without any enumeration. CTCnumbers ranged from0
to 200 cells (in 5 mL whole blood). It is important to un-
derline that this is only an estimation of the true number of
CTCs profiled for gene expression, as the profiled CTCs
were captured with a different kit. Although the CellSearch
approach and the AdnaTest are both based on EpCAM
expression, the AdnaTest also contains antibodies directed
against cell-surface MUC1 antigen. In the literature, an
agreementof 69%and73%is reportedbetween the2meth-
ods when using the 5 or 2 CTC/7.5 mL cutoffs (30),
respectively.
A heat map for samples clustered on the basis of the
expression of the PAM50 gene panel (31) is reported in Fig.
6. Except for a sample with a very high number of CTCs
(sample CTC001; 200 CTCs in 5 mL blood), no correla-
tion was observed between number of CTCs estimated by
CellSearch and the expression levels of PAM50genes.How-
ever, it should be noted that CTC counts were quite low
(median CTC count 13). Moreover, the CTCs captured
andprofiled in this still-preliminary series of clinical samples
were obtained from patients characterized by primary tu-
mors of similar subtypes, which does not allow us to observe
molecular subtype–related differences. An interesting obser-
vationwas noted for sampleCTC003, inwhichCTC status
was defined as negative byAdnaGen assay on the basis of the
low expression of 7 selected genes [EPCAM (epithelial cell
adhesion molecule), MUC1 (mucin 1, cell surface associ-
ated), ERBB2 (v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2, [HER2]), AKT2 (v-akt murine thy-
moma viral oncogene homolog 2), PIK3CA (phosphatidy-
linositol-4,5-bisphosphate 3-kinase, catalytic subunit al-
pha), TWIST1 (twist family bHLH transcription factor 1),
andALDH1A1 (aldehyde dehydrogenase 1 family,member
A1)], but still showed an expression for PAM50 panel genes
not dissimilar from that of true CTC-positive samples.
Conclusion
CTCs are rapidly moving from a simple tumor burden
marker to a potential biomarker providing information on
tumor heterogeneity and tumor biology (32). A recent
pooled analysis of patient data has confirmed that CTC
Fig. 5. Pairedplot showing correlations between fold changes
(FC) for genes found to be differentially expressed between
MCF7 cells andMDA-MB-468 cellswhen50 (A), 25 (B), and5 (C)
cells were captured from HDB versus FC obtained for differen-
tially expressed genes between isolated RNA samples from
MCF7 andMDA-MB-468 cells representing the benchmark.
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Fig. 6. Unsupervised hierarchical cluster analysis of gene expression proﬁles from7metastatic patient blood samples enriched for
CTCs with the AdnaTest EMT-1/Stem CellSelect kit.
Robust spline normalization was applied, and probes with a detection P<0.01 in at least 1 sample were selected. Horizontal rows represent genes
from the PAM50 panel, and vertical columns correspond to clinical samples. CDH3, cadherin 3, type 1, P-cadherin (placental); KRT5/17//14, keratin
1/17/14;MAPT,microtubule-associatedprotein tau;BIRC5,baculoviral IAPrepeatcontaining5;KIF2C,kinesin familymember2C;EXO1,exonuclease
1; CENPF, centromere protein F, 350/400kDa; FGFR4, ﬁbroblast growth factor receptor 4;NUF2, NDC80 kinetochore complex component (formerly
CDCA1); CDC6/20, cell division cycle 6/20; SFRP1, secreted frizzled-related protein 1; EGFR, epidermal growth factor receptor;MYBL2, v-myb avian
myeloblastosis viral oncogene homolog-like 2; PGR, progesterone receptor; FOXC1/A1, forkhead box C1/A1; MELK, maternal embryonic leucine
zipperkinase;ANLN,anillin, actinbindingprotein; TYMS, thymidylate synthetase;CEP55, centrosomalprotein55kDa;MKI67,markerofproliferation
Ki-67;UBE2C, ubiquitin-conjugating enzyme E2C;UBE2T, ubiquitin-conjugating enzyme E2T (putative); ESR1, estrogen receptor 1;MLPH,melano-
philin; GRB7, growth factor receptor-bound protein 7; TMEM45B, transmembrane protein 45B; CCNB1/E1, cyclin B1/E1; RRM2, ribonucleotide
reductase M2; ACTR3B, ARP3 actin-related protein 3 homolog B (yeast);MIA,melanoma inhibitory activity;MMP11,matrix metallopeptidase 11
(stromelysin3);SLC39A6,solutecarrier family39(zinc transporter),member6;MYC,v-mycavianmyelocytomatosisviraloncogenehomolog;MDM2,
MDM2proto-oncogene, E3ubiquitin protein ligase;BAG1,BCL2-associated athanogene;CXXC5,CXXCﬁnger protein 5;BCL2,B-cell CLL/lymphoma
2; ORC6L, origin recognition complex, subunit 6; PTTG1, pituitary tumor-transforming 1; GPR160, G protein-coupled receptor 160; PHGDH, phos-
phoglycerate dehydrogenase;NAT1,N-acetyltransferase 1 (arylamineN-acetyltransferase); BLVRA, biliverdin reductase A.
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enumeration is an independent prognosticmarker of overall
survival and progression-free survival that provides an early
assessment of treatment response in breast cancer (9, 33). It
is, however, worth reflecting on the advantages offered by
CTC molecular characterization in the clinical setting
where, so far, the most common approach has been dealing
with determination of HER2 status on CTCs.
A direct involvement of CTCs in the metastatic cas-
cade is unquestionable, but probably not all CTC subpopu-
lations have the same metastatic potential. Although not
accepted by all (34), epithelial-mesenchymal transition has
been suggested to be crucial for dissemination of tumor cells
to distant organs (35). Yu et al. (36) demonstrated the oc-
currence of dynamic changes in epithelial andmesenchymal
compositionofCTCs inpatientswithmetastatic breast can-
cer and found an association between treatment resistance
and presence of CTCs with mesenchymal features in pa-
tients who were serially monitored through disease progres-
sion. Such a study provides proof of concept that variation
of specific CTC subpopulations can serve as an indicator of
the rate of cancer adaptation during treatment and repre-
sents, therefore, an opportunity to identify new therapeutic
targets and resistance markers possibly anticipating clinical
progression.
This concept is further reinforced in the light of the
well-known intratumor spatial/temporal heterogeneity of
both primaries and metastases, which can be overcome by
exploiting liquid biopsies (37) containing materials (e.g.,
circulating tumor DNA, CTCs, circulating microRNAs)
shed in the bloodstream by primary tumors, but also by the
complete set of metastases.
To fully exploit the opportunity offered by CTC mo-
lecular characterization in the clinical setting, it therefore is
mandatory to have an approach allowing an extensive mo-
lecular characterization ofCTCs, enabling collection of data
that offer timely information on tumor progression and/or
development of treatment resistance and are suitable for
clinical studies in a multicenter setting.
Despite the many challenges, primarily having to do
with low sample input and leukocyte contamination, the
experiments run onHDB definitely support the possibil-
ity of obtaining technically reliable gene expression pro-
files from as few as 25 cells in 5 mL blood. Our data also
show that the obtained profiles convey biologically useful
information thatmay allow differences among samples to
be distinguished.
Several published studies have reported gene expres-
sion from CTCs, but these have been limited to tens or
hundreds of genes primarily detected by PCR. Whereas
someof the studies (23)used anEpCAM-based enrichment
approach, other studies, mostly dealing with single cells in
prostate cancer, relied on complex techniques that are not
suitable for translation to the clinic (38).
Our study has the advantage of providing a pipeline for
obtaining biologically reliable profiles in a way that is easily
applicable to the clinical context; this contrasts with single-
cell profilingmethods that are not yet ready to be transferred
into the daily routine. A limitation in the developedmethod
is represented by the need of somewhat high numbers of
cells compared with the median values of CTCs identified
in peripheral blood from breast cancer patients. However,
such a problem can be solved by drawing higher volumes of
blood and improving the CTC-enrichment methods to
avoid losses of not fully epithelial CTCs. In fact, on the basis
of preliminary data obtained in our laboratory on a limited
set of breast cancer patients (21 with early and 9 with met-
astatic disease), the use of improved antibody cocktails (Ad-
naTest EMT-1/StemvsAdnaTest EMT-2/StemCellSelect
kits) forCTCenrichment raised the positivity percentage 4-
and3-fold in early andmetastatic breast cancer, respectively.
Although this does not represent a direct cell count like
those obtainable with the CellSearch approach, the in-
creasedpositivity percentage is likely to be associatedwith an
increase in the absolute number of CTCs. So far, 5 CTCs/
7.5 mL is considered the clinically significant CTC thresh-
old for breast cancer patients; even at the lowest end of the
CTCnumber distribution in breast cancer patients, a blood
draw of 38 mL would be enough to guarantee the critical
number of 25 CTCs necessary for our gene expression ap-
proach. Therefore, when using the conventional CTC-
enrichmentmethods, ourGEP protocol appears to bemore
suitable for application in the metastatic context where the
number of CTCs is higher than it is in early breast cancer.
The AdnaTest-based CTC-capture approach, with its im-
proved antibody cocktail, offers an effective means to in-
crease the number of detectable CTCs.
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 Supplemental Data Table 1: Patients clinico-pathologic features and CTC status/count data 
 
Patient ID 
Approach 
used for 
CTC 
detection 
n° CTCs/     
5 mL blood 
 
Primary tumor/ 
Metastatic lesions 
Stage 
(AJCC) 
Line of 
treatment ER 
status 
** 
PR status 
** 
HER2 
status 
*** 
CTC001 CellSearch 203 Pos/Pos Neg/Neg Neg/Neg T3N1M0 III 
CTC002 CellSearch 7 Pos/Pos Pos/Pos Neg/Neg T2N1M0 I 
CTC003 AdnaGen * Pos/Pos Pos/Pos Neg/Neg T1N0M0 I 
CTC004 CellSearch 13 Pos/Pos Neg/Neg Neg/Neg T2N0M0 II 
CTC005 CellSearch 0 Pos/Pos Neg/Neg Neg/Neg  T1N0M0 I 
CTC006 CellSearch 13 Pos/Pos Pos/Pos Neg/Neg T3N0M0 II 
CTC007 CellSearch 19 Pos/Pos Pos/Pos Neg/Neg T1N1M0 III 
 
* CTC negative by AdnaTest 
** evaluated by immunohistochemistry (ER, cut off= 10% positive cells; PR, cut off_10% positive cells) according to 
Hammond M.E. et al . J Clin Oncol 2010; 28:2784-95. 
*** evaluated by immunohistochemistry and FISH (for HER2 2+ cases)  
 






Supplemental Data Figure 1 
Panel A. Pair plots showing correlations between selected samples: Gene expression intensities 
obtained from samples containing 100 ng of RNA extracted from MDA-MB-468 cells considered 
as benchmarks and correlated with intensities obtained in profiles using decreasing RNA inputs, 
respectively 10 ng, 1 ng and 0.5 ng. 
Panel B. Eulero-Venn diagrams highlighting the numbers of common and exclusive genes detected 
in samples derived from 100 ng of MDA-MB-468 RNA and from 0.5 of RNA from the same cell 
line. Gene Ontologies for exclusive genes in each set are reported using character sizes and color 
intensities directly proportional the p value for to the gene set enrichment. 
 
Supplemental Data Figure 2 
Eulero-Venn diagrams highlighting the numbers of common and exclusive genes detected in 
samples derived from 200 MCF7 cells spiked into healthy donor blood (HDB); from HDB not 
treated with AdnaWash buffer and HDB samples treated with AdnaWash buffer. Gene Ontologies 
for exclusive genes in each set are reported using character sizes and color intensities directly 
proportional the p value for to the gene set enrichment. 

Supplemental Data Figure 3 
Distribution plot of signal mean intensities in gene expression data derived from 5-10-25-50 MDA-
MB-468 (red dots) or MCF7 (blue dots) cells spiked into healthy donor blood (HDB), from cell-free 
HDB (yellow triangles), and from 100 ng of RNA isolated from MCF-7 and MDA-MB-468 cells 
(purple and green squares, respectively) profiled with the Illumina Human Whole-Genome DASL 
HT. 
 

© 2015 Wichtig Publishing
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Short communication
(Janssen Diagnostics, LCC, Raritan, NY, USA) approach was 
granted FDA approval for CTC detection and monitoring in 
metastatic solid tumors, but although it produced ample evi-
dence on the prognostic role of CTCs in metastatic (2) and 
early breast tumors (3-5), CTC enrichment with this approach 
is limited to epithelial cells and no CTCs are found in a vari-
able rate (35%-55%) of patients with metastatic disease.
In large trials such as SWOG500 (6), a change of treat-
ment based on CTC status did not benefit the patient, which 
questions the actual biological role of the CTC subpopulation 
 defined according to the CellSearch criteria. Different explana-
tions have been given for such a failure (7), including adequacy 
of treatment, but maybe it is time to concentrate our efforts 
on the approx. 50% CTC-negative subset of patients with met-
astatic breast cancer, which might contain a CTC population 
undetectable with CellSearch (8). The present work focuses 
on the issue of going beyond the simple presence/enumera-
tion of CTCs so that the molecular peculiarities of “missed” 
DOI: 10.5301/jbm.5000166
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Introduction
The number of new methods for circulating tumor cell 
(CTC) detection is rising vertiginously, but few products or de-
vices designed for CTC evaluation have provided robust and 
independently validated clinical results (1). The CellSearch™ 
abStract
Purpose: To compare circulating tumor cell (CTC) detection rates in patients with early (M
0
) and metastatic (M+) 
breast cancer using 2 positive-selection methods or size-based unbiased enrichment.
Methods: Blood collected at baseline and at different times during treatment from M
0
 patients undergoing neo-
adjuvant therapy and from M+ women starting a new line of treatment was processed in parallel using AdnaTest 
EMT-1/ and EMT-2/Stem CellSelect/Detect kits or ScreenCell Cyto devices. CTC positivity was defined according 
to the suggested cutoffs and cytological parameters, respectively.
Results: Higher CTC detection rates were obtained with the AdnaTest approach when using for CTC-enrichment 
antibodies against ERBB2 and EGFR in addition to MUC1 and the classical epithelial surface marker EPCAM (13% 
vs. 48%). In M
0 
patients mainly, CTC positivity rates further increased when EMT- and stemness-related marker 
expression (PIK3CA, AKT2 and ALDH1) was evaluated in addition to EPCAM, MUC1 and ERBB2. When the physical 
properties of tumor cells were exploited, CTCs were detected at higher percentages than with positive-selection-
based methods, without any difference between clinical stages (78% in M
0
 vs. 72% in M+ cases at baseline). Cir-
culating tumor microemboli (CTMs) were detected in addition to single CTCs with significantly higher frequency 
in M
0
 than M+ samples (78% vs. 27%, p = 0.0002).
Conclusions: Different approaches for CTC detection probably identify distinct tumor cell subpopulations, but 
need technical standardization before their clinical validity and biological specificity may be adequately inves-
tigated. The distinct role of CTMs compared with CTCs as prognostic and predictive biomarkers represents a 
further challenge.
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CTCs can be identified and further pieces of clinically impor-
tant information can be unraveled.
Methods
Case series
Patients with histologically confirmed breast cancer and 
no evidence of metastatic disease (M
0
) who were receiving 
anthracycline/taxane-based neoadjuvant therapy and trastu-
zumab if HER2 positive, and breast cancer patients with met-
astatic disease (M+) who were starting a new line of systemic 
treatment (mostly endocrine treatment) were prospectively 
recruited at the Department of Medical Oncology at Fondazi-
one IRCCS Istituto Nazionale dei Tumori, Milan (INT).
Ethical statement
The study was approved by the ethics committee of INT 
and written consent was obtained from all patients.
Blood sample collection
Samples of peripheral venous whole blood were drawn 
from all patients using a 26 G needle and collected in K
3
EDTA 
or K
2
EDTA BD Vacutainer tubes, if processed with the Ad-
naTest (AdnaGen, AG, Langenhagen, Germany) or Screen-
Cell® Cyto (ScreenCell, Paris, France) kits, respectively. The 
first blood tube was discarded to minimize the risk of con-
tamination with skin epithelial cells. Samples were stored in 
the dark at 4°C and processed within 1 hour according to the 
manufacturer’s instructions. For each patient, samples were 
collected at baseline (before starting treatment) and during 
treatment at established times: 3 and 6 months after initia-
tion of neoadjuvant treatment and around 4 weeks after mas-
tectomy in M
0
 women, and at the beginning of a new line of 
treatment and at 3 months from treatment start or at pro-
gression in M+ women.
AdnaTest approach
CTC positive enrichment
CTC enrichment with the AdnaTest EMT-1/Stem CellSelect 
(EMT1) and EMT-2/Stem CellSelect (EMT2) kit was performed 
in parallel on two 5-mL blood samples from the same patient 
according to the manufacturer’s instructions.
CTC detection
For CTC detection, the expression levels of EPCAM, MUC1, 
ERBB2, PIK3CA, AKT2, TWIST1 and ALDH1 transcripts were 
evaluated by semiquantitative multiplex PCR according to the 
manufacturer’s instructions and using the suggested thresh-
olds for positivity (0.15 ng/µL for EPCAM, MUC1, ERBB2 and 
ALDH1 and 0.25 ng/µL for PIK3CA, AKT2 and TWIST1). Sam-
ples with ACTB (beta-actin) expression <0.70 ng/µL were ex-
cluded from the analysis, whereas those passing the quality 
control criteria where considered as positive for at least 1 of 
the above-mentioned markers.
ScreenCell cyto approach
CTC enrichment by size
All blood samples were processed within 1 hour after 
collection using the ScreenCell® Cyto kit (ScreenCell, Paris, 
France) according to the manufacturer’s instructions (9). 
Briefly, blood was diluted in 4 mL of red blood cell lysis and 
fixation buffer and incubated 8 minutes at room tempera-
ture. Three filtrations of 3 mL of blood each were separately 
performed for each patient; microporous membranes were 
rinsed with PBS, collected from the device, air-dried and im-
mediately stained at room temperature for 1 minute with He-
matoxylin Solution S (Merck, Darmstadt, Germany) and then 
for 30 seconds with Shandon Eosin Y Aqueous Solution (Ther-
mo Fisher Scientific Inc., Waltham, MA, USA). Microporous 
membranes were stored at -20°C until cytological evaluation 
by a certified pathologist (JW).
Cytomorphological analysis and CTC counts
All membranes were analyzed by the same pathologist 
(JW) without knowledge of the clinical data. Major criteria 
for CTC identification were a high nuclear-to-cytoplasmic 
ratio (≥0.75) and large nuclear size (≥20 µm), whereas mi-
nor criteria included irregular nuclear contours and nucle-
ar hyperchromatism. The cytomorphological analysis and 
CTC count were based on the previously reported criteria 
of malignancy (10). Circulating tumor microemboli (CTMs) 
were defined as clusters of at least 2 CTCs, often mixed with 
platelets and various leukocytes, showing criteria of malig-
nancy like those described for single CTCs. The nuclear-to-
cytoplasmic ratios between single CTCs and CTC aggregates 
are similar (11).
Results were expressed as numbers of CTCs and CTMs for 
single membranes. For each patient, total CTC or CTM num-
bers derived from 3 membranes (corresponding to 9 mL of 
blood) were added together to better meet the criteria for 
accurate detection of rare events following the Poisson prob-
ability distribution (12). Membranes showing poor quality of 
cytology, estimated on the basis of poor preservation of the 
leukocytes, were excluded from the analysis. Samples were 
rated as CTC or CTM positive if at least 1 CTC or CTM was 
detected in the 3 membranes.
Statistical analysis
Data were analyzed using conventional descriptive statis-
tics. Contingency tables were analyzed by Fisher’s exact test 
and the quantitative measure of the agreement between 
categorical variables was evaluated by Cohen’s kappa statis-
tics, κ. Differences among ordinal variables were assessed by 
Mann-Whitney’s U test. Two-tailed p≤0.05 was adopted as 
the significance threshold.
Results
The AdnaTest EMT-1/Stem Cell Select + Detect (hereafter 
referred to as EMT1) and the AdnaTeast EMT-2/Stem Cell Se-
lect + Detect (hereafter referred to as EMT2) kits were used 
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for a head-to-head comparison of CTC identification methods 
using 2 distinct blood samples from the same patient.
Data on CTC status were separately analyzed for 21 blood 
samples derived from 13 nonmetastatic breast cancer patients 
(M
0
) undergoing neoadjuvant treatment with conventional 
anthracycline/taxane schemes, and for 9 samples derived 
from 6 women with metastatic disease (M+) who were starting 
systemic treatment.
An increase in the percentage of samples defined as CTC 
positive was observed in samples processed using the EMT2 
kit, where immunomagnetic enrichment of CTCs takes advan-
tage of the addition of antibodies against EGFR and ERBB2 
besides the classical EPCAM/MUC1 antibodies employed in 
the EMT1 kit (Tab. I). In the overall series, CTC positivity rates 
roughly passed from 13% to 47%. Such an increase in the 
number of samples defined as CTC positive was also observed 
by stratifying patients according to the clinical setting.
Consistent with the above reported observations, there 
was indeed poor overall agreement between EMT1 and EMT2 
TABlE I -  CTC positivity in blood samples processed in parallel with 
EMT1 and EMT2 kits
Clinical stage n Overall CTC detection
Emt1+ Emt2+
M0 21 2 8
M+ 9 2 6
CTC = circulating tumor cells; M0 = nonmetastatic breast cancer; M+ = meta-
static breast cancer.
TABlE II -  EMT2 CTC positivity rates according to different CTC identification criteria
Clinical stage Criteria for CTC identification
Epithelial/tumor-associated 
genes*
Epithelial/tumor-associated + 
EMT-related** genes
Epithelial/tumor-associated + EMT-related + 
stemness-related*** genes
M0 1/21 6/21 8/21
M+ 5/9 6/9 6/9
CTC = circulating tumor cells; M0 = nonmetastatic breast cancer; M+ = metastatic breast cancer.
*EPCAM, MUC1, ERBB2.
**PIK3CA, AKT2, TWIST1.
***ALDH1A.
on CTC status (κ = 0.159; 95% confidence limits -0.159-0.417). 
Only 60% of samples were concordantly rated for CTC status. 
The discordant samples were enriched in EMT1-/EMT2+ cas-
es (11 EMT1-/EMT2+ versus 1 EMT1+/EMT2-).
These results clearly show that, by using the EMT1 kit, 10 
samples (6 M
0
 and 4 M+) would have been classified as CTC 
negative. Such missed CTCs, whose clinical relevance needs 
to be defined, deserve careful molecular characterization.
To comply with the reported heterogeneity of the CTC pop-
ulation (8, 13), different CTC subpopulations identified by dis-
tinct gene expression patterns were separately evaluated. To 
this end, besides the classical epithelial-like/tumor-associated 
phenotype for CTC definition (EPCAM, MUC1, ERBB2), we also 
considered cell subpopulations expressing EMT-related genes 
(PIK3CA, AKT2, TWIST1) and stemness-related genes (ALDH1).
Overall, considering the optimal CTC selection with EMT2, 
an increase in positivity rates was observed when adding 
the expression of EMT-related genes (from 20% to 40%, NS), 
which reached 47% when expression of ALDH1 was also in-
cluded (Tab. II). The identification of CTCs including genes 
associated with EMT and with stemness, compared with 
epithelial-like and tumor-associated markers only, increased 
the positivity rates in the overall population, although the in-
crease was more evident in M
0
 than M+ patients.
In a distinct case series of 14 M
0
 and 18 M+ breast cancers, 
CTCs and CTMs were identified based on cytological criteria 
only, after unbiased CTC enrichment by size-selection. The re-
sults, expressed as total number of CTCs and CTMs in 9 mL of 
blood, are reported in Table III using 1 CTC and 1 CTM in 9 mL 
of blood as positivity cutoff.
CTCs were identified in a high percentage of samples, 
ranging from 72% to 92% without any differences between 
TABlE III -  CTC and CTM positivity rates in samples processed by size-based selection
Clinical stage Baseline During treatment Any time
n CTC* CTM* n CTC* CTM* n CTC* CTM*
M0 14 11 (78) 11 (79) 13 12 (92) 10 (77) 27 23 (85) 21 (78)
M+ 18 13 (72) 5 (28) 12 11 (92) 3 (25) 30 24 (80) 8 (27)
Overall 32 24 (75) 16 (50) 25 23 (92) 13 (52) 57 47 (82) 29 (62)
CTC = circulating tumor cells; CTM = circulating tumor microemboli; N = number; M0 = nonmetastatic breast cancer; M+ = metastatic breast cancer.
*Numbers of CTC+ or CTM+ samples (positivity percentage). Positivity cutoffs ≥1 CTC/9 mL of blood, ≥1 CTM/9 mL of blood.
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clinical stages and between samples collected at baseline or 
during treatment. CTMs, too, were present at similar rates in 
samples derived from untreated or treated women; however, 
overall the CTM presence rates were different (p = 0.0002) 
between M+ (27%) and M0 (78%) patients, and the difference 
was perceptible at baseline (p = 0.0113) and during treat-
ment (p = 0.017).
Median CTC counts did not differ between M+ and M0 pa-
tients (9 vs. 8.5 at baseline, 10 vs. 15 during treatment, and 
9 vs. 11 overall), whereas median CTM counts were higher in 
patients without clinical evidence of metastases at all tested 
times (3 vs. 0, p = 0.0056 at baseline; 2 vs. 0, p = 0.0278 dur-
ing treatment; and 2 vs. 0, p = 0.001 overall). These results 
suggest early dissemination of the disease and highlight the 
importance of better knowledge of the molecular heteroge-
neity of CTCs for predicting progression.
Discussion
CTCs, enriched and identified by their epithelial features, 
have reached a high level of evidence as prognostic tools 
in different clinical stages. However, we would like to give 
further importance to previous observations that, besides 
the purely epithelial CTCs, there is an additional, missed 
CTC population (8) whose clinical relevance is still unex-
plored and deserves further attention. Using immunomag-
netic CTC enrichment in 2 small case series in the present 
study, we were able to demonstrate that by i) optimizing the 
antibody composition of cocktails used for CTC enrichment 
by immunobeads and ii) shifting the CTC identification cri-
teria from purely epithelial features (CellSearch criteria) to 
include also mesenchymal and stem cell features, a signifi-
cantly higher number of blood samples was defined as CTC 
positive. Optimized enrichment and less strict CTC definition 
reduce the differences between clinical stages, suggesting 
that in patients without clinical evidence of metastases CTCs 
may show mesenchymal and stemness traits and lose epi-
thelial features.
The extreme approach of unbiased CTC enrichment by 
a size-based filtration method yields a further increase in 
CTC positivity rates, paradoxically abolishing the differences 
in CTC status and numbers between M
0
 and M+ patients. 
This raises interesting questions about distinct molecular 
features of CTCs in the 2 settings, which might not only de-
pend on the stage of the disease but also help in predict-
ing progression. Whereas this is a possible explanation, the 
absence of standardization in the CTC assay (with the ex-
ception of the CellSearch approach) delays the achievement 
of clinical validation and represents a limit of the present 
study.
CTMs, representing heterogeneous clusters of CTCs 
with blood cells and platelets, are an additional, promis-
ing feature worth being explored. It was recently suggested 
in animal models that CTC clusters are more proficient in 
generating metastases than single CTCs (14): from such a 
perspective, the significantly lower number of CTMs in M+ 
compared to M
0 
patients represents a new finding that (al-
though apparently not intuitive, similarly to the increases in 
CTC positivity reported above for improved detection meth-
ods) supports the necessity to uncover the message of these 
missed CTCs. We also  speculate that CTMs are particularly 
worth characterizing from the molecular point of view in M
0 
patients, whereas in M+ patients single CTCs that could de-
rive from metastatic sites may harbor the molecular makeup 
of the metastasis, recapitulating the clonal evolution of the 
disease.
It is important to mention that the currently employed 
technical approaches for CTC detection, albeit based on 
distinct properties, share a lack of biological specificity. 
Whereas it can be affirmed that the identified CTCs are by 
all criteria cancer cells, data on their ability to invade, prolif-
erate or cause metastases are as yet scanty. A different way 
of investigating the clinical role of such cells is an urgent 
need if we want to fulfill the promises of the liquid biopsy 
approach.
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